Registration No. 333-
As Filed with the Securities and Exchange Commission on June 9, 1997
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
-------------
IMATION CORP.
(Exact Name of Registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 7374 41-1838504
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification No.)
</TABLE>
<TABLE>
<CAPTION>
<S> <C>
Carolyn A. Bates
General Counsel and Assistant Secretary
1 Imation Place 1 Imation Place
Oakdale, Minnesota 55128 Oakdale, Minnesota 55128
(612) 704-4000 (612) 704-4000
(Address, including zip code, and telephone (Name, address, including zip code,
number, including area code, of Registrant's and telephone number, including
principal executive offices) area code, of agent for service)
</TABLE>
-----------------------
COPIES TO:
Gary L. Tygesson, Esq. Michael O'Donnell, Esq.
Dorsey & Whitney LLP Wilson Sonsini Goodrich & Rosati, P.C.
Pillsbury Center South 650 Page Mill Road
220 South Sixth Street Palo Alto, California 94304-1050
Minneapolis, Minnesota 55402
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE OF THE SECURITIES TO
THE PUBLIC: As promptly as practicable after this Registration Statement becomes
effective and the effective time of the proposed merger (the "Merger") of
Cemax-Icon, Inc. with and into a subsidiary of the Registrant, as described in
the Agreement and Plan of Merger, dated as of May 13 1997, attached as Exhibit A
to the Proxy Statement/Prospectus forming a part of this Registration Statement.
-----------------------
If the securities being registered on this Form are to be offered in
connection with the formation of a holding company and there is compliance with
General Instruction G, check the following box. [ ]
-----------------------
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
Proposed Proposed
Title of Each Amount Maximum Maximum Amount of
Class of Securities to be Offering Price Aggregate Registration
to be Registered Registered(1) Per Share(2) Offering Price Fee
---------------- ------------- ------------ -------------- ---
<S> <C> <C> <C> <C>
Contingent Payment Rights............. 8,000,000 rights $8.50 $68,000,000 $20,607
Common Stock, $0.01 par value......... (3) (3) (3) (3)
</TABLE>
(1) Based on the estimated maximum number of shares of common stock of
Cemax-Icon, Inc. outstanding immediately prior to the Merger.
(2) Estimated solely for purposes of calculating the registration fee pursuant
to Rule 457(f) under the Securities Act of 1933, as amended, based on the
maximum potential payments under the terms of the Contingent Payment
Rights.
(3) The estimated maximum number of shares of Common Stock of Registrant
issuable upon the exercise of Contingent Payment Rights, as described
herein.
-----------------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE
OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
CROSS-REFERENCE SHEET
Pursuant to Item 501(b) of Regulation S-K
Showing the Location in the Prospectus of the
Information Required by Part I of Form S-4
FORM S-4 ITEM LOCATION IN PROSPECTUS
A. INFORMATION ABOUT THE TRANSACTION
1. Forepart of Registration Statement and
Outside Front Cover Page of Prospectus........ Forepart of the Registration
Statement; Outside Front
Cover Page of the Prospectus
2. Inside Front and Outside Back Cover
Pages of Prospectus........................... Available Information; Table
of Contents
3. Risk Factors, Ratio of Earnings to Fixed
Charges and Other Information................. Summary; Risk Factors; The
Merger; The Merger
Agreement; Selected
Financial Data of Imation;
Selected Financial Data of
Cemax-Icon; Proforma
Unaudited Combined Summary
Financial Data; Comparative
Unaudited Per Common Share
Data
4. Terms of the Transaction...................... Summary; The Merger; The
Merger Agreement;
Description of Imation
Capital Stock; Description
of Contingent Payment Rights
5. Pro Forma Financial Information............... Summary; Pro Forma Unaudited
Combined Summary Financial
Data; Comparative Unaudited
Per Common Share Data
6. Material Contacts with the Company
Being Acquired................................ Summary; The Merger; The
Merger Agreement
7. Additional Information Required for Reoffering
by Persons and Parties Deemed to be
Underwriters.................................. Not Applicable
8. Interests of Named Experts and Counsel......... Not Applicable
9. Disclosure of Commission Position on
Indemnification for Securities Act
Liabilities................................... Not Applicable
B. INFORMATION ABOUT THE REGISTRANT
10. Information with Respect to S-3
Registrants................................... Not Applicable
11. Incorporation of Certain Information
by Reference.................................. Not Applicable
12. Information with Respect to S-2 or
S-3 Registrants............................... Not Applicable
13. Incorporation of Certain Information by
Reference..................................... Not Applicable
14. Information with Respect to Registrants
Other Than S-2 or S-3 Registrants............. Summary; Certain Information
Concerning Imation; Selected
Financial Data of Imation;
Management's Discussion and
Analysis of Imation; Audited
Consolidated Financial
Statements of Imation;
Unaudited Consolidated
Financial Statements of
Imation; Comparative
Unaudited Per Common Share
Data; Proforma Unaudited
Combined Summary Financial
Data
C. INFORMATION ABOUT THE COMPANY BEING ACQUIRED
15. Information with Respect to S-3
Companies..................................... Not Applicable
16. Information with Respect to S-2 or
S-3 Companies................................. Not Applicable
17. Information with Respect to Companies
Other Than S-2 or S-3 Companies............... Summary; Certain Information
Concerning Cemax-Icon;
Selected Financial Data of
Cemax-Icon; Management's
Discussion and Analysis of
Cemax-Icon; Audited
Financial Statements of
Cemax-Icon; Unaudited
Financial Statements of
Cemax-Icon; Comparative
Unaudited Per Common Share
Data; Proforma Unaudited
Combined Summary Financial
Data
D. VOTING AND MANAGEMENT INFORMATION
18. Information if Proxies, Consents or
Authorizations are to be Solicited............ Available Information;
Summary; The Special
Meeting; The Merger; Certain
Information Concerning
Imation; Certain Information
Concerning Cemax-Icon
19. Information if Proxies, Consents or
Authorizations are not to be
Solicited or in an Exchange Offer............. Not Applicable
[LOGO] CEMAX-ICON
Dear Stockholder:
You are cordially invited to attend a Special Meeting of Stockholders
of Cemax-Icon, Inc. ("Cemax-Icon"), to be held at _____________, _____________,
_____________, on ________, 1997, at ____ local time. A notice of the Special
Meeting, Proxy Statement/Prospectus and proxy card containing information about
the matters to be acted upon are enclosed. All holders of Cemax-Icon's
outstanding shares of common stock, $0.001 par value ("Cemax-Icon Common
Stock"), and Series A Preferred Stock, $0.001 par value ("Cemax-Icon Preferred
Stock"), as of June 1, 1997 (the "Record Date"), will be entitled to notice of
and to vote at the Special Meeting and any postponement or adjournment thereof.
At the Special Meeting, you will be asked to consider and to vote upon
a proposal to approve and adopt an Agreement and Plan of Merger (the "Merger
Agreement"), dated as of May 13, 1997, among Cemax-Icon, Imation Corp.
("Imation") and CI Acquisition Corp., a direct, wholly owned subsidiary of
Imation ("Merger Subsidiary"), pursuant to which, among other things, Merger
Subsidiary will be merged with and into Cemax-Icon (the "Merger") and Cemax-Icon
shall be the surviving corporation (the "Surviving Corporation"). If the Merger
Agreement is approved and adopted and the Merger becomes effective, (a) each
outstanding share of Cemax-Icon Common Stock will be converted into and become a
right to receive (i) a cash payment of $5.25, without interest thereon, and (ii)
one right (a "Contingent Payment Right") to receive contingent payments of up to
$8.50 over a two-year period in cash or shares of Imation Common Stock, based on
the gross revenues of the Surviving Corporation following the Merger, net of any
amount to which Imation is entitled pursuant to the offset provisions of the
Merger Agreement, and (b) each share of Cemax-Icon Preferred Stock will be
canceled and extinguished, and no payment will be made therefor (all such shares
are owned beneficially and of record by Imation). The terms of the Contingent
Payment Rights are described in more detail on the accompanying Proxy
Statement/Prospectus.
Details of the proposed Merger and other important information are set
forth in the accompanying Proxy Statement/Prospectus, which you are urged to
read carefully. The Merger is subject to the satisfaction of a number of
conditions, including, among others, approval of the Merger Agreement and the
Merger by the holders of a majority of the voting power of the outstanding
shares of Cemax-Icon Common Stock and Cemax-Icon Preferred Stock, voting as one
class.
Pursuant to agreements with Imation dated May 13, 1997, certain
stockholders of Cemax-Icon, in their individual capacities as stockholders, each
have agreed to vote all of their outstanding shares of Cemax-Icon Common Stock
(approximately 66% of the voting power of outstanding shares of record as June
1, 1997, the Record Date for the Special Meeting) in favor of approval of the
Merger Agreement and the Merger and have granted an irrevocable proxy to Imation
so to vote their respective shares. Such shares, when combined with the shares
of Cemax-Icon Preferred Stock owned by Imation, constitute approximately 71% of
the voting power of the outstanding shares entitled to vote at the Special
Meeting.
Your Board of Directors has carefully reviewed and considered the terms
and conditions of the proposed Merger. YOUR BOARD OF DIRECTORS HAS UNANIMOUSLY
APPROVED THE MERGER AND RECOMMENDS THAT YOU VOTE FOR APPROVAL AND ADOPTION OF
THE MERGER AGREEMENT.
Whether or not you plan to attend the Special Meeting, please complete,
sign and date the accompanying proxy card and return it in the enclosed prepaid
envelope. If you attend the Special Meeting, you may revoke such proxy and vote
in person if you wish, even if you have previously returned your proxy card. If
you do not attend the Special Meeting, you may still revoke such proxy at any
time prior to the Special Meeting by providing written notice of such revocation
to Michael O'Donnell, Secretary of Cemax-Icon. Your prompt cooperation will be
greatly appreciated.
__________, 1997
Very truly yours,
Terry Ross
President and Chief Executive Officer
CEMAX-ICON, INC.
47281 MISSION FALLS COURT
FREMONT, CALIFORNIA 94539
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To be held on _______, 1997
---------------------------
To the Stockholders of Cemax-Icon, Inc.:
Notice is hereby given that a Special Meeting of Stockholders of
Cemax-Icon, Inc., a Delaware corporation ("Cemax-Icon"), will be held at
_____________, _____________, _____________, on ________, 1997, at _____ local
time, for the following purposes:
1. To consider and to vote upon a proposal to approve and adopt an
Agreement and Plan of Merger (as it may be amended, supplemented or modified
from time to time, the "Merger Agreement"), dated as of May 13, 1997, among
Cemax-Icon, Imation Corp. ("Imation") and CI Acquisition Corp., a direct, wholly
owned subsidiary of Imation ("Merger Subsidiary"), pursuant to which, among
other things, Merger Subsidiary will be merged with and into Cemax-Icon (the
"Merger") and Cemax-Icon shall be the surviving corporation in the Merger (the
"Surviving Corporation"), and to approve the appointment of Michael O'Donnell
and David Titus to act as the representatives of the stockholders of Cemax-Icon
("Stockholders' Representatives") in connection with the Merger and to withhold
up to $200,000 from the initial payments to stockholders in a separate fund for
reimbursement of the Stockholders' Representatives' out-of-pocket expenses in
acting on behalf of the stockholders of Cemax-Icon in connection with the
Merger. If the Merger Agreement is approved and adopted and the Merger becomes
effective, (a) each outstanding share of common stock, $0.001 par value, of
Cemax-Icon ("Cemax-Icon Common Stock") (other than shares of Cemax-Icon Common
Stock with respect to which dissenters' rights have been properly exercised)
will be converted into and become a right to receive (i) a cash payment of
$5.25, without interest thereon, and (ii) one right (a "Contingent Payment
Right") to receive contingent payments of up to $8.50 over a two-year period in
cash or shares of Imation Common Stock, based on the gross revenues of the
Surviving Corporation following the Merger, net of any amount to which Imation
is entitled pursuant to the offset provisions of the Merger Agreement, and (b)
each share of Series A Preferred Stock, $0.001 par value, of Cemax-Icon
("Cemax-Icon Preferred Stock") will be canceled and extinguished, and no payment
will be made therefor. The terms of the Contingent Payment Rights are described
in more detail on the accompanying Proxy Statement/Prospectus.
2. To transact such other business as may properly come before the
Special Meeting or any adjournment or postponement thereof.
The close of business on June 1, 1997 (the "Record Date"), has been
fixed as the record date for the determination of the stockholders of Cemax-Icon
entitled to notice of and to vote at the Special Meeting and any adjournment or
postponement thereof. Accordingly, only holders of record of outstanding shares
of Cemax-Icon Common Stock and Cemax-Icon Preferred Stock at the close of
business on the Record Date shall be entitled to notice of and to vote at the
Special Meeting and any adjournment or postponement thereof. The Merger
Agreement is required to be approved and adopted by the affirmative vote of the
holders of a majority of the voting power of the outstanding shares of
Cemax-Icon Common Stock and Cemax-Icon Preferred Stock, voting as one class. The
meeting may be postponed or adjourned from time to time without notice other
than such notice as may be given at the meeting or any postponement or
adjournment thereof, and any business for which notice is hereby given may be
transacted at any such postponed or adjourned meeting.
Pursuant to agreements with Imation dated May 13, 1997, certain
stockholders, in their individual capacities as stockholders, each have agreed
to vote all of their outstanding shares of Cemax-Icon Common Stock
(approximately 66% of the voting power of the outstanding shares of record as of
June 1, 1997, the Record Date for the Special Meeting) in favor of approval of
the Merger Agreement and the Merger and have granted an irrevocable proxy to
Imation so to vote their respective shares. Such shares, when combined with the
shares of Cemax-Icon Preferred Stock owned by Imation, constitute approximately
71% of the voting power of the outstanding shares entitled to vote at the
Special Meeting.
A summary of certain provisions of Section 262 of the General
Corporation Law of the State of Delaware (the "DGCL") pertaining to the rights
of dissenting stockholders if the Merger is consummated is included in the
accompanying Proxy Statement under the heading "THE MERGER--Dissenters' Rights
of Appraisal," and a copy of Section 262 of the DGCL is set forth in Exhibit B
to the attached proxy statement.
Whether or not you plan to attend the Special Meeting, please complete,
sign and date the accompanying proxy card and return it promptly in the enclosed
prepaid envelope. If you attend the Special Meeting, you may revoke such proxy
and vote in person if you wish, even if you have previously returned your proxy
card. If you do not attend the Special Meeting, you may still revoke such proxy
at any time prior to the Special Meeting by providing written notice of such
revocation to Michael O'Donnell, Secretary of Cemax-Icon.
________, 1997
By Order of the Board of Directors,
Secretary
TO ASSURE YOUR REPRESENTATION AT THE SPECIAL MEETING, PLEASE COMPLETE, SIGN AND
DATE YOUR PROXY CARD AND RETURN IT PROMPTLY IN THE ENCLOSED ENVELOPE,
WHICH REQUIRES NO POSTAGE IF MAILED IN THE UNITED STATES.
DO NOT SEND ANY STOCK CERTIFICATES WITH THE ENCLOSED PROXY
CARD. THE PROCEDURE FOR THE EXCHANGE OF YOUR SHARES
AFTER THE MERGER IS CONSUMMATED IS SET FORTH IN THE
ATTACHED PROXY STATEMENT/PROSPECTUS.
THE BOARD OF DIRECTORS OF CEMAX-ICON, INC. UNANIMOUSLY
RECOMMENDS THAT STOCKHOLDERS VOTE TO APPROVE
AND ADOPT THE MERGER AGREEMENT.
CEMAX-ICON, INC.
PROXY STATEMENT
----------------
IMATION CORP.
PROSPECTUS
-----------------
This Proxy Statement/Prospectus is being furnished by Cemax-Icon, Inc.,
a Delaware corporation ("Cemax-Icon"), to holders of common stock, $0.001 par
value, of Cemax-Icon (the "Cemax-Icon Common Stock") and Series A Preferred
Stock, $0.001 par value, of Cemax-Icon (the "Cemax-Icon Preferred Stock"), in
connection with the solicitation of proxies by the Board of Directors of
Cemax-Icon for use at a Special Meeting of Stockholders of Cemax-Icon to be held
at _____________, _____________, on ________, 1997, commencing at ______ local
time, and at any adjournment or postponement thereof (the "Special Meeting").
The Special Meeting has been called to consider and to vote upon a
proposal to approve and adopt an Agreement and Plan of Merger (as it may be
amended, supplemented or otherwise modified from time to time, the "Merger
Agreement"), dated as of May 13, 1997, among Cemax-Icon, Imation Corp.
("Imation") and CI Acquisition Corp., a direct, wholly owned subsidiary of
Imation ("Merger Subsidiary"), pursuant to which, among other things, Merger
Subsidiary will be merged with and into Cemax-Icon (the "Merger") and Cemax-Icon
shall be the surviving corporation in the Merger (the "Surviving Corporation").
If the Merger Agreement is approved and adopted and the Merger becomes
effective, (a) each outstanding share of Cemax-Icon Common Stock (other than
shares of Cemax-Icon Common Stock with respect to which dissenters' rights have
been properly exercised (the "Dissenting Shares")) will be converted into and
become a right to receive (i) a cash payment of $5.25, without interest thereon,
and (ii) one right (a "Contingent Payment Right") to receive contingent payments
of up to $8.50 over a two-year period in cash or shares of Imation Common Stock,
based on the gross revenues of the Surviving Corporation following the Merger,
net of any amount to which Imation is entitled pursuant to the offset provisions
of the Merger Agreement, and (b) each share of Cemax-Icon Preferred Stock will
be canceled and extinguished, and no payment will be made therefor. See
"DESCRIPTION OF CONTINGENT PAYMENT RIGHTS." An aggregate of up to $200,000 may
be withheld from the initial payments to stockholders in a separate fund for
reimbursement of the Stockholders' Representatives' out-of pocket-expenses in
acting on behalf of stockholders of Cemax-Icon in connection with the Merger.
See "THE MERGER--Stockholders' Representatives' Fund."
The Merger is subject to the satisfaction of a number of conditions,
including, among others, approval of the Merger Agreement and the Merger by the
holders of a majority of the voting power of the outstanding shares of
Cemax-Icon Common Stock and Cemax-Icon Preferred Stock, voting as one class. See
"THE MERGER" and "THE MERGER AGREEMENT--General." Pursuant to agreements with
Imation dated May 13, 1997 (the "Stockholder Agreements"), certain stockholders,
in their individual capacities as stockholders, each have agreed to vote all of
their shares of Cemax-Icon Common Stock (approximately 66% of the voting power
of the outstanding shares of record as of June 1, 1997, the Record Date for the
Special Meeting) in favor of approval of the Merger Agreement and the Merger.
Such shares, when combined with the shares of Cemax-Icon Preferred Stock owned
by Imation, constitute approximately 71% of the voting power of the outstanding
shares entitled to vote at the Special Meeting.
This Proxy Statement/Prospectus also constitutes a prospectus of
Imation with respect to up to ____ Contingent Payment Rights issuable to the
stockholders of Cemax-Icon upon consummation of the Merger and shares of common
stock, $.01 par value, of Imation (the "Imation Common Stock") issuable at the
option of a holder of a Contingent Payment Right at the time of payment of a
Contingent Payment Right. Imation has supplied all information contained in this
Proxy Statement/Prospectus relating to Imation and Cemax-Icon has supplied all
information contained in this Proxy Statement/Prospectus relating to Cemax-Icon.
This Proxy Statement/Prospectus and the accompanying form of proxy are
first being mailed to stockholders of Cemax-Icon on or about ________, 1997.
SEE "RISK FACTORS" ON PAGE 1 FOR A DISCUSSION OF CERTAIN FACTORS THAT
SHOULD BE CONSIDERED BY HOLDERS OF SHARES OF CEMAX-ICON COMMON STOCK.
------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS
THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS
PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
------------------
The date of this Proxy Statement/Prospectus is ________, 1997
AVAILABLE INFORMATION
Imation is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "SEC" or "Commission"). The reports,
proxy statements and other information filed by Imation with the Commission may
be inspected and copied at the public reference facilities maintained by the
Commission at Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington,
D.C. 20549, and at the Regional Offices of the Commission at Seven World Trade
Center, 13th Floor, New York, New York 10048 and CitiCorp Center, 500 West
Madison Street, Suite 1400, Chicago, Illinois 60661-2511. Copies of such
material also may be obtained from the Public Reference Section of the
Commission, Washington, D.C. 20549 at prescribed rates. The Commission maintains
a Website that contains reports, proxy and information statements and other
information regarding registrants that file electronically with the Commission
at http://www.sec.gov.com. In addition, material filed by Imation may be
inspected at the offices of the New York Stock Exchange, Inc. (the "NYSE"), 20
Broad Street, New York, New York 10005.
Imation has filed with the Commission a Registration Statement on Form
S-4 (together with any amendments thereto, the "Registration Statement") under
the Securities Act of 1933, as amended (the "Securities Act"), with respect to
the Contingent Payment Rights to be issued pursuant to the Merger and shares of
Imation Common Stock that may be issued upon payment of the Contingent Payment
Rights. This Proxy Statement/Prospectus does not contain all the information set
forth in the Registration Statement, certain portions of which have been omitted
as permitted by the rules and regulations of the Commission. Such additional
information may be obtained from the Commission's principal office in
Washington, D.C. Statements contained in this Proxy Statement/Prospectus as to
the contents of any contract or other document referred to herein are not
necessarily complete, and in each instance reference is made to the copy of such
contract or other document filed as an exhibit to the Registration Statement,
each such statement being qualified in all respects by such reference.
-----------------------------
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS PROXY STATEMENT/PROSPECTUS IN
CONNECTION WITH THE SOLICITATION OF PROXIES OR THE OFFERING OF SECURITIES MADE
HEREBY AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE
RELIED UPON AS HAVING BEEN AUTHORIZED BY IMATION, CEMAX-ICON OR ANY OTHER
PERSON. THIS PROXY STATEMENT/PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL, OR
A SOLICITATION OF AN OFFER TO BUY, ANY SECURITIES, OR THE SOLICITATION OF A
PROXY, IN ANY JURISDICTION TO OR FROM ANY PERSON TO WHOM IT IS NOT LAWFUL TO
MAKE ANY SUCH OFFER OR SOLICITATION IN SUCH JURISDICTION. THIS PROXY
STATEMENT/PROSPECTUS DOES NOT COVER ANY RESALES OF THE IMATION COMMON STOCK
OFFERED HEREBY TO BE RECEIVED BY STOCKHOLDERS OF CEMAX-ICON DEEMED TO BE
"AFFILIATES" OF CEMAX-ICON OR IMATION UPON THE CONSUMMATION OF THE MERGER. NO
PERSON IS AUTHORIZED TO MAKE USE OF THIS PROXY STATEMENT/PROSPECTUS IN
CONNECTION WITH SUCH RESALES. NEITHER THE DELIVERY OF THIS PROXY
STATEMENT/PROSPECTUS NOR ANY DISTRIBUTION OF SECURITIES MADE HEREUNDER SHALL,
UNDER ANY CIRCUMSTANCES, CREATE AN IMPLICATION THAT THERE HAS BEEN NO CHANGE IN
THE AFFAIRS OF IMATION OR CEMAX-ICON SINCE THE DATE HEREOF OR THAT THE
INFORMATION HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS DATE.
-----------------------------
CERTAIN INFORMATION CONTAINED IN THIS PROXY STATEMENT/PROSPECTUS WHICH
DOES NOT RELATE TO HISTORICAL FINANCIAL INFORMATION MAY BE DEEMED TO CONSTITUTE
FORWARD LOOKING STATEMENTS. THE WORDS OR PHRASES "WILL LIKELY RESULT", "ARE
EXPECTED TO", "WILL CONTINUE", "IS ANTICIPATED", "ESTIMATE", "PROJECT",
"BELIEVE" OR SIMILAR EXPRESSIONS IDENTIFY "FORWARD LOOKING STATEMENTS" WITHIN
THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH
STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE
ACTUAL RESULTS TO DIFFER MATERIALLY FROM HISTORICAL RESULTS AND THOSE PRESENTLY
ANTICIPATED OR PROJECTED. READERS SHOULD NOT PLACE UNDUE RELIANCE ON ANY SUCH
FORWARD LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE MADE. AMONG THE
FACTORS THAT COULD CAUSE ACTUAL RESULTS IN THE FUTURE TO DIFFER MATERIALLY FROM
ANY OPINIONS OR STATEMENTS EXPRESSED WITH RESPECT TO FUTURE PERIODS ARE THOSE
DESCRIBED UNDER RISK FACTORS ON PAGE 1.
<TABLE>
<CAPTION>
TABLE OF CONTENTS
<S> <C>
SUMMARY .................................................................................... S-1
General ........................................................................... S-1
The Parties to the Merger .......................................................... S-1
Imation Corp. ............................................................. S-1
Cemax-Icon, Inc. .......................................................... S-2
CI Acquisition Corp. ...................................................... S-2
The Special Meeting ................................................................ S-2
Time, Date and Place ...................................................... S-2
Purposes of the Special Meeting ........................................... S-3
Record Date; Shares Entitled to Vote ...................................... S-3
Votes Required; Quorum .................................................... S-3
The Merger ......................................................................... S-3
Effective Time ............................................................ S-3
Effects of the Merger ..................................................... S-3
Conversion of Cemax-Icon Common Stock ..................................... S-4
Contingent Payment Rights ................................................. S-4
Effect of the Merger on Cemax-Icon Stock
Options and Cemax-Icon Warrants ....................................... S-4
Recommendation of the Board of Directors of Cemax-Icon .................... S-5
Interests of Certain Persons in the Merger;
Management of Cemax-Icon After the Merger ............................. S-5
Stockholder Agreements .................................................... S-5
Option Agreement .......................................................... S-6
Accounting Treatment ...................................................... S-6
Certain Federal Income Tax Consequences ................................... S-6
Dissenters' Rights of Appraisal ........................................... S-6
Regulatory Approvals ...................................................... S-7
The Merger Agreement ............................................................... S-7
Limitations on Negotiations by Cemax-Icon ................................. S-7
Conditions to the Merger .................................................. S-7
Termination of the Merger Agreement ....................................... S-7
Termination Fees .......................................................... S-8
Market Price Data .................................................................. S-9
Comparative Unaudited Per Common Share Data ........................................ S-9
Summary Financial Data of Imation ..................................................S-10
Summary Financial Data of Cemax-Icon ...............................................S-11
Pro Forma Unaudited Combined Summary Financial Data ................................S-12
RISK FACTORS ............................................................................... 1
Risk Factors with Respect to Imation ............................................... 1
Imation's Ability to Establish a New Brand and Identity ................... 1
Competitive Industry Conditions ........................................... 1
Changing Industry Environment ............................................. 1
Imation's Ability to Establish Independent Business Processes ............. 1
International Operations and Foreign Currency ............................. 2
Fluctuations in Operating Results ......................................... 2
Future Capital Requirements ............................................... 2
Risk Factors with Respect to Cemax-Icon ............................................ 2
Lack of Profitable Operations, Significant Losses from Operations ......... 2
Dependence upon Ability to Enhance and
Integrate Existing Product Line and Develop New Products .............. 3
Risk Related to Products Under Development ................................ 3
Risks Related to Company Reliance upon OEMs and Principal Customers ....... 3
Dependence on Emerging PACS and
Teleradiology Markets; Uncertainty of Market Acceptance ............... 3
Rapid Technological Change ................................................ 4
Long Sales and Delivery Cycle; Dependence on Future System Sales .......... 4
Competition ............................................................... 5
Risks Associated with Ability to Manage
Projected Growth; Need for Additional Qualified Personnel ............. 5
Dependence on Key Employees ............................................... 5
Dependence on Single-Source Suppliers ..................................... 6
Risks Associated with International Operations ............................ 6
FDA and Other Government Regulation ....................................... 6
Uncertain Protection for Intellectual Property;
Possible Claims of Others ............................................. 7
Uncertainty in Healthcare Industry; Government
Healthcare Reform Proposals ........................................... 7
Product Liability Risk; Limited Insurance Coverage ........................ 8
Risk Factors with Respect to Contingent Payment Rights ............................. 8
Any Payment Contingent on Future Revenues ................................. 8
Any Payment Subject to Offset Rights ...................................... 8
Restrictions on Transferability ........................................... 8
Any Payments in Imation Common Stock Subject to Stock Price Risks ......... 8
THE SPECIAL MEETING ........................................................................ 9
General ............................................................................ 9
Purposes of the Special Meeting .................................................... 9
Record Date; Shares Entitled to Vote; Required Vote; Quorum ........................ 9
Proxies ............................................................................ 10
THE MERGER ................................................................................. 11
Effective Time ..................................................................... 11
Effects of the Merger .............................................................. 11
Conversion of Cemax-Icon Common Stock .............................................. 11
Stockholders' Representatives' Fund ................................................ 12
Effect of the Merger on Cemax-Icon Stock Options and Cemax-Icon Warrants ........... 12
Background of the Merger; Relationship Between Cemax-Icon and Imation .............. 13
Cemax-Icon's Reasons for the Merger; Recommendation
of Cemax-Icon's Board of Directors .............................................. 14
Similar Customer Base/Complementary Products .............................. 14
Financial Resources ....................................................... 14
Service Capability ........................................................ 15
Market Position ........................................................... 15
Working Relationship ...................................................... 15
Imation's Reasons for the Merger ................................................... 15
Interests of Certain Persons in the Merger ......................................... 16
Stock Options and Warrants ................................................ 16
Key Management Agreements ................................................. 16
Consulting Agreement ...................................................... 17
Noncompetition Agreements ................................................. 17
Management of Cemax-Icon After the Merger .......................................... 18
Option Agreement ................................................................... 18
Stockholder Agreements ............................................................. 18
Employee Agreements ................................................................ 19
Affiliate Agreements ............................................................... 20
Accounting Treatment ............................................................... 20
Certain Federal Income Tax Consequences ............................................ 20
Dissenters' Rights of Appraisal .................................................... 21
General ................................................................... 21
Procedure ................................................................. 22
Regulatory Approvals ............................................................... 24
THE MERGER AGREEMENT ....................................................................... 24
General ........................................................................... 25
Certain Representations and Warranties ............................................. 25
Covenants .......................................................................... 25
Limitations on Negotiations ........................................................ 28
Conditions ......................................................................... 28
Termination ........................................................................ 30
Termination Fees ................................................................... 30
Survival and Offset ................................................................ 31
PRO FORMA UNAUDITED COMBINED FINANCIAL STATEMENTS .......................................... 33
COMPARATIVE UNAUDITED PER SHARE DATA ....................................................... 37
CERTAIN INFORMATION CONCERNING IMATION ..................................................... 37
General ........................................................................... 37
Business ........................................................................... 37
Revenue by Classes of Similar Products or Services ........................ 38
Data Storage Products ..................................................... 38
Printing and Publishing Systems ........................................... 39
Medical Imaging Systems and Photo Color Products .......................... 40
Customer Service Technology ............................................... 41
Document Imaging .......................................................... 41
Industry Background ....................................................... 41
Competition ............................................................... 42
Sales, Markets and Distribution Methods ................................... 42
Raw Materials ............................................................. 42
Research and Patents ...................................................... 42
Manufacturing ............................................................. 43
Employees ................................................................. 43
Environmental Matters ..................................................... 43
Relationship Between 3M and Imation ....................................... 44
Properties ......................................................................... 47
Legal Proceedings .................................................................. 47
Market for Imation Common Stock and Related Stockholder Matters .................... 48
Security Ownership ................................................................. 49
Security Ownership of Certain Beneficial Owners ........................... 49
Security Ownership of Management .......................................... 50
SELECTED FINANCIAL DATA OF IMATION ......................................................... 51
MANAGEMENT'S DISCUSSION AND ANALYSIS OF IMATION ............................................ 52
General Overview ................................................................... 52
Results of Operations .............................................................. 53
Comparison of Three Months Ended March 31, 1997 and 1996 .................. 53
Comparison of the Years Ended December 31, 1996, 1995 and 1994 ............ 55
Performance by Geographic Area ..................................................... 58
United States ............................................................. 58
Europe, Middle East and Africa ............................................ 58
Latin America, Asia and Canada ............................................ 58
Financial Position ................................................................ 58
Liquidity .......................................................................... 59
Comparison of the Three Months Ended March 31, 1997 and 1996 .............. 59
Comparison of the Years Ended December 31, 1996, 1995 and 1994 ............ 59
CERTAIN INFORMATION CONCERNING CEMAX-ICON .................................................. 60
Business ........................................................................... 60
Products .................................................................. 61
Technology ................................................................ 64
Marketing and Sales ....................................................... 64
Customers ................................................................. 66
Customer Support .......................................................... 66
Manufacturing ............................................................. 66
Competition ............................................................... 67
Patents and Intellectual Property ......................................... 67
Government Regulation ..................................................... 68
Third-Party Reimbursement ................................................. 69
Product Liability and Insurance ........................................... 69
Employees ................................................................. 69
Properties ......................................................................... 70
Security Ownership of Certain Beneficial Owners and Management ..................... 71
SELECTED FINANCIAL DATA OF CEMAX-ICON ...................................................... 73
MANAGEMENT'S DISCUSSION AND ANALYSIS OF CEMAX-ICON ......................................... 74
Results of Operations .............................................................. 74
Comparison of Three Months Ended March 31, 1997 and 1996 .................. 74
Comparison of the Years Ended December 31, 1996, 1995 and 1994 ............ 75
Liquidity and Capital Resources .................................................... 76
Comparison of the Three Months Ended March 31, 1997 and 1996 .............. 76
Comparison of the Years Ended December 31, 1996, 1995 and 1994 ............ 76
DESCRIPTION OF IMATION CAPITAL STOCK ....................................................... 77
Authorized Capital Stock ........................................................... 77
Imation Common Stock ............................................................... 77
Imation Preferred Stock ............................................................ 77
No Preemptive Rights ............................................................... 77
Transfer Agent and Registrar ....................................................... 77
DESCRIPTION OF CONTINGENT PAYMENT RIGHTS ................................................... 77
Determination of Earn-Out .......................................................... 77
Payment Election Procedure ......................................................... 79
Determination of Gross Revenues by Imation ......................................... 79
Nontransferability ................................................................. 81
Payment of the Earn-Out ............................................................ 81
Right of Offset .................................................................... 81
LEGAL MATTERS .............................................................................. 81
EXPERTS .................................................................................... 81
OTHER MATTERS .............................................................................. 82
FINANCIAL STATEMENTS ....................................................................... F-1
Exhibit A Agreement and Plan of Merger, dated as of May 13, 1997,
among Imation Corp., Cemax-Icon Acquisition Corp. and
Cemax-Icon, Inc................................................................ A-1
Exhibit B Section 262 of the General Corporation Law of the State of Delaware --
Appraisal Rights of Dissenting Stockholders.................................... B-1
</TABLE>
SUMMARY
The following is a summary of certain information contained elsewhere
in this Proxy Statement/Prospectus. This summary is not intended to be complete
and is qualified in all respects by the more detailed information included in
this Proxy Statement/Prospectus and its Exhibits. Stockholders are urged to read
carefully the entire Proxy Statement/Prospectus, including the Exhibits. Imation
has supplied all information concerning Imation included herein, and Cemax-Icon
has supplied all information concerning Cemax-Icon included herein.
GENERAL
This Proxy Statement/Prospectus relates to the proposed merger (the
"Merger") of Cemax-Icon, Inc., a Delaware corporation ("Cemax-Icon"), and CI
Acquisition Corp., a Delaware corporation ("Merger Subsidiary") and a direct,
wholly owned subsidiary of Imation Corp., a Delaware corporation ("Imation"),
pursuant to an Agreement and Plan of Merger, dated as of May 13, 1997 (the
"Merger Agreement"), among Cemax-Icon, Imation and Merger Subsidiary, a copy of
which is attached to this Proxy Statement/Prospectus as Exhibit A. As a result
of the Merger, Merger Subsidiary will merge with and into Cemax-Icon and (a)
each outstanding share of common stock, $0.001 par value, of Cemax-Icon (the
"CemaxIcon Common Stock") (other than shares of Cemax-Icon Common Stock with
respect to which dissenters' rights have been properly exercised (the
"Dissenting Shares")) will be converted into and become a right to receive (i) a
cash payment of $5.25, without interest thereon, and (ii) one right (a
"Contingent Payment Right") to receive contingent payments of up to $8.50 over a
two-year period in cash or shares of Imation Common Stock, based on the gross
revenues of the Surviving Corporation following the Merger, net of any amount to
which Imation is entitled pursuant to the offset provisions of the Merger
Agreement, and (b) each share of Series A Preferred Stock, $0.001 par value, of
Cemax-Icon (the "Cemax-Icon Preferred Stock") will be canceled and extinguished,
and no payment will be made therefor (all such shares are owned beneficially and
of record by Imation). See "DESCRIPTION OF CONTINGENT PAYMENT RIGHTS." An
aggregate of up to $200,000 may be withheld from the initial payments to
stockholders in a separate fund for reimbursement of the Stockholders'
Representatives' out-of pocket-expenses in acting on behalf of stockholders of
Cemax-Icon in connection with the Merger. See "THE MERGER--Stockholders'
Representatives' Fund."
The Merger is subject to the satisfaction of a number of conditions,
including, among others, approval of the Merger Agreement and the Merger by the
holders of a majority of the voting power of the outstanding shares of
Cemax-Icon Common Stock and Cemax-Icon Preferred Stock, voting as one class. See
"THE MERGER" and "THE SPECIAL MEETING." Pursuant to agreements with Imation
dated May 13, 1997 (the "Stockholder Agreements"), certain stockholders, in
their individual capacities as stockholders, have agreed to vote all of their
outstanding shares of Cemax-Icon Common Stock (approximately 66% of the voting
power of the outstanding shares of record as of June 1, 1997, the Record Date
for the Special Meeting) in favor of approval of the Merger Agreement and the
Merger and have granted an irrevocable proxy to Imation so to vote their
respective shares. Such shares, when combined with the shares of Cemax-Icon
Preferred Stock owned by Imation, constitute approximately 71% of the voting
power of the outstanding shares entitled to vote at the Special Meeting.
THE PARTIES TO THE MERGER
Imation Corp.
Imation is a leader in developing, manufacturing and marketing a wide
variety of products and services worldwide for data storage and imaging
applications within the information processing industry. Imation's products,
which number in excess of 10,000, are used to capture, process, store, reproduce
and distribute information and images in a wide range of information-intensive
markets, including enterprise computing, network servers, personal computing
graphic arts, photographic imaging, medical imaging, and commercial and consumer
markets.
Prior to July 1, 1996, Minnesota Mining and Manufacturing Company
("3M") operated Imation's business through various divisions and subsidiaries.
Imation was formed as a result of the decision by 3M to spin-off a separate
company comprised of substantially all of the businesses previously operated
within 3M's data storage and imaging systems groups (the "Transferred
Businesses"). To effectuate the transaction, on June 18, 1996, the Board of
Directors of 3M declared a dividend payable to the holders of record of 3M
common stock as of June 28, 1996, based upon a ratio of one share of Imation
common stock, $0.01 par value ("Imation Common Stock"), for every ten shares of
3M common stock owned on the record date. Effective July 1, 1996 (the
"Distribution Date"), the shares of Imation Common Stock were distributed to 3M
stockholders (the "Distribution"). In connection with the Distribution, 3M and
Imation entered into various agreements to facilitate the transition of Imation
to an independent business enterprise. See "CERTAIN INFORMATION CONCERNING
IMATION--Relationship Between 3M and Imation." As used herein, references to
"Imation" include the historical operating results and activities of the
business and operations which comprise Imation today.
Imation was incorporated as a Delaware corporation in March 1996.
Imation's principal executive offices are located at 1 Imation Place, Oakdale,
Minnesota 55128 and the telephone number is (612) 704-4000. For further
information concerning Imation, see "CERTAIN INFORMATION CONCERNING IMATION."
Cemax-Icon, Inc.
Cemax-Icon designs, manufactures and markets medical image information
systems which electronically acquire, archive, distribute and display medical
images throughout hospitals, outpatient facilities and integrated delivery
networks ("IDNs"). Cemax-Icon's systems interface with virtually all
commercially available imaging modalities, including x-ray, computed tomography,
magnetic resonance imaging, computed radiography, ultrasound and nuclear
medicine. By automating and increasing the availability of medical images within
a healthcare facility or throughout an IDN, Cemax-Icon's management believes
that its systems reduce the cost and improve the management of medical care.
Cemax-Icon's systems and modules are based on an open architecture and utilize
standard hardware and standard network protocols in order to facilitate
integration with existing image acquisition devices and healthcare information
systems. Cemax-Icon provides complete turn-key systems as well as scalable
software modules that integrate with commercially available third party
hardware.
Cemax-Icon was incorporated in California in 1982 and was
reincorporated in Delaware in August 1996. The principal executive offices of
Cemax-Icon are located at 47281 Mission Falls Court, Fremont, California 94539
and the telephone number is (510) 770-8612. For further information concerning
CemaxIcon, see "CERTAIN INFORMATION CONCERNING CEMAX-ICON."
CI Acquisition Corp.
CI Acquisition Corp., a Delaware corporation and wholly owned
subsidiary of Imation ("Merger Subsidiary"), was incorporated on May 13, 1997
for purposes of the transactions contemplated by the Merger Agreement. Merger
Subsidiary engages in no other business. The principal executive offices of
Merger Subsidiary are located at 1 Imation Place, Oakdale, Minnesota 55128, and
the telephone number is (612) 704-4000.
THE SPECIAL MEETING
Time, Date and Place
The Special Meeting will be held at ____ a.m., local time,
on______,_______, 1997, at ______________, ______________, ______________.
Purposes of the Special Meeting
The purposes of the Special Meeting are to (i) consider and vote on a
proposal to approve and adopt the Merger Agreement, and (ii) transact such other
business as may properly come before the Special Meeting.
Record Date; Shares Entitled to Vote
Only holders of record of shares of Cemax-Icon Common Stock and
Cemax-Icon Preferred Stock at the close of business on June 1, 1997 (the "Record
Date") are entitled to notice of and to vote at the Special Meeting. At that
date there were (a) 5,379,587 shares of Cemax-Icon Common Stock outstanding,
each of which will be entitled to one vote on each matter which may properly
come before the Special Meeting, and (b) 2,521,733 shares of Cemax-Icon
Preferred Stock outstanding and owned by Imation, each of which will be entitled
to 1/2.35 vote, for an aggregate of 1,073,077 votes, on each matter which may
properly come before the Special Meeting.
Votes Required; Quorum
The approval and adoption of the Merger Agreement by the stockholders
of Cemax-Icon will require the affirmative vote of the holders of a majority of
the voting power of the outstanding shares of Cemax-Icon Common Stock and
Cemax-Icon Preferred Stock, voting as one class. The presence, in person or by
properly executed proxy, of the holders of a majority of the voting power of the
outstanding shares of Cemax-Icon Common Stock and Cemax-Icon Preferred Stock,
considered as one class, entitled to vote at the Special Meeting is necessary to
constitute a quorum at the Special Meeting. At the Record Date, approximately
3,631,000 shares of Cemax-Icon Common Stock (approximately 56% of the voting
power of the outstanding shares of record as of the Record Date) were held by
directors, executive officers and their affiliates. Pursuant to the Stockholder
Agreements, certain stockholders, in their individual capacities as
stockholders, have agreed to vote all of their shares of Cemax-Icon Common Stock
(approximately 66% of the voting power of the outstanding shares of record as of
the Record Date) in favor of approval of the Merger Agreement and the Merger,
and have granted to Imation an irrevocable proxy so to vote their respective
shares. Such shares, when combined with the shares of Cemax-Icon Preferred Stock
owned by Imation, constitute approximately 71% of the voting power of the
outstanding shares entitled to vote at the Special Meeting. See "THE SPECIAL
MEETING--Record Date; Shares Entitled to Vote; Required Vote; Quorum."
THE MERGER
Effective Time
The Merger will become effective upon the filing of the Certificate of
Merger with the Secretary of State of the State of Delaware (the "Effective
Time"). Such filing is required by the Delaware General Corporation Law (the
"DGCL") in connection with the Merger and will be made as soon as practicable
after the adoption by the stockholders of Cemax-Icon of the Merger Agreement and
the satisfaction or waiver of all other conditions to the Merger. See "THE
MERGER--Effective Time" and "--Effects of the Merger."
Effects of the Merger
At the Effective Time, pursuant to the Merger Agreement, (a) Merger
Subsidiary will be merged with and into Cemax-Icon, which will be the surviving
corporation (the "Surviving Corporation"), (b) Cemax-Icon will become a wholly
owned subsidiary of Imation, (c) each outstanding share of Cemax-Icon Common
Stock (other than Dissenting Shares) will be converted into and become a right
to receive (i) a cash payment of $5.25, without interest thereon, and (ii) one
Contingent Payment Right and (d) each share of Cemax-Icon Preferred Stock will
be canceled and extinguished, and no payment will be made therefor. See "THE
MERGER--Contingent Payment Rights" and "DESCRIPTION OF CONTINGENT PAYMENT
RIGHTS." An aggregate of up to $200,000 may be withheld from the initial
payments to stockholders in a separate fund for reimbursement of the
Stockholders' Representatives' out-of pocket-expenses in acting on behalf of
stockholders of Cemax-Icon in connection with the Merger. See "THE
MERGER--Stockholders' Representatives' Fund." The Merger is subject to the
satisfaction of a number of conditions, including, among others, approval of the
Merger Agreement and the Merger by the requisite vote of Cemax-Icon's
stockholders.
Conversion of Cemax-Icon Common Stock
Within three business days after the Effective Time, the Paying Agent
will mail to each holder of Cemax-Icon Common Stock a letter of transmittal and
instructions for surrendering stock certificates evidencing shares of Cemax-Icon
Common Stock in exchange for cash and Contingent Payment Rights to which such
holder is entitled as a result of the Merger. STOCKHOLDERS SHOULD NOT SEND ANY
STOCK CERTIFICATES WITH THEIR PROXY CARDS. See "THE MERGER--Conversion of
Cemax-Icon Common Stock."
Contingent Payment Rights
As a result of the Merger, and in addition to the cash payment of
$5.25, without interest, thereon, holders of shares of Cemax-Icon Common Stock
will be entitled to receive one Contingent Payment Right for each share of
Cemax-Icon Common Stock. Each Contingent Payment Right will entitle the holder
to receive payments, if any, of up to $8.50 over a two year period in cash or
shares of Imation Common Stock, based on the gross revenues of the Surviving
Corporation following the Merger, net of any amount to which Imation is entitled
pursuant to the offset provisions of the Merger Agreement. See "DESCRIPTION OF
CONTINGENT PAYMENTS" and "THE MERGER AGREEMENT--Survival and Offset."
Effect of the Merger on Cemax-Icon Stock Options and Cemax-Icon
Warrants
At the Effective Time, Imation will assume the obligations of
Cemax-Icon under the Cemax-Icon, Inc. 1996 Stock Plan, the Icon Medical Systems,
Inc. 1992 Stock Option Plan and the Cemax/Icon, Inc. 1986 Amended Incentive
Stock Plan (collectively, the "Cemax-Icon Option Plans") and each option to
purchase Cemax-Icon Common Stock (a "Cemax-Icon Stock Option") granted under the
Cemax-Icon Option Plans and outstanding immediately prior to the Effective Time
(an "Outstanding Stock Option") will become an option to acquire Imation Common
Stock on the same terms and conditions as were applicable under the Cemax-Icon
Option Plans (a "Substitute Option"), except that (i) the number of shares
subject to each option and the exercise price will be appropriately adjusted to
give effect to the Common Exchange Ratio (as defined below) and (ii) each
Substitute Option that replaces an Outstanding Stock Option that vests at the
rate of either (x) 25% per year during the first year and 2% per month
thereafter or (y) 2% per month, will vest at the rate of 4% per month during the
first 12 months after the Effective Time. See "THE MERGER--Effect of the Merger
on Cemax-Icon Stock Options and Warrants."
Each outstanding warrant to purchase shares of Cemax-Icon Common Stock
(the "Cemax-Icon Warrants") will be converted into a substitute warrant to
acquire Imation Common Stock on the same terms and conditions as were applicable
under the Cemax-Icon Warrants, except that the number of shares subject to each
warrant and the exercise price will be appropriately adjusted to give effect to
the Common Exchange Ratio.
The Merger Agreement defines Common Exchange Ratio as the quotient of
(i) $11.96 and (ii) the average closing price per share of Imation Common Stock
on the New York Stock Exchange-Composite Transactions, as reported in The Wall
Street Journal, for each of the 10 consecutive trading days ending on the third
business day prior to the Effective Time.
Recommendation of the Board of Directors of Cemax-Icon
The Board of Directors of Cemax-Icon believes that the Merger is in the
best interests of Cemax-Icon and its stockholders and has unanimously approved
the Merger and the Merger Agreement. THE BOARD OF DIRECTORS OF CEMAX-ICON
UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE TO APPROVE AND ADOPT THE MERGER
AGREEMENT. This recommendation is based on a number of factors discussed in this
Proxy Statement/Prospectus. See "THE MERGER--Cemax-Icon's Reasons for the
Merger; Recommendation of the Board of Directors of Cemax-Icon."
Interests of Certain Persons in the Merger; Management of Cemax-Icon
After the Merger
Cemax-Icon, as the Surviving Corporation, will become a direct, wholly
owned subsidiary of Imation upon consummation of the Merger. The directors and
officers of Merger Subsidiary immediately prior to the Effective Time will be
the initial directors and officers of the Surviving Corporation. Imation
currently expects that, after the Effective Time, it will retain most of the
executive officers of Cemax-Icon immediately prior to the Effective Time with
duties substantially similar to those of such executive officers prior to the
Effective Time, and that Terry Ross and Jeremy B. Rubin, M.D., who are currently
directors and executive officers of Cemax-Icon, will be elected to the Board of
Directors of Cemax-Icon following the Effective Time. Pursuant to the Merger
Agreement, Imation has agreed to assume all Cemax-Icon Stock Options and
Cemax-Icon Warrants, including those held by officers and directors of
Cemax-Icon. See "THE MERGER--Effect of the Merger on Cemax-Icon Stock Options
and Warrants." Pursuant to the Stockholder Agreements, certain stockholders, in
their individual capacities as stockholders, have agreed to vote all shares of
Cemax-Icon Common Stock owned by them for adoption of the Merger Agreement and
have granted to Imation an irrevocable proxy so to vote their respective shares.
See "THE MERGER--Stockholder Agreements." In connection with the Merger
Agreement, Cemax-Icon has entered into Key Management Agreements with certain
key management employees of Cemax-Icon and Noncompetition Agreements with
certain stockholders of Cemax-Icon, and Imation has agreed to issue certain
additional Imation options to certain key management employees of Cemax-Icon in
lieu of certain restricted shares of Cemax-Icon Common Stock held by them. See
"THE MERGER--Interests of Certain Persons in the Merger." The Board of Directors
of Cemax-Icon was aware of the interests of certain persons in the Merger
described above and considered them, among other matters, in approving the
Merger Agreement and the transactions contemplated thereby.
Stockholder Agreements
As a condition to the willingness of Imation to execute the Merger
Agreement, concurrently with the execution of the Merger Agreement, certain
stockholders of Cemax-Icon, who collectively had record ownership of
approximately 3,530,000 shares of Cemax-Icon Common Stock as of the Record Date
(representing approximately 66% of the total voting power of the outstanding
shares of Cemax-Icon Common Stock and Cemax-Icon Preferred Stock on such date),
entered into separate Stockholder Agreements with Imation, pursuant to which
such stockholders, in such capacity, have agreed to vote, and have granted to
Imation an irrevocable proxy to vote, such shares (and any other shares of
Cemax-Icon Common Stock acquired after the date of the Merger Agreement,
including shares acquired pursuant to the exercise of any rights to purchase or
otherwise acquire shares) in favor of approval of the Merger Agreement and
Merger. In addition, under the Stockholder Agreements, such stockholders have
agreed that, if Cemax-Icon seeks a vote of its stockholders with respect to (i)
any proposal made in opposition to or competition with consummation of the
Merger, (ii) any merger consolidation, sale of assets, reorganization or
recapitalization, with any party other than Imation, Merger Subsidiary and their
affiliates or (iii) any liquidation or winding up of Cemax-Icon (each of (i),
(ii) and (iii), an "Opposing Proposal"), such stockholders will vote against
such Opposing Proposal. Also, under the Stockholder Agreements, such
stockholders have also agreed (i) not to solicit, initiate or encourage
submission of any proposal or offer from any person, group or entity relating to
any acquisition of the assets, business or capital stock of Cemax-Icon, or
other similar transaction or business combination involving the business of
Cemax-Icon, (ii) not to participate in any negotiations or discussions regarding
or furnish to any other person any information with respect to, or otherwise
cooperate in any way with, or assist or participate in, facilitate or encourage
any effort or attempt by any other person or entity to do or seek such
acquisition or transaction and (iii) to inform Imation of any inquiry regarding
the foregoing (i) and (ii). The Stockholder Agreements, other than the
provisions relating to the grant of an irrevocable proxy, terminate on the
earlier to occur of (i) the Effective Time or (ii) such date and time as the
Merger Agreement shall be terminated pursuant to Article VIII of the Merger
Agreement. See "THE MERGER--Stockholder Agreements."
Option Agreement
Concurrently with the execution of the Merger Agreement, Cemax-Icon and
Imation entered into an option agreement (the "Option Agreement") pursuant to
which Cemax-Icon granted to Imation an option (the "Option") to purchase up to
1,075,917 shares of Cemax-Icon Common Stock at a price equal to $11.96 per
share. Imation will be able to exercise the Option, in whole or in part, at any
time and from time to time, on or before December 31, 1997, unless the Merger
Agreement is terminated because of a material misrepresentation, material breach
of a warranty or material breach of a covenant by Imation or Merger Subsidiary
under the Merger Agreement. In addition, Imation will be entitled to
registration rights with respect to any shares of Cemax-Icon Common Stock
acquired by Imation pursuant to the Option Agreement. See "THE MERGER--Option
Agreement."
Accounting Treatment
The Merger will be accounted for under the purchase method of
accounting. See "THE MERGER--Accounting Treatment."
Certain Federal Income Tax Consequences
For federal income tax purposes, the Merger will be treated by each
holder of Cemax-Icon Common Stock (including any holder of shares who properly
exercises dissenter's rights) as a taxable sale or exchange of such stock for
cash and any cash or Imation Common Stock received pursuant to the Contingent
Payment Rights. It is expected that a stockholder who expects to recognize a
gain will be able to treat the transaction as giving rise to an installment
sale. Assuming that the shares of Common Stock exchanged by a Cemax-Icon
stockholder in connection with the Merger are capital assets in the hands of the
stockholder at the Effective Time, such stockholder may recognize a capital gain
or loss by reason of the consummation of the Merger; provided, however, that a
portion of any cash or stock received pursuant to the Contingent Payment Right
will be taxable as ordinary interest income. See "THE MERGER--Certain Federal
Income Tax Consequences."
Dissenters' Rights of Appraisal
Section 262 of the Delaware General Corporation Law (the "DGCL"), a
summary of which is provided in "THE MERGER--Dissenters' Rights of Appraisal"
and the full text of which is attached to this Prospectus/Proxy Statement as
Exhibit B, provides that a stockholder of a Delaware corporation is generally
entitled to receive payment of the appraised value of such stockholder's stock
if such stockholder dissents from a merger or consolidation. Accordingly,
holders of Cemax-Icon Common Stock will be entitled to receive the appraised
value for shares of such stock based on an appraisal conducted by the Delaware
Court of Chancery, provided that the stockholder does not vote in favor of the
Merger and complies with certain statutory procedures within the time periods
specified in the appraisal provisions of Delaware law. The value determined in
such appraisal could be more than, the same as, or less than the value of the
consideration to be received under the Merger Agreement by Cemax-Icon
stockholders who do not dissent from the Merger.
Regulatory Approvals
Consummation of the Merger is conditioned upon, among other things, the
expiration or termination of all applicable waiting periods pursuant to the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR
Act"). The HSR Act requires that parties to certain acquisitions file
notifications with the federal antitrust authorities and observe a waiting
period prior to consummation. Imation and Cemax-Icon each initially filed
Notification and Report Forms with respect to the Merger under the HSR Act on ,
1997. See "THE MERGER--Regulatory Approvals."
THE MERGER AGREEMENT
Limitations on Negotiations by Cemax-Icon
Cemax-Icon is prohibited from soliciting, initiating or encouraging
submission of any proposal or offer from any person or entity relating to any
liquidation, dissolution, recapitalization, merger, consolidation or acquisition
or purchase of all or a material portion of the assets of, or any equity
interest in, Cemax-Icon or other similar transaction or business combination
involving Cemax-Icon, or participating in any negotiations regarding, or
furnishing to any other person any information with respect to, or otherwise
cooperating in anyway with, or assisting or participating in, facilitating or
encouraging, any effort or attempt by any other person or entity to do or seek
any of the foregoing. See "THE MERGER AGREEMENT--Limitations on Negotiations by
Cemax-Icon."
Conditions to the Merger
The obligations of Imation and Cemax-Icon to effect the Merger are
subject to the satisfaction of certain conditions including, among others:
effectiveness of the Registration Statement, stockholder approval of the Merger
Agreement, the absence of any action, proceeding or injunction prohibiting
consummation of the Merger, the receipt of necessary regulatory and other
approvals and consents, continuing accuracy of representations and warranties in
the Merger Agreement, performance or compliance with the agreements and
covenants in the Merger Agreement and receipt by Imation and Cemax-Icon of
various agreements. See "THE MERGER AGREEMENT--Conditions."
Termination of the Merger Agreement
The Merger Agreement may be terminated at any time prior to the
Effective Time: (i) by mutual consent of Imation, Merger Subsidiary and
Cemax-Icon; (ii) by either Imation or Merger Subsidiary, on the one hand, or
Cemax-Icon, on the other, in the event (a) there has been a material
misrepresentation, breach of warranty or breach of covenant on the part of the
other in the representations, warranties and covenants set forth in the Merger
Agreement; (b) there shall be a final nonappealable order of a federal or state
court in effect preventing the consummation of the Merger, or there shall be any
action taken, or any statute, rule, regulation or order enacted, promulgated or
issued or deemed applicable to the Merger by any governmental authority or
agency which would make the consummation of the Merger illegal; (c) there shall
be any action taken, or any statute, rule, regulation or order enacted,
promulgated or issued or deemed applicable to the Merger by any governmental
authority or agency which would (x) prohibit Cemax-Icon's or Imation's ownership
or operation of all or a portion of Cemax-Icon's business or (y) compel Imation
or Cemax-Icon to dispose of or hold separate all or a portion of the business or
assets of Cemax-Icon or Imation as a result of the Merger; or (d) by either
Imation, on the one hand, or Cemax-Icon, on the other, in the event the
transactions contemplated by the Merger Agreement or the Certificate of Merger
have not been consummated on or before August 31, 1997; provided that neither
will be entitled to terminate the Merger Agreement if such party's willful
breach of the Merger Agreement has prevented the consummation of the
transactions contemplated by the Merger Agreement; or (iii) by Imation, if (a)
more than seven percent of the outstanding shares of Cemax-Icon Common Stock
shall be qualified to be Dissenting Shares after the first meeting of
Cemax-Icon's stockholders to approve the Merger Agreement and the Merger; or (b)
after the date of the Merger Agreement, there shall have been a material adverse
change in the assets, properties, financial condition, operating results or
business condition of Cemax-Icon which shall continue to constitute such a
material adverse change on or after July 31, 1997.
In the event of termination of the Merger Agreement by either Imation
or Cemax-Icon, under certain circumstances, either Imation or Cemax-Icon could
be required to pay to the other a termination fee, as described in the next
section and under "THE MERGER AGREEMENT--Termination Fees." See "THE MERGER
AGREEMENT--Termination."
Termination Fees
Imation and Cemax-Icon have agreed that in the event the Merger
Agreement terminates as a result of (i) the failure of a party to proceed with
the Merger even though all of the conditions of such party's obligations to
consummate the transactions contemplated by the Merger Agreement have been
satisfied or (ii) a material misrepresentation, breach of warranty or breach of
covenant on the part of a party in the representations, warranties and covenants
set forth in the Merger Agreement, where such misrepresentation or breach
results or arises from the intentional, willful or grossly negligent acts or
omissions of such party, from information or circumstances known by such party
as of the date of the Merger Agreement or from information or circumstances not
known by such party as of the date of the Merger Agreement as a result of the
intentional or willful disregard or the gross negligence of such party, the
breaching party will promptly reimburse the non-breaching party for
out-of-pocket fees and expenses up to $1,000,000. Under certain circumstances,
in the event Cemax-Icon is the breaching party, it may make such payment by
delivering to Imation shares of Cemax-Icon Common Stock valued at a price of $10
per share.
In addition, in the event (i) Imation terminates the Merger Agreement
as a result of a material misrepresentation, material breach of warranty or
material breach of covenant on the part of Cemax-Icon of the representations,
warranties and covenants set forth in the Merger Agreement and (ii) Cemax-Icon
engages in, becomes subject to, or enters into an agreement or understanding
with respect to, a Control Transaction (as defined below) with a party other
than Imation prior to December 31, 1997, Cemax-Icon shall promptly pay to
Imation $3,000,000 in addition to any amounts previously paid or required to be
paid pursuant to the termination provisions of the Merger Agreement. See "THE
MERGER AGREEMENT--Termination Fees.
A "Control Transaction" means (i) any acquisition of effective control
of Cemax-Icon, whether by merger, purchase of all or substantially all of the
assets of Cemax-Icon, purchase of a majority of the equity of Cemax-Icon or
otherwise, or (ii) any issuance by Cemax-Icon, in a single or series of
transactions, of shares of capital stock, or rights to purchase shares of
capital stock, representing equal to or greater than twenty percent (20%) of the
outstanding capital stock of Cemax-Icon. Notwithstanding the foregoing, a
Control Transaction does not include the issuance by Cemax-Icon of more than
twenty percent (20%) of the outstanding capital stock of Cemax-Icon (A) pursuant
to an initial public offering of Cemax-Icon's equity securities under Section 5
of the Securities Act, or (B) pursuant to a pro rata or substantially pro rata
offering of Cemax-Icon's securities to Cemax-Icon's current stockholders
entitled to participate in such offering pursuant to applicable securities laws,
provided, that, in either case, after such offering, (1) none of Cemax-Icon's
current stockholders is the beneficial owner of more than forty percent (40%) of
the outstanding capital stock of Cemax-Icon (computed as if all securities
beneficially owned by such stockholder which are convertible into capital stock
of Cemax-Icon had been converted), and (2) none of Imation's competitors
previously disclosed to Cemax-Icon is the beneficial owner of more than forty
percent (40%) of the outstanding capital stock of Cemax-Icon (computed as if all
securities beneficially owned by such competitor which are convertible into
capital stock of Cemax-Icon had been converted).
MARKET PRICE DATA
The Imation Common Stock is listed on the NYSE under the symbol "IMN."
On May 13, 1997, the last full trading day before Imation and Cemax-Icon
announced the execution of the Merger Agreement, the closing price per share of
Imation Common Stock was $24.50, and on_________, 1997, the closing price per
share of Imation Common Stock was $__________. There is no established trading
market for Cemax-Icon Common Stock, excluding limited trading as a result of
private negotiations not involving any broker or dealer.
COMPARATIVE UNAUDITED PER COMMON SHARE DATA
The following table presents selected comparative unaudited per common
share data with respect to Imation Common Stock and Cemax-Icon Common Stock on a
historical basis and a pro forma combined basis, giving effect to the Merger
using the purchase method of accounting. This information is derived from the
historical financial statements and the related notes thereto and the pro forma
unaudited combined financials and the related note thereto included elsewhere
herein. The per share data set forth below are presented for informational
purposes only and are not necessarily indicative of the results of the future
operations of the combined entity or the actual results that would have been
achieved had the Merger been consummated prior to the dates as assumed in
preparing such data.
<TABLE>
<CAPTION>
Imation Cemax-Icon
Common Stock Common Stock Pro Forma
Historical Historical Combined
<S> <C> <C> <C>
BOOK VALUE PER SHARE:
March 31, 1997.................................................... $ 21.53 $ (0.25) $ 21.00
CASH DIVIDENDS PER SHARE:
Three months ended March 31, 1997................................. 0 0 0
Year ended December 31, 1996...................................... 0 0 0
EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS:
Three months ended March 31, 1997................................. 0.30 (0.18) 0.26
Year ended December 31, 1996...................................... (0.49) (0.59) (0.63)
</TABLE>
SUMMARY FINANCIAL DATA OF IMATION
Set forth below is selected consolidated historical financial
information of Imation derived from the unaudited consolidated financial
statements of Imation for the three months ended March 31, 1997 and 1996 and for
the fiscal year ended December 31, 1992, and the audited consolidated financial
statements of Imation for the fiscal years ended December 31, 1996, 1995, 1994
and 1993. The information should be read in conjunction with the Management's
Discussion and Analysis of Imation, the consolidated financial statements of
Imation and related notes thereto and the pro forma unaudited combined financial
statements and the related note thereto included elsewhere herein. In the
opinion of Imation's management, the operating results for the fiscal quarters
ended March 31, 1997 and 1996 and for the fiscal year ended December 31, 1992
reflect all adjustments (consisting of normal recurring accruals except for the
restructuring charges recorded in the first quarter of 1996) necessary to
present fairly the information contained therein. Results for the three months
ended March 31, 1997 are not necessarily indicative of the results for the full
year.
<TABLE>
<CAPTION>
Three Months Ended
March 31, Years Ended December 31,
----------------------- -----------------------------------------------------------
1997 1996(a) 1996(b) 1995(c) 1994 1993 1992
(In millions, except (In millions, except per share data) (Unaudited)
per share data)
(Unaudited)
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net revenues ........ $ 548 $ 576 $ 2,278 $ 2,246 $ 2,281 $ 2,308 $ 2,350
Gross profit ........ 199 202 795 725 839 886 885
Selling, general and
administrative .... 133 131 563 539 532 529 542
Research and
development ....... 38 48 183 222 211 217 181
Operating income
(loss) ............ 28 13 (5) (149) 96 141 162
Net income (loss) ... 12 6 (21) (85) 54 75 94
Earnings (loss) per
common share ...... .30 .14 (0.49) (2.02) 1.28 n/a n/a
BALANCE SHEET DATA:
Total working capital $ 622 $ 607 $ 658 $ 714 $ 618 $ 608
Total assets ........ 1,549 1,561 1,542 1,672 1,546 1,534
Long-term obligations 245 222 97 88 85 96
Total shareholders'
equity ............ 912 930 1,149 1,300 1,200 1,172
</TABLE>
- ----------------
(a) Restructuring charges reduced results for the three months ended March 31,
1996 by $10.4 million before taxes and minority interest and $6.1 million
after taxes and minority interest. Net income for the three months ended
March 31, 1996 excluding these charges would have been $12.2 million. These
charges relate to costs for certain employee separation programs.
(b) Restructuring charges and one-time charges reduced 1996 results by $88.4
million before taxes and minority interest and $60.6 million after taxes
and minority interest. 1996 net income excluding these charges would have
been $40.1 million. These charges related to one-time costs associated with
start-up activities, restructuring charges primarily for employee severance
programs and the write-off of in-process research and development related
to the acquisition of Luminous Corporation.
(c) Restructuring charges and asset write-offs reduced 1995 results by $166.3
million before taxes and minority interest and $88.3 million after taxes
and minority interest. 1995 net income excluding these charges would have
been $3.3 million. The majority of these charges related to the write-down
of property, plant and equipment.
SUMMARY FINANCIAL DATA OF CEMAX-ICON
Set forth below is selected historical financial information of
Cemax-Icon derived from the unaudited financial statements of Cemax-Icon for the
three months ended March 31, 1997 and 1996 and for the fiscal years ended
December 31, 1993 and 1992, and the audited financial statements of Cemax-Icon
for the fiscal years ended December 31, 1996, 1995 and 1994. The information
should be read in conjunction with the Management's Discussion and Analysis of
Cemax-Icon, the financial statements of Cemax-Icon and related notes thereto and
the pro forma combined financial statements and the related note thereto
included elsewhere herein. In the opinion of Cemax-Icon's management, the
operating results for the fiscal quarters ended March 31, 1997 and 1996 and for
the fiscal years ended December 31, 1993 and 1992 reflect all adjustments
(consisting of normal recurring accruals) necessary to present fairly the
information contained therein. Results for the three months ended March 31, 1997
are not necessarily indicative of the results for the full year.
<TABLE>
<CAPTION>
Three Months Ended
March 31, Years Ended December 31,
----------------------- --------------------------------------------------------------
1997 1996 1996 1995 1994 1993 1992
(In thousands, except (In thousands, except per share data)
per share data) (Unaudited) (Unaudited)
(Unaudited)
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net revenues .............. $ 7,283 $ 4,818 $ 25,148 $ 17,030 $ 16,457 $ 12,114 $ 8,314
Gross profit .............. 2,443 2,313 10,728 6,518 7,654 6,055 5,213
Selling, general and
administrative .......... 1,693 1,507 7,178 6,235 6,010 3,947 3,851
Research and
development ............. 1,642 1,622 6,481 6,501 4,134 3,249 2,171
Operating income (loss) ... (892) (816) (2,931) (6,842) (2,490) (1,141) (809)
Net income (loss) ......... (969) (819) (3,056) (6,815) (2,578) (1,198) (843)
Earnings (loss)
per common share ........ (0.18) (0.17) (0.59) (1.75) (1.10) (0.59) (0.46)
BALANCE SHEET DATA:
Total working capital ..... $ 2,275 $ 3,454 $ (538) $ (50) $ 584 $ 1,114
Total assets .............. 16,776 16,708 9,279 7,019 5,465 3,733
Long-term obligations ..... 5,562 5,619 604 891 570 414
Accumulated deficit ....... (35,606) (34,637) (31,581) (24,766) (22,188) (20,880)
Total shareholders'
equity (net capital)
deficiency) ............. (1,366) (400) 370 235 1,098 1,594
</TABLE>
PRO FORMA UNAUDITED COMBINED SUMMARY FINANCIAL DATA
The following table summarizes certain selected pro forma unaudited
financial data for Imation and Cemax-Icon combined, giving effect to the Merger
using the purchase method of accounting. Such pro forma data assumes that the
Merger had been effective on March 31, 1997 for the balance sheet data and
January 1, 1996 for the statement of operations data. The pro forma unaudited
data set forth in the following table is derived from, and should be read in
conjunction with, the historical financial statements of Imation and Cemax-Icon,
including the respective notes thereto and the pro forma unaudited combined
financial statements and the related note thereto included elsewhere herein. The
following pro forma unaudited financial data is presented for informational
purposes only, and is not necessarily indicative of the results of the future
operations of the combined entity or the actual results that would have been
achieved had the Merger been consummated on the dates or prior to the periods
presented.
The pro forma unaudited financial data does not reflect additional
amounts of goodwill, if any, that may result should additional consideration be
issuable pursuant to the Contingent Payment Rights. Under generally accepted
accounting principles, contingent consideration is recorded when the results of
the contingency become known.
<TABLE>
<CAPTION>
Imation and Cemax-Icon Combined
-------------------------------------------
Three Months Ended Year Ended
March 31, 1997 December 31, 1996
(In millions, except per share data)
STATEMENT OF OPERATIONS DATA:
<S> <C> <C>
Net revenues.................................................... $ 555 $ 2,299
Gross profit.................................................... 201 806
Selling, general and administrative............................. 135 573
Research and development........................................ 39 190
Operating income (loss)......................................... 27 (10)
Net income (loss)............................................... 11 (26)
Earnings (loss) per common share................................ 0.26 (0.63)
BALANCE SHEET DATA (AS OF END OF PERIOD):
Total working capital........................................... $ 625
Total assets.................................................... 1,575
Long-term obligations........................................... 281
Total shareholders' equity...................................... 890
</TABLE>
RISK FACTORS
THIS PROXY STATEMENT/PROSPECTUS CONTAINS FORWARD-LOOKING STATEMENTS
THAT INVOLVE RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
FROM THOSE ANTICIPATED IN THESE FORWARD-LOOKING STATEMENTS AS A RESULT OF
CERTAIN FACTORS INCLUDING, BUT NOT LIMITED TO, THOSE SET FORTH IN THE FOLLOWING
RISK FACTORS. CERTAIN FACTORS RELATING TO (i) IMATION'S BUSINESS AND THE
INDUSTRY IN WHICH IMATION OPERATES, (ii) CEMAX-ICON'S BUSINESS AND THE INDUSTRY
IN WHICH IT OPERATES AND (iii) THE CONTINGENT PAYMENT RIGHTS SHOULD BE CAREFULLY
CONSIDERED BY HOLDERS OF CEMAX-ICON COMMON STOCK, SINCE SUCH FACTORS MAY AFFECT
THE VALUE OF THE CONTINGENT PAYMENT RIGHTS AND ANY PAYMENTS MADE THEREUNDER.
RISK FACTORS WITH RESPECT TO IMATION
Imation's Ability to Establish a New Brand and Identity
Prior to the Distribution, the Transferred Businesses had the benefit
of certain 3M trademarks and 3M's reputation in marketing their products.
Pursuant to agreements entered into with 3M, Imation continues to have the use
of certain 3M trademarks for an agreed upon period of time following the
Distribution. Imation has made and continues to make significant investments in
the development of Imation's identity and brand. However, there can be no
assurance that Imation will be successful in this regard or that the loss of use
of 3M trademarks might not have an adverse effect on the business of Imation.
Competitive Industry Conditions
Imation operates in a highly competitive environment. Imation's
competitors are both larger and smaller than Imation in terms of resources and
market shares. The marketplaces in which Imation operates are generally
characterized by rapid technological change, frequent new product introductions,
evolution to digital business solutions and declining prices. In these highly
competitive markets, Imation's success will depend to a significant extent on
its ability to continue to develop and introduce differentiated and innovative
products and customer solutions successfully on a timely basis. The success of
Imation's offerings is dependent on several factors including understanding
customer needs, strong digital technology, differentiation from competitive
offerings, market acceptance and lower costs. Although Imation believes that it
can take the necessary steps to meet the competitive challenges of these
marketplaces, no assurance can be given with regard to Imation's ability to take
these steps, the actions of competitors, some of which will have greater
resources than Imation, or the pace of technological changes.
Changing Industry Environment
The information processing industry is undergoing rapid technological
change. As there is a greatly expanding need to manage and store more complex
information in less time, with less resources and with greater accuracy, there
is an increasing emphasis in the marketplace on solutions using digital
technologies. While Imation has a number of successful digital products and
significant proprietary technologies, Imation's success will depend, in part, on
Imation's ability to anticipate the growing uses of digital technologies. In
addition, new technological innovations generally require a substantial
investment before any assurance is available as to their commercial viability.
Imation's Ability to Establish Independent Business Processes
Imation is making significant investments in establishing Imation's
information technology infrastructure and in re-engineering Imation's business
processes. Prior to the Distribution, these and other corporate services were
provided to the Transferred Businesses by 3M. For a transition period following
the Distribution, 3M is continuing to provide such services to Imation. However,
during this transitional period Imation must establish its own services and
support systems independent of 3M.
International Operations and Foreign Currency
Imation does business in more than 60 countries outside the United
States. International operations, which comprised approximately 49% of Imation's
revenues in 1996, may be subject to various risks which are not present in
domestic operations, including political instability, the possibility of
expropriation, restrictions on royalties, dividends and currency remittances,
local government involvement required for operational changes within Imation,
requirements for governmental approvals for new ventures and local participation
in operations such as local equity ownership and workers' councils. In addition,
Imation's business and financial results are affected by fluctuations in world
financial markets, including foreign currency exchange rates. Imation's foreign
currency hedging policy attempts to mitigate some of these risks; however, these
risk management activities are not comprehensive and there can be no assurance
that these programs will offset more than a portion of the adverse financial
impact resulting from unfavorable movements in foreign exchange rates.
Fluctuations in Operating Results
Imation began operations as an independent public company on July 1,
1996 and therefore does not have a lengthy operating history as an independent
company. Imation's businesses, as operated by 3M prior to the Distribution,
experienced slight declines in total annual revenues during the three year
period ending December 31, 1995. Imation's goal is to reverse this historical
trend and achieve sustainable revenue growth. Imation's strategy to achieve
revenue growth is to expand international penetration of current products and
services in higher growth regions of the world, to expand sales of Imation's
products to its existing customer base, and to develop new products and services
for the information processing industry based on proprietary technologies. While
Imation's revenues increased slightly in 1996 primarily as a result of sales of
newly introduced product platforms, there can be no assurance that Imation will
be successful in achieving sustainable revenue growth in the future. Imation's
stock price may be subject to significant volatility. If revenue or earnings in
any quarter fail to meet the investment community's expectations, there could be
an immediate impact on Imation's stock price. The stock price may also be
affected by broader market trends unrelated to Imation's performance.
Future Capital Requirements
Prior to the Distribution, the Transferred Businesses participated in
3M's centralized funding and cash and foreign currency management. The capital
requirements of the Transferred Businesses in excess of their internally
generated funds were provided by 3M. This financial support is no longer
available to Imation and Imation is now responsible for obtaining its own
financing. Imation believes that its credit facilities, cash flow from
operations and future long- and short-term debt financings will be sufficient to
satisfy its foreseeable future working capital, capital expenditures, research
and development and debt service requirements.
RISK FACTORS WITH RESPECT TO CEMAX-ICON
Lack of Profitable Operations, Significant Losses from Operations
Cemax-Icon has not been profitable since inception, has experienced
significant losses from operations, and had an accumulated deficit of
approximately $35.6 million as of March 31, 1997. Such operating losses are due
in part to the fact that Cemax-Icon's sales revenues have not increased in the
manner originally anticipated by Cemax-Icon. There can be no assurance that
Cemax-Icon will be profitable on a quarterly or annual basis in the future.
Dependence upon Ability to Enhance and Integrate Existing Product Line
and Develop New Products
The market for Cemax-Icon's systems is characterized by changes in
customer requirements and frequent new product introductions and enhancements.
Cemax-Icon's future success will depend upon its ability to enhance and
integrate its current product line, to complete products currently under
development, to develop and introduce new products and to respond to evolving
customer requirements. Any failure by Cemax-Icon to anticipate or respond
adequately to technological developments by its competitors or to changes in
customer requirements, or any significant delays in product integration,
development or introduction could result in a loss of competitiveness or
revenues. There can be no assurance that Cemax-Icon will be successful in
completing its product integration efforts or in developing and marketing new
products or product enhancements on a timely or cost-effective basis and such
failure could have a material adverse effect on Cemax-Icon's business, financial
condition and results of operations. See "CERTAIN INFORMATION CONCERNING
CEMAX-ICON--Business--Products."
Risk Related to Products Under Development
There can be no assurance that Cemax-Icon will be able to complete
development and commence shipment of modules and other products under
development in a reasonable time frame which will be acceptable to customers. In
the past, Cemax-Icon has occasionally experienced delays in development and
introduction of new products and product enhancements, and there can be no
assurance that Cemax-Icon will not experience such delays in the future.
Timeliness of delivery is of critical importance to certain customers, and
Cemax-Icon's failure to successfully develop and ship such products in a timely
manner could result in cancellation of customer orders which would have a
material adverse effect on Cemax-Icon's business, financial condition and
results of operations.
Risks Related to Company Reliance upon OEMs and Principal Customers
Cemax-Icon's success is dependent on the success of its marketing and
distribution strategy which involves, to a significant degree, reliance on
Cemax-Icon's OEMs to sell Cemax-Icon's software modules as a component of the
systems being marketed by such OEMs. Sales through OEMs accounted for 35%, 35%,
36% and 20% of Cemax-Icon's total revenues in 1994, 1995, 1996 and the three
months ended March 31, 1997, respectively. Cemax-Icon's OEM agreements are
subject to cancellation by the OEMs under certain circumstances. Certain OEMs
who are competitors of Imation may seek to terminate their agreements with
Cemax-Icon as a result of the Merger. If Cemax-Icon's current or future OEMs
elect to terminate their agreements with Cemax-Icon or elect not to include
Cemax-Icon's software modules as components in their systems or are unsuccessful
in achieving significant sales of those systems, Cemax-Icon's business,
financial condition and results of operations would be materially and adversely
affected.
Cemax-Icon expects to continue to depend upon its principal customers
for a significant portion of its sales. There can be no assurance that
Cemax-Icon's principal customers will continue to purchase systems and services
from Cemax-Icon at current levels, if at all. The loss of one or more major
customers or a change in their buying patterns could have a material adverse
effect on Cemax-Icon's business, financial condition and results of operations.
See "CERTAIN INFORMATION CONCERNING CEMAX- ICON--Business--Marketing and Sales"
and "--Customers."
Dependence on Emerging PACS and Teleradiology Markets; Uncertainty of
Market Acceptance
Cemax-Icon's success is dependent on the development of the picture
archiving and communication systems ("PACS") and teleradiology markets and on
market acceptance of its existing systems and products under development.
Substantially all of Cemax-Icon's revenues are derived from the sale of medical
image information systems for the PACS and teleradiology markets. The market for
Cemax-Icon's systems is still relatively undeveloped and may not experience
material expansion in the near future, if at all. In the event that the PACS and
teleradiology markets do not develop as anticipated by Cemax-Icon, Cemax-Icon's
business, financial condition and results of operations would be materially
adversely affected.
The commercial success of Cemax-Icon's systems will depend upon their
acceptance by the medical community as useful, cost-effective components of
radiological procedures. There can be no assurance that sales of Cemax-Icon's
systems will continue at historical rates or that Cemax-Icon will introduce new
products that achieve significant market acceptance in the future. Furthermore,
new product introductions or enhancements by Cemax-Icon's competitors or the use
of other technologies could cause a decline in sales or loss of market
acceptance of Cemax-Icon's systems. In addition, third-party payors, such as
governmental programs and private insurance plans, can indirectly affect the
pricing or the relative attractiveness of Cemax-Icon's systems by regulating the
maximum amount of reimbursement that they will provide for the taking, storing
and interpretation of medical images. A decrease in the reimbursement amounts
for radiological procedures may decrease the amount which physicians, clinics
and hospitals are able to charge patients for such services. As a result,
adoption of teleradiology and/or PACS systems may slow as capital investment
budgets are reduced, thereby significantly reducing the demand for Cemax-Icon's
systems. In the event that Cemax-Icon's existing systems and products under
development do not achieve market acceptance, Cemax-Icon's business, financial
condition and results of operations would be materially adversely affected. See
"CERTAIN INFORMATION CONCERNING CEMAX-ICON--Business--Third-Party
Reimbursement."
Rapid Technological Change
The market for Cemax-Icon's systems is subject to rapid technological
advances. Cemax-Icon's future success will depend upon its ability to develop,
introduce and successfully market new products that keep pace with technological
developments. There can be no assurance that Cemax-Icon will be successful in
developing and introducing new products that keep pace with technological
advances, and the failure to do so could have a material adverse effect on
Cemax-Icon's business, financial condition and results of operations.
Long Sales and Delivery Cycle; Dependence on Future System Sales
The decision by a healthcare provider to replace or substantially
upgrade its image information systems typically involves a major commitment of
capital and an extended review and approval process. Accordingly, the sales and
delivery cycle for Cemax-Icon's systems is typically two to 12 months from
initial contact to delivery and acceptance. The time required from initial
contact to contract execution is typically one to six months. During these
periods, Cemax-Icon may expend substantial time, effort and funds preparing a
contract proposal and negotiating the contract. Cemax-Icon does not record
revenues on systems until they have been delivered to the customer. The length
of time between contract execution and delivery typically ranges from three to
12 months depending on the size of the systems ordered, the products ordered and
the delivery terms. At March 31, 1997, Cemax-Icon had approximately $9.8 million
of signed sales contracts from systems and services which had not yet been
delivered. This amount includes contracts for system sales and services that may
include cancellation provisions, and contracts that are expected to result in
revenues over periods of as much as one year. Any significant or ongoing failure
to identify appropriate potential customers, to achieve signed contracts, to
successfully complete software modules under development or to obtain customer
acceptance after expending time, effort and funds could have a material adverse
effect on Cemax-Icon's business, financial condition and results of operations.
See "CERTAIN INFORMATION CONCERNING CEMAX-ICON--Business--Marketing and Sales"
and "--Customers."
Competition
Competition in the market for Cemax-Icon's systems is intense. A large
number of companies offer teleradiology systems which are competitive with those
of Cemax-Icon. Many of Cemax-Icon's competitors are larger and more established
and have substantially more financial, technical, research and development and
marketing resources than Cemax-Icon. Several large multi-national corporations,
including Philips Electronics N.V., Agfa-Gevaert N.V. and Siemens Medical
Systems, Inc. offer competitive products in the PACS market. Other large
corporations have the technical and financial ability to design and market
competitive products, and some of them have produced and marketed such products
in the past. There can be no assurance that such large potential competitors
will not elect to reenter the market for Cemax-Icon's systems, which could have
a material adverse effect on Cemax-Icon's ability to sell its systems. In the
past, certain competitors have from time to time offered PACS systems for sale
at substantial discounts to prevailing prices, or offered PACS systems to
customers at no additional charge in connection with the sale of complementary
products, which has had and could have a material adverse effect on Cemax-Icon's
ability to sell its systems.
Cemax-Icon's ability to compete successfully in the sale of its systems
will depend in large part upon its ability to implement successfully its
strategy of selling systems as a total solution as well as its ability to
attract new customers, sell new products, deliver and support product
enhancements to its existing customers, and respond effectively to continuing
technological change by developing new products. There can be no assurance that
Cemax-Icon will be able to compete successfully in the future, or that future
competition for product sales will not have a material adverse effect on the
business, financial condition and results of operations of Cemax-Icon. See
"CERTAIN INFORMATION CONCERNING CEMAX- ICON--Business--Competition."
Risks Associated with Ability to Manage Projected Growth; Need for
Additional Qualified Personnel
As a result of both internal development and planned expansion into
additional applications and markets, Cemax-Icon expects a period of rapid
growth. Such growth would place a significant strain on Cemax-Icon customer
service and support operations, sales, administrative personnel and other
resources. Cemax-Icon's ability to manage future growth, if any, effectively
will require Cemax-Icon to continue to improve its operational, management and
financial systems and controls and to train, motivate and manage its employees.
As a result, Cemax-Icon is subject to certain growth-related risks, including
the risk that it will be unable to retain the necessary personnel to acquire
other resources necessary to service such growth adequately. Further revenue
growth, if any, depends on Cemax-Icon's ability to rapidly grow its direct sales
force and distribution channels. There can be no assurance that Cemax-Icon can
expand those resources as rapidly as necessary. If Cemax-Icon's management is
unable to manage future growth, if any, effectively, Cemax-Icon's business,
financial condition and results of operations could be materially adversely
affected.
Dependence on Key Employees
Cemax-Icon is highly dependent on certain members of its sales and
engineering staff, the loss of services of one or more of whom could have a
material adverse effect on Cemax-Icon's business and results of operations.
Furthermore, recruiting and retaining qualified sales and technical personnel
will also be critical to Cemax-Icon's success. There can be no assurance that
Cemax-Icon will be successful in attracting and retaining skilled technical
personnel who generally are in high demand in Cemax-Icon's geographic area. The
loss of certain key employees, including Cemax-Icon's Chief Executive Officer
and Chief Technical Officer, or Cemax-Icon's inability to attract and retain
other qualified employees could have a material adverse effect on Cemax-Icon's
business, financial condition and results of operations. In connection with the
Merger, Cemax-Icon has entered into Key Management Agreements with its Chief
Executive Officer, Chief Technical Officer and certain other key management
personnel. See "THE MERGER--Interests of Certain Persons in the Merger--Key
Management Agreements."
Dependence on Single-Source Suppliers
Certain components used with Cemax-Icon's systems, including the film
digitizer, are currently obtained from single sources. Cemax-Icon is not aware
of a short-term alternative source of supply of this film digitizer. The loss of
the supply of such film digitizer for an extended period of time would have a
material adverse effect on Cemax-Icon's business, financial condition and
results of operations.
Risks Associated with International Operations
Foreign markets may be influenced by factors that are different from
those prevailing in the United States. Cemax-Icon has limited experience in
business operation outside the United States, and there can be no assurance that
Cemax-Icon's systems products will be accepted in international markets or that
Cemax-Icon can compete successfully in such markets. International operations
and sales are also subject to certain political and economic risks, including
political instability, currency controls, trade restrictions, regulatory
requirements, exchange rate fluctuations and changes in import and export
regulations, any of which could have a material adverse effect on Cemax-Icon's
business, financial condition and results of operations.
FDA and Other Government Regulation
The manufacturing and marketing of Cemax-Icon's systems are subject to
extensive government regulation as medical devices in the United States by the
Food and Drug Administration ("FDA") and in other countries by corresponding
foreign regulatory authorities. The process of obtaining and maintaining
required regulatory clearances and approvals is lengthy, expensive, and
uncertain. Cemax-Icon believes that its success depends upon commercial sales of
improved versions of its systems, certain of which cannot be marketed in the
United States and other regulated markets unless and until Cemax-Icon obtains
clearance or approval from the FDA and its foreign counterparts.
The FDA requires that a manufacturer seeking to market a new medical
device or an existing medical device for a new indication obtain either a
premarket notification clearance under Section 510(k) of the Federal Food, Drug
and Cosmetic Act or the approval of a premarket approval application under this
Act ("PMA") prior to the introduction of such product into the market. Material
changes to existing medical devices are also subject to FDA review and clearance
or approval prior to commercialization in the United States. Cemax-Icon is
currently relying on the Section 510(k) premarket notification method to obtain
governmental clearance ("510(k) clearance") to market its medical devices in the
United States. Although it is believed to be a shorter, less costly regulatory
plan than the process to obtain a PMA, the process of obtaining a 510(k)
clearance generally requires supporting data, which can be extensive and extend
regulatory review process for a considerable length of time. All models of
Cemax-Icon systems that are commercially available have received 510(k)
clearance by the FDA. In addition, Cemax-Icon recently received 510(k) clearance
for Archive Manager 2.0 and for its DICOM and AutoRad modules. There can be no
assurance that 510(k) clearance for any future product or modifications of
existing products will be granted by the FDA within a reasonable time frame, if
at all. Furthermore, the FDA may require that a request for 510(k) clearance be
supported by data from clinical trials demonstrating substantial equivalence and
the safety and effectiveness of the device, which may prolong the Section 510(k)
notification review period for a particular device or may result in a finding
that the product is not substantially equivalent, so that a full PMA could be
required.
Failure to comply with applicable regulatory requirements could result,
among other things, in warning letters, seizures of property, total or partial
suspension of production, refusal of the government to grant market clearance or
pre-market approval, withdrawal of approvals or criminal prosecution.
Cemax-Icon is also required to register as a medical device
manufacturer with the FDA and the Food and Drug Branch of the California
Department of Health Services ("CDHS"). Cemax-Icon will be inspected on a
routine basis by both the FDA and CDHS for compliance with the FDA's Good
Manufacturing Practices ("GMP") and other applicable regulations.
Cemax-Icon is also subject to other federal, state and local laws and
regulations relating to safe working conditions and manufacturing practices. The
extent of government regulation that might result from any future legislation or
administrative action cannot be predicted. Failure to comply with regulatory
requirements could have a material adverse effect on the Company's business,
financial condition and results of operations.
Sales of Cemax-Icon's systems outside the United States are subject to
foreign regulatory requirements that vary from country to country. Additional
approvals from foreign regulatory authorities may be required, and there can be
no assurance that Cemax-Icon will be able to obtain foreign marketing approvals
on a timely basis or at all, or that it will not be required to incur
significant costs in obtaining or maintaining its foreign regulatory approvals.
In Europe, Cemax-Icon will be required to obtain the certificates necessary to
enable the CE Mark, an international symbol of adherence to quality assurance
standards and compliance with applicable European Union Medical Device
Directives, to be affixed to Cemax-Icon's systems for sales in member countries.
Failure to obtain such certifications, any necessary foreign regulatory
approvals or any other failure to comply with regulatory requirements outside
the United States could have a material adverse effect on Cemax-Icon's business,
financial condition and results of operations. See "CERTAIN INFORMATION
CONCERNING CEMAX-ICON--Business--Products" and "--Government Regulation."
Uncertain Protection for Intellectual Property; Possible Claims of
Others
Cemax-Icon generally does not rely on patent protection with respect to
its products. Instead, Cemax-Icon relies on a combination of copyright and trade
secret law, employee and third-party nondisclosure agreements and other
protective measures to protect intellectual property rights pertaining to its
products and technology. There can be no assurance that applicable copyright or
trade secret law or these agreements will provide meaningful protection of
Cemax-Icon's copyrights, trade secrets, know-how or other proprietary
information in the event of any unauthorized use, misappropriation or disclosure
of such copyrights, trade secrets, know-how or other proprietary information. In
addition, the laws of certain foreign countries do not protect Cemax-Icon's
intellectual property rights to the same extent as do the laws of the United
States. There can be no assurance that Cemax-Icon will be able to protect its
intellectual property successfully.
There can be no assurance that third parties will not assert patent,
copyright or other intellectual property infringement claims against Cemax-Icon
with respect to its systems or technology or other matters. There may be
third-party patents, copyrights and other intellectual property relevant to
Cemax-Icon's systems and technology which are not known to Cemax-Icon. There can
be no assurance that litigation by a third party asserting that Cemax-Icon is
infringing such third party's patent rights, copyrights or other intellectual
property will not be initiated, that Cemax-Icon would prevail in any such
litigation or that Cemax-Icon would be able to obtain any necessary licenses on
reasonable terms if at all. Any such claims against Cemax-Icon, with or without
merit, as well as claims initiated by Cemax-Icon against third parties, can be
time-consuming and expensive to defend or prosecute and resolve. See "CERTAIN
INFORMATION CONCERNING CEMAX-ICON--Business--Patents and Intellectual Property."
Uncertainty in Healthcare Industry; Government Healthcare Reform
Proposals
The healthcare industry is subject to changing political, economic, and
regulatory influences that may affect the procurement practices and operations
of healthcare providers. Many lawmakers have announced that they intend to
propose programs to reform the United States healthcare systems. These programs
may contain proposals to increase governmental involvement in healthcare, lower
reimbursement rates and otherwise change the operating environment. Healthcare
providers may react to these proposals and uncertainty surrounding such
proposals by curtailing or deferring investments, including those for
Cemax-Icon's systems and services. Cost containment measures instituted by
healthcare providers as a result of regulatory reform or otherwise could result
in greater selectivity in the allocation of capital funds. Such selectivity
could have a material adverse effect on Cemax-Icon's ability to sell its systems
and services. See "CERTAIN INFORMATION CONCERNING CEMAX-ICON--Business--Third
Party Reimbursement."
Product Liability Risk; Limited Insurance Coverage
The manufacture and sale of medical image information systems entail
significant risk of product liability claims. There can be no assurance that
Cemax-Icon's existing insurance coverage limits are adequate to protect
Cemax-Icon from any liabilities it might incur in connection with the sale of
Cemax-Icon's systems. In addition, Cemax-Icon may require increased product
liability coverage as additional products are commercialized. Such insurance is
expensive and in the future may not be available on acceptable terms, if at all.
A successful product liability claim or series of claims brought against
Cemax-Icon in excess of its insurance coverage could have a material adverse
effect on Cemax-Icon's business, financial condition and results of operations.
RISK FACTORS WITH RESPECT TO CONTINGENT PAYMENT RIGHTS
Any Payment Contingent on Future Revenues
The right to receive any future payments under the terms of the
Contingent Payment Rights are contingent upon the ability of the image
management systems business of the Surviving Corporation to achieve certain
revenue targets specified therein. It is possible that such revenue targets will
not be achieved for any number of reasons including, but not limited to, the
risk factors with respect to Imation and Cemax-Icon set forth above and the
risk that the integration of the business operations of the Surviving
Corporation with Imation (including changes in the current Board of Directors
and management) as a result of the Merger will adversely affect the Surviving
Corporation's operations and financial results. Although Imation has agreed
pursuant to the Merger Agreement to make certain expenditures to support the
business of the Surviving Corporation following the Effective Time, there can be
no assurance that such expenditures (or any other support) will be adequate for
the Surviving Corporation to achieve the revenue targets specified in the
Contingent Payment Rights. If such revenue targets are not achieved, the amount
of any payments under the Contingent Payment Rights will be reduced or
eliminated. See "DESCRIPTION OF CONTINGENT PAYMENT RIGHTS."
Any Payment Subject to Offset Rights
Pursuant to the terms of the Merger Agreement, amounts payable under
the terms of the Contingent Payment Rights, if any, are subject to Imation's
right to offset such payments to the extent Imation has certain claims under the
terms of the Merger Agreement, subject to certain other terms, conditions and
limitations set forth in the Merger Agreement and the Contingent Payment Rights.
If Imation has the right of offset, the amount of any payments under the
Contingent Payment Rights may be reduced or eliminated. See "THE MERGER
AGREEMENT--Survival and Offset."
Restrictions on Transferability
The Contingent Payment Rights are, by their terms, non-transferable and
therefore represent an illiquid investment until such time as any payments due
thereunder are made.
Any Payments in Imation Common Stock Subject to Stock Price Risks
Prior to the time of any payments thereunder, holders of Contingent
Payment Rights will have the option to elect to receive any payments thereunder
in cash or shares of Imation Common Stock pursuant to the terms set forth
therein. See "DESCRIPTION OF THE CONTINGENT PAYMENT RIGHTS." Holders of
Contingent Payment Rights who elect to receive Imation Common Stock should
consider that an investment in Imation Common Stock involves risks and
uncertainties including, but not limited to, those set forth above. Such risks
and uncertainties may affect the market price of any Imation Common Stock
received upon payment of the Contingent Payment Rights.
THE SPECIAL MEETING
GENERAL
This Proxy Statement/Prospectus is being furnished to holders of
Cemax-Icon Common Stock and Cemax-Icon Preferred Stock in connection with the
solicitation of proxies by the Board of Directors of Cemax-Icon for use at a
Special Meeting to be held on _________, 1997 at ______________, ______________
commencing at _____ local time, and at any adjournment or postponement thereof.
This Proxy Statement/Prospectus and accompanying forms of proxy are
first being mailed to stockholders of Cemax-Icon on or about _______.
PURPOSES OF THE SPECIAL MEETING
At the Special Meeting, holders of Cemax-Icon Common Stock and
Cemax-Icon Preferred Stock will (i) consider and vote upon a proposal to adopt
the Merger Agreement and (ii) transact such other business as may properly come
before the Special Meeting or any postponement or adjournment thereof.
RECORD DATE; SHARES ENTITLED TO VOTE; REQUIRED VOTE; QUORUM
Cemax-Icon has fixed June 1, 1997 as the Record Date for the
determination of the holders of Cemax-Icon Common Stock and Cemax-Icon
Preferred Stock entitled to notice of and to vote at the Special Meeting. Only
holders of record of Cemax-Icon Common Stock and Cemax-Icon Preferred Stock on
the Record Date will be entitled to notice of and to vote at the Special
Meeting. As of the Record Date, there were 5,379,587 shares of Cemax-Icon Common
Stock outstanding and entitled to vote, which shares were held in the aggregate
by approximately 306 holders of record. Each holder of record of Cemax-Icon
Common Stock on the Record Date is entitled to cast one vote per share of
Cemax-Icon Common Stock on all matters properly submitted for the vote of
Cemax-Icon stockholders, exercisable in person or by properly executed proxy, at
the Special Meeting. As of the Record Date, there were 2,521,733 shares of
Cemax-Icon Preferred Stock outstanding and entitled to vote, all of which shares
were held of record by Imation. Each share of Cemax-Icon Preferred Stock is
entitled to cast 1/2.35 vote per share, or an aggregate of 1,073,077 votes, on
all matters properly submitted for the vote of the Cemax-Icon stockholders,
exercisable in person or by properly executed proxy, at the Special Meeting. The
presence, in person or by properly executed proxy, of the holders of a majority
of the voting power of the outstanding shares of Cemax-Icon Common Stock and
Cemax-Icon Preferred Stock, considered as one class, entitled to vote at the
Special Meeting is necessary to constitute a quorum at the Special Meeting.
The approval and adoption of the Merger Agreement by the stockholders
of Cemax-Icon will require the affirmative vote of the holders of a majority of
the voting power of the outstanding shares of Cemax-Icon Common Stock and
Cemax-Icon Preferred Stock, voting as one class. If an executed proxy card is
returned and the stockholder has abstained from voting on any matter, the shares
represented by such proxy will be considered present at the meeting for purposes
of determining a quorum and for purposes of calculating the vote, but will not
be considered to have been voted in favor of such matter. Accordingly,
abstentions will have the same effect as a vote against adoption of the Merger
Agreement. If an executed proxy card is returned by a broker holding shares of
Cemax-Icon Common Stock in street name which indicates that the broker does not
have discretionary authority as to certain shares to vote on the Merger
Agreement, such shares will be considered present at the meeting for purposes of
determining a quorum, but will not be considered to be represented at the
meeting for purposes of calculating the vote with respect to such matter.
As of the Record Date, the executive officers and directors of
Cemax-Icon collectively owned, directly or indirectly, approximately 3,631,000
shares of Cemax-Icon Common Stock (approximately 56% of the total voting power
of the outstanding Cemax-Icon Common Stock and Cemax-Icon Preferred Stock). In
addition, as of the Record Date the executive officers and directors hold
Cemax-Icon Stock Options covering an aggregate of approximately 393,000 shares
of Cemax-Icon Common Stock. Pursuant to the Stockholder Agreements, certain
stockholders, including certain executive officers and directors, each have
agreed to vote, and have granted Imation an irrevocable proxy to vote, all
shares of Cemax-Icon Common Stock collectively owned by them (approximately
3,530,000 shares of record of Cemax-Icon Common Stock, representing
approximately 66% of the total voting power of the outstanding Cemax-Icon Common
Stock and Cemax-Icon Preferred Stock as of the Record Date) for adoption of the
Merger Agreement. Such shares, when combined with the shares of Cemax-Icon
Preferred Stock owned by Imation, constitute approximately 71% of the voting
power of the outstanding shares entitled to vote at the Special Meeting. See
"THE MERGER--Stockholder Agreements."
As of the Record Date, neither Imation nor any of its directors and
executive officers nor their affiliates beneficially owned any shares of
Cemax-Icon Common Stock. As of the Record Date, Imation owned all 2,521,733
outstanding shares of Cemax-Icon Preferred Stock, representing approximately 17%
of the total voting power of the outstanding shares of Cemax-Icon Common Stock
and Cemax-Icon Preferred Stock as of such date.
PROXIES
All shares of Cemax-Icon Common Stock and Cemax-Icon Preferred Stock
represented at the Special Meeting by properly executed proxies received prior
to or at the Special Meeting, and not revoked, will be voted at the Special
Meeting in accordance with the instructions indicated on such proxies. If no
instructions are indicated, such proxies will be voted for adoption of the
Merger Agreement. If any other matters are properly presented at the Special
Meeting for consideration, including, among other things, consideration of a
motion to adjourn the Special Meeting to another time or place, the persons
named in the enclosed form of proxy and acting thereunder will have discretion
to vote on such matters in accordance with their best judgment.
Any proxy given pursuant to this solicitation may be revoked by the
person giving it at any time before it is voted. Proxies may be revoked by (1)
filing with the Secretary of Cemax-Icon, at or before the taking of the vote at
the Special Meeting, a written notice of revocation bearing a later date than
the proxy, (2) duly executing a later-dated proxy relating to the same shares
and delivering it to the Secretary of Cemax-Icon before the taking of the vote
at the Special Meeting, or (3) attending the Special Meeting and voting in
person (although attendance at the Special Meeting will not in and of itself
constitute a revocation of a proxy). Any written notice of revocation or
subsequent proxy should be sent so as to be delivered to Cemax-Icon, Inc., 47281
Mission Falls Court, Fremont, California 94539, Attention: Secretary, or
hand-delivered to the Secretary of Cemax-Icon at or before the taking of the
vote at the Special Meeting.
If a quorum is not obtained, or if fewer shares of Cemax-Icon Common
Stock and Cemax-Icon Preferred Stock are likely to be voted for adoption of the
Merger Agreement than the number required for adoption, the Special Meeting may
be adjourned for the purpose of obtaining additional proxies or votes or for any
other purpose, and, at any subsequent reconvening of the Special Meeting, all
proxies will be voted in the same manner as such proxies would have been voted
at the original convening of the meeting (except for any proxies which have
theretofore effectively been revoked or withdrawn), notwithstanding that they
may have been effectively voted on the same or any other matter at a previous
meeting.
Pursuant to the Merger Agreement, all expenses of this solicitation,
including the cost of preparing and mailing this Proxy Statement/Prospectus,
will be borne equally by Imation and Cemax-Icon except that each party shall pay
its own attorneys' and accountants' fees. In addition to use of the mails,
proxies may be solicited personally or by telephone or telegraph by directors,
officers and employees of Cemax-Icon, who will not be specially compensated for
such activities. Arrangements will be made with custodians, nominees and
fiduciaries for forwarding of proxy solicitation materials to beneficial owners
of shares of Cemax-Icon Common Stock held of record by such custodians, nominees
and fiduciaries, and Cemax-Icon will reimburse such custodians, nominees and
fiduciaries for reasonable expenses incurred in connection therewith.
STOCKHOLDERS SHOULD NOT SEND ANY STOCK CERTIFICATES WITH THEIR PROXY CARDS.
THE MERGER
THE FOLLOWING INFORMATION DESCRIBES THE MATERIAL ASPECTS OF THE MERGER.
THIS DESCRIPTION DOES NOT PURPORT TO BE COMPLETE AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO THE EXHIBITS HERETO, INCLUDING THE MERGER AGREEMENT,
WHICH IS ATTACHED TO THIS PROXY STATEMENT/PROSPECTUS AS EXHIBIT A AND IS
INCORPORATED HEREIN BY REFERENCE. ALL STOCKHOLDERS ARE URGED TO READ EXHIBIT A
IN ITS ENTIRETY. SEE ALSO "THE MERGER AGREEMENT."
EFFECTIVE TIME
If the Merger Agreement is adopted by the requisite vote of the
stockholders of Cemax-Icon and the other conditions to the Merger are satisfied
(or waived to the extent permitted), the Merger will be effected at the time and
date the Certificate of Merger is filed with the Secretary of State of the State
of Delaware. The Merger Agreement may be terminated prior to the Effective Time
by either Imation or Cemax-Icon in certain circumstances. See "THE MERGER
AGREEMENT--Termination."
EFFECTS OF THE MERGER
Upon consummation of the Merger, (a) Merger Subsidiary will merge with
and into Cemax-Icon, which will be the Surviving Corporation, (b) Cemax-Icon
will become a wholly owned subsidiary of Imation, (c) each share of Cemax-Icon
Common Stock outstanding immediately prior to the Effective Time (other than
Dissenting Shares or shares owned by Imation, Merger Subsidiary or Cemax-Icon)
will be converted into and become (i) a cash payment of $5.25, without interest
thereon, (the "1997 Cash Consideration") and (ii) one Contingent Payment Right
(collectively with the 1997 Cash Consideration, the "Merger Consideration") and
(d) each share of Cemax-Icon Preferred Stock will be canceled and extinguished,
and no payment will be made therefor. See "DESCRIPTION OF CONTINGENT PAYMENT
RIGHTS." An aggregate of up to $200,000 may be withheld from the initial
payments to stockholders in a separate fund for reimbursement of the
Stockholders' Representatives' out-of pocket-expenses in acting on behalf of
stockholders of Cemax-Icon in connection with the Merger. See "--Stockholders'
Representatives' Fund."
As of the Record Date, there were 5,379,587 shares of Cemax-Icon Common
Stock outstanding. The cash cost to Imation of acquiring all of such shares of
Cemax-Icon Common Stock in the Merger will be approximately $28,243,000 with
regard to the 1997 Cash Consideration and, in addition, approximately
$45,726,000 if the Contingent Payment Rights are paid in full and in cash.
CONVERSION OF CEMAX-ICON COMMON STOCK
As of the Effective Time, Imation will deposit, or will cause to be
deposited, with First Trust Company (the "Paying Agent"), for the benefit of the
holders of shares of Cemax-Icon Common Stock, for exchange in accordance with
the terms of the Merger Agreement, cash in the amount of the 1997 Cash
Consideration (the "Payment Fund") payable pursuant to the Merger Agreement in
exchange for outstanding shares of Cemax-Icon Common Stock. The Payment Fund
will not be used for any other purpose.
Within three business days after the Effective Time, Imation will
instruct the Paying Agent to mail to each holder of record of a certificate or
certificates which immediately prior to the Effective Time represented
outstanding shares of Cemax-Icon Common Stock (the "Certificates") (i) a letter
of transmittal in customary form (which will specify that delivery will be
effected, and risk of loss and title to the Certificates will pass, only upon
proper delivery of the Certificates to the Paying Agent), and (ii) instructions
for use in effecting the surrender of the Certificates in exchange for the
Merger Consideration. Upon surrender of a Certificate for cancellation to the
Paying Agent, together with a letter of transmittal, duly executed, and any
other documents as may be reasonably required pursuant to such instructions, the
holder of the Certificate will be entitled to receive in exchange the 1997 Cash
Consideration and Contingent Payment Rights, in each case which such holder is
entitled to receive in the Merger with respect to the shares of Cemax-Icon
Common Stock formerly represented by such Certificate, and the Certificate so
surrendered will forthwith be canceled. Until surrendered, each Certificate
shall be deemed at any time after the Effective Time to represent only the right
to receive the Merger Consideration with respect to the shares of Cemax-Icon
Common Stock formerly represented by such Certificate.
Any portion of the Payment Fund remaining undistributed one year after
the Effective Time will be returned to Imation, upon demand, and any holders of
theretofore unsurrendered Cemax-Icon Common Stock will thereafter be able to
look only to Imation for any portion of the Payment Fund to which they are
entitled.
STOCKHOLDERS OF CEMAX-ICON SHOULD NOT FORWARD THEIR STOCK CERTIFICATES TO
THE EXCHANGE AGENT WITHOUT A LETTER OF TRANSMITTAL AND SHOULD NOT RETURN
THEIR STOCK CERTIFICATES WITH THE ENCLOSED PROXY.
STOCKHOLDERS' REPRESENTATIVES' FUND
Pursuant to a separate agreement between the Paying Agent and such
persons identified as stockholders' representatives in the Merger Agreement (the
"Stockholders' Representatives"), the Paying Agent will withhold up to $200,000
from the initial payments of 1997 Cash Consideration in a separate fund (the
"Representatives' Fund") for reimbursement of the Stockholders' Representatives'
out-of-pocket expenses in acting on behalf of Cemax-Icon's stockholders in
connection with the Merger before and after the Effective Time. The Paying Agent
will distribute any remaining amounts in the Representatives' Fund to
Cemax-Icon's stockholders after the Stockholders' Representatives have completed
their representation of Cemax-Icon's stockholders in connection with the Merger
before and after the Effective Time.
The initial Stockholders' Representatives designated in the Merger
Agreement are Michael O'Donnell, Secretary of Cemax-Icon, and David Titus, a
director of Cemax-Icon. By voting to approve the Merger Agreement and the
Merger, stockholders of Cemax-Icon are also approving the initial appointment of
Messrs. O'Donnell and Titus as the Stockholders' Representatives.
EFFECT OF THE MERGER ON CEMAX-ICON STOCK OPTIONS AND CEMAX-ICON WARRANTS
At the Effective Time, Imation will assume the obligations of
Cemax-Icon under the Cemax-Icon, Inc. 1996 Stock Plan, the Icon Medical Systems,
Inc. 1992 Stock Option Plan and the Cemax/Icon, Inc. 1986 Amended Incentive
Stock Plan (collectively, the "Cemax-Icon Option Plans"), and each option to
purchase Cemax-Icon Common Stock (a "Cemax-Icon Stock Option") granted under the
Cemax-Icon Option Plans and outstanding immediately prior to the Effective Time
(an "Outstanding Stock Option") will become an option to acquire Imation Common
Stock on the same terms and conditions as were applicable under the relevant
Cemax-Icon Option Plans (a "Substitute Option"), except that (i) the number of
shares subject to each option and the exercise price will be appropriately
adjusted to give effect to Common Exchange Ratio, as defined below, (ii) each
Substitute Option that replaces an Outstanding Stock Option that vests at the
rate of either (x) 25% per year during the first year and 2% per month
thereafter or (y) 2% per month, will vest at the rate of 4% per month during the
first 12 months after the Effective Time and (iii) each Substitute Option that
replaces an Outstanding Stock Option held by a consultant, contractor or
non-employee director will not be subject to early termination as a result of
termination of status as a consultant, contractor or non-employee director of
Cemax-Icon or the Surviving Corporation and in the event of such termination
will vest and become exercisable in full (including as to shares not otherwise
exercisable as of the date of such termination).
Each outstanding warrant to purchase shares of Cemax-Icon Common Stock
outstanding immediately prior to the Effective Time (a "Cemax-Icon Warrant")
will be converted into a warrant to acquire Imation Common Stock on the same
terms and conditions as were applicable under the Cemax-Icon Warrant (a
"Substitute Warrant"), except that the number of shares subject to each warrant
and the exercise price will be appropriately adjusted to give effect to the
Common Exchange Ratio.
The Merger Agreement defines the Common Exchange Ratio as the quotient
of (i) $11.96 and (ii) the average closing price per share of Imation Common
Stock on the New York Stock Exchange--Composite Transactions, as reported in The
Wall Street Journal, for each of the 10 consecutive trading days ending on the
third business day prior to the Effective Time. On __________, 1997, the closing
price per share of Imation Common Stock was $__________.
BACKGROUND OF THE MERGER; RELATIONSHIP BETWEEN CEMAX-ICON AND IMATION
In early 1994, 3M's Medical Imaging Systems Division (now Imation's
medical imaging systems business unit) initiated an investigation of outside
partnering options which would allow 3M to add medical image management systems
products and expertise to its conventional and electronic hardcopy imaging
business. After examining various alternatives, 3M and Cemax-Icon entered into a
joint development and OEM sales relationship to integrate the component
technology and development programs of 3M's laser imaging interface systems and
Cemax-Icon's visualization and image management infrastructure systems.
In early 1995, as a result of 3M's strategic review of its medical
imaging portfolio, 3M redirected its internal development resources away from
image management products, relying more heavily on the broad range of
development and products available from Cemax-Icon. A distribution agreement was
formalized under which 3M became the exclusive private label distributor for
Cemax-Icon products in Europe. In addition, 3M and Cemax-Icon entered into a
three-year sales agreement providing for the assumption by Cemax-Icon of the
service and warranty obligations of 3M with regard to 17 PACS customer sites in
exchange for the payment by 3M to Cemax-Icon of approximately $1.0 million and
for the referral by 3M of customer leads to Cemax-Icon from sales to such
customers.
In June 1995, 3M made an equity investment of $6.9 million in
Cemax-Icon under which 3M acquired 1,985,878 shares of Cemax-Icon Preferred
Stock (representing approximately 15% of the outstanding capital stock of
Cemax-Icon at that time) and a warrant to purchase 467,267 shares of Cemax-Icon
Common Stock at an exercise price of $5.50 per share. In May 1996, Cemax-Icon
and Imation agreed to amend the warrant to reduce the exercise price to $4.25
per share and to provide that the warrant would be exercisable for 535,855
shares of Cemax-Icon Preferred Stock. Imation exercised the warrant in full in
September 1996.
In May 1996, Cemax-Icon began preparing for an initial public offering
of Cemax-Icon Common Stock based on its June 1996 financial results. The primary
purpose of the proposed initial public offering was to provide funds to
Cemax-Icon for the further growth of its business.
Beginning in August 1996, following the spin-off of Imation by 3M,
Imation and Cemax-Icon began preliminary discussion of the possible acquisition
of Cemax-Icon by Imation.
In September 1996, management of Cemax-Icon decided to postpone the
proposed initial public offering due to market conditions. As discussed above,
Imation exercised its warrant for $2.3 million of Cemax-Icon Preferred Stock in
September 1996.
Discussions between Imation and Cemax-Icon regarding a possible
acquisition continued on an ongoing basis during late 1996 and early 1997. On
March 14, 1997, Imation and Cemax-Icon signed a Letter of Intent setting forth
the basic terms for the proposed acquisition. Following the execution of the
Letter of Intent, Imation conducted its due diligence review of Cemax-Icon's
business, and Imation and Cemax-Icon negotiated the terms of the Merger
Agreement and the ancillary agreements.
On May 12, 1997, the Board of Directors of Cemax-Icon unanimously
approved the Merger Agreement and the ancillary agreements. On May 13, 1997, the
Board of Directors of Imation unanimously approved the Merger Agreement and the
ancillary agreements. The Merger Agreement and the ancillary agreements were
executed by Imation and Cemax-Icon on May 13, 1997.
CEMAX-ICON'S REASONS FOR THE MERGER; RECOMMENDATION OF CEMAX-ICON'S BOARD OF
DIRECTORS
By the unanimous vote of the entire Board of Directors of Cemax-Icon,
at a special meeting held on May 12, 1997, the Cemax-Icon Board of Directors
determined that the proposed Merger, and the terms and conditions of the Merger
Agreement, were in the best interests of Cemax-Icon and its stockholders. The
Merger Agreement and the Merger were approved unanimously by the entire Board of
Directors of Cemax-Icon, who also unanimously resolved to recommend that the
stockholders of Cemax-Icon vote FOR approval and adoption of the Merger
Agreement. See "--Background of the Merger; Relationship Between Cemax-Icon and
Imation." In reaching its conclusion to enter into the Merger Agreement and to
recommend that the stockholders of Cemax-Icon vote for the approval and adoption
of the Merger Agreement, the Board of Directors of Cemax-Icon considered a
number of factors, including, without limitation and without assigning relative
weights thereto, the following:
Similar Customer Base/Complementary Products
Both Cemax-Icon and Imation market their products to the same customer
base--users of medical images. Customers have requirements for both conventional
images and digital images. In either case, these images need to be managed and
customers look to film companies such as Imation to help provide them with image
management products and solutions. Consequently, Cemax-Icon expects that certain
sales synergies will result from the Merger.
Financial Resources
Customers primarily want to purchase an image management system (i.e.,
network infrastructure) from a larger, stable organization with a reputation for
performing on large "mission critical" projects such as an image management
system. As a stand-alone company, Cemax-Icon would continue to need to overcome
the "small company, limited resources" customer objection.
In addition, financial resources to fund growth was increasingly
becoming an issue for Cemax-Icon, particularly in light of the decision by
management, based on market conditions, to postpone the proposed initial public
offering in September 1996. The Board of Directors of Cemax-Icon believes that
Imation's current resources and access to public markets will allow Cemax-Icon
increased operating flexibility and the opportunity to pursue development
activities.
Service Capability
An image management system is "mission critical" to the operation of a
radiological department. Service availability and capability is perhaps more
important than product features in many instances. Cemax-Icon, while having
specific technical capability, was understaffed in many geographic areas. Cemax-
Icon viewed Imation as having a strong service presence throughout the U.S. and
Europe.
Market Position
Cemax-Icon has a leadership position in market share of the image
management marketplace. Imation has an established loyal customer base and
market share of the medical film marketplace. Certain synergies are expected by
Cemax-Icon's management due to cross-selling into these markets.
Working Relationship
There is a three-year history of cooperative working relationships
between Cemax-Icon and Imation in terms of personnel, technical development,
operational plans and strategies and coordination of these strategies.
Cemax-Icon expects that the combination of the two companies will be more
efficient and profitable than operating Cemax-Icon as a stand-alone unit.
FOR THE FOREGOING REASONS, THE BOARD OF DIRECTORS OF CEMAX-ICON
BELIEVES THAT THE TERMS OF THE MERGER ARE FAIR TO THE STOCKHOLDERS OF CEMAX-ICON
AND RECOMMENDS THAT THE STOCKHOLDERS OF CEMAX-ICON VOTE FOR APPROVAL AND
ADOPTION OF THE MERGER AGREEMENT.
IMATION'S REASONS FOR THE MERGER
Imation's medical imaging systems business competes in the conventional
x-ray film/screen supply business with market presence in the United States and
strong presence in certain selected European regional markets. Imation is also a
world leader in the electronic hardcopy recording segment of the medical imaging
market, based on the continued strength of its traditional wet chemistry based
laser imaging systems and the broad market acceptance of its new Dry View(TM),
dry processed diagnostic laser imaging systems. These markets continue to be the
core of the medical imaging industry and Imation expects to continue to invest
and compete in these markets.
Imation believes that two significant developments will affect the
markets for the medical imaging industry: (i) the use of electronic acquisition
technologies to capture imaging information in digital form and (ii) the
development of image management systems for the processing, display and storage
of diagnostic digital image and information data.
The first of these developments is expected, in the long-term, to lead
to the replacement of conventional film/screen materials as the method for
acquiring images. Already, a significant percentage of exams are conducted using
electronic modalities such as CT, MRI, nuclear medicine and ultrasound. The
second development, transition to electronic viewing and diagnosis, will benefit
from the development of these electronic modalities as sources of digital image
data and are expected to provide significant efficiency and cost improvements
through the ability to provide complete data where and when it is needed
throughout an integrated health care delivery system.
The core business of conventional and electronic hardcopy will continue
to be a major part of Imation's medical imaging business. The image management
systems segment adds a dynamic, potentially high-growth component to Imation's
portfolio. Imation's management believes this segment is attractive both for its
stand-alone value and for its leveraged value when combined with the current
core businesses in which Imation participates.
After examining a number of internal developments and outside
partnering opportunities, Imation's management believes that the best
opportunity to participate in the image management systems market is through the
acquisition of Cemax-Icon. The leadership, products, market position and
established business of Cemax-Icon provide an immediate path to the market in
this segment. Imation brings potentially significant synergies to the combined
operation, including a well-established sales and service organization and the
Imation portfolio of products in conventional film/screen imaging, electronic
hardcopy recording and magnetic and optical removable data storage. Imation's
management believes this combination will provide significant benefits in the
delivery of integrated workflow solutions to the health care industry.
INTERESTS OF CERTAIN PERSONS IN THE MERGER
The Board of Directors of Cemax-Icon was aware of the interests of
certain persons in the Merger described below, which are in addition to the
interests of Cemax-Icon stockholders generally, and considered those interests,
among other matters, in approving the Merger Agreement and the transactions
contemplated thereby.
Stock Options and Warrants
The Merger Agreement provides that, after the Effective Time, each
Cemax-Icon Stock Option (including Cemax-Icon Stock Options held by Cemax-Icon's
executive officers and directors) will be converted into a Substitute Option.
Likewise, each Cemax-Icon Warrant (including Cemax-Icon Warrants held by
Cemax-Icon's executive officers and directors) will be converted into a
Substitute Warrant. See "--Effect of the Merger on Cemax-Icon Stock Options and
Cemax-Icon Warrants." Of the approximately 1,181,000 Cemax-Icon Stock Options
outstanding on the Record Date, approximately 393,000 were held by directors and
executive officers of Cemax-Icon. Of the 150,000 Cemax-Icon Warrants outstanding
on the Record Date, 7,500 were held by a director of Cemax-Icon. Cemax-Icon
Stock Options are held by the following directors and executive officers of
Cemax-Icon: Terry Ross, Jeremy B. Rubin, M.D., David Titus, David White, Gregory
C. Patti, Oran E. Mudrugolu, Jean Luc-Chatelain and Grady Floyd. David Titus is
the sole director of Cemax-Icon who holds a Cemax-Icon Warrant.
Key Management Agreements
In connection with the execution of the Merger Agreement, Cemax-Icon
entered into agreements ("Key Management Agreements") with eight of its key
management employees (seven of whom serve as officers of Cemax-Icon and two of
whom are also directors of Cemax-Icon). Each of such agreements will become
effective at the Effective Time.
The form of Key Management Agreement provides, in general, for the
employment of the key management employee by the Surviving Corporation for a
term ranging from 18 months to 3 years following the Effective Time, in a
position with duties and responsibilities substantially consistent with the
duties and responsibilities of such employee immediately prior to the Effective
Time. The form of Key Management Agreement provides in general for (i) base
compensation consistent with base compensation prior to the Effective Time, (ii)
continued participation in the Cemax-Icon incentive pay plan under the modified
terms and conditions set forth in each Key Management Agreement and (iii) other
benefits provided to executive-level employees of the Surviving Corporation from
time to time. Following termination of employment and subject to the nature of
such termination, the Key Management Agreements provide for (i) continuation of
base compensation, incentive compensation and certain benefits for a period of
up to six months following the term of such Agreement and (ii) modified vesting
and termination provisions relating to the Substitute Options held by such
employee.
Cemax-Icon entered into Key Management Agreements substantially in the
form described above with Terry Ross, Jeremy B. Rubin, M.D., Gregory C. Patti,
Oran E. Mudrugolu, Jean-Luc Chatelain, Grady Floyd, Mark Falkowski and Keith
McKinnon. The Key Management Agreements with Messrs. Ross, Patti, Chatelain and
Floyd also provide for the grant, at the Effective Time, of an option to acquire
shares of Imation Common Stock under the Imation 1996 Employee Stock Incentive
Program in lieu of certain restricted shares of Cemax-Icon Common Stock held by
such employees which will be returned to Cemax-Icon for cancellation.
Each person who entered into a Key Management Agreement also entered
into, as a condition thereof, an Employee Agreement with Imation that restricts
such person's activities with respect to confidential information and future
employment. See "--Employment Agreements."
Consulting Agreement
In connection with the execution of the Merger Agreement, Cemax-Icon
also entered into an agreement (the "Consulting Agreement") with one of its
directors, Dr. David White, providing for a term expiring on June 30, 1999. The
Consulting Agreement will become effective at the Effective Time and provides
for (i) a consulting fee of $2,000 per month, (ii) the grant of an option to
purchase shares of Imation Common Stock under the Imation 1996 Employee Stock
Incentive Program and (iii) restrictions with respect to the use of confidential
information.
Noncompetition Agreements
In connection with the execution of the Merger Agreement, Cemax-Icon
entered into agreements ("Noncompetition Agreements") with eight of its
stockholders (seven of whom are officers of Cemax-Icon and two of whom are also
directors of Cemax-Icon), pursuant to which each such stockholder agreed, among
other things, that: (i) for a specified period he will not, directly or
indirectly, engage or invest in, own, manage, operate, finance, control, or
participate in the ownership, management, operation, financing, or control of,
be employed by, lend his name or any similar name to, lend his credit to, or
render services or advice to, any business whose products or activities compete
in whole or in part with the products or activities of Cemax-Icon as in
existence or proposed to be developed or acquired by Cemax-Icon on the date of
the Noncompetition Agreement and conducted by any of Imation or its subsidiaries
after the Effective Time; provided, however, that he may purchase or otherwise
acquire up to (but not more than) one percent of any class of securities of any
enterprise (but without otherwise participating in the activities of such
enterprise) if such securities are listed on any national or regional securities
exchange or have been registered under Section 12(g) of the Exchange Act; (ii)
he will not, directly or indirectly, either for himself or any other person, (a)
induce or attempt to induce any employee of any of Imation or its subsidiaries
to leave the employ of such Imation or its subsidiaries, (b) in any way
interfere with the relationship between Imation or its subsidiaries and any
employee of such Imation or its subsidiaries, (c) without the prior written
consent of Imation employ, or otherwise engage as an employee, independent
contractor or otherwise, any person who has been an employee of Cemax-Icon or
Imation or its subsidiaries during the six months preceding such employment or
(d) induce or attempt to induce any customer, supplier, licensee or business
relation of Imation or its subsidiaries to cease doing business with such
Imation or its subsidiaries, or in any way interfere with the relationship
between any customer, supplier, licensee or business relation of Imation or its
subsidiaries and (iii) he will not, directly or indirectly, either for himself
or any other person, solicit the business of any person known to him to be a
customer of Imation or its subsidiaries, whether or not he had personal contact
with such person, with respect to products or activities which compete in whole
or in part with the products or activities of Cemax-Icon as in existence or
proposed to be developed or acquired by Cemax-Icon on the date of the
Noncompetition Agreement and conducted by any of Imation or its subsidiaries
after the Effective Time.
Cemax-Icon entered into Noncompetition Agreements substantially in the
form described above with Terry Ross, Jeremy B. Rubin, M.D., Gregory C. Patti,
Oran E. Mudrugolu, Jean-Luc Chatelain, Grady Floyd, Mark Falkowski and Keith
McKinnon.
MANAGEMENT OF CEMAX-ICON AFTER THE MERGER
Cemax-Icon will be the Surviving Corporation in the Merger and will
become a wholly owned subsidiary of Imation upon consummation of the Merger. The
directors of Merger Subsidiary immediately prior to the Effective Time will be
the initial directors of the Surviving Corporation, and the officers of Merger
Subsidiary immediately prior to the Effective Time will be the initial officers
of the Surviving Corporation. Imation currently expects that, after the
Effective Time, it will retain most of the executive officers of Cemax-Icon
immediately prior to the Effective Time with duties substantially similar to
those of such executive officers prior to the Effective Time, and that Terry
Ross and Jeremy B. Rubin, M.D., who are currently directors and executive
officers of Cemax-Icon, will be elected to the Board of Directors of Cemax-Icon
following the Effective Time.
OPTION AGREEMENT
As a condition to the willingness of Imation to execute the Merger
Agreement, concurrently with the execution of the Merger Agreement, Cemax-Icon
and Imation entered into an option agreement (the "Option Agreement") pursuant
to which Cemax-Icon granted to Imation an option (the "Option") to purchase up
to 1,075,917 shares of Cemax-Icon Common Stock at a price of $11.96 per share.
Imation will be able to exercise the Option, in whole or in part, at any time
and from time to time, on or before December 31, 1997, unless the Merger
Agreement is terminated because of a material misrepresentation, material breach
of a warranty or material breach of a covenant by Imation or Merger Subsidiary
under the Merger Agreement. In addition, Imation will be entitled to
registration rights with respect to any shares of Cemax-Icon Common Stock
acquired by Imation pursuant to the Option Agreement.
STOCKHOLDER AGREEMENTS
As a condition to the willingness of Imation to execute the Merger
Agreement, concurrently with the execution of the Merger Agreement, certain
stockholders of Cemax-Icon, who collectively had record ownership of
approximately 3,530,000 shares of Cemax-Icon Common Stock as of the Record Date
(representing approximately 66% of the total voting power of the outstanding
Cemax-Icon Common Stock and Cemax-Icon Preferred Stock as of such date), entered
into separate Stockholder Agreements with Imation, pursuant to which such
stockholders, in such capacity, have agreed to vote, and have granted to Imation
an irrevocable proxy to vote, such shares (and any other shares of Cemax-Icon
Common Stock acquired after the date of the Merger Agreement, including shares
acquired pursuant to the exercise of any rights to purchase or otherwise acquire
shares) in favor of approval of the Merger Agreement and Merger. In addition,
under the Stockholder Agreements, such stockholders have agreed that, if
Cemax-Icon seeks a vote of its stockholders with respect to (i) any proposal
made in opposition to or competition with consummation of the Merger, (ii) any
merger, consolidation, sale of assets, reorganization or recapitalization, with
any party other than Imation, Merger Subsidiary and their affiliates or (iii)
any liquidation or winding up of Cemax-Icon (each of (i), (ii) and (iii), an
"Opposing Proposal"), such stockholders will vote against such Opposing
Proposal. Also, under the Stockholder Agreements, such stockholders have also
agreed (i) not to solicit, initiate or encourage submission of any proposal or
offer from any person, group or entity relating to any acquisition of the
assets, business or capital stock of Cemax-Icon, or other similar transaction or
business combination involving the business of Cemax-Icon, (ii) not to
participate in any negotiations or discussions regarding or furnish to any other
person any information with respect to, or otherwise cooperate in any way with,
or assist or participate in, facilitate or encourage any effort or attempt by
any other person or entity to do or seek such acquisition or transaction and
(iii) to inform Imation of any inquiry regarding the foregoing (i) and (ii). The
Stockholder Agreements, other than the provisions relating to the grant of an
irrevocable proxy, terminate on the earlier to occur of (1) the Effective Time
or (2) such date and time as the Merger Agreement shall be terminated pursuant
to Article VIII of the Merger Agreement. Such stockholders received no monetary
consideration for entering into the Stockholder Agreements. See "THE
MERGER--Stockholder Agreements."
EMPLOYEE AGREEMENTS
As a condition to the obligations of Imation and Merger Subsidiary to
effect the Merger, each employee of Cemax-Icon will enter into Employee
Agreements with Imation pursuant to which such employee will agree, among other
things, that (i) Inventions (as defined below) with which such employee has had
any relationship will be owned entirely by Imation, (ii) such employee will not
use or disclose to any third party any Confidential Information (as defined
below) and will not own, operate or render services, directly or indirectly, as
an employee or consultant, advisor or in any other capacity to, a Conflicting
Organization (as defined below), (iii) such employee will provide written notice
to Imation of an employment offer with a Conflicting Organization (as defined
below) and will not, if Imation makes a timely election in response to the
written notice, directly or indirectly, render services to any Conflicting
Organization in the United States or in any country in which Imation has a plant
for manufacturing a product upon which such employee works during such
employee's employment with Imation or, if such employee is employed in a sales
capacity, will not render services in the United States, directly or indirectly,
to any Conflicting Organization in connection with the development or
manufacture of any Conflicting Product (as defined below) or the marketing,
sale, merchandising, leasing, servicing or promotion of any Conflicting Product
to any person or organization upon which such employee called during the last
three years of such employee's employment with Imation, or whose account such
employee supervised on behalf of Imation at any time during the last three years
of such employee's employment by Imation and (iv) any claims or controversies
arising between such employee and Imation relating to such employee's employment
with Imation or termination thereof, and any violation of state or federal law
will be resolved by arbitration in accordance with the applicable law or
arbitration rules of the American Arbitration Association.
Confidential Information means information, not generally known, and
confidential to Imation, including all (i) trade secret information about
Imation's processes and products, (ii) information relating to research,
development, manufacture, purchasing, accounting, engineering, marketing,
merchandising, selling, leasing, servicing finance and business systems and
techniques including customer or supplier lists, or similar information of a
third party who has entrusted such information to Imation, and (iii) all
information that has been or will be disclosed to such employee, or to which
such employee has obtained or will obtain access, whether originated by such
employee or by others, during the period of such employee's employment by
Imation, which such employee has reasonable basis to believe is confidential
information. Notwithstanding the foregoing, Confidential Information shall not
include information which is lawfully disclosed to such employee by a third
party after the period of such employee's employment by Imation.
Inventions means discoveries, improvements and ideas (whether or not
shown or described in writing or reduced to practice), mask works (topography or
semiconductor chips) and works of authorship, whether or not patentable,
copyrightable or registerable, (i) which relate directly to the business of
Imation, (ii) which relate to Imation's actual or demonstrably anticipated
research or development, (iii) which result or have resulted from any work
performed by such employee for Imation, (iv) for which equipment, supplies,
facility or Confidential Information of Imation is or have been used or (v)
which are or have been developed on any Imation time.
Conflicting Product means any product, process, system or service of
any person or organization other than Imation, in existence or under
development, which is the same as or similar to or competes with, or has a usage
allied to, a product, process, system or service upon which such employee works
(in either a sales or a non-sales capacity) during the last three years of
employment by Imation, or about which such employee acquires Confidential
Information.
Conflicting Organization means any person or organization which is
engaged in or about to become engaged in, research on or development,
production, marketing, leasing, selling, licensing, or servicing of a
Conflicting Product.
AFFILIATE AGREEMENTS
In connection with the execution of the Merger Agreement, certain
persons deemed by Cemax-Icon as potential "affiliates" of Cemax-Icon for
purposes of the federal securities laws (an "Affiliate") entered into Affiliate
Agreements with Imation pursuant to which such Affiliate agreed (i) not to make
any sale, transfer or other disposition of Imation Common Stock in violation of
the Securities Act or Rule 145 of the SEC under the Securities Act and (ii) not
to sell, transfer or otherwise dispose of Imation Common Stock issued to such
Affiliate upon payment of the Contingent Payment Rights unless such sale,
transfer or other disposition is made in conformity with the requirements of
Rule 145 of the SEC under the Securities Act.
ACCOUNTING TREATMENT
The Merger will be accounted for under the purchase method of
accounting under which the total consideration paid in the Merger will be
allocated among the Surviving Corporation's consolidated assets and liabilities
based on the fair values of the assets acquired and liabilities assumed as
provided for under generally accepted accounting principles.
CERTAIN FEDERAL INCOME TAX CONSEQUENCES
Under currently existing provisions of the Internal Revenue Code of
1986, as amended (the "Code"), the Treasury Regulations promulgated thereunder,
applicable judicial decisions and administrative rulings, all of which are
subject to change, the federal income tax consequences described below are
expected to arise in connection with the Merger. Due to the complexity of the
Code, the following discussion is limited to the material federal income tax
aspects of the Merger for a Cemax-Icon stockholder who is a citizen or resident
of the United States and who, on the date of disposition of such holder's shares
of Cemax-Icon Common Stock, holds such shares as a capital asset. The general
tax principles discussed below are subject to retroactive changes that may
result from subsequent amendments to the Code. The following discussion does not
address potential foreign, state, local and other tax consequences, nor does it
address tax consequences with respect to holders of Cemax-Icon Stock Options or
Cemax-Icon Warrants, nor does it address taxpayers subject to special treatment
under the federal income tax laws, such as life insurance companies, tax-exempt
organizations, S corporations and taxpayers subject to the alternative minimum
tax. In addition, the following discussion may not apply to Cemax-Icon
stockholders who acquired their shares upon the exercise of employee stock
options or otherwise as compensation. Neither the Cemax-Icon nor Imation has
requested either the Internal Revenue Service or counsel to rule or issue an
opinion on the federal income tax consequences of the Merger. ALL STOCKHOLDERS
ARE URGED TO CONSULT THEIR OWN TAX ADVISORS REGARDING THE FEDERAL, FOREIGN,
STATE AND LOCAL TAX CONSEQUENCES OF THE DISPOSITION OF THEIR SHARES IN THE
MERGER.
For federal income tax purposes, the Merger will be treated as a
taxable sale or exchange of Cemax-Icon Common Stock for cash (including any
amount retained in the Representatives' Fund) and the Contingent Payment Right
by each holder of the Cemax-Icon Common Stock (including any holder of shares
who properly exercises dissenter's rights). Accordingly, the federal income tax
consequences to the Cemax-Icon stockholders will generally be as follows:
(i) Assuming that the shares of Common Stock exchanged by a Cemax-Icon
stockholder for cash in connection with the Merger are capital assets in the
hands of the stockholder at the Effective Time, such stockholder may recognize a
capital gain or loss by reason of the consummation of the Merger.
(ii) A Cemax-Icon stockholder who expects to recognize a gain as a
result of the Merger should be able to treat the disposition of the Cemax-Icon
Common Stock and the receipt of cash and a Contingent Payment Right as giving
rise to an installment sale subject to the provisions of Section 453 of the
Code. Such stockholders should consult with their own tax advisors regarding the
application of the installment sale provisions of the Code, the amount of gain
to be recognized in the year of the Merger, and the possible application of the
rules requiring the payment of an interest charge on deferred tax liabilities
arising in connection with certain installment sales as provided in Section 453A
of the Code.
(iii) The capital gain or loss, if any, will be long-term with respect
to shares of Cemax-Icon Common Stock held for more than twelve (12) months as of
the Effective Time and short-term with respect to such shares held for twelve
(12) months or less.
(iv) The receipt of additional cash or Imation Common Stock by a
Cemax-Icon stockholder pursuant to the Contingent Payment Right should also
result in the recognition of capital gain; provided that a portion of any such
cash or Imation Common Stock received by a Cemax-Icon stockholder will be
taxable as a ordinary interest income. The amount of such interest income will
be based on (i) the amount of any such payment pursuant to the Contingent
Payment Right, (ii) the length of time between the Effective Time of the Merger
and the date of any such payment, and (iii) the short-term applicable federal
rate as provided in the Code as of the Effective Time of the Merger. While such
short-term applicable federal rate is not presently known, the current
short-term applicable federal rate is __%, compounded semi-annually. Cemax-Icon
stockholders should consult with their own tax advisors regarding the amount of
such ordinary interest income.
Payments made pursuant to the Merger (including any cash paid to a
holder of shares who properly exercises dissenter's rights and any payments
pursuant to the Contingent Payment Right) will be reported to the extent
required by the Code to Cemax-Icon stockholders and the Internal Revenue
Service. Such amounts will ordinarily not be subject to withholding of U.S.
federal income tax. However, backup withholding of such tax at a rate of 31% may
apply to certain stockholders by reason of the events specified in Section 3406
of the Code and the Treasury Regulations promulgated thereunder, which include
failure of a stockholder to supply Cemax-Icon or its agent with such
stockholder's taxpayer identification number. Accordingly, Cemax-Icon
stockholders will be asked to provide the stockholder's correct taxpayer
identification number on a Substitute Form W-9 which is to be included in the
appropriate letter of transmittal for the Cemax-Icon shares. Withholding may
also apply to Cemax-Icon stockholders who are otherwise exempt from such
withholding, such as a foreign person, if such person fails to properly document
its status as an exempt recipient.
NO INFORMATION IS PROVIDED HEREIN WITH RESPECT TO THE TAX CONSEQUENCES,
IF ANY, OF THE MERGER UNDER APPLICABLE FOREIGN, STATE, LOCAL AND OTHER TAX LAWS
OR WITH RESPECT TO THE CEMAX-ICON STOCK OPTIONS OR THE CEMAX-ICON WARRANTS. THE
FOREGOING DISCUSSION IS BASED UPON THE PROVISIONS OF THE CODE, APPLICABLE
TREASURY REGULATIONS THEREUNDER, INTERNAL REVENUE SERVICE RULINGS AND JUDICIAL
DECISIONS, AS IN EFFECT AS OF THE DATE HEREOF. THERE CAN BE NO ASSURANCE THAT
FUTURE LEGISLATIVE, ADMINISTRATIVE OR JUDICIAL CHANGES OR INTERPRETATIONS WILL
NOT AFFECT THE ACCURACY OF THE STATEMENTS OR CONCLUSIONS SET FORTH HEREIN. ANY
SUCH CHANGE COULD APPLY RETROACTIVELY AND COULD AFFECT THE ACCURACY OF SUCH
DISCUSSION. NO RULINGS HAVE OR WILL BE SOUGHT FROM THE INTERNAL REVENUE SERVICE
CONCERNING THE TAX CONSEQUENCES OF THE MERGER.
DISSENTERS' RIGHTS OF APPRAISAL
General
Under the Delaware General Corporation Law ("DGCL") any holder of
Cemax-Icon Common Stock on the date of the Demand (as defined below) who holds
such shares continually through the Effective Time and follows the procedures
set forth in Section 262 of the DGCL ("Section 262") will be entitled to have
his Cemax-Icon Common Stock appraised by the Delaware Court of Chancery and to
receive payment in cash of the "fair value" of such Cemax-Icon Common Stock,
exclusive of any element of value arising from the accomplishment or expectation
of the Merger, as determined by such Court.
Procedure
Under Section 262, where a merger is to be submitted for approval at a
meeting of stockholders, the corporation, not less than 20 days prior to the
meeting, must notify each of its stockholders who was such on the record date
for the meeting with respect to shares for which appraisal rights are available
under Section 262 that such appraisal rights are available and include in such
notice a copy of Section 262. This Proxy Statement/Prospectus constitutes such
notice to the holder of Cemax-Icon Common Stock and Section 262 is attached to
this Proxy Statement/Prospectus as Exhibit B.
A holder of Cemax-Icon Common Stock wishing to exercise his appraisal
rights must deliver to Cemax-Icon, before the vote of the holders of Cemax-Icon
Common Stock with respect to the Merger Agreement, a written demand for
appraisal (the "Demand") of his shares and must not vote in favor of approving
the Merger Agreement. Because a proxy which does not contain voting instructions
will, unless revoked, be voted FOR adoption of the Merger Agreement, a holder of
Cemax-Icon Common Stock who votes by proxy and who wishes to exercise his
appraisal rights must (i) vote AGAINST the adoption of the Merger Agreement or
(ii) ABSTAIN from voting on the adoption of the Merger Agreement. A vote against
approval of the Merger Agreement, in person or by proxy, will not in and of
itself constitute a written demand for appraisal satisfying the requirements of
Section 262.
Only a holder of record of Cemax-Icon Common Stock is entitled to
assert appraisal rights for the Cemax-Icon Common Stock registered in that
holder's name. A demand for appraisal should be executed by or on behalf of the
holder of record, fully and correctly, as such holder's name appears on his
stock certificates. If the shares of Cemax-Icon Common Stock are owned of record
in a fiduciary capacity, such as by a trustee, guardian or custodian, execution
of the Demand must be made by the fiduciary. If the shares of Cemax-Icon Common
Stock are owned of record by more than one person, as in a joint tenancy or
tenancy in common the Demand must be executed by or on behalf of all joint
owners. An authorized agent, including an agent for two or more joint owners,
may execute a Demand on behalf of a holder of record; however, the agent must
identify the recordowner or owners and expressly disclose the fact that in
executing the Demand, the agent is acting as agent for the record owner or
owners . A record holder, such as a broker, who holds Cemax-Icon Common Stock as
nominee for several beneficial owners, may exercise appraisal rights with
respect to which the holder is record holder. In such case, the Demand must set
forth the number of shares of Cemax-Icon Common Stock as to which appraisal is
sought. Where no number of shares of Cemax-Icon Common Stock is expressly
mentioned, the Demand will be presumed to cover all shares of Cemax-Icon Common
Stock held in the name of the record owner. Beneficial owners who are not record
owners and who intend to exercise appraisal rights should instruct the record
owner to comply strictly with the statutory requirements with respect to the
exercise of appraisal rights.
A holder of shares of Cemax-Icon Common Stock held in "street name" who
desires appraisal rights with respect to such shares must take such actions as
may be necessary to ensure that a timely and proper demand for appraisal is made
by the record owner of such shares. Shares of Cemax-Icon Common Stock held
through brokerage firms, banks, and other financial institutions are frequently
deposited with and held of record in the name of a nominee of a central security
depository, such as Cede & Co., Pacific & Co., Kray Co., Philadep and others.
Any holder of Cemax-Icon Common Stock desiring appraisal rights with respect to
such shares who held his or her shares through a brokerage firm, bank or other
financial institution is responsible for ensuring that the demand for appraisal
is made by their record holder thereof. The holder should instruct such firm,
bank or institution that the demand for appraisal must be made by the record
holder of the shares, which might be the nominee of a central security
depository if the shares have been so deposited. As required by Section 262, a
demand for appraisal must reasonably inform the corporation of the identity of
the record holder (which might be a nominee as described above) and of such
holder's intention to seek appraisal of such shares.
Holders who elect to exercise appraisal rights must mail or deliver
their written demands to: Cemax-Icon, Inc., 47281 Mission Falls Court, Fremont,
California 94539, Attention: Secretary. The written demand for appraisal should
specify that the holder is thereby demanding appraisal of his or her shares.
Within 10 days after the Effective Time, Imation, as the surviving
corporation in the Merger, must send a notice as the effectiveness of the Merger
to each holder of Cemax-Icon Common Stock who has satisfied the foregoing
provisions of Section 262, which notice shall also include a copy of Section
262. Within 120 days after the Effective Time, but not thereafter, Cemax-Icon or
any former holder of Cemax-Icon Common Stock entitled to appraisal rights under
Section 262 may file a petition in the Delaware Court of Chancery demanding a
determination of the value of Cemax-Icon Common Stock. Cemax-Icon will not file
any such petition. Accordingly, the dissenting holder of Cemax-Icon Common Stock
will need to initiate all necessary action to perfect his appraisal rights
within the time periods prescribed in Section 262.
Within 120 days after the Effective Time, any former holder of
Cemax-Icon Common Stock who has complied with the requirements for exercise of
appraisal rights will be entitled, upon written request, to receive from Imation
a statement setting forth the aggregate number of shares of Cemax-Icon Common
Stock not voted in favor of the adoption of the Merger Agreement and with
respect to which demands for appraisal have been received and the aggregate
number of holders of such shares. Such statement must be mailed within 10 days
after a written request therefor has been received by Imation or within 10 days
after expiration of the period for deliver of demands, whichever is later.
If a petition for an appraisal is timely filed, after a hearing on such
petition, the Delaware Court of Chancery will determine which former holders of
Cemax-Icon Common Stock are entitled to appraisal rights and will appraise the
"fair value" of the Cemax-Icon Common Stock exclusive of any element of value
arising from the accomplishment or expectation of the Merger. Holders of
Cemax-Icon Common Stock considering seeking appraisal should be aware that the
fair value of their shares as determined under Section 262 could be more than,
the same as or less than the consideration they would receive pursuant to the
Merger Agreement, if they did not seek appraisal of their shares and that
investment advisors' opinions as to fairness from a financial point of view of
the Merger Consideration are not necessarily opinions as to fairness of their
shares under Section 262. Any judicial determination of the "fair value" of the
Cemax-Icon Common Stock could be based on numerous considerations including, but
not limited to, the market value of Cemax-Icon Common Stock prior to the Merger
and the net asset value and earnings of the Cemax-Icon. The Delaware Supreme
Court has stated that "proof of value by any techniques or methods which are
generally considered acceptable in the financial community and otherwise
admissible in court" should be considered in the appraisal proceeding. The Court
will also determine the amount of interest, if any, to be paid upon the amounts
to be received by persons whose shares have been appraised. The costs of the
proceeding may be determined by the Court and taxed upon the parties as the
Court deems equitable. The Court may also order that all or a portion of the
expenses incurred by any stockholder in connection with an appraisal proceeding,
be charged pro rata against the value of all the shares entitled to appraisal.
Any holder of Cemax-Icon Common Stock who has duly demanded an
appraisal in compliance with Section 262 will not, after the Effective Time, be
entitled to vote the shares of Cemax-Icon Common Stock subject to such demand
for any purpose or be entitled to the payment of dividends or other
distributions on those shares of Cemax-Icon Common Stock, except dividends or
other distributions payable to holders of Cemax-Icon Common Stock of record as
of a date prior to the Effective Time.
If any holder of Cemax-Icon Common Stock who demands appraisal of his
Cemax-Icon Common Stock under Section 262 fails to perfect, or effectively
withdraws or loses his right to appraisal, then the shares of Cemax-Icon Common
Stock of such holder will be converted into and become the right to receive the
Merger Consideration in accordance with the Merger Agreement. A holder of
Cemax-Icon Common Stock will fail to perfect, or effectively lose, his right of
appraisal if no petition for appraisal is filed within 120 days after the
Effective Time, or if the stockholder delivers to the Cemax-Icon a written
withdrawal of his demand for appraisal and acceptance of the Merger, except that
any such attempt to withdraw made more than 60 days after the Effective Time
will require the written approval of the Cemax-Icon.
Failure to follow the steps required by Section 262 for perfecting
rights may result in the loss of such rights.
Cash received pursuant to the exercise of dissenters' rights may be
subject to federal or state income tax. See "--Federal Income Tax Consequence."
The foregoing summary of the applicable provisions of Section 262 is
not intended to be a complete statement of such provisions and is qualified in
its entirety by reference to such Section, the full text of which is attached as
Exhibit B to this Proxy Statement/Prospectus.
REGULATORY APPROVALS
Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the
"HSR Act") and the rules promulgated thereunder by the Federal Trade Commission
(the "FTC"), certain acquisition transactions may not be consummated unless
notice has been given and certain information has been furnished to the
Antitrust Division of the United States Department of Justice (the "Antitrust
Division") and the FTC and certain waiting period requirements have been
satisfied. The Merger is subject to these requirements.
Imation and Cemax-Icon each filed with the Antitrust Division and the
FTC a Notification and Report Form with respect to the Merger on ________, 1997.
Under the HSR Act, the Merger may not be consummated until the expiration of a
waiting period of at least 30 days following the receipt of each filing, unless
the waiting period is earlier terminated.
The FTC and the Antitrust Division frequently scrutinize the legality
of transactions such as the Merger under the antitrust laws. At any time before
or after the Effective Time, the FTC or the Antitrust Division could take such
action under the antitrust laws as it deems necessary or desirable in the public
interest, including seeking to enjoin the Merger or seeking the divestiture of
Cemax-Icon by Imation, in whole or in part, or the divestiture of substantial
assets of Imation, Cemax-Icon or their respective subsidiaries. State Attorneys
General and private parties may also bring legal actions under the federal or
state antitrust laws under certain circumstances. Based upon an examination of
information available to Imation and Cemax-Icon relating to the businesses in
which Imation, Cemax-Icon and their respective subsidiaries are engaged, Imation
and Cemax-Icon believe that the consummation of the Merger will not violate the
antitrust laws. Nevertheless, there can be no assurance that a challenge to the
proposed Merger on antitrust grounds will not be made or, if such a challenge is
made, that Imation and Cemax-Icon will prevail.
Neither Imation nor Cemax-Icon is aware of any other material
governmental approvals or actions that may be required for consummation of the
Merger except as described above. Should any such approval or action be
required, it is presently contemplated that such approval or action would be
sought. There can be no assurance, however, that any such approval or action, if
needed, could be obtained and would not be conditioned in a manner that would
cause the parties to abandon the Merger.
THE MERGER AGREEMENT
THE FOLLOWING IS A BRIEF SUMMARY OF THE MATERIAL PROVISIONS OF THE
MERGER AGREEMENT. THIS DESCRIPTION DOES NOT PURPORT TO BE COMPLETE AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE MERGER AGREEMENT INCLUDED AS
EXHIBIT A TO THIS PROXY STATEMENT/PROSPECTUS AND INCORPORATED HEREIN BY
REFERENCE. ALL STOCKHOLDERS ARE URGED TO READ THE MERGER AGREEMENT IN ITS
ENTIRETY. SEE ALSO "THE MERGER."
GENERAL
The Merger Agreement provides that, upon the satisfaction or waiver of
certain conditions, Merger Subsidiary will be merged with and into Cemax-Icon,
Cemax-Icon will continue as the Surviving Corporation, and the separate
existence of Merger Subsidiary will cease. Pursuant to the Merger Agreement, at
the Effective Time, (a) each outstanding share of common stock of Merger
Subsidiary will be converted into one share of the common stock of the Surviving
Corporation, (b) each outstanding share of Cemax-Icon Common Stock (other than
Dissenting Shares or shares owned by Imation, Merger Subsidiary or Cemax-Icon)
will be converted into and become a right to receive (i) a cash payment of
$5.25, without interest thereon, and (ii) a Contingent Payment Right and (c)
each share of Cemax-Icon Preferred Stock will be canceled and extinguished, and
no payment will be made therefor. Following the Merger, the Surviving
Corporation will be a wholly owned subsidiary of Imation. An aggregate of up to
$200,000 may be withheld from the initial payments to stockholders in a separate
fund for reimbursement of the Stockholders' Representatives' out-of
pocket-expenses in acting on behalf of stockholders of Cemax-Icon in connection
with the Merger. See "THE MERGER--Stockholders' Representatives' Fund."
CERTAIN REPRESENTATIONS AND WARRANTIES
The Merger Agreement contains various representations and warranties of
Imation, Merger Subsidiary and Cemax-Icon relating to, among other things, the
following matters (which representations and warranties are subject, in certain
cases, to specified exceptions): (1) the due organization, power and standing
of, and similar corporate matters with respect to, each of Imation, Merger
Subsidiary and Cemax-Icon; (2) the authorization, execution, delivery and
performance by, and enforceability of, the Merger Agreement against each such
party; (3) corporate authorization and lack of conflicts with other agreements;
(4) except as set forth in the Merger Agreement, absence of any governmental or
regulatory authorization, consent or approval required to consummate the Merger;
and (6) the absence of any brokerage, finder's or other fees due in connection
with the Merger.
Cemax-Icon also has made certain additional representations and
warranties to Imation relating to, among other things, the following matters
(which representations and warranties are subject, in certain cases, to
specified exceptions): (1) the approval of the Merger Agreement by Cemax-Icon's
Board of Directors and its resolution to recommend the approval of the Merger
Agreement to Cemax-Icon's stockholders; (2) the proper organization and other
matters relating to Cemax-Icon's predecessors; (3) the absence of subsidiaries;
(4) capital stock; (5) financial statements; (6) the absence of undisclosed
liabilities; (7) the absence of a material adverse change the assets, financial
condition, relations with key management employees or key OEM's, operating
results or business condition of Cemax-Icon; (8) the absence of certain
developments; (9) title to properties; (10) accounts receivable; (11) inventory;
(12) tax matters; (13) Cemax-Icon's performance of material obligations in
connection with disclosed contracts and commitments; (14) intellectual property
rights; (15) the absence of material pending or threatened litigation; (16)
warranties and products; (17) employees; (18) employee benefit plans; (19)
insurance; (20) the absence of affiliate transactions; (21) customers and
suppliers; (22) officers and directors and the existence of bank accounts; (23)
compliance with applicable laws and the possession of all licenses, permits and
certificates necessary to operate the business of Cemax-Icon; (24) environmental
matters; and (25) disclosures.
Imation and Merger Subsidiary also have made certain additional
representations and warranties to Cemax-Icon relating to, among other things,
the ownership of Merger Subsidiary.
COVENANTS
Pursuant to the Merger Agreement, Cemax-Icon has agreed that, prior to
the Effective Time, except as expressly permitted by the Merger Agreement or as
otherwise consented to by Imation, Cemax-Icon will, subject to certain
exceptions, among other things, (1) carry on its business in the ordinary course
of its business and observe the following terms and not, except as permitted in
Merger Agreement, (a) take any action except in, the ordinary course of
business, on an arm's-length basis and in accordance in all material respects
with all applicable laws, rules and regulations and Cemax-Icon's past custom and
practice; (b)(i) issue or sell any additional shares of its capital stock, or
any options, warrants, conversion privileges or rights of any kind to acquire
any shares of its capital stock , except as permitted in the Merger Agreement,
(ii) sell, pledge, dispose of or encumber any of its assets, except in the
ordinary course of business, (iii) amend or propose to amend its Certificate of
Incorporation or Bylaws, (iv) split, combine or reclassify any outstanding
shares of capital stock, or declare, set aside or pay any dividend or other
distribution payable in cash, stock, property or otherwise with respect to
shares of its capital stock, (v) redeem, purchase or acquire or offer to acquire
any shares of its capital stock or other securities, except as provided for in
the Merger Agreement, (vi) acquire any corporation, partnership, joint venture
or other business combination or division or material assets thereof, (vii)
incur any indebtedness for borrowed money or issue any debt securities except
the borrowing of working capital in the ordinary course of business consistent
with past practice, (viii) accelerate or defer the payment of undisputed
accounts payable or other accrued expenses owned to trade creditors or other
third parties having business relationships with Cemax-Icon, to use or occupy
real property or exercise or waive any option, or consent to any modification,
act or omission by any landlord requiring tenant's consent under any lease, or
propose to do any of the foregoing, (ix) accelerate, beyond the normal
collection cycle, or defer collection of manufacturers' rebates, promotional
allowances and other accounts receivable, (x) enter into or modify any lease (as
defined in the Merger Agreement) or agreement or arrangement, (xi) purchase
inventories or supplies for its business in manner outside the ordinary course
of business, inconsistent in amount, nature or composition with prior practice,
(xii) sell, lease, license or otherwise dispose of any material assets or
properties, other than in the ordinary course of business, (xiii) accelerate or
defer the construction or improvements at any of the locations of its business
or (xiv) accelerate or defer the purchase of material fixtures, equipment,
leasehold improvements, vehicles, other items of machinery and equipment and
other capital expenditures, or (xv) enter into or modify any agreement,
arrangement or understanding with respect to any of the matters set forth in
items (1)(b)(i) through (1)(b)(xiv) in any material respect, or propose to do
any of the foregoing; (c)(i) enter into or modify any employment, severance or
similar agreements or arrangements with, or grant any bonuses, salary increases,
severance or termination pay to, any officers or directors or consultants or
(ii) in the case of employees, officers or consultants who earn in excess of
$75,000 per year, take any action with respect to the grant of any bonuses,
salary increases, severance or termination pay or with respect to any increase
of benefits payable in effect as of the date of the Merger Agreement; (d) adopt
or amend any bonus, profit sharing, compensation, stock option, pension,
retirement, deferred compensation, employment or other employee benefit plan,
trust, fund or group arrangement for the benefit or welfare of any employees or
of any director; (e) cancel or terminate its current insurance policies or cause
any of the coverage to lapse, except as set forth in the Merger Agreement; (f)
fail to (i) use commercially reasonable efforts to preserve intact its business
organization and goodwill, keep available the services of its officers and
employees as a group and maintain satisfactory relationships with suppliers,
distributors, customers and others with which it has business relationships,
(ii) confer on a regular and frequent basis with representatives of Imation to
report operational matters and the general status of ongoing operations, (iii)
not intentionally take any action which would render, or which reasonably may be
expected to render, any representation or warranty made by it in the Merger
Agreement untrue at the closing of the Merger, (iv) notify Imation of any
emergency or other change in the normal course of business or in the operation
of its properties and of any governmental or third party complaints,
investigations or hearings if such emergency, change, complaint, investigation
or hearing would be material, individually or in the aggregate, to the business,
operations or financial condition of Cemax-Icon or to Cemax-Icon's, Imation's or
Merger Subsidiary's ability to consummate the transactions contemplated by the
Merger Agreement, and (v) promptly notify Imation and Merger Subsidiary in
writing if Cemax-Icon discovers that any representation or warranty made by it
in the Merger Agreement was when made, or has subsequently become, untrue in any
material respect; (g) fail to (i) file all Tax (as such term is defined in the
Merger Agreement) returns, elections or information statements with respect to
any liabilities for Taxes of Cemax-Icon which pursuant to applicable law must be
filed prior to the closing of the Merger, (ii) promptly upon filing provide
copies of any such Tax returns, elections or information statements to Imation
and Merger Subsidiary, (iii) make or rescind any such Tax elections or other
discretionary positions with respect to Taxes taken by or affecting Cemax-Icon
only upon prior consultation with and consent of Imation, (iv) not amend any
Return (as such term is defined in the Merger Agreement), (v) not increase the
rate or policy for any accrual or reserve for Taxes or otherwise accrue therefor
in a manner inconsistent with its practice for previous periods and not change
any of its methods of reporting income or deductions for federal income tax
purposes from those employed in the preparation of the federal income tax
returns for the taxable year ended December 31, 1995; (h) perform any act
referenced by (or omit to perform any act which omission is referenced by) the
terms of Section 3.11 of the Merger Agreement; (2) provide to Imation full
access at all reasonable times and upon reasonable notice access to Cemax-Icon's
books and records; (3) cause to be duly called and held a meeting the Cemax-Icon
stockholders; (4) make or cause to be made all filings and submissions under the
HSR Act) and any other laws and regulatory filings required pursuant to the
Merger; (5) furnish or cause to be furnished to Imation all information
concerning Cemax-Icon required to be included in the registration statement on
Form S-4 to be filed with the SEC under the Securities Act relating to
Contingent Payment Rights and the shares of Imation Common Stock which may be
delivered to Cemax-Icon's stockholders pursuant to the Contingent Payment Rights
(the "Registration Statement") and any other applicable documents which will
include a prospectus and proxy statement (the "Prospectus-Proxy Statement"); (6)
prepare and deliver to Imation all quarterly and monthly financial statements
for such periods set forth in the Merger Agreement; (7) take all commercially
reasonable actions necessary or desirable to cause the conditions set forth in
the Merger Agreement to be satisfied and to consummate the transactions
contemplated by the Merger Agreement and obtain all consents and waivers
contemplated by the Merger Agreement; (8) except as set forth in the Merger
Agreement, refrain from soliciting, initiating and encouraging submission of any
proposal or offer from any person or entity relating to any liquidation,
dissolution, recapitalization, merger, consolidation or acquisition or purchase
of all or a material portion of the assets of, or any equity interest in, the
Cemax-Icon or other similar transaction or business combination involving
Cemax-Icon or participate in any negotiations regarding the foregoing; and (9)
distribute the Prospectus-Proxy Statement, at the relevant time, to each holder
of Cemax-Icon Options or Cemax-Icon Warrants.
Pursuant to the Merger Agreement, Imation and Merger Subsidiary have
agreed that Imation will, subject to certain exceptions, among other things, (1)
promptly as practicable after the execution of the Merger Agreement, make or
cause to be made all filings and submissions under the HSR Act and any other
applicable laws or regulations; (2) take all commercially reasonable actions
necessary or desirable to cause the conditions set forth in Section 7.02 of the
Merger Agreement to be satisfied and to consummate the transactions contemplated
by the Merger Agreement; (3) file the Registration Statement and any applicable
documents, which will include the Prospectus-Proxy Statement with the SEC; (4)
file all documents required to be filed to list the Imation Common Stock to be
issued pursuant to the Contingent Payment Rights on the New York Stock Exchange;
(5) take all corporate action necessary to ensure that any shares of Imation
Common Stock issued by Imation to the Cemax-Icon stockholders pursuant to the
Contingent Payment Rights, is duly authorized, validly issued, fully paid and
nonassessable and free of any preemptive rights or other rights to purchase
securities of Imation and is issued in full compliance with applicable
securities laws; (6) file all documents required to obtain, prior to the
Effective Time, all necessary approvals under state securities laws, if any; (7)
take all corporate action necessary to reserve for issuance a sufficient number
of shares of Imation Common Stock for delivery upon exercise of Substitute
Options and Substitute Warrants and shall file a registration statement on Form
S-8 with respect to shares of Imation Common Stock subject to Substitute
Options; (8) make certain expenditures in connection with its image management
systems business objectives after the Effective Time and (9) maintain as of the
Effective Time certain identified employee benefit plans of Cemax-Icon as in
effect immediately prior to the Effective Time, subject to the modifications set
forth in the Merger Agreement and subject to further modification, amendment or
termination by Imation or the Surviving Corporation following the Effective
Time.
LIMITATIONS ON NEGOTIATIONS
Except is set forth in the Merger Agreement, Cemax-Icon will not,
directly or indirectly, through any officer, director, stockholder, agent or
otherwise, solicit, initiate or encourage submission of any proposal or offer
from any person or entity (including any of its or their officers, stockholders
or employees) relating to any liquidation, dissolution, recapitalization,
merger, consolidation or acquisition or purchase of all or a material portion of
the assets of, or any equity interest in, Cemax-Icon or other similar
transaction or business combination involving Cemax-Icon, or participate in any
negotiations regarding, or furnish to any other person any information with
respect to, or otherwise cooperate in anyway with, or assist or participate in,
facilitate or encourage, any effort or attempt by any other person or entity to
do or seek any of the foregoing. Cemax-Icon will promptly notify Imation of any
such proposal or offer, or any inquiry from or contact with any person with
respect thereto, is made and shall promptly provide Imation with such
information regarding such proposal, offer, inquiry or contact as Imation may
request.
CONDITIONS
The Merger will occur only if the Merger Agreement is approved and
adopted by the requisite vote of the stockholders of Cemax-Icon. Consummation of
the Merger is also subject to the satisfaction of certain other conditions
specified in the Merger Agreement, unless such conditions are waived (to the
extent such waiver is permitted by law).
Each party's respective obligations to effect the Merger are subject to
various conditions, including the following, unless waived by the other party to
the extent permitted by applicable law: (1) the stockholders of Cemax-Icon shall
have approved the Merger and the Merger Agreement by requisite vote; (2) the
applicable waiting periods under the HSR Act shall have expired or been
terminated, and all material governmental filings, authorizations and approval
that are required for the consummation transactions contemplated by the Merger
Agreement or the Certificate of Merger will have been duly made and obtained;
(3) there shall not be threatened, instituted or pending any action or
proceeding, before any court or governmental authority or agency relating to and
materially adversely affecting the transactions contemplated in the Merger
Agreement; (4) there shall not be any action taken, or any statute, rule or
regulation, judgment order or injunction enacted, entered, enforced,
promulgated, issued or deemed applicable to the transactions contemplated by the
Merger Agreement which would reasonably be expected to result in any of the
consequences referred to in item (3); and (5) the Registration Statement shall
have become effective and shall not be subject to any stop order, and no action
suit, proceeding or investigation by the SEC to suspend the effectiveness of the
Registration Statement shall have been initiated and be continuing, or have been
threatened or be unresolved and Imation shall have received all necessary state
securities law authorizations.
The obligations of Imation and Merger Subsidiary to effect the Merger
are subject to the satisfaction prior to or upon the Closing of the following
conditions, unless waived by Imation and Merger Subsidiary: (1) the
representations and warranties of Cemax-Icon set forth in the Merger Agreement
shall be true and correct in all material respects at and as of the Effective
Time of the Merger as though made on and as of such date; (2) Cemax-Icon shall
have performed in all material respects all the covenants and agreements
required to be performed by it under the Merger Agreement prior to the Effective
Time; (3) the consents and approvals described in the Merger Agreement shall
have been obtained by Cemax-Icon which consents and approvals could be
reasonably expected to result in a material adverse change in the assets,
financial condition, relationship with key management employees or key OEM's,
operating results or business condition of Cemax-Icon; (4) the Merger Agreement,
the Certificate of Merger and the Merger shall have been duly and validly
approved by the Cemax-Icon's Board of Directors and the Merger Agreement shall
have been approved by the Stockholders of Cemax-Icon; (5) there shall not have
been discovered any fact existing as of the date of the Merger Agreement
regarding Cemax-Icon, which has not been disclosed to Imation and Merger
Subsidiary as of the date of the Merger Agreement which is, individually or in
the aggregate with other such facts, would result in a material adverse change
in the assets, properties, financial condition, operating results or business
condition of Cemax-Icon; (6) there shall have been no damage or destruction or
loss of or to any property or properties owned or used by Cemax-Icon, whether or
not covered by insurance, which, in the aggregate, has, or would be reasonably
likely to have, a material adverse effect on Cemax-Icon; (7) Imation shall have
received from Wilson, Sonsini, Goodrich & Rosati, P.C. a written opinion, dated
the Effective Time, addressed to Imation; (8) not more than seven percent of the
outstanding shares of Cemax-Icon Common Stock shall be qualified to be
Dissenting Shares as of the Effective Time; (9) Imation shall have received from
Ernst & Young LLP, a "comfort" letter, dated as of the effective date of the
Registration Statement; (10) Cemax-Icon shall have delivered to Imation: (a)
officers' certificates executed by officers of Cemax-Icon, (b) copies of third
party and governmental consents and certain approvals, (c) the minute books,
stock transfer records, corporate seal and other materials related to the
corporate administration of Cemax-Icon, (d) resignations from certain of
Cemax-Icon's officers and directors, (e) a copy of the certified Certificate of
Incorporation of Cemax-Icon and Certificates of Good Standing of Cemax-Icon in
such states, (f) a copy of each of (i) the text of resolutions adopted by the
board of directors of Cemax-Icon authorizing the execution, delivery and
performance of the Merger Agreement and the Certificate of Merger and the
consummation of transactions contemplated by the Merger Agreement and the
Certificate of Merger and (ii) the bylaws of Cemax-Icon certified by its
corporate secretary, (g) incumbency certificates executed on behalf of
Cemax-Icon executed on behalf of Cemax-Icon by Cemax-Icon's corporate
secretary, (h) an executed copy of each of the Related Agreements as such term
is defined in the Merger Agreement and (i) such other certificates, documents
and instruments as Imation reasonably requests related to the transactions
contemplated by the Merger Agreement; (11) Cemax-Icon's employees shall have
entered into Imation's form of Employee Agreement and (12) each of Cemax-Icon's
employees identified in the Merger Agreement shall have agreed (i) to repay to
Cemax-Icon under the terms set forth in the Merger Agreement, all interest and
principal outstanding under certain promissory notes or (ii) to permit
Cemax-Icon to deduct the amount of such interest and principal from the payment
of 1997 cash consideration to such employee.
The obligation of Cemax-Icon and the Cemax-Icon stockholders to effect
the Merger is subject to the satisfaction prior to or upon the Closing of the
following conditions, unless waived by Cemax-Icon: (1) the representations and
warranties of Imation set forth in the Merger Agreement shall be true and
correct in all material respects at and as of the Effective Time, as though made
on and as of such date; (2) Imation and Merger Subsidiary shall have performed
in all material respects all the covenants and agreements required to be
performed by them under the Merger Agreement and the Certificate of Merger prior
to the Effective Time; (3) Cemax-Icon shall have received from Dorsey & Whitney
LLP a written opinion, dated the Effective Time, addressed to Cemax-Icon; (4)
Imation and Merger Subsidiary shall have delivered to Cemax-Icon: (a) officers'
certificates executed by officers of each of Imation and Merger Subsidiary, (b)
a copy of the certified Certificate of Incorporation of each of Imation and
Merger Subsidiary and Certificates of Good Standing of Imation and Merger
Subsidiary; (c) a copy of each of (i) the text of resolutions adopted by the
board of directors of each of Imation and Merger Subsidiary authorizing the
execution, delivery and performance of the Merger Agreement and the Certificate
of Merger and the consummation of transactions contemplated by the Merger
Agreement and the Certificate of Merger and (ii) the bylaws of each of Imation
and Merger Subsidiary certified by their respective corporate secretaries; (d)
incumbency certificates executed on behalf of each of Imation and Merger
Subsidiary by their respective corporate secretaries; (e) an executed copy of
each of the Related Agreements as such term is defined in the Merger Agreement
and (f) such other certificates, documents and instruments as Cemax-Icon
reasonably requests related to the transactions contemplated by the Merger
Agreement and (5) receipt from Imation of evidence of transfer to the Transfer
Agent of cash in the amount of the 1997 Cash Consideration, along with an
executed letter of instruction to pay such funds of the Cemax-Icon stockholder.
TERMINATION
The Merger Agreement may be terminated at any time prior to the
Effective Time: (i) by mutual consent of Imation, Merger Subsidiary and
Cemax-Icon; (ii) by either Imation or Merger Subsidiary, on the one hand, or
Cemax-Icon, on the other, in the event (a) there has been a material
misrepresentation, breach of warranty or breach of covenant on the part of the
other in the representations, warranties and covenants set forth in the Merger
Agreement provided, that, in the event of a curable breach, the non-breaching
party may terminate the Merger Agreement only after the breaching party has had
a reasonable time not to exceed 30 days to cure such breach after written notice
of such breach from the non-breaching party; (b) there shall be a final
nonappealable order of a federal or state court in effect preventing the
consummation of the Merger, or there shall be any action taken, or any statute,
rule, regulation or order enacted, promulgated or issued or deemed applicable to
the Merger by any governmental authority or agency which would make the
consummation of the Merger illegal; (c) there shall be any action taken, or any
statute, rule, regulation or order enacted, promulgated or issued or deemed
applicable to the Merger by any governmental authority or agency which would (x)
prohibit Cemax-Icon's or Imation's ownership or operation of all or a portion of
Cemax-Icon's business or (y) compel Imation or Cemax-Icon to dispose of or hold
separate all or a portion of the business or assets of Cemax-Icon or Imation as
a result of the Merger; or (d) the transactions contemplated by the Merger
Agreement or the Certificate of Merger have not been consummated on or before
August 31, 1997; provided that, neither will be entitled to terminate the Merger
Agreement if such party's willful breach of the Merger Agreement has prevented
the consummation of the transactions contemplated by the Merger Agreement or the
Certificate of Merger; or (iii) by Imation, if (a) more than seven percent of
the outstanding shares of Cemax-Icon Common Stock shall be qualified to be
Dissenting Shares after the first meeting of Cemax-Icon's stockholders to
approve the Merger Agreement and the Merger or (b) after the date of the Merger
Agreement, there shall have been a material adverse change in the assets,
properties, financial condition, operating results or business condition of
Cemax-Icon which shall continue to constitute such a material adverse charge on
or after July 31, 1997.
In the event of termination of the Merger Agreement by Imation, Merger
Subsidiary or Cemax-Icon, all provisions of the Merger Agreement will terminate
except such provisions set forth in the Merger Agreement relating to termination
fees, press releases and announcements, expenses, governing law and
confidentiality, which shall survive indefinitely.
TERMINATION FEES
Imation and Cemax-Icon have agreed that in the event the Merger
Agreement terminates as a result of (i) the failure of a party to proceed with
the Merger even though all of the conditions of such party's obligations to
consummate the transactions contemplated by the Merger Agreement have been
satisfied or (ii) a material misrepresentation, breach of warranty or breach of
covenant on the part of a party in the representations, warranties and covenants
set forth in the Merger Agreement, where such misrepresentation or breach
results or arises from the intentional, willful or grossly negligent acts or
omissions of such party, from information or circumstances known by such party
as of the date of the Merger Agreement or from information or circumstances not
known by such party as of the date of the Merger Agreement as a result of the
intentional or willful disregard or the gross negligence of such party, the
breaching party will promptly reimburse the non-breaching party for
out-of-pocket fees and expenses (in an amount not to exceed $1,000,000) incurred
by the non-breaching party in connection with transactions contemplated by the
Merger Agreement, except for salaries paid to employees of Imation or Cemax-Icon
and payments to financial advisors (other than out-of-pocket expenses of such
advisors) as discussed in the Merger Agreement. In the event Imation terminates
the Merger Agreement, Cemax-Icon may, at its option make the above-referenced
payment by delivering to Imation shares of Cemax-Icon Common Stock as set forth
in the Merger Agreement valued at a price of $10 per share.
In addition, in the event (i) Imation terminates the Merger Agreement
as a result of a material misrepresentation, material breach of warranty or
material breach of covenant on the part of Cemax-Icon in the representations,
warranties and covenants set forth in the Merger Agreement and (ii) Cemax-Icon
engages in, becomes subject to, or enters into an agreement or understanding
with respect to, a Control Transaction (as such term is defined below) with a
party other than Imation prior to December 31, 1997, Imation and Cemax-Icon have
agreed that Cemax-Icon shall promptly pay to Imation $3,000,000 in addition to
any amounts previously paid or required to be paid pursuant to the termination
provisions of the Merger Agreement. The Merger Agreement defines "Control
Transaction" as (i) any acquisition of effective control of Cemax-Icon, whether
by merger, purchase of all or substantially all of the assets of Cemax-Icon,
purchase of a majority of the equity of Cemax-Icon or otherwise, or (ii) any
issuance by Cemax-Icon, in a single or series of transactions, of shares of
capital stock, or rights to purchase shares of capital stock, representing equal
to or greater than 20% of the outstanding capital stock of Cemax-Icon.
Notwithstanding the foregoing, a Control Transaction shall not include the
issuance by Cemax-Icon of more than 20% of the outstanding capital stock of
Cemax-Icon (i) pursuant to an initial public offering of Cemax-Icon's equity
securities under Section 5 of the Securities Act, or (ii) pursuant to a pro rata
or substantially pro rata offering of Cemax-Icon's securities to Cemax-Icon's
current stockholders entitled to participate in such offering pursuant to
applicable securities laws, provided, that, in either case, after such offering,
(a) none of Cemax-Icon's current stockholders is the beneficial owner of more
than 40% of the outstanding capital stock of Cemax-Icon (computed as if all
securities beneficially owned by such stockholder which are convertible into
capital stock of Cemax-Icon had been converted), and (b) none of Imation's
competitors previously disclosed to Cemax-Icon is the beneficial owner of more
than 40% of the outstanding capital stock of Cemax-Icon (computed as if all
securities beneficially owned by such competitor which are convertible into
capital stock of Cemax-Icon have been converted).
The termination fees will be cumulative and in addition to any other
right, power or remedy available to the parties, whether conferred thereunder,
under the Option Agreement or now or hereafter available at law or in equity or
by statute or otherwise.
SURVIVAL AND OFFSET
The Merger Agreement provides that the representations and warranties
contained therein will survive the closing of the Merger until 30 days after the
Determination Date for the Second Earn-Out Year (as defined under "DESCRIPTION
OF CONTINGENT PAYMENT RIGHTS") (the "Offset Period") and will have no further
force or effect thereafter.
Pursuant to the Merger Agreement, Imation will have the right to
offset, from time to time, any loss, liability, deficiency, damage, expense or
cost (including reasonable legal expenses) whether or not actually incurred or
paid during the Offset Period and after taking into effect the tax effects of
such items and any use of the Offset Right thereunder (collectively, the
"Losses"), against payments to be made by Imation relating to the Contingent
Payment Rights, which Imation or the Surviving Corporation or (but only in
connection with any Losses incurred by, or Claims (as defined below) against,
Imation or the Surviving Corporation) any of their respective affiliates,
officers, directors, employees or agents (the "Protected Parties") may suffer or
become subject to, as a result of: (1) any misrepresentation in any of the
representations and warranties of Cemax-Icon contained in the Merger Agreement
or in any of the exhibits, schedules, certificates and other documents delivered
or to be delivered by or on behalf of Cemax-Icon pursuant to the Merger
Agreement or otherwise referenced or incorporated in the Merger Agreement
(collectively, the "Related Documents"); (2) any breach of, or failure to
perform, any agreement or covenant of Cemax-Icon contained in the Merger
Agreement or any of the Related Documents; and (3) any Claim or threatened Claim
against the Protected Parties arising out of actions or inactions of Cemax-Icon
with respect to Cemax-Icon's business or all the real property used or occupied
by Cemax-Icon prior to the Effective Time.
To exercise its Offset Right, the Merger Agreement requires Imation to
deliver to the Stockholders' Representative a schedule signed by an officer of
Imation reflecting the revised payments due or to become due under the
Contingent Payment Rights after giving effect to such exercise of its Offset
Right. In the event Imation exercises its Offset Right, such offset will be
applied first to the payment to be made in 1998 under the Contingent Payment
Rights and second to the payment being made in 1999 under the Contingent Payment
Rights.
In the event any of the Protected Parties becomes involved in any
legal, governmental or administrative proceeding which may result in Losses
subject to Imation's Offset Right thereunder, or if any such proceeding is
threatened or asserted (any such third party action or proceeding being referred
to therein as a "Claim"), Imation is required to promptly notify the
Stockholders' Representatives in writing of the nature of any such Claim and
Imation's estimate of the Losses arising therefrom.
The Stockholders Representatives shall be entitled to contest and
defend such Claim under the procedures and conditions set forth in the Merger
Agreement. However, in the event of a Claim under Section 10.02(c) of the Merger
Agreement or a dispute relating to the Offset Notice under Section 10.02(d) of
the Merger Agreement and if such Claim or Offset Notice would, if determined to
be valid, result in an offset against amounts due under the Contingent Payment
Rights, Imation may exercise its Offset Right to the extent of the estimated
Losses of the Protected Parties until the resolution of such Claim or dispute;
provided, that prior to the time of such resolution, if payment of the
Contingent Payment Right against which Imation is seeking to enforce its Offset
Right would otherwise be due and payable, Imation shall instead pay the amount
of such Offset Right into an escrow account with a third-party escrow agent
mutually acceptable to Imation and the Stockholders' Representatives pursuant to
an escrow agreement. Such funds shall be held in such escrow until the time of
resolution of such Claim (even if such Claim or dispute is not resolved until
after the end of the Offset Period) and thereafter returned to Imation to the
extent that such Offset Right is allowed and otherwise paid to the Stockholders'
Representative, Cemax-Icon Stockholders or a paying agent under the Contingent
Payment Rights, as may be appropriate. The portion of any Contingent Payment
Rights payments suspended pursuant to the terms of Section 10.02(e) of the
Merger Agreement which are not subject to the exercise of the Offset Right in
dispute and which, by their terms, have become due, shall be delivered to the
Stockholders' Representative, Cemax-Icon Stockholders or a paying agent under
the Contingent Payment Rights, as may be appropriate.
The Merger Agreement provides, subject to certain exceptions for
specified matters, that the right of Imation to exercise its Offset Right
thereunder will be subject to the following limitations: (1) Imation will not be
entitled to exercise its Offset Right with respect to any Losses, until the
aggregate amount of all Losses thereunder exceeds $250,000; provided that, once
the aggregate amount of all Losses thereunder exceeds $250,000, Imation will be
entitled to exercise its Offset Right with respect to all Losses, including,
without limitation, the initial $250,000 in Losses thereunder; (2) Imation will
not be entitled to exercise its Offset Right with respect to any Losses unless
Imation delivers to Stockholders' Representatives an Offset Notice or notice of
a Claim: (i) prior to the end of the Offset Period with respect to Losses as a
result of any misrepresentation in any of the representations and warranties of
Cemax-Icon contained in Section 3.07 (Capital Stock), Section 3.15 (Tax
Matters), Section 3.17 (Intellectual Property Rights), Section 3.20 (Employees),
Section 3.21 (Employee Benefit Plans) or Section 3.27 (Environmental Matters) of
the Merger Agreement and (ii) prior to the one-year anniversary of the Effective
Time with respect to all Losses not described in the preceding clause (i); (3)
Imation will not be entitled to exercise its Offset Right with respect to any
Losses to the extent that such Losses result from or arise out of the gross
negligence or willful misconduct of any Protected Party; (4) Imation will be
entitled to exercise its Offset Right only for Losses in an aggregate amount not
exceeding $9,650,979 and (5) the Offset Right will be Imation's sole and
exclusive remedy with respect to any Losses that any Protected Party may suffer,
sustain or become subject to pursuant to the terms of the Merger Agreement, and
Imation has agreed that it will not, and waives all rights to, institute or
maintain any suit, proceeding or action against Cemax-Icon's stockholders or
Stockholders' Representatives or utilize or exercise any other legal or
equitable remedy for the purpose of recovering damages or other relief with
respect to any Losses (including, without limitation, an action seeking to
recover any portion of the purchase price previously paid to Cemax-Icon's
stockholders) except for suits, proceedings or actions necessary to enforce or
implement the Offset Right, provided that, (i) nothing contained in the Merger
Agreement shall prevent a party from bringing an action based upon allegations
of fraud or other intentional misconduct with respect to another party hereto in
connection with the Merger Agreement, and (ii) nothing contained in the Merger
Agreement shall limit in any manner any other legal rights or remedies which any
Protected Party which is a party to an agreement identified under Article XI of
the Merger Agreement has against another party to such agreement in accordance
with the terms and conditions provided therein.
PRO FORMA UNAUDITED COMBINED FINANCIAL STATEMENTS
The pro forma unaudited statements of operations for the three months
ended March 31, 1997 and for the year ended December 31, 1996 set forth the
results of operations of Imation adjusted as though the purchase of Cemax-Icon
had been completed as of January 1, 1996. The pro forma unaudited statements of
operations reflect the elimination of sales and the related cost of goods sold
from Cemax-Icon to Imation, the amortization of goodwill recorded as a result of
the transaction, the incremental interest expense on the additional debt
incurred to finance the acquisition and the tax benefit of Cemax-Icon's pre-tax
loss being utilized by Imation. A non-recurring write-off of an estimated $36.3
million of in-process research and development which resulted directly from the
transaction was not considered in the unaudited pro forma statements of
operations.
The pro forma unaudited condensed balance sheet as of March 31, 1997
reflects the financial position of Imation adjusted as though the purchase of
Cemax-Icon had been completed as of March 31, 1997. The pro forma unaudited
condensed balance sheet reflects the addition of the fair value of net assets
acquired, the recording of goodwill and the write-off of the in-process research
and development as based on a preliminary estimate of the allocation of the
purchase price, the elimination of accounts receivable and accounts payable
between Imation and Cemax-Icon and the additional borrowings to fund the
acquisition.
These pro forma unaudited condensed financial statements have been
prepared based upon assumptions deemed appropriate for the fair presentation of
financial information. The allocation of the purchase price to the assets
acquired, including the in-process research and development, and liabilities
assumed has been estimated on a preliminary basis. The final allocation will be
completed after the transaction is consummated and once final appraisals and
other analyses are completed. The final allocation could be different than the
preliminary allocation based on these final appraisals and analyses. See the
accompanying note to pro forma unaudited condensed financial statements. The pro
forma unaudited financial statements should be read in conjunction with the
historical financial statements of Imation and Cemax-Icon and the notes thereto.
See "FINANCIAL STATEMENTS."
The pro forma unaudited condensed financial statements are presented
for illustrative purposes only and are not necessarily indicative of the
financial position or results of operations which would actually have been
reported had the transactions been in effect during the periods presented or
which may be reported in the future.
<TABLE>
<CAPTION>
IMATION CORP.
PRO FORMA STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 1997 AND YEAR ENDED DECEMBER 31, 1996
(IN MILLIONS, EXCEPT FOR PER SHARE DATA)
Three Months Ended March 31, 1997 Year Ended December 31, 1996
--------------------------------------- -------------------------------------------
Pro Forma Pro Forma
Historical Adjustments Pro Forma Adjustments Pro Forma
(Unaudited) (Unaudited) (Unaudited) Historical (Unaudited) (Unaudited)
<S> <C> <C> <C> <C> <C> <C>
Net revenues ......... $ 547.7 $ 7.1(a) $ 554.8 $ 2,278.2 $ 21.2(a) $ 2,299.4
Cost of goods sold ... 348.7 4.7(a) 353.4 1,482.8 10.5(a) 1,493.3
Gross profit ......... 199.0 2.4 201.4 795.4 10.7 806.1
Operating expenses:
Selling, general and
administrative ... 133.0 2.3(b) 135.3 563.0 9.6(b) 572.6
Research and
development ...... 37.8 1.6 39.4 183.1 6.5 189.6
Restructuring
charges .......... -- -- -- 53.9 -- 53.9
Total operating
expenses ....... 170.8 3.9 174.7 800.0 16.1 816.1
Operating income
(loss) ........... 28.2 (1.5) 26.7 (4.6) (5.4) (10.0)
Interest expense and
other ............ 6.4 0.5(c) 6.9 10.4 1.9(c) 12.3
Income (loss) before
tax and minority
interest ......... 21.8 (2.0) 19.8 (15.0) (7.3) (22.3)
Income tax provision
(benefit) ........ 9.8 (0.6)(c)(d) 9.2 5.9 (1.9)(c)(d) 4.0
Minority interest .. -- -- -- (0.4) -- (0.4)
Net income (loss) .... $ 12.0 $ (1.4) $ 10.6 $ (20.5) $ (5.4) $ (25.9)
Earnings (loss) per
share .............. $ 0.30 $ 0.26 $ (0.49) $ (0.63)
</TABLE>
SEE NOTE TO PRO FORMA UNAUDITED FINANCIAL STATEMENTS.
<TABLE>
<CAPTION>
IMATION CORP.
PRO FORMA BALANCE SHEET
AS OF MARCH 31, 1997
(IN MILLIONS)
(UNAUDITED)
Pro Forma
Historical Adjustments Pro Forma
<S> <C> <C> <C>
ASSETS:
Current Assets
Cash and equivalents.............................. $ 55.2 $ 3.7 (f) $ 58.9
Accounts receivable, net.......................... 465.9 7.9 (a) 473.8
Inventories....................................... 407.5 3.3 410.8
Other current assets.............................. 85.1 0.2 85.3
Total current assets............................ 1,013.7 15.1 1,028.8
Property, Plant and Equipment, net................... 461.5 1.9 463.4
Other Assets......................................... 73.8 8.9 (b) 82.7
Total Assets...................................... $ 1,549.0 $ 25.9 $ 1,574.9
LIABILITIES AND SHAREHOLDERS' EQUITY:
Current Liabilities
Accounts payable.................................. $ 179.8 $ 4.0 (a) $ 183.8
Accrued payroll................................... 40.4 1.3 41.7
Income taxes payable.............................. 6.5 -- 6.5
Short-term debt................................... 24.3 0.3 24.6
Other current liabilities......................... 140.4 6.8 147.2
Total current liabilities....................... 391.4 12.4 403.8
Other Liabilities.................................... 96.4 0.1 96.5
Long-Term Debt....................................... 148.8 35.7 (c) 184.5
Commitments and Contingencies
Shareholders' Equity
Common stock...................................... 0.4 -- 0.4
Additional paid-in capital........................ 1,012.1 14.0 (b) 1,026.1
Retained earnings (accumulated deficit)........... 23.2 (36.3)(e) (13.1)
Unearned ESOP shares.............................. (43.8) -- (43.8)
Cumulative translation adjustment................. (66.7) -- (66.7)
Treasury stock, at cost........................... (12.8) -- (12.8)
Total shareholders' equity...................... 912.4 (22.3) 890.1
Total Liabilities and Shareholders' Equity........... $ 1,549.0 $ 25.9 $ 1,574.9
</TABLE>
SEE NOTE TO PRO FORMA UNAUDITED FINANCIAL STATEMENTS.
NOTE TO PRO FORMA UNAUDITED FINANCIAL STATEMENTS
The amounts reflected in the columns captioned "pro forma adjustments" represent
the historical financial statements of Cemax-Icon, and the pro forma adjustments
described below:
(a) Adjustments were made to eliminate sales from Cemax-Icon to Imation, to
eliminate the related cost of goods sold and to eliminate the related
accounts receivable and accounts payable. Sales from Cemax-Icon to
Imation were $0.2 million and $3.9 million for the three months ended
March 31, 1997 and the year ended December 31, 1996, respectively.
Related accounts receivable and accounts payable were $0.2 million as
of March 31, 1997.
(b) Adjustments were made to eliminate Imation's $9.2 million investment in
Cemax-Icon and to reflect $18.1 million of net goodwill resulting from
the transaction. Goodwill recorded in the pro forma balance sheet
reflects the write-off of acquired in-process research and development
(see Note (e)). Goodwill will be amortized over seven years, resulting
in amortization expense (based on what goodwill would have been as of
January 1, 1996) of $0.6 million and $2.4 million for the three months
ended March 31, 1997 and the year ended December 31, 1996,
respectively. The purchase price included $14.0 million which related
to the fair value of the substitute options and warrants on Imation
Common Stock granted to certain option and warrant holders of
Cemax-Icon to replace their Cemax-Icon options and warrants.
The pro forma unaudited financial data does not reflect additional
amounts of goodwill, if any, that may result should additional
consideration be issuable pursuant to the Contingent Payment Rights.
Under generally accepted accounting principles, contingent
consideration is recorded when the results of the contingency become
known.
(c) Adjustments were made to interest expense and long-term debt to reflect
the incremental borrowings of $30.2 million to finance the initial cash
payment of $5.25 for each outstanding share of Cemax-Icon Common Stock
and related transaction costs. The average annual interest rate used
was 5.8% and 5.9% for the three months ended March 31, 1997 and the
year ended December 31, 1996, respectively, and was based on Imation's
borrowing rate terms under its revolving credit facility during the
respective periods, resulting in additional interest expense of $0.4
million and $1.8 million, respectively. The tax benefit associated with
the additional interest expense was $0.2 million and $0.7 million for
the three months ended March 31, 1997 and the year ended December 31,
1996, respectively.
(d) Prior to the transaction, Cemax-Icon recorded a full valuation
allowance for deferred tax assets attributed to its net operating
losses as it was not considered more likely than not that Cemax-Icon
would be able to generate taxable income in the future sufficient to
recover its deferred tax assets. Adjustments of $0.4 million and $1.2
million for the three months ended March 31, 1997 and the year ended
December 31, 1996, respectively, were made to the tax provision to
reflect the use of Cemax-Icon's net operating loss in the current
period to offset Imation taxable income. No additional benefits have
been reflected in the pro forma financial statements for the
utilization of loss carryforwards as the utilization in the future is
limited by the provisions of the Internal Revenue Code.
(e) An adjustment was made to the pro forma balance sheet to reflect the
write-off of $36.3 million of acquired in-process research and
development. No adjustment has been made to the pro forma statements of
operations for this nonrecurring charge.
(f) An adjustment of $0.4 million was made to increase cash and equivalents
to reflect payments received on notes receivable from Cemax-Icon
stockholders which are due upon consummation of the Merger.
COMPARATIVE UNAUDITED PER SHARE DATA
The following table presents selected comparative unaudited per common
share data with respect to Imation Common Stock and Cemax-Icon Common Stock on a
historical basis and a pro forma combined basis, giving effect to the Merger
using the purchase method of accounting. This information is derived from the
historical financial statements and the related notes thereto. See "FINANCIAL
STATEMENTS." The per share data set forth below are presented for informational
purposes only and are not necessarily indicative of the results of the future
operations of the combined entity or the actual results that would have been
achieved had the Merger been consummated prior to the dates indicated above.
<TABLE>
<CAPTION>
Imation Cemax-Icon
Common Stock Common Stock Pro Forma
Historical Historical Combined
BOOK VALUE PER SHARE:
<S> <C> <C> <C>
March 31, 1997.................................................... $ 21.53 $ (0.25) $ 21.00
CASH DIVIDENDS PER SHARE:
Three months ended March 31, 1997................................. 0 0 0
Year ended December 31, 1996...................................... 0 0 0
NET EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS:
Three months ended March 31, 1997................................. 0.30 (0.18) 0.26
Year ended December 31, 1996...................................... (0.49) (0.59) (0.63)
</TABLE>
CERTAIN INFORMATION CONCERNING IMATION
GENERAL
Imation was incorporated as a Delaware corporation in March 1996.
Imation's principal executive offices are located at 1 Imation Place, Oakdale,
Minnesota 55128 (telephone number (612) 704-4000). Prior to July 1, 1996,
Minnesota Mining and Manufacturing Company ("3M") operated Imation's business
through various divisions and subsidiaries.
Imation was formed as a result of the decision by 3M to spin-off a
separate company comprised of substantially all of the businesses previously
operated within 3M's data storage and imaging systems groups (the "Transferred
Businesses"). To effectuate the transaction, on June 18, 1996, the Board of
Directors of 3M declared a dividend payable to the holders of record of 3M
common stock as of June 28, 1996, based upon a ratio of one share of Imation
Common Stock for every ten shares of 3M common stock owned on the record date.
Effective July 1, 1996 (the "Distribution Date"), the shares of Imation Common
Stock were distributed to 3M stockholders (the "Distribution"). In connection
with the Distribution, 3M and Imation entered into various agreements to
facilitate the transition of Imation to an independent business enterprise. See
"--Relationship Between 3M and Imation." As used herein, references to "Imation"
include the historical operating results and activities of the business and
operations which comprise Imation today.
BUSINESS
Imation develops, manufactures and markets a wide variety of products
and services worldwide for the information processing industry, specializing in
data storage and imaging applications. Imation's products, which number in
excess of 10,000, are used to capture, process, store, reproduce and distribute
information and images in a wide range of information-intensive markets,
including enterprise computing, network servers, personal computing, graphic
arts, medical imaging, photographic imaging, and commercial and consumer
markets. Approximately 57% of Imation's revenues in 1996 were derived from
products and services utilizing digital technologies. In addition, a number of
Imation's products are market leaders in the conventional/analog processes for
recording, manipulation and storage of data and images. While these established
products generate a substantial portion of Imation's revenues today, Imation is
expanding its opportunities to serve the growing needs of its customers to
create, process, manipulate, store, reproduce and distribute increasing amounts
of information and images through the use of digital technologies. Imation
intends to leverage its existing market positions to increase the use of its
products and services as well as to expand its opportunities in the information
processing industry by developing more complete workflow solutions based on
digital technologies.
Imation operates in a single industry segment, the information
processing industry, supplying products and services to meet the information
processing needs for a variety of customer applications. Below are the product
and service revenues by class of similar products or services for each of the
years ended December 31.
<TABLE>
<CAPTION>
Revenue by Classes of Similar Products or Services
1996 1995 1994
(In millions)
<S> <C> <C> <C>
Data Storage Products........................................ $ 923.0 $ 930.7 $ 935.4
Printing and Publishing Systems.............................. 529.9 542.2 566.0
Medical Imaging Systems and Photo Color Products............. 673.2 608.1 589.1
Other........................................................ 152.1 164.6 190.0
Total...................................................... $ 2,278.2 $ 2,245.6 $ 2,280.5
</TABLE>
Imation does business in more than 60 countries and nearly half of Imation's
revenues are derived internationally. Expectations are for this percentage to
grow over time. Imation reports its operating results in three geographic
areas--United States, Europe/Middle East/Africa, and Latin America/Asia/Canada.
See Note 10 of the Notes to Imation Corp. Audited Consolidated Financial
Statements included herein.
Data Storage Products
Imation is the world's largest supplier and developer of branded
removable data storage media, in both magnetic and optical formats. Imation also
is a supplier of CD-ROM and laser disc replication and software services
provided to software developers. Imation's products include:
* Data cartridge and Travan(TM) cartridge products used for backup of
data from hard disk storage systems and for applications in which large
volumes of information do not need to be retrieved on a frequent basis.
Travan(TM) cartridges more than double the storage capacity of the
prior mini- cartridge. Used primarily on desktop personal computer
systems, local area networks and workstation computer systems, the
Travan(TM) cartridges make up a family of innovative products that were
introduced in 1995 through the joint efforts of 3M, Hewlett Packard
Company and a group of drive manufacturers. Imation maintains
relationships with these and other companies regarding the production
and joint marketing of compatible drives and cartridge storage media
and the development of future versions of the technology.
* Computer cartridge tapes used for near-line data storage and retrieval,
mass storage and archival storage of data. Large cartridge tapes are
used primarily on enterprise computer systems and in data library
systems that store very large volumes of data. The smaller 4 mm and 8
mm cartridges are used primarily in workstations and mid-size computer
systems and networks for backup and other data storage applications.
* Diskettes (3.5 inch, 5.25 inch and 8 inch) used for personal file
storage, for backup and for exchange of data. Diskettes are used
primarily in desktop and notebook personal computer systems, and also
in workstations, word processors and computer control equipment. In
April 1996, Imation released the LS-120 diskette, a "next generation"
3.5-inch diskette with a formatted capacity of 120 MB. The LS-120
diskette provides more than 80 times the storage capacity of a standard
diskette, and is read/write backward-compatible with the installed base
of more than 5 billion 1.44 MB and 720 KB DOS-formatted diskettes. The
LS-120 technology was originally developed as part of the Laser Servo
120 MB program in which Imation, Compaq Computer Corporation and MKE
are co- developers. In late 1996 and early 1997, drive manufacturers
MKE and Mitsubishi Electric Corp. announced that their production
facilities are capable of producing LS-120 drives in high volumes, and
OR Technology announced a strategic alliance with Kaifa Group, one of
the largest computer component manufacturers in China, to mass produce
an ultra slim-line LS-120 drive for notebook computers in 1997. Several
leading PC original equipment manufacturers, including Compaq Computer
Corporation and two European companies, Siemens Nixdorf Information
Systems AG and Fujitsu ICL Computers, Ltd., have announced plans to
integrate LS-120 drives into certain of their PC lines.
* Rewritable optical disks including magneto-optical (90mm and 130mm),
phase change disks (PD) and CD recordable disks used for the storage of
data and images on personal computers, workstations and local area
networks. These disks are also used in library systems for multi-
user/client server computer installations.
* Laserdiscs, CD-ROM and DVD-ROM products produced on a made-to-order
basis and used for the distribution of data and software to the
personal computer and mid-range markets. Imation recently announced it
will begin offering full DVD-ROM manufacturing, mastering, replication,
packaging and fulfillment services from Imation's Menomonie, Wisconsin
facility beginning in late 1997. DVD is a high-density, next generation
compact disc, identical in size and appearance to current CDs.
Printing and Publishing Systems
Imation manufactures and markets products and provides service and
technical support for the printing, publishing and graphic arts markets.
Products include conventional color proofing systems, digital color proofing
systems and software, pre-press software (Luminous), laser films and image
setting materials, metal printing plates, graphic arts films, photographic
chemicals and miscellaneous supplies. Imation also markets carbonless paper
products, such as multi-part business forms. Imation has strong leadership
positions in certain product areas, including the Matchprint(TM) color proofing
system, an industry standard for more than 20 years. More recently, the
Rainbow(TM) color proofing system, which provides color proofs from digital data
before a job is put on a printing press, also has established a leadership role,
winning both industry awards and acceptance as the digital proofer of choice
among many graphic arts professionals. Imation offers a two-page digital
proofing system (the Rainbow(TM) model 2730 digital proofer) and has announced
it intends to introduce a two-page digital proofer for professional applications
(the Rainbow(TM) model 2740 digital proofer). Imation has also announced it will
expand its line of Rainbow(TM) color proofers with a new four-page (A2 size) ink
jet digital proofing solution for users who require large format, contract
quality proofs. The new Rainbow(TM) model 4700 proofer is expected to be
available during the second quarter of 1997. In addition, in 1996 Imation
announced the development of two new Viking(TM) metal laser plates and a third
infrared thermal plate, which were designed for computer-to-plate printing
technology. Imation began shipping the two new Viking(TM) laser plates in
December 1996 and expects to introduce the third plate in the third quarter of
1997.
In October 1996, Imation acquired Luminous Corporation of Seattle,
Washington, a developer and marketer of desktop software for the prepress, print
production, printing and graphic arts industries. Luminous' portfolio of desktop
prepress software products strengthens Imation's existing digital capabilities
through its Rainbow(TM) digital color proofing systems and Color Locking
Software. As an increasing number of commercial printing operations are moving
their production processes to the desktop and are expanding their use of color
and networked computing, the need for integrated digital workflow solutions is
dramatically increasing. The acquisition of Luminous, combined with Imation `s
expertise in digital proofing, color science and high-capacity digital storage,
expands Imation's leadership in prepress workflow software to speed development
of integrated digital prepress solutions.
In addition to expanding its offerings of digital workflow solutions,
Imation intends to continue to develop its conventional product lines. In 1996,
Imation announced plans to leverage its proprietary dry film technology in the
medical imaging industry to develop a proprietary new dry imagesetting film for
the printing industry. The dry imagesetting film will be used in a new family of
dry film imagesetters being developed by systems developers including Scitex
Corporation Ltd., ECRM Incorporated and Ultre Division of Linotype-Hell Company,
and is expected to be available in late-1997. Imation also has announced it
intends to introduce a new line of high-quality, medium-run "no-process"
printing plates in the third quarter of 1997. The advantages to the user of both
the dry imagesetting film and the "no-process" plates include reduced operating
costs, increased productivity and the elimination of "wet chemistry" processing
resulting in substantial benefits to the environment. During 1996, Imation also
expanded its line of films and bases available for its conventional proofing
systems by introducing new large format Matchprint(TM) color proofing films and
bases. In November 1996, Imation announced its strategic decision to discontinue
manufacturing 3M(TM) Onyx(TM) polyester printing plates effective June 30, 1997.
The decision to exit the Onyx(TM) business was made to allow Imation to focus on
strategic conventional and digital platforms and to align Imation's product mix
with Imation's strategy of focusing on higher value-added products and services.
Medical Imaging Systems and Photo Color Products
Imation develops, manufactures and markets diagnostic imaging film,
film processors and imaging systems for both conventional X-ray film/screen and
electronic imaging systems. Imation's customers include major hospital network
buying groups as well as individual hospitals and medical imaging centers.
Imation participates in the conventional X-ray film market and is the world's
leading supplier of high-quality laser imagers for producing medical diagnostic
images directly from MRI, CT, ultrasound, nuclear and other electronic systems,
with more than 10,000 laser imagers installed worldwide. In late 1995, Imation
began shipping its proprietary line of DryView(TM) laser imagers that produce
high-quality film images without using standard wet chemistry through a
specially designed photothermographic process. Since no wet chemistry is
involved, the DryView(TM) laser imagers represent a significant technological
breakthrough and offer significant cost savings, productivity gains and
environmental benefits to the health care industry. In 1996, Imation introduced
a new desk-top version of the DryView(TM) laser imager, which conveniently may
be located in a variety of settings. As of December 31, 1996, Imation had
shipped more than 1,500 units of its DryView(TM) laser imaging systems. Through
an alliance with Cemax-Icon, hardware and software solutions are provided to
clients that help them manage, distribute and archive their medical images.
Under the alliance, in the U.S. Imation sells its DryView(TM) products and other
medical imaging equipment, and refers customers, to Cemax-Icon for solutions to
their image management systems needs. In Europe, Imation is the exclusive
private label distributor of the Cemax-Icon product family.
Imation is one of the world's leading suppliers of private label film
for the amateur photography retail market. Imation's primary geographic markets
for color photographic film are the United States and Europe, which represents
approximately 70% of the global demand for film. Imation manufactures a complete
line of print and slide films which fit in standard 35mm, 110, and 126 cameras
used by consumers globally. Imation also manufactures single use cameras which
are sold preloaded with Imation's ISO 400 speed film. Single-use cameras
represent a high growth segment of the consumer film market. Imation's color
print film can be found in more than 125 private label brands, as well as 3M's
Scotch(TM) brand. Imation continues to use certain 3M trademarks and tradenames
including the Scotch brand for a period of time following the Distribution. See
"--Relationship Between 3M and Imation--Intellectual Property Agreement." These
products and brands are positioned as a high value, comparable quality
alternative to global brands such as Kodak and Fuji.
In 1996, Imation announced the development of a new product that allows
desktop computer users to print photo-quality images on color ink jet printers.
The new photographic paper for ink jet printers is believed to provide superior
image quality and color reproduction, and significantly faster drying time than
competitive products. The new product, which was designed for use with a variety
of color ink jet printers, is expected to be available during the first half of
1997 through mass retail and photo stores.
Customer Service Technology
Imation's team of field service technicians provides technical
servicing and other post-sale technical support for equipment sold by Imation
and by 3M. Imation offers 24 hour information and customer support telephone
lines for the products it supports. Customers also benefit from user-friendly
product documentation and training programs in a variety of languages. Imation
intends to expand its technical service and support capabilities to assist
customers with the installation, service, support, integration and optimization
of equipment and systems offered for sale by Imation and other manufacturers.
Document Imaging
Imation supplies office and engineering document archiving and
management systems and produces and distributes black-and-white dry photographic
papers and films for the industrial imaging market.
Industry Background
The information processing industry in which Imation operates is
concerned with the creation, capture, manipulation, storage, production and
distribution of information. In data storage and imaging applications in which
Imation specializes, the industry has been profoundly impacted by advancements
in digital technologies. Digital technologies provide much needed information
processing solutions as users are required to use, manage and store more complex
information in less time and with fewer resources and greater accuracy. The
industry is also being profoundly impacted by the availability of new methods of
transporting and accessing data through software developments, networking and
the development of the World Wide Web.
Removable data storage solutions, based on digital technologies, are
used in applications across all computing platforms--enterprise systems, network
servers, desktop systems and mobile computing. International Data Corporation
("IDC") has estimated that there are over 150 million computer systems in use
worldwide that use removable data storage technologies. Removable data storage
technologies are used in a variety of applications including graphic imaging,
video imaging, medical diagnostics, communications systems and consumer
entertainment electronics. Overall, the data storage solution market is growing
at a double digit rate annually, with Asia, Latin America and Eastern Europe
leading this growth, although there is significant price competition. Customer
demand for these solutions is growing at an increasing pace due to enhanced
enabling software that increases the applications and usage rates and the
developing need by customers to manipulate, store and protect even larger
databases. The need for convenient digital storage solutions is also
accelerating as people gain access to information of all types from many
sources, including the Internet. Increasingly, end users want to download files
and information for later use. As the number of Internet users grow and the
variety of information increases, the demand for portable, cost-effective data
storage and output media also will grow. This is true in both commercial and
consumer markets.
Imaging technologies also have been profoundly impacted by advancements
in digital technologies as many users begin to convert their conventional/analog
processes to proprietary digital processes to capture, create, manipulate,
process, transmit and store still and moving images. Conventional/analog
technologies rely upon chemical or electrical processes which capture
information onto paper, film or other media by reacting to external stimuli.
Digital technologies have significantly increased the amount of information that
can be used, managed and stored and have reduced the need for film and chemicals
in the imaging process. Many work processes in use today are hybrid systems in
which users continue to use conventional materials for certain processes in
their work flows while utilizing the speed of digital processing.
Competition
Imation operates in a highly competitive environment. Imation's
principal competitors include large, well capitalized technology companies based
in the United States, Europe and Japan. These competitors include Eastman Kodak,
Fuji Photo Film, Sony, Agfa, Polaroid, Konica, KAO, Sterling and DuPont. Imation
also competes in certain product markets with smaller, more specialized firms
such as Polychrome, Scitex America, ADAC and Iomega. Businesses in the
information processing industry compete on a variety of factors such as price,
value, product quality, customer service, breadth of product line and
availability of system solutions.
Sales, Markets and Distribution Methods
Imation's products and services are sold directly to users through
Imation's field sales organizations and through numerous wholesalers, retailers,
jobbers, distributors and dealers in over 60 countries. No one customer
individually accounts for a material amount of Imation's total sales.
Raw Materials
The principal raw materials used by Imation are silver, polyester film
and aluminum. Imation makes significant purchases of these and other materials
and components used in Imation's manufacturing operations from many domestic and
foreign sources. Imation has been able to obtain sufficient materials and
components from sources around the world to meet its needs. 3M continues to be a
major supplier to Imation of certain raw materials and intermediate products
including film, specialty chemicals and abrasives, and certain contract
manufacturing services, primarily equipment assembly services. See
"--Relationship Between 3M and Imation--Supply, Service and Contract
Manufacturing Agreements."
Research and Patents
Research and product development have historically played an important
role in Imation's activities. Imation has research laboratories for the
improvement of its existing products and development of new products. Imation's
research and development expenses were $183.1 million, $222.4 million, and
$211.2 million for 1996, 1995 and 1994, respectively, Imation expects its
research and development expenses, as a percent of total revenues, to remain in
the 7-8% range during the next several years.
In connection with the Distribution, Imation was granted rights, on
both exclusive and non-exclusive bases, from 3M and others which enable it to
continue to use the intellectual property previously utilized by Imation when it
was part of 3M. See "--Relationship Between 3M and Imation--Intellectual
Property Agreement." Imation does not consider that its business as a whole is
materially dependent upon any one patent, license or trade secret or any group
of related patents, licenses or trade secrets, except with respect to those
rights granted from 3M.
Manufacturing
During 1996 Imation consolidated its manufacturing facilities by
centralizing such operations into the United States and Italy. This
consolidation was implemented in order to reduce costs and improve quality by
allowing Imation to adjust its capacity to current needs and take advantage of
the facilities with the most advanced quality management systems. In August
1996, Imation sold its offset printing plate production facility in Sulmona,
Italy, and in connection with the sale Imation entered into a contract with the
purchaser of the facility to supply Imation with Viking(TM) printing plates for
the European market. Imation has also announced it will close its manufacturing
facility in Rochester, New York by June 30, 1997. Costs associated with this
plant closing were recorded by Imation in its 1995 and 1996 consolidated
financial statements.
The core manufacturing competencies of Imation include coating, fine
chemical production for photographic film, state-of-the-art molding
capabilities, hardware prototyping and unit cost reduction. These competencies,
combined with Imation's research and development competencies of materials
science, color management, hardcopy imaging and magnetic and optical recording,
give Imation a strong technological base to take advantage of the opportunities
in the evolving information processing industry.
Employees
In connection with the Distribution, Imation achieved significant cost
reductions through changes in its corporate structure, including a more than 20
percent reduction in head count from the levels prior to the Distribution. As of
March 31, 1997, Imation had approximately 9,700 employees, approximately 5,700
in the United States and 4,000 internationally. As of December 31, 1995, Imation
had approximately 12,300 employees, which included both direct employees and
indirect equivalent positions in staff services functions at 3M which
historically provided services to Imation's businesses prior to the
Distribution. Approximately 1,600 positions were reduced prior to the
Distribution Date through employee separation programs and as a result of the
consolidation of Imation's manufacturing operations. The separation costs
associated with these reductions were recorded by Imation in its 1996
consolidated financial statements. Most of the cash requirements of the
separation programs were funded by 3M. In addition, approximately 1,100 staff
services equivalent positions remained with 3M. Imation continues to incur some
of the costs related to the staff services support provided by these employees
through a services agreement with 3M. See "--Relationship Between 3M and
Imation--Corporate Services Transition Agreement."
Environmental Matters
Imation's operations are subject to a wide range of environmental
protection laws. Imation has remedial and investigatory activities underway at
some of its current facilities. In connection with the Distribution, Imation
assumed and agreed to indemnify 3M from all liabilities relating to, arising out
of or resulting from (i) operations at Imation's facilities as conducted prior
to the Distribution Date; (ii) the disposal of hazardous materials from
Imation's facilities before the Distribution Date and at disposal sites operated
by third parties ("Superfund Sites"), where such liabilities are discovered
after the Distribution Date, or (iii) operations of Imation's businesses on and
after the Distribution Date. 3M agreed to retain responsibility for
environmental liabilities relating to former premises which may have been
associated with Imation's businesses prior to the Distribution Date and known
Superfund Sites associated with Imation's properties as of the Distribution
Date.
It is Imation's policy to accrue environmental remediation costs if it
is probable that a liability has been incurred and the amount of such liability
is reasonably estimable. As assessments and remediations proceed, these accruals
are reviewed periodically and adjusted, if necessary, as additional information
becomes available. The accruals for these liabilities can change due to such
factors as additional information on the nature or extent of contamination,
methods of remediation required, the allocated share of responsibility among
other parties, if applicable, and other actions by governmental agencies or
private parties. However, it is often difficult to estimate the future impact of
environmental matters, including potential liabilities.
As of December 31, 1996, Imation had reserved approximately $6 million
with respect to environmental liabilities. Although Imation believes that its
reserves are adequate, there can be no assurance that the amount of expenses
relating to remedial actions and compliance with applicable environmental laws
will not exceed the amounts reflected in Imation's reserves. Imation believes
that such additional charges, if any, will not have a material adverse effect on
the financial position, results of operations or cash flows of Imation.
Relationship Between 3M and Imation
For purposes of governing certain of the relationships between 3M and
Imation following the Distribution, 3M and Imation entered into the Transfer and
Distribution Agreement described below and various ancillary agreements to which
they are parties, including those described below. Certain of these agreements
have been filed as exhibits to Imation's Registration Statement on Form 10
relating to the Distribution, and the following summaries are qualified in their
entirety by reference to the agreements as filed.
TRANSFER AND DISTRIBUTION AGREEMENT. 3M and Imation have entered into
the Transfer and Distribution Agreement, which provides for, among other things,
the principal corporate transactions required to effect the Distribution, the
transfer to Imation of the Transferred Businesses, the division between 3M and
Imation of certain liabilities and certain other agreements governing the
relationship between 3M and Imation following the Distribution.
TAX SHARING AND INDEMNIFICATION AGREEMENT. 3M and Imation entered into
a Tax Sharing and Indemnification Agreement (the "Tax Sharing Agreement"),
providing for their respective obligations concerning various tax liabilities.
The Tax Sharing Agreement provides that 3M shall pay, and indemnify Imation if
necessary, with respect to all federal, state, local and foreign income taxes
relating to the Transferred Businesses for any taxable period ending on or
before the Distribution Date except that Imation shall indemnify 3M for any
income taxes arising out of the failure of the Distribution or any of the
transactions related to it to qualify as tax free as a result of certain actions
taken by Imation or any of its subsidiaries. Prior to the Distribution, 3M
received a ruling from the Internal Revenue Service that 3M stockholders who
received shares of Imation Common Stock in connection with the Distribution
would not recognize income, gain or loss upon receipt of such shares, except in
connection with any cash received in lieu of fractional shares. 3M also
generally agreed to pay all other taxes (other than those which are imposed
solely on Imation) that are payable in connection with the Distribution and the
transactions related to it the liability for which arose on or before the
Distribution Date. The Tax Sharing Agreement further provides for cooperation
with respect to certain tax matters, the exchange of information and the
retention of records which may affect the income tax liability of either party.
CORPORATE SERVICES TRANSITION AGREEMENT. 3M and Imation entered into a
Corporate Services Transition Agreement (the "Corporate Services Agreement")
pursuant to which 3M agreed to provide to Imation certain services, including
engineering and environmental services, logistics and information technology
services, financial services, human resources administration services and tax,
insurance, treasury and employee benefits administration, which 3M historically
provided to the Transferred Businesses prior to the Distribution Date. The
length of time that 3M will provide such services and the amount that Imation
will pay for such services varies based on the type of service. Generally, no
services are expected to be provided beyond two years following the Distribution
Date, and after such time Imation expects to provide such services on its own
behalf. The Corporate Services Agreement is terminable by each party upon 90
days notice, provided that 3M is not permitted to terminate certain specified
services, which the parties have determined will require a longer period to
replace. The costs associated with the services provided by 3M are either a
fixed dollar amount based on the estimated cost of the services provided, or an
amount determined pursuant to a formula based on the services actually provided.
Any services required by Imation beyond the first year will be based on costs
incurred plus an 8% mark-up. Certain foreign subsidiaries of Imation and 3M
entered into corporate services agreements pursuant to which 3M agreed to
provide to such subsidiaries services similar to those being provided to Imation
pursuant to the Corporate Services Agreement. The cost of all such services
supplied by 3M to Imation during the last six months of 1996 totaled
approximately $51 million.
ENVIRONMENTAL MATTERS AGREEMENT. 3M and Imation entered into an
Environmental Matters Agreement (the "Environmental Matters Agreement")
providing for their respective obligations concerning environmental liabilities
arising out of the operation of the premises of the Transferred Businesses and
other environmental matters.
Under the Environmental Matters Agreement, Imation assumed and agreed
to indemnify 3M for all liabilities relating to, arising out of or resulting
from (i) operations at Imation's facilities as conducted before the Distribution
Date; (ii) the disposal of hazardous materials from Imation's facilities before
the Distribution Date and at Superfund Sites, where such liabilities are
discovered after the Distribution Date; or (iii) operations of the Transferred
Businesses on and after the Distribution Date. 3M agreed to retain
responsibility for environmental liabilities relating to former premises which
may have been associated with the Transferred Businesses, and known Superfund
sites associated with the properties of the Transferred Businesses on or before
the Distribution Date.
INTELLECTUAL PROPERTY AGREEMENT. 3M and Imation entered into an
Intellectual Property Rights Agreement (the "Intellectual Property Agreement")
pursuant to which 3M granted to Imation, effective as of the Distribution Date,
rights to use certain intellectual property (such as patent rights, copyrights,
mask work rights and proprietary information) exclusively in the fields of use
in which the Transferred Businesses operated as of the Distribution Date and
non-exclusively in certain other fields. In addition, 3M transferred to Imation
title to certain intellectual property rights previously used by the Transferred
Businesses, subject to certain rights of 3M to continue to use such intellectual
property rights. The Intellectual Property Agreement further provides for
cross-licensing of certain future intellectual property developed during a
transition period. In addition, for various transition periods specified in the
Intellectual Property Agreement, Imation is granted the right to use certain 3M
trademarks under a royalty-bearing license. Trademarks used only by the
Transferred Businesses were assigned to Imation as of the Distribution Date.
The Intellectual Property Agreement provides that the costs associated
with the procurement and maintenance of patents and trademarks licensed to
either party by the other under the Intellectual Property Agreement are the
responsibility of the party owning the particular patent or trademark. However,
with respect to patents, either party may designate a patent or patent
application under which it is licensed by the other party to be of "common
interest." The licensed party is granted certain rights to participate in
decisions involving such common interest patents and patent applications, and
the costs thereof are shared by the parties. The costs of enforcing licensed
patents against an infringer will be borne by the party instituting the lawsuit
unless the parties agree otherwise. For jointly-owned patents, enforcement costs
are shared if both parties desire to participate. The licensed party's
enforcement of patents requires prior approval by the party owning the patent.
With the exception of licensed trademark rights, no royalties or fees
are payable by Imation to 3M for the assignment and license of intellectual
property to Imation under the Intellectual Property Agreement. With respect to
licensed trademarks, Imation is required to pay a royalty, which Imation
believes is reasonable, through cash payments, commitments to purchase product
from 3M and/or engaging in certain other activities benefiting 3M.
The parties have agreed to cross-license each other under certain
patents and proprietary information developed by each party during the two year
period following the Distribution Date. The cross- licenses are royalty-free and
generally of the same scope (i.e., exclusive or non-exclusive in defined fields)
as the licenses granted to and retained by Imation and 3M, respectively, under
the patents and proprietary information existing at the time of the
Distribution.
Imation and 3M have entered into joint development agreements pursuant
to which the parties will assist each other in the development of new products
following the Distribution Date. The relationship between the parties under the
agreements varies from simple purchased research to shared product development.
3M and Imation agreed not to compete with each other in their
respective businesses for a period of five years following the Distribution
Date. 3M agreed that, except for ancillary activity involving an insubstantial
business, it would not compete directly or indirectly in Imation's Exclusive
Fields (which, as defined in the Intellectual Property Agreement, are generally
the fields of business in which Imation was engaged as of the Distribution
Date). Imation agreed that, except for ancillary activity involving an
insubstantial business, it would not compete, directly or indirectly in the 3M
Business Fields (which, as defined in the Intellectual Property Agreement, are
generally the fields of business in which 3M was engaged as of the Distribution
Date). However, this provision does not preclude Imation from indirect activity,
outside of the 3M Reserved Fields (which, as defined in the Intellectual
Property Agreement, are generally fields closely related to Imation's Exclusive
Fields where 3M has retained exclusive rights), involving working with a third
party on that party's imaging and electronic information processing needs,
internal or external, as long as the activity does not benefit, in more than an
ancillary way, a product or service of the third party which competes with a
product or service in the 3M Business Fields.
SUPPLY, SERVICE AND CONTRACT MANUFACTURING AGREEMENTS. 3M and Imation
entered into various product and service supply agreements (the "Supply
Agreements") providing for the supply by 3M to Imation and by Imation to 3M, of
certain products and services. Under the Supply Agreements, 3M supplies to
Imation certain raw material and intermediate products including film, specialty
chemicals and abrasives and provides to Imation certain contract manufacturing
services, primarily equipment assembly services. Under the Supply Agreements,
Imation supplies to 3M certain semi-finished products and components and
provides to 3M certain contract manufacturing and other services, including
converting, slitting and coating services and technical field service. The
prices for products supplied by either party under the Supply Agreements are
based on the cost of supplying such product plus a 5% mark-up in 1996, a 10%
mark-up in 1997 and a 15% mark-up in 1998 and thereafter. The prices paid for
contract manufacturing services provided by either party vary depending on the
services provided but generally are based on costs incurred plus an 8% mark-up.
The net cost to Imation of all such transactions between 3M and Imation totaled
approximately $60 million in 1996.
SHARED FACILITY AND LEASE AGREEMENTS. 3M and Imation entered into
various lease agreements with respect to certain facilities (the "Shared
Facility Agreements") at which 3M and Imation share space. With respect to each
of these facilities, the party that is the owner (or primary tenant) of the
facility leases to the other party a portion of the facility so as to enable the
other party to conduct operations at such facility.
The form of lease entered into by 3M and Imation provides for the
payment of rent in an amount approximating the standard recharge rate used by
the lessor with respect to internal uses of such facilities. The leases
generally provide for a two year term, in some cases with an option to extend
for an additional two years. The amount paid by 3M to Imation during the last
six months of 1996 with respect to Shared Facility Agreements totaled
approximately $400,000 and the amount paid by Imation to 3M during the same
period and for the same purpose totaled approximately $9 million.
Imation has commenced construction of an office building and research
and development facilities at its headquarters site in Oakdale in order to
consolidate its headquarters operations. Imation will continue to lease certain
laboratory and manufacturing space from 3M following the consolidation of its
headquarters operations. See "--Properties."
PROPERTIES
Imation's headquarters are located in Oakdale, Minnesota. Imation is in
the process of constructing an office building and research and development
facilities at its Oakdale site in order to consolidate its headquarters
operations. The costs of construction of these research and development
facilities will be financed through a synthetic lease financing arrangement.
Construction of these facilities will enable Imation to re-locate approximately
1,100 employees currently located in facilities being leased by Imation from 3M.
Imation's major facilities (all of which are owned by Imation, except where
noted), and the products manufactured at such facilities are listed below.
Imation's facilities are in good operating condition suitable for their
respective uses and adequate for Imation's current needs.
FACILITY PRODUCTS
Domestic
Camarillo, California Data tape
Fremont, California (leased) CD-ROM
Menomonie, Wisconsin (leased) Laserdisc, CD-ROM and DVD-ROM
Middleway, West Virginia Printing plates
Nekoosa, Wisconsin Carbonless paper
Oakdale, Minnesota Headquarters
Pine City, Minnesota Micrographic cards
St. Paul, Minnesota (leased) Laboratory facilities
Tucson, Arizona Data tape
Vadnais Heights, Minnesota (leased) Optical
Wahpeton, North Dakota Diskettes/molding
Weatherford, Oklahoma Diskettes/photographic film
White City, Oregon Imagers/X-ray films
International
Bracknell, United Kingdom Administrative
Breda, Netherlands (leased) CD-ROM services
Milan, Italy (leased) Administrative
Rotterdam, Netherlands (leased) Administrative
Ferrania, Italy X-ray films/photographic film
Florida, Argentina X-ray films
Harlow, United Kingdom Research facility
London, Ontario, Canada Administrative
LEGAL PROCEEDINGS
In connection with the Distribution, Imation assumed substantially all
liabilities for legal proceedings relating to Imation's businesses as conducted
prior to the Distribution Date. See "--Relationship Between 3M and
Imation--Transfer and Distribution Agreement." In addition, in the normal course
of business, Imation is subject to proceedings, lawsuits and other claims,
including proceedings under laws and regulations related to environmental and
other matters. All such matters are subject to many uncertainties and outcomes
that are not predictable with assurance. Consequently, Imation is unable to
ascertain the ultimate aggregate amount of monetary liability or financial
impact with respect to these matters as of March 31, 1997. While these matters
could materially affect operating results of any one quarter when resolved in
future periods, it is management's opinion that after final disposition, any
monetary liability or financial impact to Imation beyond that provided in the
consolidated balance sheet as of March 31, 1997 would not be material to
Imation's financial position or annual results of operations or cash flows.
MARKET FOR IMATION COMMON STOCK AND RELATED STOCKHOLDER MATTERS
As of February 28, 1997, there were 42,627,470 shares of Imation Common
Stock outstanding held by approximately 67,394 stockholders of record. Imation
Common Stock is listed on the New York and Chicago Stock Exchanges. Imation did
not pay any dividends during 1996. Future dividends will be determined by the
Board of Directors.
In connection with Imation's acquisition of Luminous Corporation on
October 11, 1996, Imation issued 922,845 shares of Imation Common Stock to the
stockholders of Luminous Corporation in exchange for all of the issued and
outstanding shares of that company. The issuance of the shares of Imation Common
Stock did not involve a public offering and was exempt from registration
pursuant to Section 4(2) of the Securities Act.
The following table sets forth, for the periods indicated, the high and
low sales prices of Common Stock as reported on the New York Stock Exchange
Composite Transactions. Imation Common Stock commenced regular way trading on
the New York Stock Exchange on July 15, 1996:
Sales Prices
----------------------
High Low
PERIOD:
Third Quarter 1996................................... $ 26.25 $ 20.38
Fourth Quarter 1996.................................. 33.00 22.75
First Quarter 1997................................... 30.38 25.00
Second Quarter 1997
(through ___)......................................
On May 13, 1997, the last full trading day before Imation and
Cemax-Icon announced the execution of the Merger Agreement, the closing price
per share of Imation Common Stock was $24.50, and on_________, 1997, the closing
price per share of Imation Common Stock was $__________.
SECURITY OWNERSHIP
Security Ownership of Certain Beneficial Owners
The following table sets forth the holdings, as of the date indicated,
of Imation Common Stock of each person known to Imation to own beneficially (as
defined by the Securities and Exchange Commission for proxy statement purposes)
more than 5% of any class of Imation's voting securities.
<TABLE>
<CAPTION>
Name and Address Amount and Nature of
Beneficial Owner Beneficial Ownership Percent of Class
<S> <C> <C>
FMR Corp. 5,450,891(1) 13.0%
82 Devonshire Street
Boston, Massachusetts 02109
State Street Bank and Trust Company 2,536,503(2) 5.93%
225 Franklin Street
Boston, Massachusetts 02110
</TABLE>
- ------------------
(1) Imation received a copy of a Schedule 13G filed with the Securities and
Exchange Commission by FMR Corp., indicating that, at November 30, 1996,
FMR Corp. and certain of its affiliates and subsidiaries, as investment
advisor to various investment company mutual funds, beneficially held a
total of 5,450,891 shares of Imation Common Stock. Such entities had sole
power to vote 2,201 of such shares and sole dispositive power with respect
to all such shares.
(2) Imation received a copy of a Schedule 13G filed with the Securities and
Exchange Commission by State Street Bank and Trust Company, indicating
that, at December 31, 1996, State Street Bank and Trust Company, as trustee
of the Imation Retirement Investment Plan and other trust accounts, held a
total of 2,536,503 shares of Imation Common Stock. Of such shares, State
Street Bank and Trust Company had sole power to vote 236,902 shares, shared
power to vote 2,292,321 shares, sole power to dispose of 240,795 shares and
shared power to dispose of 2,295,708 shares.
Security Ownership of Management
The following table sets forth the number of shares of Imation Common
Stock beneficially owned as of February 28, 1997, by each director, the five
most highly compensated executive officers in 1996, and all directors and
executive officers as a group. Except as otherwise indicated, the named
beneficial owner has sole voting and investment power with respect to the shares
held by such beneficial owner.
Amount and Nature of
Name of Beneficial Owner Beneficial Ownership (1)(2)
William T. Monahan 6,485
Lawrence E. Eaton 10,386
William W. George 3,631
Linda W. Hart 890
Ronald T. LeMay 373
Marvin L. Mann 2,000
Mark A. Pulido 1,252(3)
Daryl J. White 373
Krzysztof K. Burhardt 2,011
Clifford T. Pinder 1,097
Charles D. Oesterlein 309
Dennis A. Farmer 1,745
All Directors and Executive
Officers as a Group (23 persons) 40,860
- -----------------
(1) Includes the following shares allocated as of February 28, 1997 to the
accounts of participants under the Imation Retirement Investment Plan: W.
T. Monahan, 353 shares; K. K. Burhardt, 206 shares; C. T. Pinder, 235
shares; C. D. Oesterlein, 205 shares; D. A. Farmer, 261 shares; and all
executive officers as a group, 3611 shares. The participants in the Imation
Retirement Investment Plan have shared voting and investment power with
respect to such shares.
(2) As of February 28, 1997, the percentage of shares of Common Stock
beneficially owned by any director, by any named executive officer and by
all directors and executive officers as a group was less than 1% of the
outstanding Imation Common Stock.
(3) Includes 276 shares owned by Mr. Pulido's wife, as to which Mr. Pulido
disclaims beneficial ownership.
SELECTED FINANCIAL DATA OF IMATION
Set forth below is selected consolidated historical financial
information of Imation derived from the unaudited consolidated financial
statements of Imation for the three months ended March 31, 1997 and 1996 and for
the fiscal year ended December 31, 1992, and the audited consolidated financial
statements of Imation for the fiscal years ended December 31, 1996, 1995, 1994
and 1993. The information should be read in conjunction with the Management's
Discussion and Analysis of Imation, the consolidated financial statements of
Imation and related notes thereto and the pro forma unaudited combined financial
statements and the related note thereto included elsewhere herein. In the
opinion of Imation's management, the operating results for the fiscal quarters
ended March 31, 1997 and 1996 and for the fiscal year ended December 31, 1992
reflect all adjustments (consisting of normal recurring accruals except for the
restructuring charges recorded in the first quarter of 1996) necessary to
present fairly the information contained therein. Results for the three months
ended March 31, 1997 are not necessarily indicative of the results for the full
year.
<TABLE>
<CAPTION>
Three Months Ended
March 31, Years Ended December 31,
------------------- ---------------------------------------------------------
1997 1996(a) 1996(b) 1995(c) 1994 1993 1992
(In millions, except (In millions, except per share data) (Unaudited)
per share data)
(Unaudited)
STATEMENT OF OPERATIONS DATA:
<S> <C> <C> <C> <C> <C> <C> <C>
Net revenues .......... $ 548 $ 576 $ 2,278 $ 2,246 $ 2,281 $ 2,308 $ 2,350
Gross profit .......... 199 202 795 725 839 886 885
Selling, general and
administrative ...... 133 131 563 539 532 529 542
Research and
development ......... 38 48 183 222 211 217 181
Operating income (loss) 28 13 (5) (149) 96 141 162
Net income (loss) ..... 12 6 (21) (85) 54 75 94
Earnings (loss) per
common share ........ .30 .14 (0.49) (2.02) 1.28 n/a n/a
BALANCE SHEET DATA:
Total working capital . $ 622 $ 607 $ 658 $ 714 $ 618 $ 608
Total assets .......... 1,549 1,561 1,542 1,672 1,546 1,534
Long-term obligations . 245 222 97 88 85 96
Total shareholders'
equity ............ 912 930 1,149 1,300 1,200 1,172
</TABLE>
- ------------------
(a) Restructuring charges reduced results for the three months ended March 31,
1996 by $10.4 million before taxes and minority interest and $6.1 million
after taxes and minority interest. Net income for the three months ended
March 31, 1996 excluding these charges would have been $12.2 million. These
charges relate to costs for certain employee separation programs.
(b) Restructuring charges and one-time charges reduced 1996 results by $88.4
million before taxes and minority interest and $60.6 million after taxes
and minority interest. 1996 net income excluding these charges would have
been $40.1 million. These charges related to one-time costs associated with
start-up activities, restructuring charges primarily for employee severance
programs and the write-off of in-process research and development related
to the acquisition of Luminous Corporation.
(c) Restructuring charges and asset write-offs reduced 1995 results by $166.3
million before taxes and minority interest and $88.3 million after taxes
and minority interest. 1995 net income excluding these charges would have
been $3.3 million. The majority of these charges related to the write-down
of property, plant and equipment.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF IMATION
GENERAL OVERVIEW
On June 18, 1996, the Board of Directors of 3M approved the
Distribution of Imation, which is comprised of substantially all of the
businesses previously operated within 3M's data storage and imaging systems
groups. To effectuate the transaction, the Board of Directors of 3M declared a
dividend payable to the holders of record of 3M common stock as of June 28,
1996, based upon a ratio of one share of Imation Common Stock for every ten
shares of 3M common stock owned on the record date. Effective July 1, 1996,
shares of Imation Common Stock were distributed to 3M stockholders. Following
the Distribution, Imation began operations as an independent, publicly held
company. Prior to July 1, 1996, the financial statements reflect the results of
operations, financial position and cash flows of the businesses transferred to
Imation from 3M as they operated within 3M. As a result, the financial
statements of Imation prior to July 1, 1996 have been carved out from the
financial statements of 3M using the historical results of operations and
historical basis of the assets and liabilities of such businesses. Imation's
statements of operations prior to July 1, 1996 include all of the related costs
of doing business, including charges for the use of facilities and for employee
benefits, and include an allocation of certain general corporate expenses of 3M
which were not directly related to these businesses, including costs for
corporate logistics, corporate research and development, information
technologies, finance, legal and corporate executives. Management of Imation
believes these allocations were made on a reasonable basis. The financial
information for periods prior to July 1, 1996 included herein, however, may not
necessarily be indicative of the results of operations, financial position and
cash flows of Imation in the future or what the results of operations, financial
position and cash flows would have been had Imation been a separate, independent
company during the periods presented.
In late 1995, Imation developed a reorganization plan to rationalize
its manufacturing operations, streamline its organizational structure and write
off impaired assets. Imation has made significant progress in implementing this
plan, including the closure or consolidation of five factory locations and the
consolidation of Imation laboratories from fourteen to seven. As part of the
reorganization, the number of reported employees of Imation was reduced from
approximately 12,300 at December 31, 1995 to 9,400 at December 31, 1996 through
voluntary and involuntary separation programs offered to employees of Imation
prior to the Distribution, as well as the retention by 3M of staff services
positions which had been allocated to Imation as part of 3M. Imation continues,
however, to obtain certain staff services functions from 3M pursuant to the
Corporate Services Agreement entered into between 3M and Imation in connection
with the Distribution.
During 1995 and 1996, Imation recorded one-time pre-tax charges of
$254.7 million based upon the timing criteria required for the recognition of
such charges. Imation recorded $166.3 million of these charges in its 1995
statement of operations, primarily for the write-down of assets associated with
its manufacturing rationalization programs and $76.4 million in the first six
months of 1996, primarily related to employee separations for direct employees
of Imation and one-time charges associated with start-up activities. In
addition, in the fourth quarter of 1996, Imation recognized a non-deductible
write-off of $12.0 million for the in-process research and development related
to its acquisition of Luminous Corporation (see Note 3 of the Notes to Imation
Corp. Audited Consolidated Financial Statements included herein).
At the time of the Distribution, Imation established an overall
financial goal of improving Imation economic profit (measured as operating
income after taxes in excess of a charge for the use of capital) by $150 million
by the end of 1998. This goal is based on anticipated cost reductions and
Imation objectives for improved revenue growth and increased asset utilization.
During 1996, Imation's economic profit improved by $65 million over
1995, with all three components contributing to the improvement. Cost reductions
contributed $30 million to the increased economic profit, revenue growth
contributed $5 million and improved asset management contributed $30 million.
The improvement in economic profit due to cost reductions was driven by
Imation's lower cost structure following the Distribution, including more than a
20 percent reduction in headcount from the levels prior to the Distribution. In
addition, improved factory performance and lower material costs contributed to
the cost improvement. These cost reductions were partially offset by recurring
start-up costs for establishing the Imation brand and identity, and activities
to design and implement more efficient business processes. The improvement in
economic profit from revenue growth was driven by sales of Imation's newly
introduced product platforms, primarily Travan(TM) data cartridges and
DryView(TM) laser imagers. The economic profit improvement from better asset
utilization was driven by working capital reductions in accounts receivable and
inventory and lower levels of fixed assets due to the asset write-offs at the
end of 1995.
During the first quarter of 1997, Imation improved economic profit by
$7.5 million over the first quarter of 1996. Cost reductions and improved asset
management generated approximately $7.0 million and $6.0 million, respectively,
of this improvement, partially offset by the revenue decline. Since the
beginning of 1996, economic profit has improved by approximately $72 million,
with $36 million of the improvement coming from cost reductions and $36 million
from improved asset management.
RESULTS OF OPERATIONS
Comparison of Three Months Ended March 31, 1997 and 1996
The following table displays the components of Imation's consolidated
statements of operations as a percentage of total revenues. The 1996 percentages
exclude the impact of $10.4 million of pretax restructuring charges ($6.1
million after tax) recorded in the first quarter of 1996.
<TABLE>
<CAPTION>
Three Months Ended March 31,
----------------------------
Adjusted
1997 1996
<S> <C> <C>
Net revenues ........................................ 100.0% 100.0%
Cost of goods sold................................... 63.7 64.9
Gross profit ...................................... 36.3 35.1
OPERATING EXPENSES:
Selling, general and administrative................ 24.3 22.7
Research and development........................... 6.9 8.3
Total............................................ 31.2 31.0
Operating income..................................... 5.1 4.1
OTHER INCOME AND EXPENSE:
Interest expense................................... 0.4 0.6
Other, net......................................... 0.7 (0.1)
Total............................................ 1.1 0.5
Income before tax and minority interest.............. 4.0 3.6
Income tax provision................................. 1.8 1.5
Minority interest.................................... -- --
Net income........................................... 2.2% 2.1%
</TABLE>
Net revenues for the first quarter of 1997 were $547.7 million, a
decrease of $28.4 million or 4.9 percent from the same period in 1996. Volume
increases of 3.5 percent were more than offset by price declines of 4.9 percent
and the negative effect of changes in currency exchange rates of 3.5 percent.
Volume growth was negatively impacted approximately 2.6 percent by Imation's
decision to reduce sales in certain low margin product lines in which Imation is
operating under a harvest strategy, including a portion of Imation's non-branded
duplicator diskette sales, certain photo color markets and certain graphic arts
supplies. Volume growth was also negatively impacted by weakness in Imation's
European operations. Imation's growth portfolio, including Luminous software
products, represented approximately 16 percent of revenues, up from 7 percent in
the first quarter of 1996 and up from 11 percent for the full year of 1996.
Price erosion of 4.9 percent improved from the price erosion experienced in the
first quarter of 1996 of 5.6 percent and is consistent with Imation's
expectations.
Net revenues in the United States decreased 1.7 percent with volume
increases of 1.3 percent more than offset by pricing declines of 3.0 percent.
Internationally, net revenues decreased 8.0 percent. Volume increases of 5.5
percent were more than offset by price declines of 6.7 percent and a 6.8 percent
negative effect of changes in currency exchange rates. Based on the currency
exchange rates as of March 31, 1997, changes in currency exchange rates will
continue to negatively impact revenues and earnings on a quarter over the same
quarter of the previous year basis for the remainder of 1997, although to a
lesser degree than in the first quarter of 1997. International revenues
accounted for 49.6 percent of first quarter 1997 revenues, down from 51.3
percent of total revenues for first quarter 1996.
Gross profit in the first quarter of 1997 was $199.0 million or 36.3
percent of revenues, an increase of 1.2 percentage points from the first quarter
of 1996. This increase is due to unit cost reductions, raw material price
declines and the reduction of sales in some low margin product lines, partially
offset by negative pricing pressure and foreign currency impacts.
Selling, general and administrative expenses were $133.0 million or
24.3 percent of revenues, up $2.3 million or 1.6 percentage points from the same
period in 1996. The increase is driven by $4.7 million, or 0.9% of revenues, of
costs related to designing and implementing more efficient business processes
and developing Imation's brand identity that were incurred in the first quarter
of 1997. There were no comparable costs in the first quarter of 1996. It is
expected that these start-up costs will continue throughout 1997. The remaining
increase in selling, general and administrative expenses as a percentage of
revenues is primarily due to the decline in revenues.
Research and development costs totaled $37.8 million or 6.9 percent of
revenues in the first quarter of 1997, down $10.1 million or 1.4 percentage
points from the same period in 1996. This decrease reflects the efficiencies and
productivity Imation has obtained by the consolidation of laboratories and the
reduction of spending on harvest businesses, partially offset by investment in
key future technology programs.
Imation recorded restructuring charges of $10.4 million in the first
quarter of 1996 reflecting costs for certain voluntary employee separation
programs. No such charges were recorded in the first quarter of 1997.
Operating income for the first quarter of 1997 was $28.2 million, or
5.1 percent of revenues. This represents a $4.5 million increase over operating
income in the first quarter of 1996 of $23.7 million, after excluding the first
quarter 1996 restructuring charges.
First quarter 1997 interest expense was $2.4 million, down $1.3 million
from the same quarter last year. This decrease was due to lower average debt
balances and a lower effective interest rate. Interest expense prior to July 1,
1996 was based on an assumed $250 million in outstanding debt and 3M's effective
interest rate during the period. The allocation of interest expense for periods
prior to July 1, 1996 is more fully discussed in Note 7 of the Notes to Imation
Corp. Audited Consolidated Financial Statements included herein.
The net other income and expense in the first quarter of 1997 totaled
$4.0 million of expense, compared to $0.5 million of income in the comparable
period of 1996. The 1997 expense is primarily due to transaction losses on
foreign currency exposures.
Imation's effective tax rate in the first quarter of 1997 was 45.0
percent, compared to 41.0 percent in the first quarter of 1996 and 48.2 percent
in the last six months of 1996 (excluding the impact of the non-deductible $12.0
million write-off of the in-process research and development related to the
Luminous acquisition that occurred in the fourth quarter of 1996). The first
quarter 1997 rate is lower than the rate incurred as an independent company in
1996 as Imation has started to realize the benefits of its new, tax-effective
structure.
Net income in the first quarter of 1997 was $12.0 million, or $.30 per
share. Net income in the comparable period of 1996 was $6.1 million, or $.14 per
share. Excluding restructuring charges, first quarter 1996 net income would have
been $12.2 million, or $.29 per share.
Comparison of the Years Ended December 31, 1996, 1995 and 1994
The following table sets forth the components of net revenue changes
for 1996 and 1995.
<TABLE>
<CAPTION>
1996 1995
------------------------------------------ ----------------------------------------
United States International Worldwide United States International Worldwide
<S> <C> <C> <C> <C> <C> <C>
Volume................ 5.6 % 10.1 % 7.9 % (0.5)% 6.3 % 2.7 %
Price................. (2.9) (7.0) (4.9) (5.4) (7.3) (6.3)
Translation........... -- (2.9) (1.5) -- 4.3 2.0
Total.............. 2.7 % 0.2 % 1.5 % (5.9)% 3.3 % (1.6)%
</TABLE>
The following table sets forth Imation's consolidated statements of
operations, restructuring and other one-time charges and resulting adjusted
balances for the years ending December 31, 1996 and 1995. The adjusted balances
are also presented as a percentage of net revenues.
<TABLE>
<CAPTION>
Year Ended December 31, 1996 Year Ended December 31, 1995
----------------------------------------------- -----------------------------------------------
One Time Percent of One Time Percent of
Reported Charges Adjusted Revenues Reported Charges Adjusted Revenues
(Dollars in millions, except per share data)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Net revenues ................... $ 2,278.2 $ -- $ 2,278.2 100.0% $ 2,245.6 $ -- $ 2,245.6 100.0%
Cost of goods sold ............. 1,482.8 (7.9) 1,474.9 64.7 1,520.9 (50.2) 1,470.7 65.5
Gross profit ................. 795.4 7.9 803.3 35.3 724.7 50.2 774.9 34.5
OPERATING EXPENSES:
Selling, general and
administrative ............. 563.0 (14.6) 548.4 24.1 539.4 -- 539.4 24.0
Research and development ..... 183.1 (12.0) 171.1 7.5 222.4 (4.3) 218.1 9.7
Restructuring charges ........ 53.9 (53.9) -- -- 111.8 (111.8) -- --
Total operating expenses . 800.0 (80.5) 719.5 31.6 873.6 (116.1) 757.5 33.7
OTHER INCOME AND EXPENSES:
Operating income (loss) ...... (4.6) 88.4 83.8 3.7 (148.9) 166.3 17.4 0.8
Interest expense and other ... 10.4 -- 10.4 0.5 17.9 -- 17.9 0.8
Income (loss) before tax
and minority interest ...... (15.0) 88.4 73.4 3.2 (166.8) 166.3 (0.5) 0.0
Income tax provision (benefit) 5.9 27.8 33.7 1.4 (70.5) 70.3 (0.2) 0.0
Minority interest ............ (0.4) -- (0.4) 0.0 (11.3) 7.7 (3.6) (0.1)
Net income (loss) ............ $ (20.5) $ 60.6 $ 40.1 1.8% $ (85.0) $ 88.3 $ 3.3 0.1%
Earnings (loss) per share .... $ (0.49) $ 1.46 $ 0.97 $ (2.02) $ 2.10 $ 0.08
</TABLE>
Net revenues increased 1.5 percent in 1996 compared to a decline of 1.6
percent in 1995. Volume growth was 7.9 percent in 1996 compared to 2.7 percent
in 1995. Volume growth in 1996 was driven by increased sales of newly introduced
product platforms (principally Travan(TM) data cartridges and DryView(TM) laser
imagers) and greater international market penetration. Price declines were 4.9
percent in 1996 compared to 6.3 percent in 1995. Price erosion lessened in 1996
compared to 1995 due to product mix and greater pricing discipline. Changes in
currency exchange rates negatively impacted net revenues 1.5 percent in 1996
while positively impacting net revenues 2.0 percent in 1995. The 1.6 percent
decline in net revenues in 1995 as compared to 1994 was primarily due to the
effects of downward pricing pressures which exceeded Imation's volume growth.
Imation's expectation is for price erosion to continue in the same general range
in the near term.
Approximately 49 percent of Imation's net revenues in 1996 were from
sales outside the United States compared to 50 percent in 1995, with this
decrease due to the impact of currency exchange rates. In 1994, 47 percent of
Imation net revenues were from outside the United States. In Imation's
international operations, volume rose 10.1 percent in 1996 and 6.3 percent in
1995. The increase in volume growth in 1996 was due to greater market
penetration. Price declines of 7.0 percent and 7.3 percent occurred in 1996 and
1995, respectively. The net result of the volume and price changes was a 3.1
percent growth in local currencies in 1996 while local currency revenue
decreased 1.0 percent in 1995. Changes in currency exchange rates negatively
impacted international net revenues by 2.9 percent in 1996 and positively
impacted international net revenues by 4.3 percent in 1995. Based on the
strengthening of the U.S. dollar during the first part of 1997, changes in
currency exchange rates are likely to negatively impact 1997 revenues and
earnings.
United States net revenues increased by 2.7 percent in 1996 compared to
a decline of 5.9 percent in 1995. The increase in 1996 was driven by sales of
the newly introduced product platforms mentioned above. Volume growth was 5.6
percent in 1996 while volume declined slightly in 1995. Price declines were 2.9
percent in 1996 compared to 5.4 percent in 1995, with price erosion lessening
due to product mix and greater pricing discipline.
Gross profit for 1996 was $795.4 million, which includes the impact of
$7.9 million in one-time charges primarily related to the write-off of certain
packaging materials in connection with the Distribution. Gross profit in 1995
was $724.7 million, which includes the impact of $50.2 million in one-time
charges primarily related to asset write-offs. Excluding the impact of one-time
charges, gross profit in 1996 would have been $803.3 million or 35.3 percent of
revenues compared to $774.9 million or 34.5 percent of revenues in 1995. This
margin improvement was primarily due to volume increases, productivity
improvements, and lower raw material costs, partially offset by lower selling
prices. In 1994, gross profit was 36.8 percent of revenues. The decrease from
1994 to 1995 was primarily due to the effect of lower selling prices.
In 1996, selling, general and administrative expenses were $563.0
million. Excluding special one-time charges of $14.6 million related to
activities in connection with the Distribution, selling, general and
administrative expenses would have been $548.4 million, or 24.1 percent of
revenues. This is essentially unchanged from 1995, when selling, general and
administrative expenses were 24.0 percent of revenues. The full year 1996
selling, general and administrative expenses include $41.8 million of start-up
costs related to designing and implementing more efficient business processes
and developing Imation brand identity, offset by reduced sales related costs. It
is expected that these start-up costs will continue in 1997. In 1994, selling,
general and administrative expenses were 23.3 percent of revenues. The increase
in selling, general and administrative expenses as a percentage of revenues in
1995 over 1994 was primarily due to the decline in the revenue base. Imation's
goal is to lower the level of selling, general and administrative expenses as a
percentage of revenues as a part of achieving its economic profit goal discussed
in "--General Overview."
Research and development expenses in 1996 were $183.1 million, which
includes a non-deductible charge of $12.0 million for the acquired in-process
research and development related to Imation's acquisition of Luminous
Corporation. Research and development expenses in 1995 were $222.4 million,
which includes $4.3 million in one-time charges related to asset write-offs.
Excluding the impact of one-time charges, research and development expenses in
1996 would have been $171.1 million or 7.5 percent of revenues compared to
$218.1 million or 9.7 percent of revenues in 1995. This decrease is due to a
consolidation of laboratories from fourteen to seven, the implementation of a
more efficient research and development cost structure and higher than normal
spending in 1995 reflecting investments made in a number of Imation's new
products which came to market during 1995 and early 1996. In 1997, Imation
expects to continue to gain the benefits of this restructuring. In 1994,
research and development expenses were 9.3 percent of revenues. The increase in
1995 over 1994 was due to higher than normal spending in 1995 on new products as
noted above.
Imation recorded restructuring charges of $53.9 million in 1996. These
charges primarily relate to employee separation programs. In 1995, Imation
recorded restructuring charges of $111.8 million related to world-wide
manufacturing rationalization programs to exit less profitable manufacturing
locations and to centralize manufacturing in the United States and in Italy, and
consists principally of write-offs of property, plant and equipment.
The operating loss for 1996 totaled $4.6 million while the operating
loss for 1995 was $148.9 million. Losses in both years were the result of the
restructuring and other one-time charges discussed above. Excluding these
charges, operating income would have been $83.8 million in 1996 and $17.4
million in 1995, an improvement of $66.4 million. This improvement is primarily
a result of higher gross profit, lower research and development spending and
sales growth as discussed above. Operating income in 1995, excluding special
charges, would have been $17.4 million, or $78.4 million lower than 1994
operating income of $95.8 million. This decline primarily reflects the factors
affecting the lower gross profit as discussed above, and to a lesser extent the
increase in research and development spending.
Non-operating expense (primarily interest expense) for 1996 totaled
$10.4 million, down $7.5 million from 1995. This decrease is due to an increase
in other income of $2.9 million, primarily related to investment gains prior to
the Distribution, and to lower interest expense due to lower outstanding debt
levels and a lower effective interest rate. Interest expense prior to the
Distribution was based on an assumed $250 million in outstanding debt and 3M's
effective interest rate during the period. The allocation of interest prior to
the Distribution is more fully discussed in Note 7 of the Notes to Imation Corp.
Audited Consolidated Financial Statements contained herein. Non-operating
expense in 1995 was $17.9 million, up from $14.5 million in 1994. This increase
is due to 3M's rising effective interest rate in 1995 over 1994.
Excluding restructuring and one-time charges, Imation's effective tax
rate was 45.9, 42.3 and 36.0 percent of pre-tax income for 1996, 1995 and 1994,
respectively. Although a new, tax effective structure was implemented in 1996,
Imation continues to earn profits in high tax jurisdictions. Benefits from the
new structure will be realized over time, with an expected decrease in future
rates. Management believes Imation will generate sufficient income in future
periods to fully recover Imation's deferred tax assets.
Minority interest was $0.4 million, $11.3 million and $2.3 million in
1996, 1995 and 1994, respectively. The 1995 minority interest includes $7.7
million of restructuring charges related to Imation's operations in Japan.
The net loss for 1996 totaled $20.5 million compared to a net loss of
$85.0 million in 1995. Excluding restructuring and one-time charges, net income
would have been $40.1 million ($0.97 per share) in 1996 and $3.3 million ($0.08
per share) in 1995, an improvement of $36.8 million or $0.89 per share. Net
income in 1994 was $54.3 million or $1.28 per share. All per share amounts prior
to the Distribution are based on an average number of shares outstanding equal
to one-tenth the weighted average number of 3M shares outstanding based on the
distribution ratio of one share of Imation Common Stock for ten shares of 3M
common stock.
PERFORMANCE BY GEOGRAPHIC AREA
United States
In 1996, United States net revenues totaled $1,159.5 million, up 2.7
percent from $1,128.8 million in 1995. Volume increased 5.6 percent while
selling prices decreased 2.9 percent. Operating loss was $95.3 million in 1996
compared to $169.0 in 1995. Excluding restructuring and one-time charges of
$77.1 million in 1996 and $99.8 million in 1995, the operating loss would have
been $18.2 million in 1996 and $69.2 million in 1995, an improvement of $51.0
million. The improvement in the United States results was primarily due to
increased volume growth, reduced spending and the lessening of price erosion.
Europe, Middle East and Africa
Net revenues totaled $816.2 million in 1996, up 1.0 percent from $808.4
million in 1995. Excluding restructuring and one-time charges in Europe of $9.8
million in 1996 and $20.4 million in 1995, operating income would have been
$88.6 million in 1996 and $76.2 million in 1995, an increase of $12.4 million.
In 1996, volume increased 7.6 percent, selling prices declined 5.3 percent, and
changes in currency exchange rates negatively impacted revenues by 1.3 percent.
Latin America, Asia and Canada
Net revenues declined by 1.9 percent in 1996 to $302.5 million. Changes
in currency exchange rates caused revenues to decrease by 7.1 percent. In local
currencies, revenues were up 5.2 percent due to volume increases of 16.7 percent
offset by selling price declines of 11.5 percent. Operating income increased by
$3.0 million, after excluding special charges of $1.5 million in 1996 and $46.1
million in 1995.
FINANCIAL POSITION
Imation had 3.4, 3.2 and 3.4 months of inventory on hand as of March
31, 1997, December 31, 1996 and December 31, 1995, respectively. The accounts
receivable days sales outstanding was 76, 75 and 78 days as of March 31, 1997,
December 31, 1996 and December 31, 1995, respectively. Other current assets were
$94.5 million at December 31, 1996, an increase of $45.7 million over the 1995
balance. This increase is primarily due to an increase in current deferred tax
assets of $14.9 million, an increase in prepaid value added taxes in Europe of
$11.9 million and an increase in other prepaid expenses of $5.8 million.
The book value of property, plant and equipment at March 31, 1997 was
$461.5, a decrease of $18.6 million from the December 31, 1996 balance of $480.1
million. This decrease is primarily due to capital spending being lower than
depreciation. The December 31, 1996 net book value of property, plant and
equipment was $33.1 million lower than the December 31, 1995 balance of $513.2
million. This decrease is due to capital spending being lower than depreciation
and the sale of Imation's Sulmona, Italy facility. The decrease in machinery and
equipment cost of $143.6 million is primarily due to the disposal in 1996 of
machinery and equipment that was fully reserved for in 1995 as part of the
restructuring and other one-time charges.
Accounts payable at December 31, 1996 increased $56.2 million from
December 31, 1995. This increase is primarily due to establishing the normal
third party payables to 3M for products and transitional services that were
previously eliminated as intercompany balances. The balance in other current
liabilities at December 31, 1996 was $151.2 million, an increase of $25.3
million over 1995. This increase is primarily due to an increase in the accrual
for value added taxes in Europe and an increase in self insurance reserves.
LIQUIDITY
Comparison of the Three Months Ended March 31, 1997 and 1996
Prior to July 1, 1996, cash and equivalents and debt were not allocated
to Imation from 3M since 3M uses a centralized approach to cash management and
the financing of its operations. Imation financing requirements prior to July 1,
1996 are represented by cash transactions with 3M and are reflected in "Net cash
(paid to) received from 3M" in the consolidated statements of cash flows. This
financial support was discontinued following the Distribution.
Cash provided by operating activities was $19.2 million during the
three months ended March 31, 1997, compared to $69.7 million during the same
period in 1996. This change was primarily due to working capital increasing
$38.0 million in the first quarter of 1997, while working capital decreased $7.8
million in the comparable period of 1996. In addition, depreciation decreased
$10.4 million, from $48.5 million in the first quarter of 1996 to $38.1 million
in the first quarter of 1997.
Cash used in investing activities was $40.2 million for the first three
months of 1997 compared to $40.1 million in the comparable period of 1996.
Investing activities included capital expenditures of $28.0 million for the
first quarter of 1997 compared to $40.7 million during the same period of 1996.
It is expected that capital expenditures will approximately equal depreciation
for all of 1997. Capitalized software was $11.2 million in the first quarter of
1997, primarily related to establishing information technology systems
independent of 3M. It is expected that capitalized software costs related to
establishing independent systems will continue through the remainder of 1997.
Amortization of these costs will not begin until the systems are implemented,
beginning in late 1997.
Financing activities during the first quarter of 1997 provided cash of
$15.2 million. Financing activities primarily related to the net borrowing of
$25.1 million and the payment of $12.8 million to repurchase approximately
514,000 shares of Imation Common Stock. In the first quarter of 1997, Imation's
Board of Directors authorized Imation to repurchase up to six million shares of
Imation Common Stock.
At March 31, 1997, Imation's ratio of total debt to total capital was
15.9%. Imation believes this ratio will increase over time due to the cash
requirements for funding future growth opportunities. Imation also believes it
has the financial resources needed to meet its business requirements in the
foreseeable future.
Comparison of the Years Ended December 31, 1996, 1995 and 1994
Cash provided by operating activities was $306.0 million in 1996,
$256.8 million in 1995 and $170.1 million in 1994. The adjustments to net income
include depreciation, which ranged from $181.1 million to $189.5 million per
year during these periods, and restructuring and other one-time charges which
were $88.4 million in 1996 and $166.3 million in 1995. Working capital and
related cash requirements decreased $40.3 million in 1996 and $30.7 million in
1995, while in 1994 working capital and related cash requirements increased
$91.8 million.
Investing activities, mainly capital expenditures, utilized cash of
$184.6 million in 1996, $187.5 million in 1995 and $179.7 million in 1994. It is
expected that capital expenditures in 1997 will be similar to the expenditures
made in 1996 of $167.4 million. In addition to capital expenditures in 1996,
Imation capitalized $13.5 million of software expenditures related to the
development and implementation of independent Imation-supported systems to
replace those provided by 3M through service contracts.
During 1996, Imation established a $350 million credit facility with a
syndicate of banks. At the time of the Distribution, Imation borrowed
approximately $155.0 million to purchase from 3M certain assets located outside
the United States and to repay intercompany indebtedness assumed by Imation in
connection with the Distribution. During the third quarter, Imation borrowed an
additional $50 million to loan to the ESOP for the purchase of Imation Common
Stock to satisfy Imation's obligation to make matching contributions with
respect to employee salary deferrals and other performance based contributions.
Additional funds were borrowed and repaid from time to time for funding working
capital needs. At year-end, Imation had borrowed $120.0 million under the credit
facility. In addition, certain international subsidiaries have arranged
borrowings locally outside the credit facility. As of year end, $29.6 million of
borrowings were outstanding, primarily short term, under these arrangements. As
of December 31, 1996, Imation had a ratio of total debt to total capital of
approximately 13.9 percent. Imation believes this ratio will increase over time
due to the cash requirements for funding future growth opportunities.
In connection with Imation's acquisition of Luminous Corporation in
October 1996, Imation issued 922,845 shares of Imation Common Stock.
CERTAIN INFORMATION CONCERNING CEMAX-ICON
BUSINESS
Cemax-Icon designs, manufactures and markets medical image information
systems which electronically acquire, archive, distribute and display medical
images throughout hospitals, outpatient facilities and integrated delivery
networks ("IDNs"). Cemax-Icon's systems interface with virtually all
commercially available imaging modalities, including x-rays, computed tomography
("CT"), magnetic resonance imaging ("MRI"), computed radiography, ultrasound and
nuclear medicine. By automating and increasing the availability of medical
images within a healthcare facility or throughout an IDN, management believes
that Cemax-Icon's systems reduce the cost and improve the management of medical
care. Cemax-Icon's systems and modules are based on an open architecture and
utilize standard hardware and standard network protocols in order to facilitate
integration with existing image acquisition devices and healthcare information
systems. Cemax-Icon provides complete turn-key systems as well as scalable
software modules that integrate with commercially available third-party
hardware. Cemax-Icon sells its systems and software directly to end-users as
well as through OEMs and distributors. Cemax-Icon's OEM relationships are with
several leading suppliers of imaging and information systems to the healthcare
industry, including Imation, Toshiba Corporation ("Toshiba"), Lucent
Technologies, Inc. (formerly a division of AT&T, "Lucent"), Picker
International, General Electric Co. ("General Electric") and Eastman Kodak
Company ("Kodak"). Cemax-Icon's systems and software are installed at over 1,600
sites worldwide.
Cemax-Icon's systems enable healthcare providers to cost-effectively
implement picture archiving and communication systems ("PACS") within a
healthcare facility or throughout an IDN. Cemax-Icon's systems, designed in
consultation with clinicians, enable healthcare providers to reengineer the
management of medical images to increase the productivity of radiologists, other
clinicians and support staff. Cemax-Icon's systems also reduce film use and
film-related expenses, clinical problems and costs related to lost films, and
costs of storing and accessing medical images. In addition, Cemax-Icon's systems
increase the accessibility of medical images to clinical staff, both within an
institution and at remote sites and enable healthcare providers to broaden their
geographic service areas.
Cemax-Icon's systems are designed to address the technical challenges
in implementing PACS. Cemax-Icon's systems are based on an open architecture
adhering to industry standards, allowing customers to choose from a variety of
standard commercially available hardware. For these reasons and because
Cemax-Icon's systems are modular in design, investment in early systems
implementation is preserved as the network expands. Cemax-Icon's systems acquire
images from virtually all commercially available imaging modalities including
x-ray, CT, MRI, computed radiography, ultrasound and nuclear medicine.
Cemax-Icon has developed a large library of interfaces to provide connectivity
with standard interfaces as well as the large installed base of proprietary
image acquisition devices. Cemax-Icon's systems utilize a distributed server and
database architecture and advanced image compression technology to
cost-effectively store and transmit large image data sets at clinically
acceptable speeds.
Products
Cemax-Icon's medical image information systems are primarily
software-based and consist of the following modules: (i) INPUT MODULES enable
Cemax-Icon's medical image information system to digitally acquire images from
virtually all commercially available imaging modalities including x-rays, CT,
MRI, computed radiology, ultrasound and nuclear medicine; (ii) DISTRIBUTION AND
STORAGE MODULES route medical images throughout the network and save images for
immediate retrieval and long-term storage; (iii) DISPLAY MODULES display,
process or print medical images supporting a wide range of clinical needs and
applications ranging from centralized diagnostic reading to remote clinical
review; and (iv) HARDWARE PRODUCTS allow costly and specialized medical-imaging
specific functions to be performed on cost-effective PC platforms.
The following chart summarizes the various software modules comprising
Cemax-Icon's systems:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
Acquisition Modalities Input Modules Distribution & Storage Modules Display Modules
* X-rays * DICOM * ImageServer(TM) * Clinical View(TM)
* CT * Legacy * ImageCom(TM) * Diagnostic View(TM)
* MRI * Printer * Network Film Server(TM) * VIP(TM)
* Computed * Digitizer * Archive Manager(TM)1.0 * RadAccess(TM)
* Radiography * CR * Archive Manager(TM)2.0 * TeleMax(TM)
* Ultrasound * AutoRad(TM)
* Nuclear Medicine
</TABLE>
INPUT MODULES. Cemax-Icon's family of input modules enables
Cemax-Icon's medical image information systems to interface with virtually all
commercially available medical imaging modalities. Each of these modules
acquires medical images and associated patient and study information from the
imaging devices in digitized format and distributes them to the network in
compliance with the emerging industry- standard communications protocol for an
open network, DICOM (Digital Image Communications in Medicine). Cemax-Icon has
developed approximately 125 ScanLink interfaces.
* DICOM SCANLINKS are platform-independent software modules which
interface with DICOM- compliant image acquisition devices to support
sending, querying, receiving and printing images and study information.
DICOM SCANLINKS incorporate Cemax-Icon's compression technology which
allows transmission over low bandwidth connections such as telephone
lines.
* LEGACY SCANLINKS interface with virtually all existing CT and MRI
scanners which utilize a proprietary network protocol (a standardized
method to move data over a network between two computers). LEGACY
SCANLINKS are a differentiating technology for Cemax-Icon because most
vendors do not have access to the proprietary information necessary to
develop interfaces for devices other than their own. Cemax-Icon has
been able to obtain protocol specifications from the majority of CT and
MRI scanner vendors due to its many longstanding OEM relationships.
* PRINTER SCANLINKS interface with many medical scanners which output
images to commercial medical film printers but which are not designed
to interface with any network, whether proprietary or DICOM-compliant.
PRINTER SCANLINKS emulate the interface on these scanners to digitally
send images to an open network. For teleradiology applications, up to
four scanners may share a centralized PRINTER SCANLINK by performing
remote image acquisition using up to four TECHNOLOGIST KEYPADS
described below.
* DIGITIZER SCANLINKS digitize and route film-based medical images to an
open network. DIGITIZER SCANLINKS support virtually all medical film
digitizers. DIGITIZER SCANLINK software provides full control over the
image digitization process (a process of converting an analog image
into a digital image) including selection of image resolution, image
grayscale (the number of levels of gray used to display an image),
image orientation, default window/level setting (the grayscale setting
used to adjust image brightness and/or contrast) and region of
interest. The software also supports a quality-assurance function
allowing technologists to review the scanned image and make corrections
prior to saving it.
* CR SCANLINKS interface with virtually all computed radiography devices,
allowing x-ray images to be directly input and accessible on an open
network without ever having been filmed. CR SCANLINKS automatically
receive images from computed radiography devices, extract patient,
study and image information from the proprietary file format and apply
proprietary image processing as specified by parameters in the image
file, for routing to other DICOM-compliant devices.
DISTRIBUTION AND STORAGE MODULES. Cemax-Icon's distribution and storage
modules route digital images from Cemax-Icon's input modules throughout an open
network and save images for immediate and long-term storage and retrieval.
* IMAGESERVER is a distributed image database which allows users to
access specific images regardless of where the images are stored or the
users are located. The IMAGESERVER is integrated with CLINICALVIEW,
DIAGNOSTICVIEW, VIP and NETWORK FILM SERVER modules as described below.
IMAGESERVER may be integrated with Cemax-Icon's display modules as well
as with any DICOM-compliant devices. The distributed scalable nature of
the database provides maximum availability of information in the
unlikely event any one or more servers on an open network fail.
* IMAGECOM provides the ability to send, receive, retrieve and track
medical imaging studies to and from remote locations. This module
supports optimized compression for transmission over low bandwidth
connections as well as transmission over a range of wide area
connections including telephone lines, T1 and Frame Relay (each a
wide-area network communications link which allows standard network
protocols to move data from one site to another) and ISDN. IMAGECOM
provides fail-safe telecommunications allowing it to run in an
unattended mode and resume transmission automatically after an
interruption.
* NETWORK FILM SERVER transmits images from CLINICALVIEW, DIAGNOSTICVIEW
or VIP to virtually all medical film printers, including those produced
by Imation, Agfa-Gevaert N.V., Sterling Diagnostics, Inc., Fuji Photo
Film Co., Ltd., Kodak and Konica Corporation.
* ARCHIVE MANAGER 1.0 provides the ability to store images to removable
tape cartridges for later retrieval and to manage the tapes as a large
shelf library. ARCHIVE MANAGER 1.0 is expected to be superseded by
ARCHIVE MANAGER 2.0.
* ARCHIVE MANAGER 2.0, currently in production, is a scalable rules-based
medical image information warehouse that automatically stores,
retrieves and distributes medical images. ARCHIVE MANAGER 2.0 is a
distributed object-oriented DICOM-compliant database that supports the
reliability and volume demands of PACS and health care information
systems environments. ARCHIVE MANAGER 2.0 offers capabilities ranging
from routine queries to complex data mining, supporting utilization
review and research applications. Its sophisticated hierarchial storage
management capability allows it to automatically migrate images between
rapid on-line storage and lower cost jukebox media (a removable disk
cartridge used for data storage). The module supports medical-optimized
compressions allowing medical facilities to specify that archived
studies be compressed in order to lower storage costs and expand
capacity.
DISPLAY MODULES. Cemax-Icon's display modules enable Cemax-Icon's
medical image information system to support a wide range of clinical needs and
applications ranging from remote clinical review to centralized diagnostic
reading. Each of these modules allows the user to access and display specific
medical images and associated patient and study information from Cemax-Icon's
distribution and storage systems.
* CLINICALVIEW is a Unix-based software module designed for use by
clinical staff to display and review patients' current and historical
medical images from an open network, regardless of where the images are
stored or the users are physically located. CLINICALVIEW is
DICOM-compliant, presents images at medium resolution (1,500 lines) on
one or two monitors and provides a simple intuitive user interface
which allows clinicians to perform basic image manipulation and
enhancement.
* DIAGNOSTICVIEW is a Unix-based software module designed for use by
radiologists for diagnostic reading of medical images from an open
network, regardless of where the images are stored or the users are
physically located. DIAGNOSTICVIEW is DICOM-compliant, presents images
at high-resolution (2,000 lines) on one or two monitors, and provides
access to powerful image manipulation, enhancement and printing
functions.
* VIP is a Unix-based software module designed for use by radiologists
whose practice requires three dimensional ("3D") reconstruction and
visualization capability. VIP receives two dimensional CT and MRI
images and renders these as 3D images which may be viewed and
manipulated electronically. User definable protocols provide a powerful
tool to automate complex image processing and presentation functions.
Additional features include real-time monitoring of scan progress,
real-time multi-planar reconstruction, interactive tissue
classification and disarticulation and creation of spinal and dental
clinical protocol packages.
* TELEMAX DISPLAY software is designed for use by radiologists and
clinical staff at home or office using their existing Windows 95 based
or Macintosh personal computers. TELEMAX works in conjunction with
ImageCom software which transfers medical images over telephone lines
or ISDN. TELEMAX allows users to create predefined or custom annotated
illustrated reports which may be printed or faxed to referring
physicians. TELEMAX software presents images at conventional PC
resolution (500- 1,000 lines) on a single monitor and provides image
viewing and manipulation functions.
* AUTORAD, currently under ongoing development, is a DICOM-compliant
primary diagnostic reading module which optimizes radiologists'
clinical productivity and enhances communications of images and results
with clinical staff. Cemax-Icon currently has 25 AUTORAD clinical
sites, ranging in scale from a freestanding imaging center to a
teaching hospital. AUTORAD enables healthcare institutions to
transition from film-based to filmless reading of medical images.
AUTORAD displays medical images on as many as four high-resolution
monitors (2,500 lines) using Cemax-Icon developed graphics-accelerated
PCI display controllers. It allows multiple image files to be accessed
and compared simultaneously, providing the capability to view
electronically high volumes of medical images faster than with film. By
automatically sorting and arranging current and historical studies in
accordance with each radiologist's preference, AUTORAD significantly
increases the efficiency of interpretation. AUTORAD allows radiologists
to annotate selected images with text notes and to incorporate them
into illustrated reports which may be printed or faxed to referring
clinicians.
HARDWARE PRODUCTS. Cemax-Icon designs hardware products to enable its
software to implement fully functional image information networks on
cost-effective industry standard hardware. Cemax-Icon's hardware products use
industry standard PCI interfaces for maximum performance and compatibility with
existing PC platforms.
* PCI DISPLAY CONTROLLER allows standard PCs to display high resolution
images on medical monitors up to a resolution of 2,500 x 2,000 lines.
To Cemax-Icon's knowledge, PCI DISPLAY CONTROLLER is the only
commercially available controller at this resolution to drive up to two
monitors from each controller card, allowing a typical PC system to
drive up to eight monitors.
* PCI ANALOG and DIGITAL PRINTER INTERFACES acquire images from
proprietary medical scanners not designed to support a network
connection. An advanced switching capability allows the operator to
select among three modes without reconfiguring the system: (i) print to
the network; (ii) print to the film printer; and (iii) print to both
the network and the film printer. This allows the users to transition
to a filmless environment and still have back-up use of the printer in
the event of network failure.
* TECHNOLOGIST KEYPAD is an LCD-based controller which allows
technologists to monitor and control image input and routing in
conjunction with the PCI ANALOG and DIGITAL PRINTER INTERFACES
described above. This product provides barcode input capability which
eliminates the requirement for manual entry of patient and study
demographics.
* REMOTE WORKSTATION allows up to four remote users to have full
keyboard, mouse and monitor control over a shared central teleradiology
acquisition system. This product reduces cost in teleradiology
applications by eliminating the need to install a dedicated input
computer for each remote monitor.
* LASERLINK connects to the printer port on commercially available
medical film printers and allows users to print electronic medical
images to a medical film printer from any station on the network. This
controller emulates the digital printer interface found on current
generation CT and MRI scanners. It supports virtually all of the
commercially available printing protocols.
Technology
Cemax-Icon's software is developed using object-oriented design
methodology and leading commercial C/C++ (standard programming languages)
compilers. Cemax-Icon's core technologies have been developed using an open,
platform-independent architecture. Communications modules are compliant with
industry standard DICOM 3.0, TCP/IP and HL-7. Archive modules under development
utilize a commercially available distributed object-oriented database.
Cemax-Icon's systems operate on a wide range of platforms including SUN
Sparc/Sparcstation work stations under Unix, Pentium PC's under Windows 95 and
NT, and Macintosh computers under MacOS 7.5. Acquisition and display hardware
products are based on PCI interfaces and support industry- standard drivers for
Windows 95, NT and Macintosh.
All Cemax-Icon systems are designed and developed according to product
development procedures reviewed by the FDA and stringent quality assurance
procedures which meet or exceed FDA Good Manufacturing Practices.
Marketing and Sales
The primary market for Cemax-Icon's systems includes hospitals,
outpatient facilities and IDNs. Cemax-Icon currently sells its products directly
through its own sales organization and indirectly through OEMs, including
Imation, Toshiba, Lucent, Sterling, General Electric and Kodak, and three
distributors. The use of OEMs and distributors allows Cemax-Icon to leverage its
sales force and to penetrate accounts which have strong customer loyalty to the
OEM.
Cemax-Icon's OEM relationships often consists of multi-year
distribution agreements providing the OEMs with the right to acquire
Cemax-Icon's systems at a discount and to offer such systems to third parties
under private labels. Cemax-Icon's distributor relationships consist of
multi-year agreements providing the distributors with the right to purchase
Cemax-Icon's systems at a discount for resale. When working with an OEM or
distributor, Cemax-Icon's sales people work as a complementary extension of
their sales team. Further revenue growth depends, in part, on Cemax-Icon's
ability to successfully maintain and expand OEM and distributor relationships
and rapidly grow its direct sales force.
Cemax-Icon has entered into an international distribution agreement
with Imation in addition to its domestic OEM arrangements. This distribution
agreement provides Imation with exclusive sales rights to jointly label
Cemax-Icon's products for sale in Europe through the Imation sales force and
calls for minimum quarterly purchase commitments by Imation. Other OEMs and
distributors can sell private label Cemax-Icon products in Europe.
Cemax-Icon's foreign sales totaled $6.0 million and $1.1 million for
the year ended December 31, 1996 and for the three months ended March 31, 1997,
respectively.
Cemax-Icon currently sells its products directly through eight
representatives located in Chicago, Kansas City, Los Angeles, New Haven, San
Antonio, San Francisco and Sarasota with marketing, sales and technical support
provided through Cemax-Icon's headquarters in Fremont, California.
Cemax-Icon's marketing department is comprised of technical personnel
experienced in network analysis, product management, target marketing,
competitive analysis, sales support, quoting, proposals and advertising.
Cemax-Icon supports these efforts by publishing articles, presenting or
sponsoring talks at professional meetings, assuming leadership positions in
professional organizations, participating in trade shows, advertising in trade
magazines and issuing frequent announcements to the trade press. Prospective
clients are identified through the marketing programs of Cemax-Icon's OEMs and
distributors, as well as Cemax-Icon's own direct mail and telemarketing efforts.
Cemax-Icon's success is dependent on the success of its marketing and
distribution strategy which involves, to a significant degree reliance on
Cemax-Icon's OEMs to sell its software modules as a component of the systems
being marketed by such OEMs. Cemax-Icon's OEM agreements are subject to
cancellation by the OEMs under certain circumstances. If Cemax-Icon's current or
future OEMs elect to terminate their agreements with Cemax-Icon or elect not to
include Cemax-Icon's software modules as components in their systems or are
unsuccessful in achieving significant sales of the systems, Cemax-Icon's total
business would be materially and adversely affected. In addition, a significant
portion of Cemax-Icon's total revenues are derived from a small number of
customers.
Cemax-Icon expects to continue to depend upon its principal customers
for a significant portion of its revenues, although there can be no assurance
that Cemax-Icon's principal customers will continue to purchase systems and
services from Cemax-Icon at current levels, if at all. The loss of one or more
major customers or a change in their buying pattern could have a material
adverse effect on Cemax-Icon's business and results of operations. Recruiting
and retaining qualified sales, customer service and technical personnel will
also be critical to Cemax-Icon's success. There can be no assurance that
Cemax-Icon will be successful in attracting and retaining skilled technical
personnel who generally are in high demand in Cemax-Icon's geographic area. The
loss of certain key employees or Cemax-Icon's inability to attract and retain
other qualified employees could have a material adverse effect on Cemax-Icon's
business.
Customers
Cemax-Icon's customers include healthcare providers located throughout
the United States, Europe and Japan. As of March 31, 1997, Cemax-Icon had over
1,600 end-user customers. Cemax-Icon believes that the installed customer base
of its OEMs and distributors also represents a significant opportunity to market
and sell its systems and services.
The decision by a healthcare provider to replace or substantially
upgrade its image information systems typically involves a major commitment of
capital and an extended review and approval process. Accordingly, the sales and
delivery cycle for Cemax-Icon's system is typically two to 12 months from
initial contact to delivery and acceptance. The time required from initial
contact to contract execution is typically one to six months. During these
periods, Cemax-Icon may expend substantial time, effort and funds preparing a
contract proposal and negotiating the contract. Any significant or ongoing
failure to identify appropriate potential customers, to achieve signed
contracts, to successfully complete products under development, and to obtain
customer acceptance after expending time, effort and funds could have a material
adverse effect on Cemax-Icon's business, financial condition and results of
operations.
At March 31, 1997, Cemax-Icon had approximately $9.8 million of signed
sales contracts for systems and services which had not yet been delivered but
are scheduled for delivery within the next twelve months, including products
under development. Cemax-Icon adjusts the timing of an installation, which
typically requires one to six months to complete, to accommodate customers'
needs, and Cemax-Icon cannot accurately predict the time it will take to
complete products under development. Consequently, Cemax-Icon cannot accurately
predict the amount of revenue it expects to achieve in any particular period. A
termination or installation delay of one or more contracts, or the failure of
Cemax-Icon to procure additional contracts, could have a material adverse effect
on Cemax-Icon's business.
A sample of Cemax-Icon's direct customers include the following
purchasers of PACS systems having a sales price of over $500,000:
Northwest Texas Hospital, Amarillo, TX
Saint Vincent Medical Center, Toledo, OH
Slagelse Central Hospital, West-Zealand County, Denmark
Stanford Health Services, Stanford, CA
University of Iowa, Iowa City, IA
University of North Carolina Medical Center, Chapel Hill, NC
Turku University Central Hospital, Turku, Finland
Veteran's Administration Medical Center Oklahoma, Oklahoma City, OK
Customer Support
Cemax-Icon currently intends to continue to invest in the customer
service area by increasing headcount, building infrastructure (including a
state-of-the-art customer call handling service management system and diagnostic
service and installation tools), and developing and implementing training
programs for its internal staff, customers, OEMs and distributors. Customer
support is provided either directly from Cemax-Icon by on-site staff visits,
technical support by phone or direct log onto the system via modem, or through
Cemax-Icon's OEM relationships.
Manufacturing
Cemax-Icon's manufacturing activities consist primarily of assembling
and testing components and subassemblies acquired from qualified vendors, and
subsequently integrating the appropriate application software programs.
Cemax-Icon operates under the FDA Good Manufacturing Practices guidelines and is
a registered medical device manufacturer. Cemax-Icon has recently received ISO
9001 award certification.
Cemax-Icon purchases industry-standard parts and components for the
assembly of its products, generally from multiple vendors. Cemax-Icon generally
maintains good relationships with its vendors and, to date, has not experienced
any material supply problems.
Competition
Competition in the market for Cemax-Icon's systems is intense. A large
number of companies offer teleradiology systems which are competitive with those
of Cemax-Icon. Many of Cemax-Icon's competitors are larger and more established
and have substantially more financial, technical, research and development and
marketing resources than Cemax-Icon. Several large multi-national corporations,
including Philips, Agfa and Siemens, offer competitive products in the PACS
market. Other large corporations have the technical and financial ability to
design and market competitive products, and some of them have produced and
marketed such products in the past. There can be no assurance that such large
potential competitors will not elect to reenter the market for Cemax-Icon's
systems, which could have a material adverse effect on Cemax-Icon's ability to
sell its products. In the past, certain competitors have from time to time
offered PACS for sale at substantial discounts to prevailing prices or offered
PACS to customers at no additional charge in connection with the sale of
complementary systems, which has had and could have a material adverse effect on
Cemax-Icon's ability to sell its systems.
Cemax-Icon's ability to compete successfully in the sale of its systems
will depend in large part upon its ability to implement successfully its
strategy of selling systems as a total solution as well as its ability to
attract new customers, sell new systems, deliver and support system enhancements
to its existing customers and respond effectively to continuing technological
change by developing new systems. There can be no assurance that Cemax-Icon will
be able to compete successfully in the future, nor that future competition for
product sales will not have a material adverse effect on the business, results
of operations and financial condition of Cemax-Icon.
Cemax-Icon believes that the principal competitive factors in its
market are customer recommendations and references, company reputation, system
reliability, system features (including ease of use), technological
advancements, breadth of product line, customer service and support, the
effectiveness of marketing and sales efforts, product price and performance. In
addition, Cemax-Icon believes that the speed with which companies in its market
can anticipate the evolving healthcare industry structure and identify unmet
needs are important competitive factors. There can be no assurance that
Cemax-Icon will be able to compete successfully in the future against existing
or potential competitors.
Patents and Intellectual Property
Cemax-Icon generally does not rely on patent protection with respect to
its products. Instead, Cemax-Icon relies on a combination of copyright and trade
secret law, employee and third-party nondisclosure agreements, and other
protective measures to protect intellectual property rights pertaining to its
systems and technology. There can be no assurance, however, that applicable
copyright or trade secret law or these agreements will provide meaningful
protection of Cemax-Icon's copyrights, trade secrets, know-how or other
proprietary information in the event of any unauthorized use, misappropriation
or disclosure of such copyrights, trade secrets, know-how or other proprietary
information. In addition, the laws of certain foreign countries do not protect
Cemax-Icon's intellectual property rights to the same extent as do the laws of
the United States. There can be no assurance that Cemax-Icon will be able to
protect its intellectual property successfully.
Cemax-Icon's systems and technology incorporate subject matter that
Cemax-Icon believes is in the public domain or that it otherwise has the right
to use. There can be no assurance that third parties will not assert patent,
copyright or other intellectual property infringement claims against Cemax-Icon
with respect to its products or technology or other matters. There may be
third-party patents, copyrights and other intellectual property relevant to
Cemax-Icon's systems and technology which are not known to Cemax-Icon. There can
be no assurance that litigation by a third party asserting that Cemax-Icon is
infringing such third party's patent rights, copyrights or other intellectual
property will not be initiated, that Cemax-Icon would prevail in any such
litigation or that Cemax-Icon would be able to obtain any necessary licenses on
reasonable terms if at all. Any such claims against Cemax-Icon, with or without
merit, as well as claims initiated by Cemax-Icon against third parties, can be
time-consuming and expensive to defend or prosecute and to resolve.
Government Regulation
The manufacturing and marketing of Cemax-Icon's systems are subject to
extensive government regulation as medical devices in the United States by the
FDA and in other countries by corresponding foreign regulatory authorities. The
process of obtaining and maintaining required regulatory clearances and
approvals is lengthy, expensive and uncertain. Cemax-Icon believes that its
success depends upon commercial sales of improved versions of its systems,
certain of which cannot be marketed in the United States and other regulated
markets unless and until Cemax-Icon obtains clearance or approval from the FDA
and its foreign counterparts.
The FDA requires that a manufacturer seeking to market a new medical
device or an existing medical device for a new indication obtain either a
premarket notification clearance under Section 510(k) of the Federal Food, Drug
and Cosmetic Act or the approval of a premarket approval application under this
Act ("PMA") prior to the introduction of such product into the market. Material
changes to existing medical devices are also subject to FDA review and clearance
or approval prior to commercialization in the United States. Cemax-Icon is
currently relying on the Section 510(k) premarket notification method to obtain
governmental clearance ("510(k) clearance") to market its medical devices in the
United States. Although it is believed to be a shorter, less costly regulatory
plan than the process to obtain a PMA, the process of obtaining a 510(k)
clearance generally requires supporting data, which can be extensive and extend
the regulatory review process for a considerable length of time. All models of
Cemax-Icon's systems that are commercially available have received 510(k)
clearance by the FDA. In addition, Cemax-Icon recently received 510(k) clearance
for ARCHIVE MANAGER 2.0 and for its DICOM and AUTORAD modules. There can be no
assurance that 510(k) clearance for any future product or modifications of
existing products will be granted by the FDA within a reasonable time frame, if
at all. Furthermore, the FDA may require that a request for 510(k) clearance be
supported by data from clinical trials demonstrating substantial equivalence and
the safety and effectiveness of the device, which may prolong the Section 510(k)
notification review period for a particular device or may result in a finding
that the product is not substantially equivalent, so that a full PMA could be
required.
Failure to comply with applicable regulatory requirements could result
among other things, in warning letters, seizures of products, total or partial
suspension of production refusal of the government to grant market clearance or
pre-market approval withdrawal of approvals or criminal prosecution.
Cemax-Icon is also required to register as a medical device
manufacturer with the FDA and the Food and Drug Branch of the California
Department of Health Services ("CDHS"). Cemax-Icon will be inspected on a
routine basis by both the FDA and CDHS for compliance with the FDA's Good
Manufacturing Practices and other applicable regulations.
Cemax-Icon is also subject to other federal, state and local laws and
regulations relating to safe working conditions and manufacturing practices. The
extent of government regulation that might result from any future legislation or
administrative action cannot be predicted. Failure to comply with regulatory
requirements could have a material adverse effect on Cemax-Icon's business,
financial condition and results of operations.
Sales of Cemax-Icon's systems outside the United States are subject to
foreign regulatory requirements that vary from country to country. Additional
approvals from foreign regulatory authorities may be required, and there can be
no assurance that Cemax-Icon will be able to obtain foreign marketing approvals
on a timely basis or at all, or that it will not be required to incur
significant costs in obtaining or maintaining its foreign regulatory approvals.
In Europe, Cemax-Icon will be required to obtain the certificates necessary to
enable the CE Mark, an international symbol of adherence to quality assurance
standards and compliance with applicable European Union Medical Device
Directives, to be affixed to Cemax-Icon's systems for sales in member countries.
Failure to obtain such certifications, any necessary foreign regulatory
approvals or any other failure to comply with regulatory requirements outside
the United States could have a material adverse effect on Cemax-Icon's business,
financial condition and results of operations.
Third-Party Reimbursement
Third-party payors, such as governmental programs and private insurance
plans, can indirectly affect the pricing or the relative attractiveness of
Cemax-Icon's systems by regulating the maximum amount of reimbursement that they
will provide for the acquisition, storage and interpretations of medical images.
In recent years, healthcare costs have risen substantially, and third-party
payors have come under increasing pressure to reduce such costs. In this regard,
extensive studies undertaken by the federal government, even though not
successfully translated into regulatory action, have stimulated widespread
analysis and reactions in the private sector focused on healthcare cost
reductions, which may involve reductions in reimbursement rates in radiology. A
decrease in the reimbursement amounts for radiological procedure may decrease
the amount which physicians, clinics and hospitals are able to charge patients
for such services. As a result, adoption of teleradiology and PACS may slow as
capital investment budgets are reduced, and the demand for Cemax-Icon's systems
could be significantly reduced.
Product Liability and Insurance
The manufacture and sale of medical image information systems entail
significant risk of product liability claims. There can be no assurance that
Cemax-Icon's existing insurance coverage limits are adequate to protect
Cemax-Icon from any liabilities it might incur in connection with the sale of
Cemax-Icon's systems. In addition, Cemax-Icon may require increased product
liability coverage as additional systems are commercialized. Such insurance is
expensive and in the future may not be available on acceptable terms, if at all.
A successful product liability claim or series of claims brought against
Cemax-Icon in excess of its insurance coverage could have a material adverse
effect on Cemax-Icon's business, financial condition and results of operations.
Employees
As of March 31, 1997, Cemax-Icon had 153 full-time employees, including
43 employees in research and development, 72 in quality, service and support, 23
in sales and marketing and support activities and 13 in general administration
and finance. Two employees reside in Europe performing sales and technical
customer support roles. Cemax-Icon also relies on several part-time employees
and consultants. None of Cemax-Icon's employees is represented by a collective
bargaining agreement nor has Cemax-Icon experienced a work stoppage. Management
believes that Cemax-Icon's relationship with its employees is good.
PROPERTIES
Cemax-Icon's principal facilities are located in Fremont, California,
in an approximately 26,000 square foot facility leased through December 1998.
Cemax-Icon anticipates that additional space will be required as its business
expands and believes that it will be able to obtain suitable space as needed.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Set forth below are the names and addresses of and the number of shares
held as of the Record Date for the Special Meeting by (i) those persons who may
be deemed to own beneficially, whether directly or indirectly 5% or more of the
outstanding shares of Cemax-Icon Common Stock, (ii) each executive officer or
director of Cemax-Icon and (iii) all directors and executive officers of
Cemax-Icon as a group. Each shareholder named below has sole voting and
investment power over the shares shown in the table, unless otherwise indicated.
<TABLE>
<CAPTION>
Name and Address Beneficially Owned (1) Percent of Class (2)
<S> <C> <C>
Jeremy B. Rubin, M.D.(3) 1,748,672 32.5%
Cemax-Icon, Inc.
47281 Mission Falls Court
Fremont, CA 94539
Imation Corp.(4) 1,073,077 16.6%
1 Imation Place
Oakdale, Minnesota 55128
Entities affiliated with 800,152 14.9%
Institutional Venture Partners(5)
3000 Sand Hill Road
Building 2, Suite 290
Menlo Park, CA 94025
Reid W. Dennis(5) 800,152 14.9%
Institutional Venture Partners
3000 Sand Hill Road
Building 2, Suite 290
Menlo Park, CA 94025
Philip E. McCarthy(6)(8) 482,859 9.0%
MBW Venture Partners
365 South Street
Morristown, NJ 07960
Entities affiliated with 482,848 9.0%
MBW Management(6)
365 South Street
Morristown, NJ 07960
Entities affiliated with 325,151 6.0%
Technology Funding Inc.(7)
2000 Alameda de las Pulgas
San Mateo, CA 94403
Terry Ross(9) 311,127 5.8%
David N. White, M.D.(10) 90,293 1.7%
Gregory C. Patti(11) 67,771 1.3%
Jean-Luc Chatelain(12) 63,235 1.2%
Oran E. Murduroglu(13) 82,688 1.5%
Grady Floyd(14) 38,243 1.0%
M. David Titus(15) 12,823 *
All directors and officers as a group 3,697,861 67.8%
(10 persons)(16)
</TABLE>
- --------------
* Represents beneficial ownership of less than 1%.
(1) Beneficial ownership is determined by the rules of the Securities and
Exchange Commission and generally includes voting or investment power
with respect to securities. Shares of Cemax-Icon Common Stock subject
to stock options and warrants currently exercisable or exercisable
within 60 days of the date of this table are deemed to be outstanding
for computing the percentage ownership of the person holding such
options and the percentage ownership of any group of which the holder
is a member, but are not deemed outstanding for computing the
percentage of any other person. Except as indicated by footnotes, and
subject to community property laws where applicable, the persons named
in the table have sole voting and investment power with respect to all
shares of Cemax-Icon Common Stock shown beneficially owned by them.
(2) Applicable percentage of ownership is based on 5,379,587 shares of
Cemax-Icon Common Stock outstanding.
(3) Includes 4,900 shares issuable pursuant to options exercisable within
60 days of the Record Date.
(4) Assumes conversion of 2,521,733 outstanding shares of Cemax-Icon
Preferred Stock held by Imation to Cemax-Icon Common Stock.
(5) Includes 11,986 shares held by Institutional Venture Management III,
L.P. ("IVMIII") and 788,166 shares held by Institutional Venture
Partners III, L.P. ("IVPIII"). Reid W. Dennis, a director of
Cemax-Icon, is a general partner of IVMIII and the general partner of
IVPIII.
(6) Includes 395,935 shares held by MBW Venture Partners, L.P. and 86,913
shares held by Michigan Investment Fund, L.P. Philip E. McCarthy, a
director of Cemax-Icon, is Managing Director of MBW Management and the
authorized agent of MBW Venture Partners and Michigan Investment Fund.
(7) Includes 72,264 shares held by Technology Funding Inc. TTEE Technology
Funding Partners I Liquidating Trust, 86,446 shares are held by
Technology Funding Inc. TTEE Funding Partners II and 166,441 shares are
held by Technology Funding Private Reserve, L.P.
(8) Includes 11 shares held by the Philip E. McCarthy Pension Fund.
(9) Includes 4,255 shares held by Guarantee & Trust Co. Cdn Terry Ross IRA
and includes 14,000 shares issuable pursuant to options exercisable
within 60 days of the Record Date.
(10) Includes 2,100 shares issuable pursuant to options exercisable within
60 days of the Record Date.
(11) Includes 4,255 shares held by Guarantee & Trust Co. Cdn Gregory C.
Patti and includes 2,100 shares issuable pursuant to options
exercisable within 60 days of the Record Date.
(12) Includes 188 shares issuable pursuant to options exercisable within 60
days of the Record Date by Mr. Chatelain's wife and includes 5,600
shares issuable pursuant to options exercisable by Mr. Chatelain within
60 days of the Record Date.
(13) Includes 33,495 shares issuable pursuant to options exercisable within
60 days of the Record Date.
(14) Includes 4,200 shares issuable pursuant to options exercisable within
60 days of the Record Date.
(15) Includes 4,254 shares issuable pursuant to options exercisable within
60 days of the Record Date.
(16) Includes 70,837 shares issuable pursuant to options exercisable within
60 days of the Record Date.
As of the Record Date, Imation owned all 2,521,733 outstanding shares
of Cemax-Icon Preferred Stock, representing approximately 17% of the total
voting power of the outstanding shares of Cemax-Icon Common Stock and Cemax-Icon
Preferred Stock as of such date.
SELECTED FINANCIAL DATA OF CEMAX-ICON
Set forth below is selected historical financial information of
Cemax-Icon derived from the unaudited financial statements of Cemax-Icon for the
three months ended March 31, 1997 and 1996 and for the fiscal years ended
December 31, 1993 and 1992, and the audited financial statements of Cemax-Icon
for the fiscal years ended December 31, 1996, 1995 and 1994. The information
should be read in conjunction with the Management's Discussion and Analysis of
Cemax-Icon, the financial statements of Cemax-Icon and related notes thereto and
the pro forma combined financial statements and the related note thereto
included elsewhere herein. In the opinion of Cemax-Icon's management, the
operating results for the fiscal quarters ended March 31, 1997 and 1996 and for
the fiscal years ended December 31, 1993 and 1992 reflect all adjustments
(consisting of normal recurring accruals) necessary to present fairly the
information contained therein. Results for the three months ended March 31, 1997
are not necessarily indicative of the results for the full year.
<TABLE>
<CAPTION>
Three Months Ended
March 31, Years Ended December 31,
--------------------- ----------------------------------------------------------------
1997 1996 1996 1995 1994 1993 1992
(In millions, except (In millions, except per share data)
per share data) (Unaudited) (Unaudited)
(Unaudited)
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net revenues .......... $ 7,283 $ 4,818 $ 25,148 $ 17,030 $ 16,457 $ 12,114 $ 8,314
Gross profit .......... 2,443 2,313 10,728 6,518 7,654 6,055 5,213
Selling, general and
administrative ...... 1,693 1,507 7,178 6,235 6,010 3,947 3,851
Research and
development ......... 1,642 1,622 6,481 6,501 4,134 3,249 2,171
Operating income (loss) (892) (816) (2,931) (6,842) (2,490) (1,141) (809)
Net income (loss) ..... (969) (819) (3,056) (6,815) (2,578) (1,198) (843)
Earnings (loss) per
common share ........ (0.18) (0.17) (0.59) (1.75) (1.10) (0.59) (0.46)
BALANCE SHEET DATA:
Total working capital . $ 2,275 $ 3,454 $ (538) $ (50) $ 584 $ 1,114
Total assets .......... 16,776 16,708 9,279 7,019 5,465 3,733
Long-term obligations . 5,562 5,619 604 891 570 414
Accumulated deficit ... (35,606) (34,637) (31,581) (24,766) (22,188) (20,880)
Total shareholders'
equity (net capital
deficiency) ......... (1,366) (400) 370 235 1,098 1,594
</TABLE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF CEMAX-ICON
RESULTS OF OPERATIONS
The following table sets forth, for the periods indicated, certain
operating data as a percentage of total revenues.
<TABLE>
<CAPTION>
Three Months Ended
March 31, Year Ended December 31,
------------------ -------------------------------
1997 1996 1996 1995 1994
<S> <C> <C> <C> <C> <C>
REVENUES:
Product revenues .................. 90.0% 84.0% 86.8% 88.4% 91.2%
Service revenues .................. 10.0 16.0 13.2 11.6 8.8
Total revenues .................. 100.0 100.0 100.0 100.0 100.0
COST OF REVENUES:
Cost of product revenues .......... 47.2 35.2 40.0 45.7 43.5
Cost of service revenues .......... 19.3 16.7 17.4 16.0 10.0
Total cost of revenues .......... 66.5 51.9 57.4 61.7 53.5
Gross profit ........................ 33.5 48.1 42.6 38.3 46.5
OPERATING EXPENSE:
Research and development .......... 22.5 33.6 25.8 38.2 25.1
Sales, general and administrative.. 23.2 31.3 28.5 36.6 36.5
Merger related expense ............ -- -- -- 3.7 --
Total operating expenses ........ 45.7 64.9 54.3 78.5 61.6
Loss from operations ................ (12.2) (16.8) (11.7) (40.2) (15.1)
Interest and other income (expense).. (1.1) (0.1) (0.5) 0.2 (0.6)
Net loss ............................ (13.3)% (16.9)% (12.2)% (40.0)% (15.7)%
</TABLE>
Comparison of Three Months Ended March 31, 1997 and 1996
Cemax-Icon's total revenues were $7.3 million for the three months
ended March 31, 1997, compared to $4.8 million for the same period in 1996, an
increase of $2.5 million or 51.2%. Product revenue was $6.6 million, a 61.9%
increase to the same period in 1996. The product revenue improvement was driven
by increased PACS and Autorad systems sales. Service revenue was $0.7 million
for the three months ended March 31, 1997, essentially flat compared to the same
period in 1996.
Gross profit for the first quarter of 1997 was $2.4 million or 33.5% of
revenues compared to $2.3 million or 48.1% for the first quarter of 1996. The
gross margin change was the result of the significant mix changes between the
systems and OEM software business, due to one time OEM contracts in the first
quarter of 1996, and the increased investment in the service business in the
first quarter of 1997. During the first quarter of 1996, Cemax-Icon had $2.7
million of license agreements, primarily from Toshiba, Imation and Kodak. These
agreements were primarily software with gross margins in the range of 90% to
95%. During the first quarter of 1997, the total OEM business segment accounted
for $1.5 million of revenue, 45.8% lower than prior year. Direct systems
business accounted for $5.1 million of revenue with a gross margin of 49.2 % for
the first quarter of 1997 compared to $1.4 million of revenue the prior year.
Service gross profit(loss) for the first quarter of 1997 was ($0.7)
million, or (92.8%) of service revenues, compared to a break even gross profit
for the first quarter of 1996. Cost of service revenue includes cost related to
pre-installation logistics, on-site installation, technical support and spare
parts. This increase in total dollar spending relates directly to increased
staffing and service activities.
Research and development expenses include expenses associated with the
development of new products, enhancements of existing products and quality
assurance activities, and consist principally of personnel costs, overhead costs
relating to occupancy, equipment depreciation and supplies. Cost related to
research, design and development of products are charged to research and
development expense as incurred. Research and development expenses were $1.6
million for the three months ended March 31, 1997 compared to $1.6 million for
the same period of 1996. As a percentage of total revenues, these expenses were
22.5% in the first three months of 1997, compared to 33.6% for the first quarter
of 1996.
Sales, general and administrative expenses consist of salaries, sales
commissions, promotional expenses, legal and travel for sales, marketing and
finance staffs. Sales, general and administrative expenses were $1.7 million for
the three months ended March 31, 1997 and $1.5 million for the first quarter of
1996. The increase in spending was due primarily to increases in sales and
marketing headcount and related travel expenses. As a percentage of total
revenues, sales, general and administrative expenses improved to 23.2% of total
revenues for first quarter of 1997, compared to 31.3% in the first quarter of
1996.
Comparison of the Years Ended December 31, 1996, 1995 and 1994
Cemax-Icon's total revenues were $25.1 million, $17.0 million and $16.5
million in 1996, 1995 and 1994, respectively, increasing 47.7% from 1995 to
1996, and 3.5% from 1994 to 1995. Product revenue was $21.8 million, $15.1
million and $15.0 million in 1996, 1995 and 1994, respectively, increasing 45.0%
from 1995 to 1996 and 0.3% from 1994 to 1995. The increase from 1995 to 1996
resulted primarily from increased volumes in the PACS and Autorad product lines,
and increased licensing revenues from OEMs. From 1994 to 1995, product revenues
were relatively flat due to the adverse effect of the merger of Cemax, Inc. and
Icon Medical Systems, Inc. and related restructuring, which temporarily
disrupted the sales organization and sales activities. Service revenue was $3.3
million, $2.0 million and $1.4 million in 1996, 1995 and 1994 respectively. The
increase from 1995 to 1996 and from 1994 to 1995 was the result of increased
staffing levels and management's focus on providing increased service offerings
to customers.
International revenue represents revenue from customers located outside
North America, primarily Europe and Japan. International revenue (export sales)
as a percentage of total revenues represented approximately 24%, 17% and 22% in
1996, 1995 and 1994, respectively. All sales are denominated in United States
dollars.
Gross profit was $10.7 million, $6.5 million and $7.7 million in 1996,
1995 and 1994 respectively. Gross profit from product revenue was $11.8 million,
$7.3 million and $7.9 million, respectively. The improvement in gross margin
from 1995 to 1996 reflects the mix change of higher OEM business during the
period as well as the growth in the more profitable PACS and Autorad product
lines. The decrease in gross margin from 1994 to 1995 was due to price erosion
on certain mature products. Gross profit(loss) from service revenue was ($1.1)
million, ($0.7) million, and ($0.2) million in 1996, 1995 and 1994,
respectively. The increase in the cost of service revenue across all three
periods resulted from Cemax-Icon's increased investment in customer service and
support.
Research and development expenses were $6.5 million, $6.5 million and
$4.1 million, respectively, unchanged from 1995 to 1996 and increasing 57.3%
from 1994 to 1995. Increased expenses from 1994 to 1995 were due to increased
investment associated with integrating the product lines of Cemax, Inc. and Icon
Medical Systems, Inc. following the merger, as well as costs associated with
developing new products. Research and development expenses as a percentage of
total revenues were 25.8%, 38.2% and 25.1% in 1996, 1995 and 1994, respectively.
Sales, general and administrative expenses were $7.2 million, $6.2
million and $6.0 million in 1996, 1995 and 1994, respectively. The increase from
1995 to 1996 was due to an increase in the bad debt reserve of $0.5 million and
increases to sales and marketing headcount, including related travel costs. The
increase from 1994 to 1995 was due to increased promotional expenses related to
an industry trade show. Sales, general and administrative expenses as a
percentage of total revenues were 28.5%, 36.6% and 36.5% in 1996, 1995 and 1994,
respectively.
LIQUIDITY AND CAPITAL RESOURCES
Comparison of the Three Months Ended March 31, 1997 and 1996
Cemax-Icon's cash and cash equivalents were $3.3 million at March 31
1997, down from $6.3 million at year end 1996. Cash used from operating
activities was $2.5 million during the first quarter of 1997 compared to $0.1
million provided by operating activities in the first quarter of 1996. This
change was primarily due to the growth in receivables and inventories resulting
from $7.3 million of revenue during the quarter. Cash used in investing
activities was $0.4 million during the quarter which represented expenditures
for computer equipment in support of headcount growth. Cash used in financing
was $0.1 million which included the paydown of existing equipment loans.
Comparison of the Years Ended December 31, 1996, 1995 and 1994
Cemax-Icon's cash and cash equivalents balance was $6.3 million, $1.8
million and $2.5 million at December 31, 1996, 1995 and 1994, respectively. Cash
used in operating activities was $1.8 million during 1996, resulting primarily
from a $3.1 million net loss and increases to accounts receivable and
inventories of $2.0 million and $0.9 million, respectively. The increases to
accounts receivable and inventories were a result of revenue growth during the
year from $17.0 million in 1995 to $25.1 million in 1996. Cash was provided by
increases to accounts payable, other accrued liabilities and deferred revenue.
During 1995, cash used in operating activities was $5.9 million, resulting
primarily from a $6.8 million net loss and increases to accounts receivable and
inventories of $1.8 million and $0.6 million, respectively. Offsets during 1995
included increases to accounts payable, other accrued liabilities and deferred
revenue. During 1994, cash provided by operating activities was $0.8 million
resulting from a $2.6 million net loss, offset by increases to accounts payable,
other accrued liabilities and deferred revenue.
Cash used in investing activities was $1.1 million, $1.4 million and
$0.9 million during 1996, 1995 and 1994. These expenditures were primarily for
computer equipment in support of headcount growth.
Cash provided by financing activities was $7.4 million, $6.5 million
and $0.7 million during 1996, 1995 and 1994. In September 1996, Imation
exercised an outstanding warrant for 535,855 shares of Cemax-Icon Preferred
Stock for $2.1 million. Also in September 1996, Cemax-Icon issued a $5.0 million
convertible note payable to Dominion Fund IV. In addition, Cemax-Icon issued
$0.5 million of Cemax-Icon Common Stock upon the exercise of stock options and
warrants. During June 1995, Cemax-Icon issued 1,985,878 shares of Cemax-Icon
Preferred Stock to Imation for $6.9 million. During 1994, $0.7 million of cash
was provided by proceeds from equipment financing, a revolving line of credit
and proceeds from a note payable.
DESCRIPTION OF IMATION CAPITAL STOCK
AUTHORIZED CAPITAL STOCK
Under Imation's Certificate of Incorporation, the total number of
shares of all classes of stock that Imation has authority to issue is
125,000,000, of which 25,000,000 are shares of preferred stock and 100,000,000
are shares of Imation Common Stock.
IMATION COMMON STOCK
The holders of Imation Common Stock are entitled to one vote for each
share on all matters voted on by stockholders, and the holders of such shares
possess all voting power, except as otherwise required by law or provided in any
resolution adopted by the Board of Directors of Imation with respect to any
series of preferred stock of Imation (the "Imation Preferred Stock"). Subject to
any preferential or other rights of any outstanding series of Imation Preferred
Stock that may be designated by the Board of Directors of Imation, the holders
of Imation Common Stock are entitled to such dividends as may be declared from
time to time by the Board of Directors of Imation from funds available therefor,
and upon liquidation are entitled to receive pro rata all assets of Imation
available for distribution to such holders.
IMATION PREFERRED STOCK
The Board of Directors of Imation are authorized to provide for the
issuance of shares of preferred stock, in one or more series, and to fix for
each such series such voting powers, designations, preferences and relative,
participating, optional and other special rights, and such qualifications,
limitations or restrictions, as are stated in the resolution adopted by the
Board of Directors of Imation providing for the issuance of such series as are
permitted by the DGCL.
NO PREEMPTIVE RIGHTS
No holder of any stock of Imation of any class has any preemptive right
to subscribe to any securities of Imation of any kind or class.
TRANSFER AGENT AND REGISTRAR
The Transfer Agent and Registrar for the Imation Common Stock is
Norwest Bank Minnesota, N.A.
DESCRIPTION OF CONTINGENT PAYMENT RIGHTS
Pursuant to the Merger Agreement, Imation has agreed to deliver to each
holder of shares of Cemax-Icon Common Stock one Contingent Payment Right per
share of Cemax-Icon Common Stock. Each Contingent Payment Right will represent
only a right to receive a cash or stock payment (the "Earn-Out") from Imation,
subject to the terms set forth below. Contingent Payment Rights will not possess
any attributes of common stock and will not entitle the holders of the
Contingent Payment Rights to any rights of any kind other than as specifically
set forth therein.
DETERMINATION OF EARN-OUT
Each Contingent Payment Right will represent only a right to receive
the Earn-Out from Imation. The term "Earn-Out Year" refers to each of the
following twelve-month periods: (a) the period from July 1, 1997 through June
30, 1998 (the "First Earn-Out Year"), and (b) the period from July 1, 1998
through June 30, 1999 (the "Second Earn-Out Year"). Holders of Contingent
Payment Rights will be entitled to receive the Earn-Out no later than 30 days
after the Determination Date (as defined below) for each Earn-Out Year. The term
"Determination Date" means the date of final determination of Gross Revenues (as
defined below) for an Earn-Out Year as set for the below.
Subject to Imation's right of offset set forth in the Merger Agreement,
the Earn-Out in the First Earn- Out Year will be $2.50 in cash (the "1998
Payment"), in the event that Gross Revenues during the First Earn- Out Year
("1998 Gross Revenues"), equal or exceed $45,000,000. In the event that 1998
Gross Revenues are less than $45,000,000, the 1998 Payment will be reduced as
follows:
1998 Gross Revenues Adjusted Amount of
Equal or Greater Than Less Than 1998 Payment
$0 $35 million $0.00
$35 million $36 million $1.25
$36 million $37 million $1.45
$37 million $38 million $1.65
$38 million $39 million $1.85
$39 million $40 million $2.05
$40 million $45 million Pro rata portion
of $2.50
Any 1998 Payment, as adjusted if appropriate, may be paid, at the
election of the holders of the Contingent Payment Rights ("Holders"), in whole
shares of Imation Common Stock equal to the quotient of (i) the 1998 Payment, as
adjusted if appropriate, and (ii) the average closing price per share of Imation
Common Stock on the New York Stock Exchange--Composite Transactions, as reported
in The Wall Street Journal, for each of the 10 consecutive trading days ending
on the third business day prior to June 30, 1998.
In the event that 1998 Gross Revenues exceed $45,000,000, any such
excess up to $5,000,000 will be carried forward and counted as part of 1999
Gross Revenues (as defined below).
Subject to Imation's right of offset set forth in the Merger Agreement,
the Earn-Out in the Second Earn-Out Year will be $6.00 in cash (the "1999
Payment"), in the event that Gross Revenues during the twelve-month period from
July 1, 1998 through June 30, 1999, plus any amount of 1998 Gross Revenues
carried forward as set forth above ("1999 Gross Revenues"), equal or exceed
$60,000,000. In the event that 1999 Gross Revenues are less than $60,000,000,
the 1999 Payment will be reduced as follows:
1999 Gross Revenues Adjusted Amount of
Equal or Greater Than Less Than 1998 Payment
$0 $50 million $0.00
$50 million $51 million $3.00
$51 million $52 million $3.50
$52 million $53 million $4.00
$53 million $54 million $4.50
$54 million $55 million $5.00
$55 million $60 million Pro rata portion
of $6.00
In the event that 1998 Gross Revenues are less than $45,000,000 and
1999 Gross Revenues exceed $60,000,000, the amount of 1999 Gross Revenues in
excess of $60,000,000, up to $5,000,000, will be treated as 1998 Gross Revenues
and the 1999 Payment will be increased above $6.00 by an amount equal to the
difference between (i) the amount of the 1998 Payment computed after including
such excess 1999 Gross Revenues and (ii) the amount of the 1998 Payment.
Any 1999 Payment, as adjusted if appropriate, may be paid, at the
election of the Holders, in whole shares of Imation Common Stock equal to the
product of (i) the 1999 Payment, as adjusted if appropriate, divided by $6.00
and (ii) 0.17.
The term "Gross Revenues" means gross revenues of the Image Management
Systems Business (as defined below) of Imation, the Surviving Corporation and
their affiliated companies, reduced only by customer trade discounts actually
given in good faith and actual returns, and determined in accordance with
generally accepted accounting principles consistent with past practices of
Cemax-Icon and its annual financial statements; provided that the Surviving
Corporation will receive credit for the full commercial value (as represented by
standard sales prices) of any product (a) provided by the Surviving Corporation
to any other business division of Imation for resale, or (b) given or sold by
the Surviving Corporation at the direction of Imation or one of its affiliated
companies (other than the Surviving Corporation) to customers at a discount to
induce the purchase of products or services (other than products or services of
the Image Management Systems Business) of Imation or its affiliated companies.
Gross Revenues will not include revenues of the Image Management Systems
Business of Imation, the Surviving Corporation or their affiliated companies
attributable to the acquisition (by purchase, license or other means) of any
related businesses, products or services in a single transaction or series of
transactions after the Effective Time.
The term "Image Management Systems Business" means (i) products
currently sold by Cemax-Icon or under research and/or development by Cemax-Icon
and any natural extensions thereof, and (ii) services related to such products
provided by Cemax-Icon, Imation or their affiliated companies.
PAYMENT ELECTION PROCEDURE
Holders of Contingent Payment Rights may elect whether to receive any
payment to which they are entitled thereunder in cash or shares of Imation
Common Stock. To facilitate such election, Imation will provide written notice
to the Holders (either the "1998 Earn-Out Notice" or "1999 Earn-Out Notice," as
applicable), together with such updated disclosure concerning Imation as
Imation, in its sole discretion, deems necessary or appropriate, within 15 days
after the Determination Date for 1998 Gross Revenues or 1999 Gross Revenues, as
applicable, which notice will specify the amount of the 1998 Payment or 1999
Payment, as applicable, and the amount of Imation Common Stock receivable in
lieu of cash in connection with the 1998 Payment or 1999 Payment, as applicable.
Each Holder may elect to receive Imation Common Stock in lieu of all (but not
less than all) of the cash otherwise payable in connection with the 1998 Payment
or 1999 Payment, as applicable, by providing written notice of such election to
Imation within 15 days after receiving the 1998 Earn-Out Notice or 1999 Earn-Out
Notice, as applicable. Any Holder which does not provide such written notice
will receive solely cash in connection with the 1998 Payment or 1999 Payment, as
applicable.
DETERMINATION OF GROSS REVENUES BY IMATION
Within 15 days after the end of each Earn-Out Year, Imation will
prepare and deliver to the Stockholders' Representatives a statement (an
"Earn-Out Statement"), certified as being true and correct in all material
respects by an officer of Imation, which will identify the Gross Revenues for
such Earn-Out Year in reasonable detail and the Earn-Out resulting from such
Gross Revenues.
The Earn-Out Statement will be subject to review and verification by
the Stockholders' Representatives or, at their option and expense (unless such
accounting firm will discover a discrepancy of at least ten percent, in which
case the fees of such accounting firm will be paid by Imation), by an
independent public accounting firm of their choice. Imation will permit the
Stockholders' Representatives and their representatives to have reasonable
access to the data and information on which the Earn-Out Statement was prepared
and to Imation's employees and/or representatives who assisted in its
preparation to the extent necessary to verify such information.
The Stockholders' Representatives will be deemed to have accepted the
Earn-Out Statement and the Earn-Out indicated therein, on behalf of the Holders,
unless within 20 days after the date of delivery of the Earn-Out Statement, the
Stockholders' Representatives give written notice to Imation of objection to any
item thereon, which notice will specify in reasonable detail the basis for such
objection. If the Stockholders' Representatives give such notice of objection,
Imation and the Stockholders' Representatives will attempt in good faith to
resolve the dispute as promptly as possible.
If Imation and the Stockholders' Representatives have not been able to
agree upon a resolution of the dispute within 30 days after the date the
Stockholders' Representatives gave such notice of objection (the "Objection
Notice"), such dispute will be resolved fully and finally in the jurisdiction of
the principal office of Imation by an arbitration governed by the Center for
Public Resources Rules for Non-Administered Arbitration of Business Disputes,
provided that a sole arbitrator will be employed. The arbitration will be
governed by the state equivalent of the Federal Arbitration Act, 9 U.S.C. ss.
1-16, and judgment upon the award rendered by the arbitrator may be entered by
any court having jurisdiction thereof. The parties will have 10 days from the
end of the discussion among the Stockholders' Representatives and Imation to
agree upon a mutually acceptable person to act as arbitrator. The arbitrator
will be a neutral person (i.e., a person not affiliated with either of the
parties). If no arbitrator has been selected within such time, the Stockholders'
Representatives and Imation will jointly request the Center for Public Resources
or another mutually agreed upon organization to supply within 10 days of such
request a list of potential arbitrators with qualifications as specified by the
parties in the joint request. Within five days of receipt of the list, the
Stockholders' Representatives and Imation will independently rank the proposed
candidates, will simultaneously exchange rankings, and will be deemed to have
selected as the arbitrator the individual receiving the highest combined ranking
who is available to serve. If there is a tie, then the tie will be broken by
putting the names on slips of paper, mixing them up and having one party draw
one slip of paper. If either the Stockholders' Representatives or Imation will
not cooperate in the selection of the arbitrator, the other may solely select
the arbitrator utilizing the procedures set forth in the Merger Agreement. The
costs of arbitration will be apportioned between the Stockholders'
Representatives and Imation as determined by the arbitrator in such manner as
the arbitrator deems reasonable taking into account the circumstances of the
case, the conduct of the parties during the proceeding, and the result of the
arbitration.
Notwithstanding any of the foregoing, any amount which is due and
payable and not in dispute will immediately be paid to the Paying Agent or the
Stockholders' Representatives. Any disputed amount will be deposited into escrow
on terms as set forth in the Merger Agreement. Nothing contained in the Merger
Agreement will act to prevent Cemax-Icon or the Stockholders' Representatives
from commencing litigation to compel payment of any due and payable amounts not
in dispute thereunder.
The Earn-Out payments, if any, will not include any interest computed
from the Effective Time of the Merger to the date of each such payment.
NONTRANSFERABILITY
The Contingent Payment Rights are personal to each initial holder
thereof and are and will remain nontransferable for any reason other than by
operation of law or by will or the laws of descent and distribution. Any
attempted transfer of a Contingent Payment Right by any holder thereof (other
than as set forth in the preceding sentence) will be null and void.
Consequently, the Contingent Payment Rights are an illiquid investment until
such time as any payments due thereunder are made.
PAYMENT OF THE EARN-OUT
Payment of the Earn-Out will be made by Imation to the Paying Agent
together with a letter of instructions for payment no later than 30 days after
Determination Date for each Earn-Out Year, for distribution by the Paying Agent
as promptly as practicable thereafter, after taking such action as is necessary
to assure that all applicable federal or state payroll, income withholding and
any other taxes are withheld, to the accounts of the Holders in accordance with
their respective ownership interests as of the Effective Time.
Payment of the Earn-Out is contingent upon the ability of the Image
Management Systems Business to achieve the Gross Revenues targets specified
above. It is possible that such Gross Revenues targets will not be achieved for
any number of reasons, including the risk factors relating to Cemax-Icon and
Imation discussed herein. See "RISK FACTORS." Although Imation has agreed
pursuant to the Merger Agreement to make certain expenditures to support the
Image Management Systems Business following the Effective Time, there can be no
assurance that such expenditures (or any other support) will be adequate for the
Gross Revenues targets to be achieved. If Gross Revenues targets are not
achieved, the amount of the Earn-Out payments will be reduced or eliminated as
described above. See "--Determination of Earn-Out."
RIGHT OF OFFSET
Imation will have the right to offset the amount of each Earn-Out by
Losses in accordance with the Merger Agreement, but will have no other right to
reduce or offset the amount of each Earn Out. See "THE MERGER
AGREEMENT--Survival and Offset." If Imation has the right to offset an Earn-Out
payment, the amount of such Earn-Out payment may be reduced or eliminated.
LEGAL MATTERS
The validity of the Contingent Payment Rights to be issued in
connection with the Merger and any shares of Imation Common Stock to be issued
upon payment of the Contingent Payment Rights will be passed upon for Imation by
Dorsey & Whitney LLP.
EXPERTS
The consolidated balance sheets as of December 31, 1996 and 1995, and
the consolidated statements of operations and cash flows for each of the three
years in the period ended December 31, 1996 of Imation, included in this Proxy
Statement/Prospectus, have been included herein in reliance on the report of
Coopers & Lybrand L.L.P., independent accountants, given on the authority of
that firm as experts in auditing and accounting. With respect to the unaudited
interim consolidated financial information for the periods ended March 31, 1997
and 1996 of Imation, included in this Proxy Statement/Prospectus, Coopers &
Lybrand L.L.P. has reported that they have applied limited procedures in
accordance with professional standards for a review of such information.
However, their separate report included in the Company's quarterly report on
Form 10-Q for the quarter ended March 31, 1997, and included herein, states that
they did not audit and they do not express an opinion on that interim
consolidated financial information. Accordingly, the degree of reliance on their
report on such information should be restricted in light of the limited nature
of the review procedures applied. Coopers & Lybrand L.L.P. is not subject to the
liability provisions of Section 11 of the Securities Act for their report on the
unaudited interim consolidated financial information because that report is not
a "report" or a "part" of the Registration Statement prepared or certified by
the accountants within the meaning of Sections 7 and 11 of the Securities Act.
The financial statements of Cemax-Icon, Inc. at December 31, 1995 and
1996, and for each of the three years in the period ended December 31, 1996,
included in the Proxy Statement of Cemax-Icon, which is referred to and made a
part of this Prospectus and Registration Statement, have been audited by Ernst &
Young LLP, independent auditors, as set forth in their report appearing
elsewhere herein, and are included in reliance upon such report given upon the
authority of such firm as experts in accounting and auditing.
OTHER MATTERS
The management of Cemax-Icon is not aware of any other business that
may come before the Special Meeting. However, if additional matters properly
come before the Special Meeting, proxies will be voted at the discretion of the
proxy holders.
INDEX TO FINANCIAL STATEMENTS
Page
IMATION CORP. AUDITED CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Accountants......................................F-2
Consolidated Statements of Operations for the years ended
December 31, 1996, 1995 and 1994...................................F-3
Consolidated Balance Sheets as of December 31, 1996 and 1995...........F-4
Consolidated Statements of Cash Flows for the years ended
December 31, 1996, 1995 and 1994...................................F-5
Notes to Consolidated Financial Statements.............................F-6
IMATION CORP. UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Accountants.....................................F-22
Consolidated Statements of Operations for the
three month periods ended March 31, 1997 and 1996................F-23
Condensed Consolidated Balance Sheets as of March 31, 1997
and December 31, 1996.............................................F-24
Condensed Consolidated Statements of Cash Flows for the
three month periods ended March 31, 1997 and 1996.................F-25
Notes to Consolidated Financial Statements............................F-26
CEMAX-ICON, INC. AUDITED FINANCIAL STATEMENTS
Report of Independent Auditors........................................F-29
Statements of Operations for the years ended
December 31, 1996, 1995 and 1994..................................F-30
Balance Sheets as of December 31, 1996 and 1995.......................F-31
Statements of Stockholders' Equity (Net Capital Deficiency)
for the years ended December 31, 1996, 1995 and 1994.............F-32
Statements of Cash Flows for the years ended
December 31, 1996, 1995 and 1994..................................F-33
Notes to Financial Statements.........................................F-35
CEMAX-ICON, INC. UNAUDITED FINANCIAL STATEMENTS
Statements of Operations for the three month periods ended
March 31, 1997 and 1996...........................................F-43
Balance Sheets as of March 31, 1997 and December 31, 1996.............F-44
Statements of Cash Flows for the three month periods ended
March 31, 1997 and 1996...........................................F-45
Notes to Financial Statements.........................................F-46
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders, Imation Corp.:
We have audited the accompanying consolidated balance sheets of Imation
Corp. and subsidiaries as of December 31, 1996 and 1995, and the related
consolidated statements of operations and cash flows for each of the three years
in the period ended December 31, 1996. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present
fairly, in all material respects, the consolidated financial position of Imation
Corp. and subsidiaries as of December 31, 1996 and 1995, and the consolidated
results of their operations and their cash flows for each of the three years in
the period ended December 31, 1996, in conformity with generally accepted
accounting principles.
/s/ COOPERS & LYBRAND L.L.P.
COOPERS & LYBRAND L.L.P.
Minneapolis, Minnesota
February 14, 1997
IMATION CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
<S> <C> <C> <C>
Net revenues .................................. $ 2,278.2 $ 2,245.6 $ 2,280.5
Cost of goods sold ............................ 1,482.8 1,520.9 1,442.0
Gross profit ................................. 795.4 724.7 838.5
Operating expenses:
Selling, general and administrative .......... 563.0 539.4 531.5
Research and development ..................... 183.1 222.4 211.2
Restructuring charges ........................ 53.9 111.8 --
Total operating expenses ................. 800.0 873.6 742.7
Other income and expenses:
Operating income (loss) ...................... (4.6) (148.9) 95.8
Interest expense and other ................... 10.4 17.9 14.5
Income (loss) before tax and minority interest (15.0) (166.8) 81.3
Income tax provision (benefit) ................ 5.9 (70.5) 29.3
Minority interest ............................. (0.4) (11.3) (2.3)
Net income (loss) ............................. $ (20.5) $ (85.0) $ 54.3
Earnings (loss) per common share .............. $ (0.49) $ (2.02) $ 1.28
Average shares outstanding .................... 41.3 42.0 42.3
</TABLE>
THE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ARE AN INTEGRAL PART
OF THESE STATEMENTS.
IMATION CORP.
CONSOLIDATED BALANCE SHEETS
(In millions, except share amounts)
<TABLE>
<CAPTION>
As of December 31,
1996 1995
<S> <C> <C>
ASSETS:
Current Assets
Cash and equivalents .............................................. $ 61.7 $ --
Accounts receivable, net .......................................... 467.6 479.5
Inventories ....................................................... 392.8 426.3
Other current assets .............................................. 94.5 48.8
Total current assets ............................................ 1,016.6 954.6
Property, Plant and Equipment, Net ................................. 480.1 513.2
Other Assets ....................................................... 64.6 73.7
Total Assets ...................................................... $ 1,561.3 $ 1,541.5
LIABILITIES AND SHAREHOLDERS' EQUITY:
Current Liabilities
Accounts payable .................................................. $ 182.1 $ 125.9
Accrued payroll ................................................... 41.9 44.4
Income taxes payable .............................................. 7.6 --
Short-term debt ................................................... 26.5 --
Other current liabilities ......................................... 151.2 125.9
Total current liabilities ....................................... 409.3 296.2
Other Liabilities .................................................. 98.6 96.6
Long-term Debt ..................................................... 123.1 --
Commitments and Contingencies
Shareholders' Equity
Preferred stock, $.01 par value, authorized 25,000,000 shares, none
issued and outstanding .......................................... -- --
Common stock, $.01 par value, authorized 100,000,000 shares,
issued and outstanding 42,879,880 as of December 31, 1996 ....... .4 --
Additional paid-in capital ........................................ 1,011.5 --
Retained earnings ................................................. 11.2 --
Unearned ESOP shares .............................................. (46.6) --
Cumulative translation adjustment ................................. (46.2) (39.1)
Net investment by 3M .............................................. -- 1,187.8
Total shareholders' equity ...................................... 930.3 1,148.7
Total Liabilities and Shareholders' Equity ...................... $ 1,561.3 $ 1,541.5
</TABLE>
THE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ARE AN INTEGRAL PART
OF THESE STATEMENTS.
IMATION CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) ......................................... $ (20.5) $(85.0) $ 54.3
Adjustments to reconcile net income (loss) to
net cash provided by operating activities:
Depreciation ............................................. 181.1 189.5 185.9
Deferred income taxes .................................... 12.6 (68.1) 14.0
Restructuring and other one-time charges ................. 88.4 166.3 --
Accounts receivable ...................................... 12.0 (0.6) (16.8)
Inventories .............................................. 22.3 25.4 (87.8)
Other current assets ..................................... (29.8) 1.1 (1.1)
Accounts payable ......................................... 73.7 (4.5) 11.7
Accrued payroll and other current liabilities ............ (37.9) 9.3 2.2
Other .................................................... 4.1 23.4 7.7
Net cash provided by operating activities .............. 306.0 256.8 170.1
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures ...................................... (167.4) (180.2) (182.7)
Capitalized software ...................................... (13.5) -- --
Other ..................................................... (3.7) (7.3) 3.0
Net cash used in investing activities (184.6) (187.5) (179.7)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in short-term debt ............................. 25.4 -- --
Borrowings on long-term debt .............................. 270.3 -- --
Repayment of long-term debt ............................... (146.3) -- --
Loan to ESOP .............................................. (50.0) -- --
Decrease in unearned ESOP shares .......................... 3.4 -- --
Net cash (paid to) received from 3M ....................... (155.9) (72.9) 18.5
Net cash (used in) provided
by financing activities ............................... (53.1) (72.9) 18.5
Effect of exchange rate changes on cash ................... (6.6) 3.6 (8.9)
Change in cash and equivalents ............................ 61.7 -- --
Cash and equivalents - beginning of year .................. -- -- --
Cash and equivalents - end of year ........................ $ 61.7 $ -- $ --
</TABLE>
THE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ARE AN INTEGRAL PART
OF THESE STATEMENTS.
IMATION CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. BACKGROUND AND BASIS OF PRESENTATION
BACKGROUND
Imation Corp. (the "Company") became an independent, publicly held
company as of July 1, 1996 (the "Distribution Date"), when Minnesota Mining and
Manufacturing Company ("3M") spun off its data storage and imaging systems
businesses as an independent, publicly owned company (the "Distribution"). One
share of the Company's common stock was issued for every ten shares of 3M stock
outstanding to stockholders of record on June 18, 1996.
BASIS OF PRESENTATION
Subsequent to the Distribution, the consolidated financial statements
include the accounts and operations of the Company on a stand-alone basis. 3M
and the Company have entered into a number of agreements to facilitate the
transition of the Company to an independent business enterprise.
Prior to the Distribution, the consolidated financial statements
reflect the assets, liabilities, revenues and expenses that were directly
related to the Company as they were operated within 3M. Where assets and
liabilities were not specifically identifiable to any particular business of 3M,
only those assets and liabilities transferred to the Company are included in the
Company's consolidated balance sheets. Regardless of the allocation of these
assets and liabilities, however, the Company's consolidated statements of
operations include all of the related costs of doing business including an
allocation of certain general corporate expenses of 3M which were not directly
related to the Company including costs for corporate logistics, corporate
research and development, information technologies, finance, legal and corporate
executives. These allocations were based on a variety of factors including, for
example, personnel, space, time and effort, and sales volume. Management
believes these allocations were made on a reasonable basis.
Cash and equivalents and debt were not allocated to the Company in the
financial statements as 3M uses a centralized approach to cash management and
the financing of its operations. The consolidated statements of operations
include an allocation of 3M's interest expense (see Note 7). The Company's
financing requirements are represented by cash transactions with 3M and are
reflected in the "Net Investment by 3M" account (see Note 9). Certain assets and
liabilities of 3M such as certain employee benefit and income tax-related
balances have not been allocated to the Company and are included in the Net
Investment by 3M account. Activity in the Net Investment by 3M equity account
relates to net cash flows of the Company as well as changes in the assets and
liabilities not allocated to the Company.
The Company also participated in 3M's centralized interest rate risk
management function. As part of this activity, derivative financial instruments
were utilized to manage risks generally associated with interest rate market
volatility. 3M did not hold or issue derivative financial instruments for
trading purposes. 3M was not a party to leveraged derivatives. The consolidated
balance sheets of the Company do not reflect any of the associated asset or
liability positions resulting from this activity because the Company did not
assume any of 3M's derivative financial instruments in connection with the
Distribution. The consolidated statements of operations and statements of cash
flows, however, do reflect an allocation of the related gains and losses. Such
gains and losses were recognized by 3M as interest expense over the borrowing
period and, as a result, are reflected in the effective interest rates utilized
by the Company in deriving its interest expense.
The minority interest within the consolidated statements of operations
gives recognition to the Company's share of net income (loss) of certain
majority owned subsidiaries of 3M. The minority shareholders' proportionate
interests in the Company's net assets of majority owned subsidiaries have not
been presented in the consolidated balance sheets as the Company obtained 100
percent ownership of the assets and liabilities of these subsidiaries in
connection with the Distribution.
The financial information included herein for periods prior to the
Distribution may not necessarily be indicative of the financial position,
results of operations or cash flows of Company if it had been a separate,
independent company during the periods prior to the Distribution.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
CONSOLIDATION
Commencing with the Distribution, the consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries. Prior to
the Distribution, the consolidated financial statements include the accounts of
the Company as described in Note 1. All significant intercompany transactions
and balances have been eliminated.
FOREIGN CURRENCY
Local currencies are considered the functional currencies outside the
U.S. except for Imation Europe B.V., the Company's European holding company, and
subsidiaries located in highly inflationary economies. For operations in local
currency environments, assets and liabilities are translated at year-end
exchange rates with cumulative translation adjustments included as a component
of shareholders' equity. Income and expense items are translated at average
rates of exchange prevailing during the year. For operations in which the U.S.
dollar is considered the functional currency, certain financial statement
amounts are translated at historical exchange rates, with all other assets and
liabilities translated at year-end exchange rates. These translation adjustments
are reflected in the results of operations.
The Company enters into foreign currency forward exchange and
derivative contracts to hedge foreign currency transaction exposures. Gains and
losses arising from foreign currency contracts offset gains and losses resulting
from the underlying hedged transactions. The Company's policy is to selectively
hedge anticipated transaction exposures. Aggregated transaction gains and losses
included in the determination of net income (loss) are not material for any
period presented. As of December 31, 1996, the notional amount of outstanding
forward contracts was not material.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates. Principal
areas requiring the use of estimates include: the allocation of financial
statement amounts between the Company and 3M for periods prior to the
Distribution, determination of allowances for uncollectible accounts receivable
and obsolete/excess inventories, and assessments of the recoverability of
deferred tax assets and certain long-lived assets.
CASH EQUIVALENTS
Cash equivalents consist of temporary investments purchased with
original maturities of three months or less.
INVENTORIES
Inventories are stated at the lower of cost or market, with cost
generally determined on a first-in first-out basis.
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are recorded at cost. Plant and equipment
are generally depreciated on a straight-line basis over their estimated useful
lives. Maintenance and repairs are expensed as incurred. Periodic reviews for
impairment of the carrying value of property, plant and equipment are made based
on undiscounted expected future cash flows.
OTHER ASSETS
Other assets consist primarily of deferred taxes, goodwill, capitalized
software and investments. Intangible assets are amortized over their useful
lives, which currently range from five to seven years. The carrying value of
intangible assets are periodically reviewed to assess recoverability based on
undiscounted expected future cash flows.
EMPLOYEE SEVERANCE INDEMNITIES
Employee severance indemnities consist of termination indemnities and
are accrued for each employee in accordance with labor legislation in each
applicable country.
REVENUE RECOGNITION
Revenue is recognized upon shipment of goods to customers or upon
performance of services. Revenues from service contracts are deferred and
recognized over the life of the contracts as service is performed.
CONCENTRATIONS OF CREDIT RISK
The Company sells a wide range of products and services to a
diversified base of customers around the world and performs ongoing credit
evaluations of its customers' financial condition, and therefore believes there
is no material concentration of credit risk.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are charged to expense as incurred.
ADVERTISING COSTS
Advertising costs are charged to expense as incurred and totaled $73
million, $52 million and $52 million in 1996, 1995 and 1994 respectively.
Advertising costs in 1996 include $22 million related to start-up costs for
identity development.
INCOME TAXES
Upon the Distribution, the Company became responsible for its income
taxes and will file its own income tax returns. Prior to the Distribution, the
Company did not file separate tax returns but rather was included in the income
tax returns filed by 3M and its subsidiaries in various domestic and foreign
jurisdictions. For purposes of the Company's consolidated financial statements
prior to the Distribution, the Company's allocated share of 3M's income tax
provision was based on the "separate return" method, except that the tax benefit
of the Company's tax losses in certain jurisdictions was allocated to the
Company on a current basis if such losses could be utilized by 3M in its tax
returns and an assessment of realizability of certain deferred tax assets was
made assuming the availability of future 3M taxable income. Had the Company's
1996 provision for income taxes been calculated on a purely "separate return"
method, the impact on the Company's 1996 results of operations would not have
been material. Prior to the Distribution, the balance of accrued current income
taxes for the Company's operations is included in the Net Investment by 3M
equity account because 3M paid all taxes and received all tax refunds on the
Company's behalf.
STOCK-BASED COMPENSATION
The Company adopted Statement of Financial Accounting Standards No.
123, "Accounting for Stock-Based Compensation", in 1996. This standard gives
entities the choice of recognizing stock-based compensation by adopting the new
fair value method or to continue to measure compensation expense using the
intrinsic value approach under Accounting Principles Board Opinion (APB) No. 25,
"Accounting for Stock Issued to Employees". The Company has chosen to account
for stock-based compensation under APB No. 25. Accordingly, compensation cost
for stock options is measured as the excess, if any, of the quoted market price
of the Company's common stock at the date of the grant over the amount an
employee must pay to acquire the stock.
EARNINGS PER SHARE
For periods after the Distribution, earnings per share are computed
using the weighted average shares outstanding during the period, net of
unallocated shares held by the Company's ESOP. Common share equivalents were not
material. For periods prior to the Distribution, the number of weighted average
shares outstanding used in the earnings per share calculation is one-tenth of
the weighted average number of 3M shares outstanding based on the distribution
of one share of the Company for ten shares of 3M pursuant to the Distribution.
3. ACQUISITION
In October 1996, the Company acquired all of the outstanding common and
preferred shares of Luminous Corporation (Luminous) for cash, 922,845 shares of
the Company common stock and assumption of Luminous' obligations under
outstanding employee stock options, which, after conversion to options to
purchase the Company common stock, represent options to purchase 317,062 shares
of the Company common stock. Luminous is a developer and marketer of desktop
software to the prepress, print production, printing and graphic arts
industries. The acquisition was accounted for using the purchase method of
accounting. The Company allocated a portion of the purchase price to in-process
research and development projects that had not yet reached technological
feasibility and had no probable alternative future uses, which resulted in a
one-time non-deductible charge of $12.0 million. The Company has allocated the
remaining excess purchase price over net assets acquired to goodwill which is
being amortized over seven years. Operating results for Luminous are included in
results of operations since the date of acquisition. The pro forma effect on
prior periods' results of operations is not material.
4. SUPPLEMENTAL BALANCE SHEET INFORMATION
1996 1995
(In millions)
ACCOUNTS RECEIVABLE:
Accounts receivable ................. $ 490.9 $ 497.0
Less allowances ..................... (23.3) (17.5)
Accounts receivable, net ......... $ 467.6 $ 479.5
INVENTORIES:
Finished goods ...................... $ 248.1 $ 244.0
Work in process ..................... 57.3 81.2
Raw materials and supplies .......... 87.4 101.1
Total inventories ................ $ 392.8 $ 426.3
OTHER CURRENT ASSETS:
Deferred taxes ...................... $ 38.3 $ 23.4
Other ............................... 56.2 25.4
Total other current assets ....... $ 94.5 $ 48.8
PROPERTY, PLANT AND EQUIPMENT:
Land ................................ $ 8.3 $ 7.7
Buildings and leasehold improvements 185.0 180.9
Machinery and equipment ............. 1,472.6 1,616.2
Construction in progress ............ 44.0 63.5
Total ............................ 1,709.9 1,868.3
Less accumulated depreciation ....... 1,229.8 1,355.1
Property, plant and equipment, net $ 480.1 $ 513.2
OTHER ASSETS:
Deferred taxes ...................... $ 8.1 $ 60.6
Other ............................... 56.5 13.1
Total other assets ............... $ 64.6 $ 73.7
OTHER CURRENT LIABILITIES:
Accrued rebates ..................... $ 42.9 $ 44.6
Deferred income ..................... 26.1 35.8
Taxes other than income taxes ....... 23.2 11.7
Other ............................... 59.0 33.8
Total other current liabilities .. $ 151.2 $ 125.9
OTHER LIABILITIES:
Employee severance indemnities ...... $ 49.3 $ 59.2
Other ............................... 49.3 37.4
Total other liabilities .......... $ 98.6 $ 96.6
5. RESTRUCTURING CHARGES AND OTHER ONE-TIME COSTS
In late 1995, the Company initiated a review of all of its operations,
including its organizational structure, manufacturing operations, products and
markets. In connection with this review, the Company adopted a reorganization
plan to rationalize its manufacturing operations, streamline its organizational
structure and write-off impaired assets.
The Company has reflected restructuring and other one-time charges of
$254.7 million in its financial statements, partially in 1995 and partially in
1996 based upon the timing recognition criteria required for the restructuring
charges. The Company recorded $166.3 million of these charges ($88.3 million
after taxes and minority interest) in its 1995 financial statements and an
additional $88.4 million ($60.6 million after taxes) in 1996.
The 1995 special charges of $166.3 million includes $111.8 million
related to world-wide manufacturing rationalization programs to exit less
profitable manufacturing locations and to centralize manufacturing in the U.S.
and in Italy, and consists principally of write-offs of property, plant and
equipment. This $111.8 million charge is included as a separate restructuring
charge in the statement of operations. The remaining 1995 special charges of
$54.5 million relates primarily to asset write-offs included in cost of goods
sold.
In 1996, special charges of $88.4 million were recorded. These charges
include $53.9 million in restructuring charges primarily for employee separation
programs resulting in the reduction of approximately 1,600 employees and $22.5
million of one-time charges associated with start-up activities which are
included in costs of goods sold and selling, general and administrative
expenses. The unpaid restructuring charges for the employee separation programs
as of June 30, 1996, were retained by 3M pursuant to the Distribution. In
addition to the above charges, the Company also recognized a non-deductible
write-off of $12.0 million for the in-process research and development related
to the Luminous acquisition (see Note 3).
6. INCOME TAXES
The components of income (loss) before tax and minority interest are as
follows:
1996 1995 1994
(In millions)
United States ................ $ (16.9) $ (136.1) $ 63.2
International ................ 1.9 (30.7) 18.1
Total ....................... $ (15.0) $ (166.8) $ 81.3
The income tax provision (benefit) is as follows:
1996 1995 1994
(In millions)
Currently payable (refundable)
Federal ..................... $ (9.9) $ (14.0) $ 8.3
State ....................... (0.4) (4.3) 1.7
International ............... 3.9 15.6 4.6
Deferred
Federal ..................... 3.3 (34.9) 9.4
State ....................... (0.4) (3.1) 0.8
International ............... 9.4 (29.8) 4.5
Total ..................... $ 5.9 $ (70.5) $ 29.3
The components of net deferred tax assets and liabilities are as
follows:
1996 1995
(In millions)
Receivables ............................ $ 7.8 $ 4.0
Inventories ............................ 15.4 5.9
Property, plant and equipment .......... (0.4) 44.5
Payroll ................................ 3.2 19.2
Other, net ............................. 17.9 9.5
Net deferred tax assets and liabilities $ 43.9 $ 83.1
Management believes the Company, or in certain cases 3M prior to the
Distribution, will generate sufficient taxable income in future periods to fully
recover the Company's deferred tax assets.
The provision (benefit) for income taxes differs from the amount
computed by applying the statutory U.S. income tax rate (35%) because of the
following items:
1996 1995 1994
(In millions)
Tax at statutory U.S. tax rate .............. $ (5.3) $ (58.4) $ 28.5
State income taxes, net of federal benefit .. (1.2) (5.4) 2.9
International taxes in excess of
statutory U.S. tax rate.................... 7.1 (7.7) (3.0)
Non-deductible expense related to acquisition 4.9 -- --
Other ....................................... 0.4 1.0 0.9
Income tax provision (benefit) .............. $ 5.9 $ (70.5) $ 29.3
As of December 31, 1996, approximately $151 million of earnings
attributable to international subsidiaries (inclusive of earnings prior to the
Distribution for certain international subsidiaries) were considered to be
permanently invested. No provision has been made for taxes that might be payable
if these earnings were remitted to the U. S. It is not practical to determine
the amount of incremental tax that might arise if these earnings were to be
remitted.
Cash paid for income taxes in the period from July 1, 1996 to December
31, 1996 was not material. Prior to July 1, 1996, 3M paid all taxes and received
all tax refunds on the Company's behalf.
7. DEBT
The components of long-term debt as of December 31, 1996, are as
follows:
(In millions)
Revolving credit facility $ 120.0
Other ................... 4.0
124.0
Less current portion .... (0.9)
Total long-term debt ... $ 123.1
The Company maintains a $350 million revolving credit facility with a
syndicate of banks which expires on June 30, 2001. The commitment fee for the
credit facility is based on the Company interest coverage ratio, and as of
December 31, 1996, was .15 of one percent on the total amount of the credit
facility. Borrowings under the credit facility bear interest based on the London
interbank offered rate (LIBOR) or the administrative agent bank's base rate,
plus an applicable margin based on the Company interest coverage ratio. As of
December 31, 1996, $120 million in borrowings under this credit facility were
outstanding at interest rates ranging from 5.80% to 5.86%. The agreement
contains financial covenants that include a maximum debt to capital ratio, a
minimum interest coverage ratio, and a minimum tangible net worth. As of
December 31, 1996, the Company was in compliance with these covenants.
Long-term debt maturities are as follows:
1997 1998 1999 2000 2001
(In millions)
Long-term debt maturities... $ 0.9 $ 1.0 $ 1.0 $ 1.1 $ 120.0
Short-term debt as of December 31, 1996, consisted of $25.6 million of
uncollateralized borrowings primarily held by international subsidiaries. These
borrowings have original maturities of one year or less and have a weighted
average interest rate of 2.9% as of December 31, 1996. As of December 31, 1996,
the Company had an additional $53 million available under credit facilities held
by various subsidiaries outside the U. S.
The Company estimates that the fair value of short-term and long-term
debt approximates the carrying amount of debt.
The Company's interest expense for the period from July 1, 1996 through
December 31, 1996 was $6.8 million and cash paid for interest was $6.2 million.
Prior to the Distribution, the Company's financial statements include
allocations of 3M's interest expense totaling $7.4 million for the period from
January 1, 1996 to June 30, 1996, $18.8 million for 1995 and $16.3 million for
1994. Total 1996 interest expense was $14.2 million. Allocations prior to the
Distribution were based on an assumed non-ESOP debt level of $250 million. The
interest rates used were 6.4%, 7.5% and 6.5% in 1996, 1995 and 1994,
respectively, which reflect 3M's weighted average effective interest rates on
non-ESOP debt during these periods. The consolidated balance sheet of the
Company prior to the Distribution does not include this debt as the total
capitalization of the Company was reflected in Net Investment by 3M.
8. LEASES
Rent expense under operating leases, which primarily relate to
equipment and office space, amounted to $15.1 million, $9.0 million and $9.0
million in 1996, 1995 and 1994, respectively. The following table sets forth the
minimum rental payments under operating leases with non-cancelable terms in
excess of one year as of December 31, 1996:
After
1997 1998 1999 2000 2001 2001 Total
(in millions)
Minimum Lease Payments....$ 9.5 $ 6.5 $ 3.5 $ 2.1 $ 0.9 $ 0.2 $ 22.7
9. SHAREHOLDERS' EQUITY
The Company authorized stock consists of 100,000,000 shares of common
stock, par value $0.01, and 25,000,000 shares of preferred stock, par value
$0.01. Common shares issued as of December 31, 1996 were 42,879,880 shares.
There were no preferred shares issued as of December 31, 1996.
The Company maintains a stockholder rights plan under which the Company
has issued one preferred share purchase right (Right) for each common share of
the Company. Each Right will entitle its holder to purchase one one-hundredth of
a share of Series A Junior Participating Preferred Stock at an exercise price of
$125, subject to adjustment. The Rights are exercisable only if a person or
group acquires beneficial ownership of 15 percent or more of the Company's
outstanding common stock. The Rights expire on July 1, 2006 and may be redeemed
earlier by the Board of Directors for $0.01 per Right.
The following table summarizes the changes in the components
of shareholders' equity:
<TABLE>
<CAPTION>
Additional Unearned Cumulative Net Total
Common Paid-In Retained ESOP Translation Investment Shareholders'
Stock Capital Earnings Shares Adjustment by 3M Equity
(In millions)
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31,1993 $ (73.1) $ 1,272.9 $ 1,199.8
Net income ................ 54.3 54.3
Net amount received
from 3M.................. 18.5 18.5
Net change in cumulative
translation.............. 27.4 27.4
Balance at December 31, 1994 -- -- -- -- (45.7) 1,345.7 1,300.0
Net loss................... (85.0) (85.0)
Net amount paid to 3M...... (72.9) (72.9)
Net change in cumulative
translation............. 6.6 6.6
Balance at December 31, 1995 -- -- -- -- (39.1) 1,187.8 1,148.7
Net equity transactions
with 3M.................. (164.0) (164.0)
Issuance of common
stock to 3M shareholders
(41,930,187 shares)...... $ 0.4 $ 991.7 (992.1) --
Loan to ESOP............... $ (50.0) (50.0)
Amortization of
unearned ESOP shares..... -- 0.4 3.4 3.8
Issuance of common
stock (922,845 shares)
in connection
with acquisition........ -- 14.6 14.6
Value of stock options
issued in connection
with acquisition........ -- 4.8 4.8
Exercise of stock
options (26,848 shares).. -- -- --
Net income (loss).......... $ 11.2 (31.7) (20.5)
Net change in cumulative
translation ............. (7.1) (7.1)
Balance at December 31, 1996 $ 0.4 $ 1,011.5 $ 11.2 $ (46.6) $ (46.2) -- $ 930.3
</TABLE>
10. SEGMENT INFORMATION
The Company operates in one industry segment, the imaging and
information industry, supplying products and services to meet the information
processing needs for a variety of customer applications. Geographic information
in the table below is presented on the same basis utilized by the Company to
manage its business. Export sales and certain income and expense items are
reported in the geographic area where the final sale to customers is made,
rather than where the transaction originates.
<TABLE>
<CAPTION>
Other
United International Eliminations Total
Year States Europe(1) Areas(2) And Other Company
(In millions)
<S> <C> <C> <C> <C> <C> <C>
Net revenues to customers............... 1996 $ 1,159.5 $ 816.2 $ 302.5 $ 2,278.2
1995 1,128.8 808.4 308.4 2,245.6
1994 1,199.9 764.1 316.5 2,280.5
Transfers between geographic areas...... 1996 $ 351.1 $ 92.5 $ 6.8 $ (450.4)
1995 290.9 76.2 4.0 (371.1)
1994 341.2 89.4 0.1 (430.7)
Operating income (loss)................. 1996(3) $ (95.3) $ 78.8 $ 11.9 $ (4.6)
1995(4) (169.0) 55.8 (35.7) (148.9)
1994 1.5 72.9 21.4 95.8
Identifiable assets..................... 1996 $ 777.1 $ 618.1 $ 166.1 -- $ 1,561.3
1995 816.4 575.7 149.7 $ (0.3) 1,541.5
1994 894.9 582.9 194.7 (0.8) 1,671.7
</TABLE>
(1) Includes operations in the Middle East and Africa since such regions
are managed together with Europe. These operations are not material to
the overall financial results of the Company.
(2) Includes Latin America, Asia and Canada.
(3) Includes restructuring and one-time charges of $77.1 million in the
United States, $9.8 million in Europe and $1.5 million in Other
International Areas.
(4) Includes restructuring and one-time charges of $99.8 million in the
United States, $20.4 million in Europe and $46.1 million in Other
International Areas.
11. RETIREMENT PLANS
The Company has various non-contributory defined benefit employee
pension plans covering substantially all U.S. employees and certain employees
outside the U.S. For the U.S. plan, employees are eligible to participate at
date of hire and are fully vested after five years of service, including pension
service time while employed by 3M. Benefits are based primarily on employees'
annual salary and annual interest credits. For plans outside the U.S., benefits
are based principally on years of service and compensation near retirement. The
Company's funding policy is to deposit with a Trustee amounts at least equal to
those required by law. Pension investments consist primarily of common stocks
and fixed-income securities. The Company has not made any contributions to the
U.S. plan as of December 31, 1996, as such funding is not required until 1997.
Prior to the Distribution, employees of the Company participated in
various 3M-sponsored retirement plans. For U.S. employees, 3M has retained
responsibility for the benefits earned under the plan. For plans outside the
U.S., the Company generally has assumed the assets and related liabilities. For
periods prior to the Distribution, pension expense was allocated to the Company
as part of 3M. Allocated pension expense was $12 million in the period January
1, 1996 to June 30, 1996, $24 million in 1995 and $25 million in 1994. Total
pension expense in 1996 was $21.3 million.
The following table details net pension cost for period July 1, 1996 to
December 31, 1996:
United States International
Plan Plans
(In millions)
Service cost ................. $ 7.5 $ 1.5
Interest cost ................ -- 2.0
Return on plan assets - actual -- (2.0)
Net amortization and deferral -- 0.3
Net pension cost ............. $ 7.5 $ 1.8
The following table details the funded status of the pension plans as
of December 31, 1996:
<TABLE>
<CAPTION>
United States International
Plan Plans
(In millions)
<S> <C> <C>
Actuarial present value of:
Vested benefit obligation ............................ $ 6.9 $ 36.2
Non-vested benefit obligation ........................ 0.6 5.6
Accumulated benefit obligation ....................... $ 7.5 $ 41.8
Projected benefit obligation ......................... $ 7.5 $ 60.3
Plan assets at fair value ............................ -- $ 52.5
Plan assets less than the projected benefit obligation $ (7.5) $ (7.8)
Unrecognized net transition obligation ............... -- 0.9
Other unrecognized items ............................. -- 5.6
Accrued pension cost ................................. $ (7.5) $ (1.3)
</TABLE>
The assumptions at year end are as follows:
<TABLE>
<CAPTION>
United States International
Plan Plans
<S> <C> <C>
Discount rate ........................................ 8.00% 8.00%
Compensation rate increase .......................... 4.75% 6.20%
Long-term rate of return on assets .................. 9.00% 8.30%
</TABLE>
Net pension cost was determined using assumptions as of July 1, 1996
(Distribution Date), which were the same as the December 31, 1996 assumptions
used to determine the funded status.
In addition to the above, the Company's Italian subsidiary sponsors an
employee severance indemnity as required by law. The accrued liability for this
severance indemnity is included in other liabilities and was $49.3 million and
$59.2 million as of December 31, 1996 and 1995, respectively. The Company
measures the vested benefit obligation as the amount that would be payable if
the employees under the plan would separate currently. Expense for this plan was
$5.0 million, $7.8 million and $6.3 million in 1996, 1995 and 1994,
respectively.
12. EMPLOYEE SAVINGS AND STOCK OWNERSHIP PLANS
The Company sponsors a 401(k) retirement savings plan under which
eligible U.S. employees may choose to save up to 15% of eligible compensation on
a pre-tax basis, subject to certain IRS limitations. The Company matches
employee contributions 100% on the first three percent of eligible compensation
and 25% on the next three percent of eligible compensation. The Company also
sponsors a variable compensation program, in which the Company will contribute
up to three percent of eligible employee compensation to employees' 401(k)
retirement accounts, depending upon Company performance.
The Company established an Employee Stock Ownership Plan (ESOP) during
1996 as a cost-effective way of funding the employee retirement savings benefits
noted above. The ESOP borrowed $50.0 million from the Company and used the
proceeds to purchase approximately 2.2 million shares of the Company's common
stock, with the ESOP shares pledged as collateral for the debt. The Company
makes monthly contributions to the ESOP equal to the debt service plus an
applicable amount so that the total contribution releases a number of shares
equal to that required to satisfy the Company's matching requirements. As the
debt is repaid, shares are released from collateral and allocated to employee
accounts. The shares pledged as collateral are reported as unearned ESOP shares
in the consolidated balance sheets. The Company reports compensation expense
equal to the current market price of the shares released, and released shares
are considered outstanding for the computation of earnings per share.
Compensation expense related to the ESOP was $3.8 million in the period from
July 1, 1996 to December 31, 1996.
The ESOP shares as of December 31, 1996 are as follows:
Released and allocated shares ......................... 146,149
Unreleased shares ..................................... 2,029,738
Total ESOP shares .................................... 2,175,887
Fair value of unreleased shares as of December 31, 1996 $57,086,000
Prior to the July 1, 1996, U.S. employees of the Company participated
in a 3M-sponsored employee savings plan under Section 401(k) of the Internal
Revenue Code. 3M matched employee contributions of up to six percent of
compensation at rates ranging from 35 to 85 percent depending upon financial
performance. The Company's allocation of the expense related to the 3M employee
savings plan was $2.3 million in the period from January 1, 1996 to June 30,
1996, $4.5 million in 1995 and $4.6 million in 1994. Total expense for 1996 was
$6.1 million.
13. EMPLOYEE STOCK PLANS
The Company currently has stock options outstanding under the Imation
1996 Employee Stock Incentive Program (the "Employee Plan"), the Imation 1996
Directors Stock Compensation Program (the "Directors Plan") and the Imation
Stock Option Plan for Employees of Luminous Technology Corporation (the
"Luminous Plan").
The Employee Plan was approved and adopted by 3M on June 18, 1996, as
the sole stockholder of the Company, and became effective on July 1, 1996, the
Distribution Date. The total number of shares of common stock that may be issued
or awarded under the Employee Plan may not exceed 6,000,000. All shares subject
to awards under the Employee Plan that are forfeited or terminated will be
available again for issuance pursuant to awards under the Employee Plan.
Generally, grant prices are equal to the fair market value of the Company's
common stock at date of grant. The options normally have a term of ten years and
become exercisable from one to five years after grant date. At December 31,
1996, there were 3,677,532 shares available for grant under the Employee Plan.
The Directors Plan was also approved and adopted by 3M prior to the
Distribution Date, as the sole shareholder of the Company, and became effective
on July 1, 1996. The total number of shares of common stock that may be issued
or awarded under the Directors Plan may not exceed 800,000. The outstanding
options are non-qualified options with a term of ten years and generally become
exercisable one year after grant. Grant prices are equal to the fair market
value of the Company's common stock at date of grant. As of December 31, 1996,
there were 740,000 shares available for grant under the Directors Plan.
The Luminous Plan was approved and adopted by the shareholders of
Luminous Corporation (Luminous) prior to the acquisition of Luminous by the
Company (see Note 3). In connection with the acquisition, the Company assumed
certain outstanding stock options held by Luminous employees and agreed to
convert such options into 317,062 options to purchase the Company's common
stock. The outstanding options were amended to accelerate the dates on which the
options become exercisable. No additional grants may be made pursuant to the
Luminous Plan.
The following table summarizes stock option activity for 1996:
Weighted Average
Stock Options Exercise Price
Granted ................ 2,699,530 $ 21.14
Exercised .............. 26,848 2.16
Forfeited .............. 24,525 22.54
Outstanding, End of Year 2,648,157 $ 21.31
Exercisable, End of Year 131,857 $ 10.58
The following table summarizes information about stock options
outstanding as of December 31, 1996:
<TABLE>
<CAPTION>
Weighted
Average Options Options
Remaining Outstanding- Exercisable-
Range of Options Contractual Weighted Average Options Weighted Average
Exercise Prices Outstanding Life Exercise Price Exercisable Exercise Price
<S> <C> <C> <C> <C> <C>
$ 0.31 171,754 9 years $ 0.31 74,219 $ 0.31
$ 22.38 to $26.80 2,476,403 9 years 22.76 57,638 23.81
$ 0.31 to $26.80 2,648,157 131,857
</TABLE>
The Company has adopted the disclosure only provisions of Statement of
Financial Accounting Standard No. 123 (SFAS 123), "Accounting for Stock-Based
Compensation". Accordingly, no compensation expense has been recognized for the
stock option plans. If the fair value of options granted had been recognized as
compensation expense on a straight-line basis over the vesting periods in
accordance with the provisions of SFAS 123, pro forma pretax loss would have
been $9.4 million higher ($5.1 million after tax or $0.12 per share) in 1996 and
$3.4 million higher ($1.9 million after tax or $0.05 per share) in 1995. The pro
forma effects on net income (loss) for 1996 and 1995 are not representative of
the pro forma effects on net income (loss) in future years due to differences
between the Company's and 3M's option plans, including vesting periods, and the
exclusion of compensation expense related to the vesting of grants made prior to
1995.
The weighted average fair value at date of grant for options granted in
1996 was as follows:
Exercise price equals market price on grant date: $ 8.96
Exercise price less than market price on grant date: $ 21.97
As part of 3M, certain employees of the Company were granted stock
options prior to the Distribution to purchase 3M stock. Options granted to the
Company's employees under 3M's General Employees' Stock Purchase Plan (GESPP)
were 72,522 from January 1, 1996 to June 30, 1996 and 144,366 in 1995. The
weighted average fair value per option granted under the GESPP was $10.37 in
1996 and $8.60 in 1995. Options granted to the Company's employees under 3M's
Management Stock Option Plan (MSOP) were 271,200 in 1995 with a weighted average
fair value of $12.48 per option. No options were issued to the Company's
employees under the MSOP in 1996. Pursuant to the Distribution, options granted
to the Company's employees while part of 3M have not been converted into options
to purchase shares of the Company's stock.
The fair values at date of grant were estimated using the Black-Scholes
option pricing model with the following weighted average assumptions (1995
grants reflect 3M assumptions):
1996 1995
Volatility ..................................... 40.0% 14.4%
Risk free interest rate......................... 6.38% 5.90%
Expected life (months).......................... 49 66
Dividend growth................................. Zero 5.2%
14. SUPPLEMENTAL NON-CASH ITEMS
Pursuant to the Distribution on July 1, 1996, certain assets and
liabilities with a net value of $8.1 million were retained by 3M, primarily
comprised of certain deferred tax assets of $26.9 million and severance
obligations of $23.9 million. Pursuant to the acquisition of Luminous (see Note
3), the Company issued $14.6 million of common stock and $4.8 million of stock
options.
15. COMMITMENTS AND CONTINGENCIES
In connection with the Distribution, the Company assumed substantially
all liabilities for legal proceedings relating to the Company's businesses as
conducted prior to the Distribution.
In addition, in the normal course of business, the Company is subject
to proceedings, lawsuits and other claims, including proceedings under laws and
regulations related to environmental and other matters. All such matters are
subject to many uncertainties and outcomes that are not predictable with
assurance. Consequently, the Company is unable to ascertain the ultimate
aggregate amount of monetary liability or financial impact with respect to these
matters at December 31, 1996. While these matters could materially affect
operating results of any one quarter when resolved in future periods, it is
management's opinion that after final disposition, any monetary liability or
financial impact to the Company beyond that provided in the consolidated balance
sheet as of December 31, 1996 would not be material to the Company financial
position, or annual results of operations or cash flows.
16. QUARTERLY DATA (UNAUDITED)
<TABLE>
<CAPTION>
First Second Third Fourth Total
(In millions, except per share data)
1996
<S> <C> <C> <C> <C> <C>
Net revenues ......... $ 576.1 $ 561.2 $ 559.3 $ 581.6 $ 2,278.2
Gross profit ......... 202.3 192.7 196.6 203.8 795.4
Operating income (loss) 13.3 (55.6) 24.5 13.2 (4.6)
Net income (loss) .... 6.1 (37.8) 11.8 (0.6) (20.5)
Earnings (loss) per
common share ...... 0.14 (0.90) 0.29 (0.02) (0.49)
1995
Net revenues ......... $ 576.7 $ 565.0 $ 546.2 $ 557.7 $ 2,245.6
Gross profit ......... 212.5 194.6 181.7 135.9 724.7
Operating income ..... 18.2 (1.9) (1.3) (163.9) (148.9)
Net income (loss) .... 7.5 (3.2) (1.8) (87.5) (85.0)
Earnings (loss) per
common share ...... 0.18 (0.08) (0.04) (2.08) (2.02)
</TABLE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders of Imation Corp.:
We have reviewed the accompanying condensed consolidated balance sheet
of Imation Corp. (the Company) and subsidiaries as of March 31, 1997, and the
related consolidated statements of operations and condensed consolidated
statements of cash flows for the three-month periods ended March 31, 1997 and
1996. These consolidated financial statements are the responsibility of the
Company's management.
We conducted our reviews in accordance with standards established by
the American Institute of Certified Public Accountants. A review of interim
financial information consists principally of applying analytical procedures to
financial data and making inquiries of persons responsible for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, the objective of which is
the expression of an opinion regarding the financial statements taken as a
whole. Accordingly, we do not express such an opinion.
Based on our reviews, we are not aware of any material modifications
that should be made to the consolidated financial statements referred to above
for them to be in conformity with generally accepted accounting principles.
We have previously audited, in accordance with generally accepted
auditing standards, the consolidated balance sheet as of December 31, 1996, and
the related consolidated statements of operations and cash flows for the year
then ended; and in our report dated February 14, 1997, we expressed an
unqualified opinion on those consolidated financial statements. In our opinion,
the information set forth in the accompanying condensed consolidated balance
sheet as of December 31, 1996, is fairly stated in all material respects in
relation to the consolidated balance sheet from which it has been derived.
/s/ COOPERS & LYBRAND L.L.P.
COOPERS & LYBRAND L.L.P.
Minneapolis, Minnesota
April 30, 1997
IMATION CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
Three months ended March 31,
1997 1996
Net revenues .......................... $ 547.7 $ 576.1
Cost of goods sold .................... 348.7 373.8
Gross profit ......................... 199.0 202.3
Operating expenses:
Selling, general and administrative .. 133.0 130.7
Research and development ............. 37.8 47.9
Restructuring charges ................ -- 10.4
Total ............................. 170.8 189.0
Operating income ...................... 28.2 13.3
Other income and expense:
Interest expense ..................... 2.4 3.7
Other, net ........................... 4.0 (0.5)
Total ............................. 6.4 3.2
Income before tax and minority interest 21.8 10.1
Income tax provision .................. 9.8 4.1
Minority interest ..................... -- (0.1)
Net income ............................ $ 12.0 $ 6.1
Earnings per share .................... $ 0.30 $ 0.14
Weighted average shares outstanding ... 40.7 41.9
THE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ARE AN INTEGRAL PART
OF THESE STATEMENTS.
IMATION CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except share amounts)
March 31, December 31,
1997 1996
(Unaudited)
ASSETS:
Current Assets
Cash and equivalents ........................ $ 55.2 $ 61.7
Accounts receivable - net ................... 465.9 467.6
Inventories ................................. 407.5 392.8
Other current assets ........................ 85.1 94.5
Total current assets ..................... 1,013.7 1,016.6
Property, Plant and Equipment - net .......... 461.5 480.1
Other Assets ................................. 73.8 64.6
Total Assets ............................... $ 1,549.0 $ 1,561.3
LIABILITIES AND SHAREHOLDERS' EQUITY:
Current Liabilities
Accounts payable ............................ $ 179.8 $ 182.1
Accrued payroll ............................. 40.4 41.9
Income taxes payable ........................ 6.5 7.6
Short-term debt ............................. 24.3 26.5
Other current liabilities ................... 140.4 151.2
Total current liabilities ................ 391.4 409.3
Other Liabilities ............................ 96.4 98.6
Long-Term Debt ............................... 148.8 123.1
Commitments and Contingencies
Shareholders' Equity - net ................... 912.4 930.3
Shares issued:
March 31, 1997: 42,898,045
December 31, 1996: 42,879,880
Total Liabilities and Shareholders' Equity $ 1,549.0 $ 1,561.3
THE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ARE AN INTEGRAL PART
OF THESE STATEMENTS.
IMATION CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
Three months ended March 31,
1997 1996
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income .............................................. $ 12.0 $ 6.1
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation ........................................... 38.1 48.5
Deferred income taxes .................................. 3.7 6.1
Restructuring and other one-time charges................ -- 10.4
Working capital changes ................................ (38.0) 7.8
Other .................................................. 3.4 (9.2)
Net cash provided by operating activities ............... 19.2 69.7
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures ................................... (28.0) (40.7)
Capitalized software ................................... (11.2) --
Other .................................................. (1.0) 0.6
Net cash used in investing activities ................... (40.2) (40.1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net change in short-term debt .......................... (0.9) --
Borrowings of long-term debt ........................... 246.6 --
Repayment of long-term debt ............................ (220.6) --
Purchases of treasury shares ........................... (12.8) --
Decrease in unearned ESOP shares ....................... 2.8 --
Employee stock plans and other ......................... 0.1 --
Net cash paid to 3M .................................... -- (27.0)
Net cash provided by (used in) financing activities ..... 15.2 (27.0)
Effect of exchange rate changes on cash ................. (0.7) (2.6)
Net change in cash and equivalents ...................... (6.5) --
Cash and equivalents - beginning of period .............. 61.7 --
Cash and equivalents - end of period .................... $ 55.2 $ --
THE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS ARE AN INTEGRAL PART
OF THESE STATEMENTS.
IMATION CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. FINANCIAL STATEMENTS
Imation Corp. (the "Company") became an independent, publicly held
company as of July 1, 1996 (the "Distribution Date"), when Minnesota Mining and
Manufacturing ("3M") spun off its data storage and imaging businesses as an
independent, publicly held company (the "Distribution"). One share of the
Company's common stock was issued for every ten shares of 3M stock outstanding
to stockholders of record on June 18, 1996. 3M and the Company have entered into
a number of agreements to facilitate the transition of the Company to an
independent business enterprise. Descriptions of the various agreements are set
forth under the caption "Relationship Between 3M and the Company" contained in
the Company's 1996 Annual Report on Form 10-K filed with the Securities and
Exchange Commission.
The consolidated financial statements for periods prior to July 1, 1996
reflect the assets, liabilities, revenues, and expenses that were directly
related to the Company as it was operated within 3M. The Company's consolidated
statements of operations for periods prior to July 1, 1996 include all of the
related costs of doing business including an allocation of certain general
corporate expenses of 3M which were not directly related to these businesses,
including costs for corporate logistics, corporate research and development,
information technologies, finance, legal and corporate executives.
Management believes these allocations were made on a reasonable basis.
All material inter- company transactions and balances between the Company's
businesses have been eliminated. The financial information included herein for
periods prior to July 1, 1996 may not necessarily be indicative of the results
of operations or cash flows of the Company if it had been a separate,
independent company during the periods prior to July 1, 1996.
The interim consolidated financial statements are unaudited but, in the
opinion of management, reflect all adjustments necessary for a fair presentation
of financial position, results of operations and cash flows for the periods
presented. These adjustments, except for the restructuring charges recorded in
1996, consist of normal, recurring items. The results of operations for any
interim period are not necessarily indicative of results for the full year. The
consolidated financial statements and notes are presented as permitted by the
requirements of the Securities and Exchange Commission relating to quarterly
financial statements and do not contain certain information included in the
Company's annual consolidated financial statements and notes. These consolidated
financial statements and notes should be read in conjunction with the Company's
consolidated financial statements and notes included elsewhere in this Proxy
Statement/Prospectus.
2. SUPPLEMENTAL BALANCE SHEET INFORMATION
March 31, December 31,
1997 1996
(In millions)
(unaudited)
Inventories
Finished goods ....................... $ 270.2 $ 248.1
Work in process ...................... 57.4 57.3
Raw materials and supplies ........... 79.9 87.4
Total inventories ................. $ 407.5 $ 392.8
Property, Plant and Equipment
Property, plant and equipment ........ $ 1,700.8 $ 1,709.9
Less accumulated depreciation ........ (1,239.3) (1,229.8)
Property, plant and equipment - net $ 461.5 $ 480.1
Shareholders' Equity
Common stock ......................... $ 0.4 $ 0.4
Additional paid-in capital ........... 1,012.1 1,011.5
Retained earnings .................... 23.2 11.2
Unearned ESOP shares ................. (43.8) (46.6)
Cumulative translation adjustment .... (66.7) (46.2)
Treasury stock, at cost
March 31, 1997: 514,141 shares ... (12.8) --
Total shareholders' equity ........ $ 912.4 $ 930.3
3. COMMITMENTS AND CONTINGENCIES
The Company, in the ordinary course of its business, is the subject of
various pending or threatened legal actions. All such matters are subject to
many uncertainties and outcomes that are not predictable with assurance.
Consequently, the Company is unable to ascertain the ultimate aggregate amount
of monetary liability or financial impact with respect to these matters. While
these matters could materially affect operating results of any one quarter when
resolved in future periods, it is management's opinion that after final
disposition, any monetary liability or financial impact to the Company beyond
that provided in the condensed consolidated balance sheet would not be material
to the Company's financial position or annual results of operations or cash
flows.
4. MASTER LEASE AND SECURITY AGREEMENT
In March 1997, the Company entered into a Master Lease and Security
Agreement in connection with the construction of a new research and development
facility at the Company's headquarters site. Construction is expected to be
completed in June 1998, at which time the lease payments will commence. The
Company has the option to purchase the facility at the end of the lease term,
March 2002. In the event the Company chooses not to exercise this purchase
option, the Company is obligated to arrange for the sale of the facility and has
guaranteed the lessor a sale price of $58.5 million.
5. INTEREST RATE SWAP AGREEMENT
Effective March 25, 1997, the Company entered into an interest rate
swap agreement with a financial institution. The notional amount of the interest
rate swap agreement is $100 million with the Company paying fixed rate and
receiving variable rate. The agreement expires March 31, 2000. Net payments or
receipts under the agreement are recorded as adjustments to interest expense. As
of March 31, 1997, the effective interest rate on the $146.0 million in debt
outstanding under the Company's revolving credit facility was 6.42%, including
the effect of the interest rate swap agreement.
6. EARNINGS PER SHARE
The number of weighted average shares outstanding used in the
computation of earnings per share (EPS) for the first quarter of 1996 is equal
to one-tenth the weighted average number of 3M shares outstanding based on the
distribution ratio of one share of Imation Corp. for every ten shares of 3M
pursuant to the spin-off on July 1, 1996.
In February 1997, the Financial Accounting Standards Board issued
Statement No. 128, "Earnings Per Share". This statement establishes standards
for computing and presenting basic and diluted earnings per share for financial
statements issued for periods ending after December 15, 1997. The adoption of
this statement is not expected to have a material effect on the Company's
reported EPS.
*****
Coopers & Lybrand L.L.P., the Company's independent accountants, have
performed a review of the unaudited interim consolidated financial statements
included herein and their report thereon accompanies this filing.
REPORT OF INDEPENDENT AUDITORS
The Board of Directors and Stockholders
Cemax-Icon, Inc.
We have audited the accompanying balance sheets of Cemax-Icon, Inc. as
of December 31, 1996 and 1995, and the related statements of operations,
stockholders' equity (net capital deficiency) and cash flows for each of the
three years in the period ended December 31, 1996. These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of Cemax-Icon, Inc. at
December 31, 1996 and 1995, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 1996 in conformity
with generally accepted accounting principles.
/s/ ERNST & YOUNG LLP
ERNST & YOUNG LLP
Palo Alto, California
March 12, 1997
CEMAX-ICON, INC.
STATEMENTS OF OPERATIONS
(In thousands)
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
<S> <C> <C> <C>
Revenues:
Product revenues, including sales to Imation $ 21,841 $ 15,059 $ 15,017
Service revenues ........................... 3,307 1,971 1,440
Total revenues .............................. 25,148 17,030 16,457
Costs of revenues:
Cost of product revenues ................... 10,054 7,793 7,165
Cost of service revenues ................... 4,366 2,719 1,638
Total cost of revenues ...................... 14,420 10,512 8,803
Gross profit ................................ 10,728 6,518 7,654
Operating expenses:
Research and development ................... 6,481 6,501 4,134
Sales, general and administrative .......... 7,178 6,235 6,010
Merger related expense ..................... -- 624 --
Total operating expenses .................... 13,659 13,360 10,144
Loss from operations ........................ (2,931) (6,842) (2,490)
Interest and other income (expense), net .... (125) 27 (88)
Net loss .................................... $ (3,056) $ (6,815) $ (2,578)
Net loss per share .......................... $ (0.59) $ (1.75) $ (1.10)
Shares used in calculating
net loss per share ......................... 5,181 3,895 2,347
</TABLE>
SEE ACCOMPANYING NOTES.
CEMAX-ICON, INC.
BALANCE SHEETS
(In thousands, except share data)
<TABLE>
<CAPTION>
As of December 31,
1996 1995
<S> <C> <C>
ASSETS:
Current assets
Cash and cash equivalents ................................... $ 6,302 $ 1,775
Accounts receivable, less allowance for doubtful accounts
of $1,230 in 1996 and $773 in 1995 ....................... 5,540 3,510
Note receivable-related party ............................... -- 300
Inventories ................................................. 2,945 2,005
Other current assets ........................................ 156 177
Total current assets ......................................... 14,943 7,767
Property and equipment, net .................................. 1,765 1,512
$ 16,708 $ 9,279
LIABILITIES AND STOCKHOLDERS' EQUITY (NET CAPITAL DEFICIENCY):
Current liabilities
Accounts payable ............................................ $ 3,699 $ 2,479
Accrued compensation ........................................ 1,113 796
Other accrued liabilities ................................... 1,799 699
Sales tax accrual ........................................... 567 600
Deferred revenue ............................................ 4,019 3,520
Equipment financing, current portion ........................ 292 211
Total current liabilities .................................... 11,489 8,305
Accrued rent ................................................. 44 53
Equipment financing, less current portion .................... 575 551
Convertible note payable ..................................... 5,000 --
Commitments
Stockholders' equity (net capital deficiency):
Convertible preferred stock, $0.001 par value:
30,000,000 shares authorized, issuable in series:
2,521,733 and 1,985,878 shares designated series A,
issued and outstanding as of December 31, 1996
and 1995, respectively, aggregate liquidation
preference of $10,087 at December 31, 1996 ............. 3 2
Common stock, $0.001 par value:
50,000,000 shares authorized: 5,362,595 and 4,877,325
shares issued and outstanding at December 31, 1996
and 1995, respectively ................................. 5 5
Additional paid-in capital ................................ 34,599 31,944
Notes receivable from stockholders ........................ (370) --
Accumulated deficit ....................................... (34,637) (31,581)
Total stockholders' equity (net capital deficiency) .......... (400) 370
$ 16,708 $ 9,279
</TABLE>
SEE ACCOMPANYING NOTES.
CEMAX-ICON, INC.
STATEMENTS OF STOCKHOLDERS' EQUITY (NET CAPITAL DEFICIENCY)
FOR THE YEARS ENDED DECEMBER 31, 1996, 1995 AND 1994
(In thousands, except share data)
<TABLE>
<CAPTION>
Total
Notes Stock-
Receivables holders'
Additional From Equity (Net
Preferred Stock Common Stock Paid-In Stock- Accumulated Capital
Shares Amount Shares Amount Capital holders Deficit (Deficiency)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balances at December 31, 1993 ........ 10,341,460 $ 10 2,221,719 $ 2 $ 23,274 $-- $(22,188) $ 1,098
Issuance of Series D preferred stock
in June 1994 for cancellation of
subordinated convertible notes
with principal of $1,464 and
accrued interest of $36, net of
issuance costs ($9) ............... 500,048 1 -- -- 1,490 -- -- 1,491
Issuance of common stock for cash
and conversion of notes payable ... -- -- 20,053 -- 150 -- -- 150
Issuance of common stock upon
the exercise of stock options ..... -- -- 286,142 1 73 -- -- 74
Net loss ........................... -- -- -- -- -- -- (2,578) (2,578)
Balances at December 31, 1994 ........ 10,841,508 $ 11 2,527,914 $ 3 $ 24,987 $-- $(24,766) $ 235
Conversion of Series A, B,
C and D preferred stock in
June 1995 to common stock ......... (10,841,508) (11) 2,305,907 2 9 -- -- --
Issuance of Series A preferred
stock in June of 1995 for cash
investment and conversion of
bridge note, net of issuance
costs ($13) ....................... 1,985,878 2 -- -- 6,930 -- -- 6,932
Issuance of common stock upon the
exercise of stock options ......... -- -- 43,504 -- 18 -- -- 18
Net loss ........................... -- -- -- -- -- -- (6,815) (6,815)
Balances at December 31, 1995 ........ 1,985,878 $ 2 4,877,325 $ 5 $ 31,944 $-- $(31,581) $ 370
Issuance of Series A preferred
stock upon exercise of warrant
by Imation, net of issuance costs . 535,855 1 -- -- 2,113 -- -- 2,114
Issuance of common stock upon the
exercise of stock options and
warrants .......................... -- -- 485,270 -- 542 (370) -- 172
Net loss ........................... -- -- -- -- -- -- (3,056) (3,056)
Balances at December 31, 1996 ........ 2,521,733 $ 3 5,362,595 $ 5 $ 34,599 $(370) $(34,637) $ (400)
</TABLE>
SEE ACCOMPANYING NOTES.
CEMAX-ICON, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
CASH FLOWS FROM OPERATING ACTIVITIES:
<S> <C> <C> <C>
Net loss ................................................... $(3,056) $(6,815) $(2,578)
Adjustments to reconcile net loss to net cash (used in)
provided by operating activities:
Depreciation and amortization ........................... 827 662 761
Loss on disposal and retirement of property and equipment -- 342 --
Changes in assets and liabilities:
Accounts receivable .................................. (2,030) (1,784) (429)
Note receivable-related party ........................ 300 (300) --
Inventories .......................................... (940) (550) (424)
Other current assets ................................. 21 18 (79)
Accounts payable ..................................... 1,220 597 960
Accrued compensation ................................. 317 329 215
Other accrued liabilities ............................ 1,058 127 1,086
Deferred revenue ..................................... 499 1,519 1,277
Net cash (used in) provided by operating activities ........ (1,784) (5,855) 789
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment ...................... (1,084) (1,376) (913)
Proceeds from sale of property and equipment ............... 4 -- --
Net cash used in investing activities ...................... (1,080) (1,376) (913)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from equipment financing .......................... 341 575 250
Repayment of equipment financing ........................... (236) (708) (206)
Net proceeds from revolving line of credit ................. -- (314) 232
Proceeds from note payable ................................. 5,000 -- 300
Proceeds from issuance of preferred stock .................. 2,114 6,932 --
Proceeds from issuance of common stock ..................... 172 18 74
Net cash provided by financing activities .................. 7,391 6,503 650
Net increase (decrease) in cash and cash equivalents ....... 4,527 (728) 526
Cash and cash equivalents at beginning of year ............. 1,775 2,503 1,977
Cash and cash equivalents at end of year ................... $ 6,302 $ 1,775 $ 2,503
</TABLE>
SEE ACCOMPANYING NOTES.
CEMAX-ICON, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
<TABLE>
<CAPTION>
Year Ended December 31,
1996 1995 1994
<S> <C> <C> <C>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid ...................................................... $ 218 $ 114 $ 46
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock in exchange
for notes receivable .............................. $ 370 $ -- $ --
Conversion of Series A, B, C and D preferred stock
into common stock ................................. $ -- $7,749 $ --
Property and equipment acquired under capital leases ............... $ -- $ -- $ 16
Conversion of subordination convertible notes
and accrued interest into Series D preferred
stock, net of issuance costs ...................... $ -- $ -- $1,491
Issuance of common stock for conversion of
note payable ...................................... $ -- $ -- $ 150
</TABLE>
SEE ACCOMPANYING NOTES.
CEMAX-ICON, INC.
NOTES TO FINANCIAL STATEMENTS
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND DESCRIPTION OF BUSINESS
Cemax-Icon, Inc. (the "Company"), formerly Cemax, Inc. and ICON Medical
Systems, Inc., designs, manufactures and markets picture archiving and
communication systems ("PACS") and teleradiology systems which are used
primarily by medical imaging providers and users. The Company's software
products provide image management solutions using advanced technology to assist
radiology departments reduce operating expenses and improve efficiency. The
Company markets its medical imaging software to both Other Equipment
Manufacturers ("OEMs") and end users.
In March 1997, the Company signed a letter of intent to merge with
Imation Corporation, a related party and a customer. Under the proposed terms of
the agreement, holders of Cemax-Icon common stock outstanding at the time of
merger will be entitled to receive cash consideration in the amount not to
exceed $13.75 per share payable in cash or shares of Imation common stock
payable over two years from the date of merger. The portion of the purchase
price payable after the one and two year anniversary dates of the agreement is
subject to reduction if certain levels of revenue as defined, are not met.
Additionally, holders of options and warrants to purchase Cemax-Icon common
stock will be able to convert their options and warrants into options and
warrants of Imation based on the specified exchange ratio. According to the
terms of the Company's convertible note payable (see Note 2), on the sale or
merger of the Company, the note holder has the option to require repayment of
the convertible note.
REVERSE STOCK SPLIT
On June 13, 1996, the Board of Directors of the Company authorized a
reverse stock split in which each 2.35 shares of common stock were split into
one share of common stock. All the share and per share data in the accompanying
financial statements have been adjusted retroactively to give effect to the
reverse stock split.
BUSINESS COMBINATION
On June 14, 1995, Cemax, Inc. ("Cemax") completed its merger with ICON
Medical Systems, Inc. ("ICON"), a teleradiology company located in Campbell,
California. In accordance with the agreement, the exchange ratio for each share
of ICON common stock and common stock option was 0.271 of a share of Cemax
common stock and common stock option, respectively (total of 1,879,157 shares of
Cemax common stock and 323,211 options to purchase Cemax common stock). In
conjunction with the offering, 10,841,508 shares of Cemax preferred stock
converted to 2,305,907 shares of common stock. The merger was accounted for as a
pooling of interests and, accordingly, the recorded book values of the assets
and liabilities and prior operating results are combined retroactively.
The Company incurred costs in connection with the merger and
consolidation of operations. Included in the accompanying statements of
operations for the year ended December 31, 1995 are merger related expenses of
$624,000, consisting primarily of charges for transaction and professional fees,
personnel severance costs, and elimination of duplicate facilities.
Results of operations for the periods ending December 31, 1995 and 1994
are as follows (in thousands):
<TABLE>
<CAPTION>
Merger
Cemax- Related
Icon Cemax Icon Expenses Combined
<S> <C> <C> <C> <C> <C>
Year ended December 31, 1995
Net revenues ............... $ 9,510(1) $ 4,178(2) $ 3,342 (2) $ -- $ 17,030
Net loss ................... $ (4,388)(1) $ (316)(2) $ (1,487)(2) $ (624) $ (6,815)
Year ended December 31, 1994
Net revenues ............... $ -- $ 8,711 $ 7,746 $ -- $ 16,457
Net income (loss) .......... $ -- $ 34 $ (2,612) $ -- $ (2,578)
</TABLE>
(1) For the periods June 1, 1995 through December 31, 1995.
(2) For periods January 1, 1995 through May 31, 1995.
USE OF ESTIMATES
The preparation of the financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS
Cash and cash equivalents are held in United States banks. Cash
equivalents consist of financial investments with original maturities of 90 days
or less at time of acquisition that are readily convertible into cash and have
insignificant interest rate risk.
The Company classifies its investments as available-for-sale. As of
December 31, 1996, and 1995, the Company's investments consisted of money market
funds. Investments are recorded at market value. In 1996, the Company did not
realize any material gains or losses on its investments. There was no difference
between cost and market value at December 31, 1996.
INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out
method) or market. Inventories at December 31, 1996 and 1995 consist of the
following:
1996 1995
(In thousands)
Raw materials ................................. $1,572 $ 522
Finished goods, service and marketing inventory 1,373 1,483
$2,945 $2,005
PROPERTY AND EQUIPMENT
Property and equipment are stated at cost. Depreciation is computed on
the straight-line method using useful lives of three to five years.
Property and equipment at December 31, 1996 and 1995 are as follows:
1996 1995
(In thousands)
Machinery and equipment ...................... $ 165 $ 569
Computer equipment ........................... 2,901 3,680
Furniture and fixtures ....................... 57 96
Leasehold improvements ....................... 152 95
3,275 4,440
Less accumulated depreciation and amortization (1,510) (2,928)
$ 1,765 $ 1,512
REVENUE RECOGNITION
Product revenues are derived from system sales, software licenses, and
development contracts. Systems and licensing revenue is generated from software
licenses that grant the right to use the Company's software modules and hardware
products which are typically sold in conjunction with the Company's systems. In
addition to the software license typically sold as part of a system, the Company
generates revenue from sales of software licenses to its OEMs.
Service and maintenance revenue is generated from installation,
training, documentation, maintenance and support services. Fees for such
services are generally charged separately from the Company's software license
fees.
Revenue from systems sales is recognized upon delivery of the system,
which typically occurs from one to six months after execution of a contract,
depending on the size and complexity of the system if no significant vendor
obligations remain and collection of the resulting receivable is probable.
Revenue from software licenses sold to OEMs is recognized upon shipment, or upon
completion of specific milestones. Service and maintenance contract revenue is
recognized ratably over the service period, generally twelve months.
SOFTWARE DEVELOPMENT COSTS
Statement of Financial Accounting Standard No. 86, "Accounting for the
Costs of Computer Software to be Sold, Leased or Otherwise Marketed," requires
capitalization of certain software development costs subsequent to the
establishment of technological feasibility. Based on the Company's product
development process, technological feasibility is established upon completion of
a working model. Costs incurred by the Company between completion of the working
model and the point at which the product is ready for general release have been
insignificant.
NET LOSS PER SHARE
Net loss per share is computed using the weighted average number of
shares of common stock outstanding. Common stock equivalent shares from
convertible preferred stock, stock options and warrants are not included as
their effect is anti-dilutive.
CONCENTRATION OF CREDIT RISK
The Company sells its processing workstations and software to customers
in the medical and health care industries primarily in North America. The
Company performs ongoing credit evaluations of its customers and generally does
not require collateral. The Company maintains reserves for potential credit
losses and such losses have been within management's expectations. One customer
accounted for 15% of total revenues in 1996, one customer accounted for 13% of
total revenues in 1995 and one customer accounted for 10% of total revenues in
1994. One customer accounted for 19% of total accounts receivable at December
31, 1996. The Company also derives revenues from the sale of its product to
customers in foreign geographic areas, including Europe and Asia. Revenue from
export sales was $6.0 million, $2.8 million and $3.6 million for the years ended
December 31, 1996, 1995 and 1994, respectively.
STOCK-BASED COMPENSATION
As permitted under Financial Accounting Standards Board Statement No.
123, "Accounting for Stock-Based Compensation" ("FASB 123"), the Company has
elected to follow Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees" ("APB 25") in accounting for stock- based awards to
employees.
Under APB 25, the Company generally recognizes no compensation expense
with respect to such awards. However, FASB 123 requires estimation of the fair
value of options granted and related disclosures, if material. The Company has
utilized the minimum value method for estimating the fair value of options
granted. The minimum value method is similar to the Black-Scholes option
valuation model except that it excludes the factor for volatility. The
Black-Scholes Model was developed for use in estimating the fair value of
publicly traded options which have no vesting restrictions and are fully
transferable.
Because the Company's employee stock options have characteristics
significantly different from those of traded options, and because changes in the
subjective input assumptions can materially affect the fair value estimate, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options. The effect of
applying the minimum value method for estimating the fair value of the Company's
stock option grants did not result in pro forma net loss that is materially
different from historical amounts reported. Therefore, such pro forma disclosure
information is not separately presented herein. Future pro forma net income
(loss) and net income (loss) per share results may be materially different from
actual amounts reported. The fair value of each option is estimated on the date
of grant using the minimum value method with the following assumptions: no
dividends, an expected life of four years and a risk-free rate of 6% for the
year ended December 31, 1996, and 1995. The weighted average value of options
granted during 1995 and 1996 was $0.31 and $1.09 respectively.
TRANSACTIONS WITH IMATION CORP.
In June 1995, the Company sold 1,985,878 shares of its Series A
Preferred Stock to Imation and issued to Imation a warrant exercisable for
467,267 shares of Common Stock of the Company at an exercise price of $5.50 per
share. In May 1996, the Company and Imation agreed to amend the warrant to
reduce the exercise price to $4.25 per share and to provide that the warrant
would be exercisable for 535,855 shares of Series A Preferred Stock. In
addition, Imation agreed to exercise the warrant in full prior to September 30,
1996. The exercise occurred in September 1996.
In addition to the sale of the Series A Preferred Stock and the
issuance of the warrant to Imation, the Company and Imation entered into a sales
agreement having a term of three years providing for the Company to assume
service and warranty obligations of Imation with regard to 17 PACS customer
sites in exchange for the payment by Imation to the Company of approximately $
1.0 million and for Imation to refer customer leads to the Company from sales to
such customers. The Company recorded product and service revenues of $3,852,000
from Imation during 1996 and had accounts receivable of $240,000 from Imation as
of December 31, 1996.
2. CONVERTIBLE NOTE PAYABLE
In September 1996, the Company issued a $5 million convertible note
payable to Dominion Fund IV. The note payable bears interest at 11% per annum
through September 30, 1998 and at 12% thereafter until paid or converted.
Interest is payable monthly. The principal of the note is repayable in ten equal
quarterly installments of $500,000 beginning June 30, 1998. The note is
repayable earlier, in whole or in part, upon the occurrence of an initial public
offering which results in gross proceeds of at least $25 million. Should the
Company complete such a transaction which results in gross proceeds of less than
$25 million, then the Company shall be obligated to make a payment on the
remaining outstanding balance of the note and accrued interest of up to 20% of
the gross proceeds received in such offering. The note holder also has the
option to require repayment of the note, in whole or in part, in the event of a
sale of the Company or substantially all of its assets, or a merger in which the
stockholders of the Company control less than a majority of the merged entity.
The note is secured by substantially all assets of the Company.
Up to $2.5 million of the note may be converted to common stock at the
option of the holder on or after the earlier of April 15, 1998 or the closing of
an initial public offering. If the initial public offering occurs prior to April
15, 1998, the conversion price shall be equal to the price per share paid in the
initial public offering. If the initial public offering occurs after April 15,
1998, or does not occur, then the conversion price shall be equal to the lesser
of $10 per share or the price per share paid in the initial public offering. The
fair value of the convertible note payable at December 31, 1996, approximated
the carrying value based on the Company's current incremental borrowing rate for
similar types of borrowing arrangements.
In connection with the note payable, the Company issued warrants to
acquire up to $1.5 million of common stock at either $8 or $10 per share,
depending on the occurrence and timing of specific events. The warrants expire
in October 2001. The Company believes that the value of the warrants at the date
of their issuance was not material, and no value has been attributed to them in
these financial statements.
3. EQUIPMENT FINANCING AND RENTAL COMMITMENTS
In October 1996, the Company established an equipment purchase line of
credit for $341,000. Borrowings bear interest at 14.05% per annum and are
secured by property and equipment. During 1995, the Company borrowed $575,000 on
a bank equipment purchase line of credit. Borrowings bear interest at 12.16% per
annum and are secured by property and equipment. During 1994, the Company
borrowed $250,000 on a bank equipment purchase line of credit. Borrowings bear
interest at prime plus 1.5% and are secured by property and equipment. The fair
value of these borrowings at December 31, 1996, approximated the carrying value,
based on the Company's current incremental borrowing rates for similar types of
borrowing arrangements.
The Company leases facilities and equipment under noncancelable
operating leases. As of December 31, 1996, future minimum lease commitments
under operating leases and equipment purchase lines of credit are as follows:
Equipment and
Operating Purchase Lines
Leases of Credit
(In thousands)
Year ended December 31,
1997 ....................................... $ 194 $ 385
1998 ....................................... 169 298
1999 ....................................... -- 287
2000 ....................................... -- 81
Total minimum payments required ................. $ 363 $1,051
Less amount representing interest ............... (184)
Present value of minimum lease payment .......... 867
Less current portion of capital lease obligations (292)
Long-term portion of capital lease obligations .. $ 575
Rent expense for operating leases was approximately $229,000, $267,500
and $350,000 in 1996, 1995 and 1994, respectively.
4. NOTES RECEIVABLE FROM STOCKHOLDERS
During the year ended December 31, 1995, the Company made a loan
totaling $300,000 to an officer of the Company. Principal plus accrued interest
(at prime plus 1 %) was repaid in December 1996. Additionally, the Company has
recorded stockholder notes receivable for amounts loaned to employees used to
purchase shares pursuant to stock options. These amounts have been recorded as a
separate component of stockholders equity in the accompanying balance sheets.
5. INCOME TAXES
As of December 31, 1996, the Company had net operating loss and
research and development credit carryforwards of approximately $23,000,000. The
net operating loss and credit carryforwards will expire at various dates
beginning in 1997 through 2011, if not utilized.
Utilization of the net operating losses and credits will be subject to
a substantial limitation due to the ownership change provisions of the Internal
Revenue Code of 1986. Because of an ownership change in 1995, a substantial
amount of the Company's net operating losses and credits will expire before
being utilized.
As of December 31, 1996 and December 31, 1995, the Company had deferred
tax assets of approximately $5,400,000 and $5,300,000 respectively. The net
deferred tax asset has been fully offset by a valuation allowance. Deferred tax
assets relate primarily to net operating loss carryforwards, research credits
and capitalized research and development costs.
6. PREFERRED STOCK
Series A preferred stock entitles the holder to receive noncumulative
dividends of $0.32 per share if declared by the board of directors. The Series A
preferred stock is convertible at the option of the holder, or automatically
upon a public offering with aggregate proceeds greater than $5,000,000 at the
rate of one share of common stock for each 2.35 shares of preferred stock
(subject to antidilution provisions). The holders of these shares are entitled
to one vote for each share of common stock into which such shares can be
converted. The terms of the preferred stock purchase also limit the number of
future shares which may be granted as incentive options or stock purchase rights
to 500,000 shares.
At any time after January 1, 2000, the Company may redeem, at the
option of the board of directors, all outstanding shares of Series A preferred
stock at the redemption price of $4.00 per share plus any declared and unpaid
dividends. Upon liquidation of the Company, Series A preferred stockholders
shall have a liquidation preference of $4.00 per share plus all declared but
unpaid dividends. If the assets and funds of the Company are insufficient to pay
the preferential amounts in full, such assets and funds shall be distributed to
the holders of preferred stock in proportion to the full amount to which each
holder is entitled. After such payments, the holders of common shares are
entitled to receive all remaining assets of the Company.
7. STOCK OPTION AND EMPLOYEE INCENTIVE PLANS
In 1986, the Company established the 1986 Amended Incentive Stock Plan.
As amended there are 1,276,596 shares of common stock reserved for issuance
under this plan.
In June 1996, the Board of Directors of the Company adopted the 1996
Stock Plan which authorized the issuance of 700,000 shares of common stock, the
1996 Employee Stock Purchase Plan which authorized the issuance of 150,000
shares of common stock and the 1996 Director Option Plan which authorized the
issuance of 100,000 shares of common stock.
Options, which may be either incentive stock options or nonstatutory
stock options, may be granted at prices greater than or equal to the fair value
of the stock on the date of grant, as determined by the board of directors.
Generally options may be exercised at any time, vest over four years and expire
five to ten years from the date of grant.
Stock option activity is summarized below:
<TABLE>
<CAPTION>
Weighted
Shares Average Aggregate
Incentive Nonstatutory Exercise Exercise
Options Options Price Price
<S> <C> <C> <C> <C>
Options outstanding at
December 31, 1993 889,197 53,540 $ 0.98 $ 921,803
Granted .............. 241,884 14,681 0.58 137,208
Exercised ............ (263,389) (22,752) 0.41 (117,318)
Canceled ............. (141,096) (1,595) 0.66 (94,176)
Options outstanding at
December 31, 1994 726,596 43,874 $ 1.10 $ 847,517
Granted .............. 393,034 -- 1.62 636,715
Exercised ............ (39,249) (4,255) 0.39 (16,967)
Canceled ............. (79,411) -- 4.05 (321,615)
Options outstanding at
December 31, 1995 1,000,970 39,619 $ 1.10 $ 1,145,650
Granted .............. 578,815 -- 5.10 2,951,957
Exercised ............ (473,674) (4,000) 0.96 (458,567)
Canceled ............. (55,011) -- 1.74 (95,719)
Options outstanding at
December 31, 1996 1,051,100 35,619 $ 3.23 $ 3,543,321
</TABLE>
At December 31, 1996 and 1995, 377,986 and 541,947, respectively, of
the outstanding options to purchase common stock were exercisable. Options
exercised prior to the vesting date are subject to stock purchase agreements
that allow the Company to repurchase, at the original issuance price, unvested
shares upon termination of employment. As of December 31, 1996 and 1995, 152,479
and 38,283 shares, respectively, were subject to this repurchase provision at
the original price ($0.35 - $1.41 per share). Vesting of such shares is
generally ratable over a four-year period, as determined by the board of
directors.
The following table summarizes information about options outstanding at
December 31, 1996:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
----------------------------------------------------------------- --------------------------------
Weighted
Average Weighted Weighted
Range of Number Remaining Average Number Average
Exercise Outstanding Contractual Exercise Exercisable Exercise
Price at 12/31/96 Life Price at 12/31/96 Price
<S> <C> <C> <C> <C> <C>
$ 0.35 - 0.71 180,608 6.46 $ 0.41 141,365 $ 0.39
$ 1.06 - 1.76 341,141 7.18 $ 1.43 223,704 $ 1.44
$ 5.00 - 11.75 564,970 9.84 $ 5.22 12,917 $ 6.71
$ 0.35 - 11.75 1,086,719 8.44 $ 3.23 377,986 $ 1.23
</TABLE>
CEMAX-ICON, INC.
STATEMENTS OF OPERATIONS
(In thousands, unaudited)
Three Months Ended
March 31,
1997 1996
Revenues:
Product revenues ................ $ 6,554 $ 4,048
Service revenues ................ 729 770
Total revenues ............... 7,283 4,818
Cost of revenues:
Cost of product revenues ........ 3,436 1,698
Cost of service revenues ........ 1,404 807
Total cost of revenues ....... 4,840 2,505
Gross profit .................... 2,443 2,313
Operating expenses:
Research and development ........ 1,642 1,622
Sales, general and administrative 1,693 1,507
Total operating expenses ..... 3,335 3,129
Loss from operations ............ (892) (816)
Interest income ................. 52 20
Interest expense ................ (162) (23)
Other income (expense) .......... 33 --
(77) (3)
Income (loss) before taxes ...... (969) (819)
Income taxes .................... -- --
Net loss ..................... $ (969) $ (819)
Net loss per share .............. $ (0.18) $(0.17)
Shares used in calculating
net loss per share ............. 5,367 4,896
SEE ACCOMPANYING NOTES.
<TABLE>
<CAPTION>
CEMAX-ICON, INC.
BALANCE SHEETS
(In thousands)
March 31, December 31,
1997 1996
(Unaudited)
<S> <C> <C>
ASSETS:
Cash and cash equivalents .................................... $ 3,283 $ 6,302
Accounts receivable, net ..................................... 8,059 5,540
Inventories .................................................. 3,333 2,945
Other current assets ......................................... 180 156
Total current assets ...................................... 14,855 14,943
Property and equipment, net .................................. 1,921 1,765
$ 16,776 $ 16,708
LIABILITIES AND STOCKHOLDERS' EQUITY (NET CAPITAL DEFICIENCY):
Accounts payable ............................................. $ 4,163 $ 3,699
Accrued compensation ......................................... 1,286 1,113
Other accrued liabilities .................................... 1,946 1,799
Sales tax accrual ............................................ 567 567
Deferred revenue ............................................. 4,340 4,019
Equipment financing, current portion ......................... 278 292
Total current liabilities ................................. 12,580 11,489
Accrued rent ................................................. 39 44
Equipment financing, less current portion .................... 523 575
Convertible note payable ..................................... 5,000 5,000
Commitments
Stockholders' equity (net capital deficiency):
Preferred stock .............................................. 2 3
Common stock ................................................. 6 5
Note receivable from stockholder ............................. (373) (370)
Additional paid-in capital ................................... 34,605 34,599
Accumulated deficit .......................................... (35,606) (34,637)
Total stockholders' equity (net capital deficiency) ....... (1,366) (400)
$ 16,776 $ 16,708
</TABLE>
SEE ACCOMPANYING NOTES.
<TABLE>
<CAPTION>
CEMAX-ICON, INC.
STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
Three Months Ended
March 31,
1997 1996
<S> <C> <C>
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss ................................................. $ (969) $ (819)
Adjustments to reconcile net loss to net cash (used in)
provided by operating activities:
Depreciation and amortization ......................... 262 186
Changes in assets and liabilities:
Accounts receivable ................................. (2,519) 273
Note receivable-related party ....................... 3 (42)
Inventories ......................................... (388) (291)
Other current assets ................................ (24) 16
Accounts payable .................................... 464 (334)
Accrued compensation ................................ 173 273
Other accrued liabilities ........................... 141 351
Deferred revenue .................................... 321 466
Net cash (used in) provided by operating activities $(2,536) $ 79
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment .................... (418) (182)
Net cash used in investing activities: .............. $ (418) (182)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from equipment financing ........................ -- --
Repayment of equipment financing ......................... (65) (54)
Proceeds from note payable ............................... -- --
Proceeds from issuance of preferred stock ................ -- --
Proceeds from issuance of common stock ................... -- 36
Net cash used in financing activities ............... $ (65) $ (18)
Net decrease in cash and cash equivalents ............. (3,019) (121)
Cash and cash equivalents at beginning of period ...... 6,302 1,777
Cash and cash equivalents at end of period ............ $ 3,283 $ 1,656
</TABLE>
SEE ACCOMPANYING NOTES.
CEMAX-ICON, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The accompanying financial information is unaudited, but, in the
opinion of management, reflects all adjustments (which include only normally
recurring adjustments) necessary for a fair presentation of the Company's
financial position, operating results and cash flows for those periods
presented. Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to the rules and regulations
of the Securities and Exchange Commission. The financial information should be
read in conjunction with the audited financial statements and notes thereto
included elsewhere herein. The accompanying balance sheet at December 31, 1996
is derived from audited financial statements at that date. Results for the
interim period are not necessarily indicative of results for the entire year.
2. NET LOSS PER SHARE
Net loss per share is computed using the weighted average number of
shares of common stock outstanding. Common stock equivalent shares from
convertible preferred stock, stock options and warrants are not included as
their effect is anti-dilutive.
3. INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out
method) or market. Inventories at March 31, 1997 and December 31, 1996 consist
of the following:
March 31, December 31,
1997 1996
Raw Materials .................................. $2,045 $1,572
Finished goods, services and marketing inventory $1,288 $1,373
$3,333 $2,945
EXHIBIT A
AGREEMENT AND PLAN OF MERGER
by and among
IMATION CORP.,
CI ACQUISITION CORP.
AND
CEMAX-ICON, INC.
May 13, 1997
TABLE OF CONTENTS
ARTICLE I - THE MERGER ................................................ 1
1.01 The Merger ................................................... 1
1.02 Effect of Merger. ............................................ 1
1.03 Effective Time ............................................... 2
1.04 Directors and Officers ....................................... 2
1.05 Certificate of Incorporation; Bylaws ......................... 2
1.06 Taking of Necessary Action; Further Action ................... 2
1.07 The Closing .................................................. 3
ARTICLE II - MERGER CONSIDERATION/EFFECT ON CAPITAL STOCK ............. 3
2.01 Effect on Securities ......................................... 3
2.02 Dissenting Shares ............................................ 5
2.03 Payment of Consideration for Company Capital Stock ........... 6
2.04 Stock Transfer Books ......................................... 7
ARTICLE III - REPRESENTATIONS AND WARRANTIES OF THE
COMPANY .................................................... 7
3.01 Incorporation and Corporate Power ............................ 7
3.02 Execution, Delivery; Valid and Binding Agreement ............. 8
3.03 Approval of Agreement; Meeting of Stockholders ............... 8
3.04 No Breach .................................................... 8
3.05 Governmental Authorities; Consents ........................... 8
3.06 Subsidiaries; Predecessors ................................... 9
3.07 Capital Stock ................................................ 11
3.08 Financial Statements ......................................... 12
3.09 Absence of Undisclosed Liabilities ........................... 13
3.10 No Material Adverse Changes .................................. 14
3.11 Absence of Certain Developments. ............................. 14
3.12 Title to Properties .......................................... 17
3.13 Accounts Receivable .......................................... 18
3.14 Inventory .................................................... 18
3.15 Tax Matters .................................................. 18
3.16 Contracts and Commitments .................................... 21
3.17 Intellectual Property Rights ................................. 23
3.18 Litigation ................................................... 25
3.19 Warranties; Products ......................................... 25
3.20 Employees .................................................... 25
3.21 Employee Benefit Plans ....................................... 26
3.22 Insurance .................................................... 29
3.23 Affiliate Transactions ....................................... 29
3.24 Customers and Suppliers ...................................... 30
3.25 Officers and Directors; Bank Accounts ........................ 30
3.26 Compliance with Laws; Permits ................................ 30
3.27 Environmental Matters ........................................ 31
3.28 Brokerage .................................................... 33
3.29 Disclosure ................................................... 33
ARTICLE IV - REPRESENTATIONS AND WARRANTIES OF PARENT AND
MERGER SUBSIDIARY ......................................... 34
4.01 Incorporation and Corporate Power ............................ 34
4.02 Execution, Delivery; Valid and Binding Agreement ............. 34
4.03 No Breach .................................................... 34
4.04 Merger Subsidiary ............................................ 35
4.05 Governmental Authorities; Consents ........................... 35
4.06 Brokerage .................................................... 35
ARTICLE V - COVENANTS OF THE COMPANY .................................. 36
5.01 Conduct of the Business ...................................... 36
5.02 Access to Books and Records .................................. 39
5.03 Meeting of Stockholders ...................................... 39
5.04 Regulatory Filings ........................................... 39
5.05 Registration Statement ....................................... 40
5.06 Financial Statements ......................................... 40
5.07 Conditions ................................................... 40
5.08 No Negotiations .............................................. 41
5.09 Substitute Options and Warrants .............................. 41
ARTICLE VI - COVENANTS OF PARENT AND MERGER SUBSIDIARY ................ 41
6.01 Regulatory Filings ........................................... 41
6.02 Conditions ................................................... 42
6.03 Registration Statement ....................................... 42
6.04 Stock Exchange Listings ...................................... 42
6.05 Due Authorization, etc. of Stock Issued in Merger ............ 43
6.06 Blue Sky Approvals ........................................... 43
6.07 Substitute Options Registration Statement .................... 43
6.08 Operation of the Business .................................... 43
6.09 Employee Benefit Plans ....................................... 43
ARTICLE VII - CONDITIONS TO CLOSING ................................... 44
7.01 Conditions to Parent's and Merger Subsidiary's Obligations ... 44
7.02 Conditions to the Company's and the Stockholders' Obligations 47
ARTICLE VIII - TERMINATION ............................................ 50
8.01 Termination .................................................. 50
8.02 Effect of Termination ........................................ 51
8.03 Termination Fees ............................................. 51
ARTICLE IX - THE STOCKHOLDERS' REPRESENTATIVE ......................... 53
9.01 Appointment .................................................. 53
9.02 Election and Replacement ..................................... 53
9.03 Authority .................................................... 54
9.04 No Liability of Parent ....................................... 54
ARTICLE X - SURVIVAL AND OFFSET ....................................... 54
10.01 Survival of Representations and Warranties ................... 54
10.02 Right of Offset .............................................. 55
ARTICLE XI - ANCILLARY AGREEMENTS ..................................... 60
11.01 Option Agreement ............................................. 60
11.02 Stockholder Agreements ....................................... 60
11.03 Affiliate Agreements ......................................... 60
11.04 Key Management Agreements .................................... 60
11.05 Noncompetition Agreements .................................... 61
ARTICLE XII - MISCELLANEOUS ........................................... 61
12.01 Press Releases and Announcements ............................. 61
12.02 Expenses ..................................................... 61
12.03 Amendment and Waiver ......................................... 61
12.04 Notices ...................................................... 62
12.05 Assignment .................................................. 63
12.06 Severability ................................................. 63
12.07 Complete Agreement ........................................... 63
12.08 Counterparts ................................................. 63
12.09 Governing Law ................................................ 63
12.10 Knowledge .................................................... 63
AGREEMENT AND PLAN OF MERGER
This Agreement and Plan of Merger (this "Agreement") dated as of May
13, 1997, is made and entered into by and among Imation Corp., a Delaware
corporation ("Parent"), CI Acquisition Corp., a Delaware corporation and wholly
owned subsidiary of Parent ("Merger Subsidiary"), and Cemax-Icon, Inc., a
Delaware corporation (the "Company"). Merger Subsidiary and the Company are
hereinafter sometimes collectively referred to as the "Constituent
Corporations."
WHEREAS, the respective Boards of Directors of Parent, Merger
Subsidiary and the Company have determined that it is advisable and in the best
interests of the respective corporations and their stockholders that Merger
Subsidiary be merged with and into the Company in accordance with the General
Corporation Law of the State of Delaware (the "Delaware Act") and the terms of
this Agreement, pursuant to which the Company will be the surviving corporation
as a wholly owned subsidiary of Parent (the "Merger"); and
WHEREAS, Parent, Merger Subsidiary and the Company desire to make
certain representations, warranties, covenants, indemnities and agreements in
connection with, and establish various conditions precedent to, the Merger.
NOW, THEREFORE, in consideration of the foregoing, the representations,
warranties, covenants, indemnities and agreements set forth in this Agreement,
and other good and valuable consideration, the adequacy and receipt of which is
hereby acknowledged, the parties hereto hereby agree as follows:
ARTICLE I
THE MERGER
1.01 THE MERGER. At the Effective Time (as defined in Section 1.03
hereof), and subject to the terms and conditions of this Agreement and the
Certificate of Merger (as defined in Section 1.03 hereof), the Merger Subsidiary
shall be merged with and into the Company, the separate existence of the Merger
Subsidiary shall cease, and the Company shall continue as the surviving
corporation under the corporate name of the Company. In its capacity as the
corporation surviving the Merger, the Company is hereinafter sometimes referred
to as the "Surviving Corporation."
1.02 EFFECT OF MERGER. The effect of the Merger shall be as set forth
in Section 259 of the Delaware Act, and the Surviving Corporation shall succeed
to and possess all the properties, rights, privileges, immunities, powers,
franchises and purposes, and be subject to all the duties, liabilities, debts,
obligations, restrictions and disabilities, of the Constituent Corporations, all
without further act or deed.
1.03 EFFECTIVE TIME. The consummation of the Merger shall be effected
as promptly as practicable, but in no event more than three business days, after
the satisfaction or waiver of the conditions set forth in Article VII of this
Agreement, and the parties hereto will cause a copy of the Certificate of
Merger, attached hereto as Exhibit 1.03(i) (the "Certificate of Merger"), to be
executed, delivered and filed with the Secretary of State of the State of
Delaware in accordance with the Delaware Act. The Merger shall become effective
at the time and date of the filing of the Certificate of Merger with the
Secretary of State of the State of Delaware. The date and time on which the
Merger shall become effective is referred to herein as the "Effective Time."
1.04 DIRECTORS AND OFFICERS. From and after the Effective Time, the
directors and officers of the Surviving Corporation shall be the persons who
were the directors and officers of the Merger Subsidiary immediately prior to
the Effective Time. Such directors and officers of the Surviving Corporation
shall hold office for the term specified in, and subject to the provisions
contained in, the Certificate of Incorporation and Bylaws of the Surviving
Corporation and applicable law. If, at or after the Effective Time, a vacancy
shall exist on the Board of Directors or in any of the offices of the Surviving
Corporation, such vacancy shall be filled in the manner provided in the
Certificate of Incorporation and Bylaws of the Surviving Corporation.
1.05 CERTIFICATE OF INCORPORATION; BYLAWS. From and after the Effective
Time and until further amended in accordance with applicable law, the
Certificate of Incorporation of Merger Subsidiary as in effect immediately prior
to the Effective Time shall be the Certificate of Incorporation of the Surviving
Corporation; provided, that, at the Effective Time, Article I of the Certificate
of Incorporation of the Surviving Corporation shall be amended to read in full
as follows: "The name of this corporation is Cemax-Icon, Inc." From and after
the Effective Time and until further amended in accordance with applicable law,
the Bylaws of Merger Subsidiary as in effect immediately prior to the Effective
Time shall be the Bylaws of the Surviving Corporation.
1.06 TAKING OF NECESSARY ACTION; FURTHER ACTION. Parent, Merger
Subsidiary and the Company, respectively, shall each use its best efforts to
take all such action as may be necessary or appropriate to effectuate the Merger
under the Delaware Act at the time specified in Section 1.03. If, at any time
after the Effective Time, any further action is necessary or desirable to carry
out the purposes of this Agreement and to vest the Surviving Corporation with
full right, title and possession to all properties, rights, privileges,
immunities, powers and franchises of either of the Constituent Corporations, the
officers of the Surviving Corporation are fully authorized in the name of each
Constituent Corporation or otherwise to take, and shall take, all such lawful
and necessary action.
1.07 THE CLOSING. The closing of the transactions contemplated by this
Agreement (the "Closing") will take place at the offices of Cemax-Icon, Inc.,
47281 Mission Falls Court, Fremont, California 94539, and will be effective as
of the Effective Time. At the Closing, the parties shall deliver to each other
the documents required to be delivered pursuant to Article VII hereof.
ARTICLE II
MERGER CONSIDERATION/EFFECT ON CAPITAL STOCK
2.01 EFFECT ON SECURITIES.
(a) Conversion of Securities. At the Effective Time, by virtue of the
Merger and without any action on the part of Parent, Merger Subsidiary, the
Company, the Surviving Corporation or the holder of any of the following
securities:
(i) Each share of Common Stock, par value $0.001 per share, of
the Company ("Company Common Stock"), issued and outstanding
immediately prior to the Effective Time and not held of record by
Parent shall be converted into and become a right to receive (A) a cash
payment of $5.25, without interest thereon, payable on or after the
Effective Time in accordance with, and subject to the deductions set
forth in, Section 2.03 (the "1997 Cash Consideration"), and (B) one
contingent payment right, as described and payable in accordance with
the terms set forth in Exhibit 2.01(a)(i) (a "Contingent Payment
Right," and collectively with the 1997 Cash Consideration, the "Merger
Consideration");
(ii) Each share of Series A Preferred Stock, par value $0.001
per share, of the Company ("Company Preferred Stock"), issued and
outstanding immediately prior to the Effective Time, and each share of
Company Common Stock issued and outstanding immediately prior to the
Effective Time and held of record by Parent, shall be canceled and
extinguished, and no payment shall be made therefor; and
(iii) Each share of Common Stock, par value $0.001 per share,
of the Merger Subsidiary ("Merger Subsidiary Stock"), issued and
outstanding immediately prior to the Effective Time shall be converted
into and become a right to receive one share of Common Stock, par value
$0.001 per share, of the Surviving Corporation ("Surviving Corporation
Stock").
(b) Effect on Stock Options and Warrants.
(i) Any option issued pursuant to the Cemax-Icon, Inc. 1996
Stock Plan, the Icon Medical Systems, Inc. 1992 Stock Option Plan and
the Cemax/Icon, Inc. 1986 Amended Incentive Stock Plan (collectively,
the "Option Plans") and outstanding immediately prior to the Effective
Time (an "Outstanding Stock Option"), shall be converted into, without
any further action on the part of Parent, Merger Subsidiary, the
Company, the Surviving Corporation or the holder thereof, a substitute
option (a "Substitute Option") to purchase a number of shares of Parent
equal to the number of shares subject to such Outstanding Stock Option
immediately prior to the Effective Time multiplied by the Common
Exchange Ratio (as defined below), and the exercise price of such
Substitute Option shall be equal to the exercise price of such
Outstanding Stock Option immediately prior to the Effective Time
divided by the Common Exchange Ratio. Each Substitute Option will be
subject to the existing terms and conditions of the Option Plan and
stock option agreement governing the Outstanding Stock Option
immediately prior to the Effective Time, except, that (A) no Substitute
Option will be intended to qualify as an incentive stock option within
the meaning of Section 422 of the Internal Revenue Code of 1986, as
amended (the "Code"), (B) each Substitute Option replacing an
Outstanding Stock Option that vests at the rate of either (x)
twenty-five percent (25%) per year during the first year and two
percent (2%) per month thereafter or (y) two percent (2%) per month
will vest at the rate of four percent (4%) per month during the first
12 months after the Effective Time, and (C) each Substitute Option
replacing an Outstanding Stock Option held by a consultant, contractor
or non-employee director will not be subject to early termination as a
result of termination of status as a consultant, contractor or director
of the Company or Surviving Corporation and in the event of such
termination shall vest and become exercisable in full (including as to
shares not otherwise exercisable as of the date of such termination).
(ii) Any warrant to purchase Company Common Stock issued and
outstanding immediately prior to the Effective Time (an "Outstanding
Stock Warrant"), shall be converted into, without any further action on
the part of Parent, Merger Subsidiary, the Company, the Surviving
Corporation or holder thereof, a substitute warrant (a "Substitute
Warrant") to purchase a number of shares of Parent equal to the number
of shares subject to such Outstanding Stock Warrant immediately prior
to the Effective Time multiplied by the Common Exchange Ratio (as
defined below), and the exercise price of such Substitute Warrant shall
be equal to the exercise price of such Outstanding Stock Warrant
immediately prior to the Effective Time divided by the Common Exchange
Ratio. Each Substitute Warrant will be subject to the existing terms
and conditions of the stock subscription warrant governing the
Outstanding Stock Warrant immediately prior to the Effective Time.
(iii) For purposes of this Section 2.01(b), "Common Exchange
Ratio" shall mean the quotient of (A) $11.96, and (B) the average
closing price per share of Parent Common Stock on the New York Stock
Exchange Composite Transactions, as reported in The Wall Street
Journal, for each of the 10 consecutive trading days ending on the
third business day prior to the Effective Time.
2.02 DISSENTING SHARES.
(a) Notwithstanding anything in this Agreement to the contrary, if
Section 262 of the Delaware Act shall be applicable to the Merger, shares of
Company Common Stock that are issued and outstanding immediately prior to the
Effective Time and which are held by stockholders who have not voted such shares
in favor of the Merger, who shall have delivered, prior to any vote on the
merger, a written demand for the fair value of such shares in the manner
provided in Section 262 of the Delaware Act and who, as of the Effective Time,
shall not have effectively withdrawn or lost such right to appraisal rights
("Dissenting Shares"), shall not be converted into or represent a right to
receive the Merger Consideration pursuant to Section 2.01 hereof, but the
holders thereof shall be entitled only to such rights as are granted by Section
262 of the Delaware Act. Each holder of Dissenting Shares who becomes entitled
to payment for such shares pursuant to Section 262 of the Delaware Act shall
receive payment therefor from the Surviving Corporation in accordance with the
Delaware Act; provided, however, that if any such holder of Dissenting Shares
shall have effectively withdrawn such holder's demand for appraisal of such
shares or lost such holder's right to appraisal and payment of such shares under
Section 262 of the Delaware Act, such holder or holders (as the case may be)
shall forfeit the right to appraisal of such shares and each such share shall
thereupon be deemed to have been canceled, extinguished and converted, as of the
Effective Time, into and represent the right to receive payment from the
Surviving Corporation of the consideration provided for in Section 2.01 hereof.
(b) The Company shall give Parent (i) prompt notice of any written
demand for fair value, any withdrawal of a demand for fair value and any other
instrument served pursuant to Section 262 of the Delaware Act received by the
Company, and (ii) the opportunity to direct all negotiations and proceedings
with respect to demands for fair value under such Section 262 of the Delaware
Act. The Company shall not, except with the prior written consent of Parent,
voluntarily make any payment with respect to any demand for fair value or offer
to settle or settle any such demand.
2.03 PAYMENT OF CONSIDERATION FOR COMPANY CAPITAL STOCK.
(a) As of the Effective Time, Parent shall deposit, or shall cause to
be deposited, cash in the amount of the aggregate 1997 Cash Consideration (the
"Payment Fund") with First Trust Company or such other bank or trust company
designated by Parent and acceptable to the Company (the "Paying Agent"), for the
benefit of the Company's stockholders and in exchange for outstanding shares of
Company Common Stock. The Payment Fund shall not be used for any other purpose.
(b) Within three business days after the Effective Time, Parent shall
instruct the Paying Agent to mail to each holder of record (the "Company
Stockholders") of a certificate or certificates which immediately prior to the
Effective Time represented outstanding shares of Company Common Stock (the
"Certificates"), a (i) a letter of transmittal (which shall specify that
delivery shall be effected, and risk of loss and title to the Certificates shall
pass, only upon proper delivery of the Certificates to the Paying Agent and
shall be in customary form), and (ii) instructions for use in effecting the
surrender of the Certificates in exchange for the Merger Consideration. Upon
surrender of a Certificate for cancellation to the Paying Agent, together with
such letter of transmittal, duly executed, and such other documents as may be
reasonably required pursuant to such instructions, the holder of such
Certificate shall receive in exchange the 1997 Cash Consideration and shall be
entitled to the Contingent Payment Right as set forth in Exhibit 2.01(a)(i), in
each case which such holder is entitled to receive in the Merger with respect to
the shares of Company Common Stock formerly represented by such Certificate, and
the Certificate so surrendered shall forthwith be canceled. Until surrendered as
contemplated by this Section 2.03(b), each Certificate shall be deemed at any
time after the Effective Time to represent solely the right to receive the
Merger Consideration with respect to the shares of Company Common Stock formerly
represented by such Certificate.
Pursuant to a separate agreement between the Paying Agent and the
Stockholders' Representatives (on behalf of the Company's stockholders), the
Paying Agent shall withhold up to Two Hundred Thousand Dollars ($200,000) from
the initial payments of 1997 Cash Consideration in a separate fund (the
"Representatives' Fund") for reimbursement of the Stockholders' Representatives'
out-of-pocket expenses in acting on behalf of the Company's stockholders in
connection with the Merger before and after the Effective Time. The Paying Agent
shall distribute any remaining amounts in the Representatives' Fund to the
Company's stockholders after the Stockholders' Representatives have completed
their representation of the Company's stockholders in connection with the Merger
before and after the Effective Time.
(c) Any portion of the Payment Fund which remains undistributed to the
Company Stockholders for one year after the Effective Time shall be delivered to
Parent, upon demand, and any Common Stockholders who have not theretofore
complied with this Section 2.03 shall thereafter look only to Parent for the
Merger Consideration to which they are entitled under Section 2.01(a)(i).
2.04 STOCK TRANSFER BOOKS. At the Effective Time, the stock transfer
books of the Company shall be closed and there shall be no further registration
of transfers of shares of Company Common Stock thereafter on the records of the
Company. From and after the Effective Time, the holders of certificates
representing shares of Company Common Stock immediately prior to the Effective
Time shall cease to have any rights with respect to such shares of Company
Common Stock except as otherwise provided in this Agreement or by law.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company hereby represents and warrants to Parent and Merger
Subsidiary that, except as set forth in the Disclosure Schedule delivered by the
Company to Parent and Merger Subsidiary on the date hereof (the "Disclosure
Schedule"):
3.01 INCORPORATION AND CORPORATE POWER. The Company is a corporation
duly incorporated, validly existing and in good standing under the laws of the
state of Delaware and, subject to approval of this Agreement by the Company's
stockholders, the Company has the requisite corporate power and authority to
execute and deliver this Agreement the Certificate of Merger and the agreements
identified in Article XI to which the Company is a party (the "Company Ancillary
Agreements") and to perform its obligations hereunder and thereunder. The
Company has the corporate power and authority and all authorizations, licenses,
permits and certifications necessary to own and operate its properties and to
carry on its business as now conducted and presently proposed to be conducted.
The copies of the Certificate of Incorporation and Bylaws of the Company which
have been furnished by the Company to Parent prior to the date hereof reflect
all amendments made thereto and are correct and complete as of the date hereof.
The Company is qualified to do business as a foreign corporation in every
jurisdiction in which the nature of its business or its ownership of property
requires it to be so qualified, except for those jurisdictions in which the
failure to be so qualified would not, individually or in the aggregate, have a
material adverse effect on the business or results of operations of the Company.
3.02 EXECUTION, DELIVERY; VALID AND BINDING AGREEMENT. The execution,
delivery and performance of this Agreement, the Certificate of Merger and the
Company Ancillary Agreements and the consummation of the transactions
contemplated hereby and thereby have been duly and validly authorized by all
requisite corporate action, and no other corporate proceedings on its part are
necessary to authorize the execution, delivery and performance of this
Agreement, the Certificate of Merger and the Company Ancillary Agreements, other
than the approval of this Agreement by the Company's stockholders. This
Agreement and the Company Ancillary Agreements have been duly executed and
delivered by the Company and constitute the valid and binding obligations of the
Company, enforceable in accordance with their terms, and the Certificate of
Merger, when executed and delivered by the Company, will constitute the valid
and binding obligation of the Company, enforceable in accordance with its terms.
3.03 APPROVAL OF AGREEMENT; MEETING OF STOCKHOLDERS. The Company hereby
represents that its Board of Directors has, by resolutions duly adopted by
written consent effective as of May 12, 1997, approved this Agreement, the
Certificate of Merger and the Company Ancillary Agreements and the transactions
contemplated hereby and thereby, including the Merger, and resolved to recommend
approval of this Agreement by the Company's stockholders. None of the
resolutions described in this Section 3.03 has been amended or otherwise
modified in any respect since the date of adoption thereof and all such
resolutions remain in full force and effect.
3.04 NO BREACH. The execution, delivery and performance of this
Agreement, the Certificate of Merger and the Company Ancillary Agreements by the
Company and the consummation by the Company of the transactions contemplated
hereby and thereby do not conflict with or result in any breach of any of the
provisions of, constitute a default under, result in a violation of, result in
the creation of a right of termination or acceleration or any lien, security
interest, charge or encumbrance upon any assets of the Company, or require any
authorization, consent, approval, exemption or other action by or notice to any
court or other governmental body, under the provisions of the Certificate of
Incorporation or Bylaws of the Company or any indenture, mortgage, lease, loan
agreement or other agreement or instrument by which the Company is bound or
affected, or any law, statute, rule or regulation or order, judgment or decree
to which the Company is subject.
3.05 GOVERNMENTAL AUTHORITIES; CONSENTS. Except for the applicable
requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, and the rules and regulations promulgated thereunder (the "HSR Act"),
and except for the filing of the Certificate of Merger with the Secretary of
State of the State of Delaware, the Company is not required to submit any
notice, report or other filing with any governmental authority in connection
with the execution or delivery by it of this Agreement, the Certificate of
Merger or the Company Ancillary Agreements or the consummation of the
transactions contemplated hereby or thereby. No consent, approval or
authorization of any governmental or regulatory authority or any other party or
person (except the approval of this Agreement by the stockholders of the
Company) is required to be obtained by the Company in connection with its
execution, delivery and performance of this Agreement, the Certificate of Merger
or the Company Ancillary Agreements or the transactions contemplated hereby or
thereby.
3.06 SUBSIDIARIES; PREDECESSORS.
(a) The Company does not own any stock, partnership interest, joint
venture interest or any other security or ownership interest issued by any other
corporation, organization, joint venture, partnership, limited liability company
or entity.
(b) The Company is the successor-in-interest to the assets, liabilities
and business of ICON Medical Systems, Inc., a California corporation ("ICON") as
a result of a merger (the "ICON Merger") of ICON into the Company pursuant to
and in accordance with the Agreement and Plan of Reorganization (the
"Reorganization Agreement"), dated April 12, 1995, by and between the Company
and ICON, a correct and complete copy of which has heretofore been delivered to
Parent. As a result of the ICON Merger, pursuant to the provisions of applicable
corporate law, the separate existence of ICON ceased, with the Company remaining
as the sole surviving corporation and possessing all of the assets, liabilities
and business of ICON, except as otherwise provided in the Reorganization
Agreement. The ICON Merger was effective as of June 14, 1995 in accordance with
applicable corporate law.
The Reorganization Agreement and the ICON Merger were duly and validly
authorized by all necessary corporate actions on the part of each of the parties
to the Reorganization Agreement, pursuant to the provisions of the applicable
charter, bylaws and other organizational documents of each party thereto and
applicable law; and all necessary consents and approvals to the ICON Merger and
transfer of the rights, liabilities, assets and business of ICON to the Company
pursuant to the ICON Merger have been obtained. The execution and performance of
the Reorganization Agreement and the consummation of the transactions therein
contemplated did not and will not (i) violate any provisions of the charter or
bylaws, or other organization documents of the Company or ICON, (ii) conflict
with, result in the breach or violation of, or constitute, either by itself or
upon notice or passage of time, or both, a default under any agreement,
mortgage, deed of trust, lease, franchise, license, indenture, permit or other
instrument to which the Company or ICON, is or was, as the case may be, a party
or by which the Company or ICON, or any of their properties, may be or may have
been, as the case may be, bound or affected, or (iii) conflict with or violate
any statue or any authorization, judgment, decree, order, rule or regulation of
any court or any regulatory body, administrative agency or other governmental
body applicable to the Company or ICON, or any of their properties, in any such
case in a manner that would have a material adverse effect on the Company.
The Company has made no claims for breach of a representation, warranty
or covenant in the Reorganization Agreement. All income, sales and other taxes
and recording and other fees arising out of or relating to the transfer from
ICON to the Company of liabilities, assets and business of ICON have been (or,
if not yet due, will be) paid in a timely manner by ICON or the Company as
applicable. All of the shares of capital stock of ICON issued and outstanding as
of the time immediately preceding the ICON Merger were duly authorized and
validly issued, were fully paid and nonassessable, were issued in compliance
with all registration and qualification provisions of applicable federal and
state securities laws, and were not issued in violation of or subject to any
preemptive rights or other rights to subscribe for or purchase securities.
Pursuant to the terms of the Reorganization Agreement, all the outstanding
capital stock of ICON was converted into the right to receive shares of capital
stock of the Company, all of which have previously been delivered.
(c) The Company is the successor-in-interest to the assets, liabilities
and business of Virtual Imaging, Inc., a California corporation ("Virtual") as a
result of a merger (the "Virtual Exchange") of Virtual into the Company pursuant
to and in accordance with the Plan and Agreement of Reorganization Agreement
(the "Exchange Agreement"), dated as of January 11, 1993, by and between the
Company and Virtual, a correct and complete copy of which has heretofore been
delivered to Parent. As a result of the Virtual Exchange, pursuant to the
provisions of applicable corporate law, the separate existence of Virtual
ceased, with the Company remaining as the sole surviving corporation and
possessing all of the assets, liabilities and business of Virtual, except as
otherwise provided in the Exchange Agreement. The Virtual Exchange was effective
as of January 11, 1993 in accordance with applicable corporate law.
The Exchange Agreement and the Virtual Exchange were duly and validly
authorized by all necessary corporate actions on the part of each of the parties
to the Exchange Agreement, pursuant to the provisions of the applicable charter,
bylaws and other organizational documents of each party thereto and applicable
law; and all necessary consents and approvals to the Virtual Exchange and
transfer of the rights, liabilities, assets and business of Virtual to the
Company pursuant to the Virtual Exchange have been obtained. The execution and
performance of the Exchange Agreement and the consummation of the transactions
therein contemplated did not and will not (i) violate any provisions of the
charter or bylaws, or other organization documents of the Company or Virtual,
(ii) conflict with, result in the breach or violation of, or constitute, either
by itself or upon notice or passage of time, or both, a default under any
agreement, mortgage, deed of trust, lease, franchise, license, indenture, permit
or other instrument to which the Company or Virtual, is or was, as the case may
be, a party or by which the Company or Virtual, or any of their properties, may
be or may have been, as the case may be, bound or affected, or (iii) conflict
with or violate any statue or any authorization, judgment, decree, order, rule
or regulation of any court or any regulatory body, administrative agency or
other governmental body applicable to the Company or Virtual, or any of their
properties, in any such case in a manner that would have a material adverse
effect on the Company.
The Company has made no claims for breach of a representation, warranty
or covenant in the Exchange Agreement. All income, sales and other taxes and
recording and other fees arising out of or relating to the transfer from Virtual
to the Company of liabilities, assets and business of Virtual have been (or, if
not yet due, will be) paid in a timely manner by Virtual or the Company as
applicable. Pursuant to the terms of the Exchange Agreement, all the outstanding
capital stock of Virtual was converted into the right to receive shares of
capital stock of the Company, all of which have previously been delivered.
3.07 CAPITAL STOCK.
(a) The authorized capital stock of the Company consists of 50,000,000
shares of Company Common Stock, par value $0.001 per share, of which, as of the
date hereof, 5,379,587 shares are issued and outstanding, 30,000,000 shares of
preferred stock, par value $0.001 per share, of which as of the date hereof
1,985,878 shares are designated Company Preferred Stock, as of which as of the
date hereof 1,073,077 shares are issued and outstanding. The Company Common
Stock and Company Preferred Stock is held of record by the persons and in the
amounts set forth on the Disclosure Schedule. All such outstanding shares of
Company's capital stock (i) have been duly authorized and are validly issued,
fully paid and nonassessable, (ii) are not subject to preemptive rights created
by statute, the Company's Certificate of Incorporation or Bylaws, or any other
agreement to which either the Company or, the knowledge of the Company, the
Company's stockholders are bound, and (iii) were issued in full compliance with
all applicable securities laws. As of June 30, 1997, a total of 121,306 shares
of Company Common Stock, held of record by the persons and in the amount set
forth in the Disclosure Schedule, will be subject to repurchase by the Company,
at the original purchase price (the "Restricted Common Stock").
(b) The Company has reserved a total of 2,549,806 shares of Company
Common Stock for issuance to employees, directors and consultants pursuant to
the Option Plans, under which options to purchase 1,180,640 shares of Company
Common Stock are outstanding, with a weighted average exercise price of $3.773
per share. The Company has reserved a total of (i) 150,000 shares of Company
Common Stock for issuance pursuant to a warrant held by Dominion Fund IV, and
(ii) 250,000 shares of Company Common Stock for issuance pursuant to convertible
debt held by Dominion Fund IV. The Disclosure Schedule sets forth for each
Outstanding Stock Option and Outstanding Stock Warrant, the number of shares of
Company Common Stock subject to such option or warrant, the exercise price of
such option or warrant, the expiration date of such option or warrant, and the
vesting schedule of such option or warrant (including the extent vested to date
and the extent, if any, to which exercisability will be accelerated by the
transactions contemplated by this Agreement). The Company has reserved a total
of 170,000 shares of Company Common Stock for the Picker Shares and Warrants (as
defined in Section 5.01(i)). Except for the Outstanding Stock Options and
Outstanding Stock Warrants identified on the Disclosure Schedule, the Picker
Shares and Warrants, and the conversion and other rights of the Company
Preferred Stock specified in the Company's Certificate of Incorporation, there
are no rights, subscriptions, warrants, options, conversion rights or agreements
of any kind outstanding to purchase or otherwise acquire from the Company any
shares of capital stock or other securities of the Company of any kind, there
are no agreements or other obligations (contingent or otherwise) which may
require the Company to repurchase or otherwise acquire any shares of its capital
stock, and there are no agreements or other obligations of the Company to grant,
extend, accelerate the vesting of, change the price of or otherwise amend any
Outstanding Stock Option or Outstanding Stock Warrant (except as otherwise set
forth herein or in the Key Management Agreements). Except to reflect the
2.35-for-1 reverse split of shares of Company Common Stock effective July 1996,
no adjustment has occurred with respect to the number of shares of Common Stock
issuable upon conversion of the Company Preferred Stock since the original
issuance thereof. The holders of Outstanding Stock Options and Outstanding Stock
Warrants have been or will be given, or shall have properly waived, any required
notice prior to the Merger. The Company has delivered to Parent complete and
accurate stock record books reflecting original issuances and, transfers of
capital stock of the Company and its predecessors, in all material respects.
(c) The Disclosure Schedule sets forth those persons who are, in the
Company's reasonable judgment, "affiliates" of the Company within the meaning of
Rule 145 promulgated by the Securities Exchange Commission (the "SEC") under the
Securities Act of 1933, as amended (the "Securities Act").
3.08 FINANCIAL STATEMENTS.
(a) The Company has delivered to Purchaser copies of (i) the unaudited
balance sheets, as of March 31, 1997, of the Company (the "Latest Balance
Sheet") and the unaudited statements of earnings, stockholders' equity and cash
flows of the Company for the three-month period ended March 31, 1997 (such
statements and the Latest Balance Sheet being herein referred to as the "Latest
Financial Statements"), and (ii) the audited balance sheets, as of December 31,
1996, December 31, 1995 and December 31, 1994, of the Company and the audited
statements of earnings, stockholders' equity and cash flows of the Company for
each of the years ended December 31, 1996, December 31, 1995 and December 31,
1994 (collectively, the "Annual Financial Statements"). The Latest Financial
Statements and the Annual Financial Statements are based upon the information
contained in the books and records of the Company and fairly present the
financial condition of the Company as of the dates thereof and respective
results of operations for the periods referred to therein. The Annual Financial
Statements have been prepared in accordance with generally accepted accounting
principles, consistently applied through the periods indicated, and the Latest
Financial Statements have been prepared in accordance with generally accepted
accounting principles applicable to unaudited interim financial statements (and
thus may not contain all notes and may not contain prior period comparative data
which are required to be prepared in accordance with generally accepted
accounting principles), are consistent with the Annual Financial Statements and
reflect all adjustments necessary to a fair statement of the results for the
interim period(s) presented.
(b) The Disclosure Schedule includes the Company's financial
projections for results of operations on a stand-alone basis for the
twelve-month periods ending June 30, 1998 and June 30, 1999 (the "Projections").
The Company represents and warrants that the Projections were prepared by
management of the Company in good faith and, as of March 12, 1997, represent the
best estimates of such officers of the Company for the periods then ending,
based on assumptions they believed were reasonable as of such date, but without
adjustment for the Merger and the consummation of the other transactions
contemplated hereby. The assumptions underlying the Projections consist of
various factors based upon the information available to such officers as of the
date of the preparation of the Projections, including the financial and business
condition of the Company, the development stage, size and strength of markets
for the Company's products, the status of the Company's competitors and their
products, the continuation of the Company's management personnel and the
Company's continued ability to attract and retain suitable employees, the
continued successful technical development of the Company's existing and
anticipated future products, general conditions in the health care industry, and
economic conditions and government regulatory and reimbursement policies. Parent
and Merger Subsidiary acknowledge that no representation or warranty of any kind
is made that the Projections will accurately reflect the actual results of
future operations, and that actual results of operations during the projection
period may vary from the Projections.
3.09 ABSENCE OF UNDISCLOSED LIABILITIES. Except as reflected in the
Latest Balance Sheet, the Company has no liabilities (whether accrued, absolute,
contingent, unliquidated or otherwise, whether due or to become due, whether
known or unknown, and regardless of when asserted) arising out of transactions
or events heretofore entered into, or any action or inaction, or any state of
facts existing, with respect to or based upon transactions or events heretofore
occurring, except liabilities which have arisen after the date of the Latest
Balance Sheet in the ordinary course of business (none of which is a material
uninsured liability for breach of contract, breach of warranty, tort,
infringement, claim or lawsuit).
3.10 NO MATERIAL ADVERSE CHANGES. Since the date of the Latest Balance
Sheet (the "Balance Sheet Date"), there has been no material adverse change in
the assets, financial condition, relations with key management employees or key
OEM's, operating results or business condition of the Company.
3.11 ABSENCE OF CERTAIN DEVELOPMENTS. Since the Balance Sheet Date, the
Company has not:
(a) borrowed any amount or incurred or become subject to any liability
in excess of $50,000, except (i) current liabilities incurred in the ordinary
course of business and (ii) liabilities under contracts entered into in the
ordinary course of business;
(b) mortgaged, pledged or subjected to any lien, charge or any other
encumbrance, any of its assets with a fair market value in excess of $25,000,
except (i) liens for current property taxes not yet due and payable, (ii) liens
imposed by law and incurred in the ordinary course of business for obligations
not yet due to carriers, warehousemen, laborers, materialmen and the like, (iii)
liens in respect of pledges or deposits under workers' compensation laws, (iv)
liens set forth in the Disclosure Schedule, or (v) liens voluntarily created in
the ordinary course of business, all of which liens aggregate less than $25,000;
(c) discharged or satisfied any lien or encumbrance or paid any
liability, in each case with a value in excess of $50,000, other than current
liabilities paid in the ordinary course of business;
(d) sold, assigned or transferred (including, without limitation,
transfers to any employees, affiliates or stockholders) any tangible assets with
a fair market value in excess of $50,000, or canceled any debts or claims, in
each case, except in the ordinary course of business;
(e) sold, assigned or transferred (including, without limitation,
transfers to any employees, affiliates or stockholders) any patents, trademarks,
trade names, copyrights, trade secrets or other intangible assets;
(f) disclosed, to any person other than Parent or Merger Subsidiary and
authorized representatives of Parent or Merger Subsidiary, any proprietary
confidential information, other than pursuant to a confidentiality agreement
prohibiting the use or further disclosure of such information, which agreement
is identified in the Disclosure Schedule and is in full force and effect on the
date hereof;
(g) waived any rights of material value or suffered any extraordinary
losses or adverse changes in collection loss experience, whether or not in the
ordinary course of business or consistent with past practice;
(h) declared or paid any dividends or other distributions with respect
to any shares of the Company's capital stock or redeemed or purchased, directly
or indirectly, any shares of the Company's capital stock or any options;
(i) issued, sold or transferred any of its equity securities,
securities convertible into or exchangeable for its equity securities or
warrants, options or other rights to acquire its equity securities, or any bonds
or debt securities except the Picker Shares and Warrants or as described in the
Disclosure Schedule;
(j) taken any other material action or entered into any other material
transaction other than in the ordinary course of business and in accordance with
past custom and practice, or entered into any transaction with any "insider" (as
defined in Section 3.23 hereof) other than employment arrangements otherwise
disclosed in this Agreement and the Disclosure Schedule, or the transactions
expressly contemplated by this Agreement;
(k) suffered any material theft, damage, destruction or loss of or to
any property or properties owned or used by it, whether or not covered by
insurance;
(l) made or granted any bonus, or any wage, salary or compensation
increase to any director, officer, employee or consultant who earns more than
$75,000 per year, or made or granted any increase in any employee benefit plan
or arrangement, or amended or terminated any existing employee benefit plan or
arrangement, or adopted any new employee benefit plan or arrangement or made any
commitment or incurred any liability to any labor organization;
(m) made any single capital expenditure or commitment therefor in
excess of $20,000, except any single capital expenditure or commitment in the
ordinary course of business consistent with past practice not in excess of
$50,000;
(n) made any loans or advances to, or guarantees for the benefit of,
any persons (except advances for customary travel and entertainment expenditures
in the ordinary course of business);
(o) made any charitable contributions or pledges;
(p) made any change in accounting principles or practices from those
utilized in the preparation of the Latest Financial Statements;
(q) experienced any amendment, modification or termination of any
existing, or entered into any new, contract, agreement, plan, lease, license,
permit or franchise which is, either individual or in the aggregate, material to
the business, operations, financial position or prospects of the Company other
than in the ordinary course of business;
(r) experienced any labor dispute material to the business, operations,
financial position or prospects of the Company;
(s) experienced any change in any method of calculating, any bad debt,
inventory, contingency or other reserve;
(t) written off as uncollectible any note or account receivable, or
canceled any debts, other than in the ordinary course of business and consistent
with past practice;
(u) except as previously discussed with and agreed to by Parent, failed
to replace or replenish inventory or supplies as such inventory or supplies may
have been depleted from time to time, collect accounts receivable, pay accounts
payable or shorten or lengthen the customary payment cycles for any of its
payables or receivables or otherwise manage its working capital accounts in a
manner consistent with past practice;
(v) experienced any writedown or writeup of (or failed to writedown or
writeup in accordance with generally accepted accounting principles) the value
of any inventories, receivables or other assets, or revalued any assets of the
Company;
(w) failed to maintain all material physical assets in accordance with
good business practice and in good operating condition and repair, ordinary wear
and tear excepted;
(x) experienced any lapse or termination of any material permit that
was issued or relates to the Company or its business, or any failure to renew
any such permit; or
(y) discontinued or altered, in any material respect, its advertising
or promotional activities or its pricing and purchasing policies other than in a
manner consistent with past practices.
3.12 TITLE TO PROPERTIES.
(a) The Company does not own, and neither the Company nor any of its
predecessors has owned, any real property. The real property demised by the
leases (the "Leases") described in the Disclosure Schedule constitutes all of
the real property used or occupied by the Company (the "Real Property"). The
Real Property has access, sufficient for the conduct of the business of the
Company as now conducted to public roads and to all utilities, including
electricity, sanitary and storm sewer, potable water, natural gas and other
utilities, used in the operation of the business of the Company at that
location.
(b) The Leases are in full force and effect, and the Company holds a
valid and existing leasehold interest under each of the Leases for the term set
forth in the Disclosure Schedule. The Company has delivered to Parent complete
and accurate copies of each of the Leases, and none of the Leases has been
modified in any respect, except to the extent that such modifications are
disclosed by the copies delivered to Parent. The Company is not in default, and
to the knowledge of the Company no circumstances exist which, if unremedied,
would, either with or without notice or the passage of time or both, result in
such default under any of the Leases; nor to the knowledge of the Company is any
other party to any of the Leases in default.
(c) The Company owns good and marketable title to each of the tangible
properties and tangible assets reflected on the Latest Balance Sheet or acquired
since the date thereof, free and clear of all liens and encumbrances, except for
(i) liens for current taxes not yet due and payable, (ii) liens set forth in the
Disclosure Schedule, (iii) the properties subject to the Leases, (iv) assets
disposed of since the date of the Latest Balance Sheet in the ordinary course of
business, (v) liens imposed by law and incurred in the ordinary course of
business for obligations not yet due to carriers, warehousemen, laborers and
materialmen and (vi) liens in respect of pledges or deposits under workers'
compensation laws, all of which liens aggregate less than $25,000.
(d) All of the buildings, machinery, equipment and other tangible
assets necessary for the conduct of the business of the Company are in good
condition and repair, ordinary wear and tear excepted, and are usable in the
ordinary course of business. There are no defects in such assets or other
conditions relating thereto which, individually or in the aggregate, materially
adversely affect the operation or value of such assets. The Company owns or
leases under valid leases, all buildings, machinery, equipment and other
tangible assets necessary for the conduct of its business as presently
conducted.
(e) The Company is not in violation of any applicable zoning ordinance
or other law, regulation or requirement relating to the operation of any
properties used in the operation of its business, and the Company has not
received any notice of any such violation, or the existence of any condemnation
proceeding with respect to any of the Real Property, except, in each case, with
respect to violations the potential consequences of which do not or will not
have a material adverse effect on the Company.
(f) The Company has no knowledge of improvements made or contemplated
to be made by any public or private authority, the costs of which are to be
assessed as special taxes or charges against any of the Real Property, and there
are no present assessments.
3.13 ACCOUNTS RECEIVABLE. The accounts receivable reflected on the
Latest Balance Sheet are valid receivables, are not subject to valid
counterclaims or set-offs, and will be collected in accordance with their terms,
except to the extent set forth on the Disclosure Schedule. The accounts
receivable reflected on the Company's books and records arising after the date
of the Latest Balance Sheet and prior to the Effective Time are valid
receivables, are not subject to valid counterclaims or set- offs, and are
collectible in a manner consistent with past practices in accordance with the
Company's standard terms and conditions of sale.
3.14 INVENTORY. The inventory of raw materials, work in process and
finished goods of the Company consists of items of a quality and quantity usable
and, with respect to finished goods only, salable in the ordinary course of the
business of the Company. The inventory of finished goods of the Company is not
slow-moving as determined in accordance with past practices, obsolete or damaged
and is merchantable and fit for its particular use. The Company has on hand or
has ordered and expects timely delivery of such quantities of raw materials, and
has on hand such quantities of work in process and finished goods, in each case
as are reasonably required timely to fill current orders on hand which require
delivery within sixty (60) days and to maintain the manufacture and shipment of
products at its normal level of operations. As of the date of the Latest Balance
Sheet, the values at which such inventory is carried on the Latest Balance Sheet
are in accordance with generally accepted accounting principles. The Disclosure
Schedule contains a materially complete and accurate summary of the Company's
inventory of raw materials, work in progress and finished goods as of March 31,
1997.
3.15 TAX MATTERS.
(a) Each of the Company and any affiliated, combined or unitary group
of which the Company is or was a member, any predecessor of the Company and any
"Plans" (as defined in Section 3.21 hereof), as the case may be (each, a "Tax
Affiliate" and, collectively, the "Tax Affiliates"), has: (i) timely filed
(after taking into account any properly applicable extension of the due date of
such Returns) all returns, declarations, reports, estimates, information
returns, and statements ("Returns") required to be filed or sent by it in
respect of any "Taxes" (as defined in subsection (p) below) or required to be
filed or sent by it by any taxing authority having jurisdiction and all such
Returns are true and correct in all material respects; (ii) timely and properly
paid (or has had paid on its behalf) all Taxes due and payable with respect to
the periods covered by such Returns; (iii) established on its Latest Balance
Sheet, in accordance with generally accepted accounting principles, reserves
that are adequate for the payment of any Taxes for all Tax periods or portions
thereof ending on, prior to or including the Closing Date, the amount of which
as of the date of the Latest Balance Sheet is set forth in the Disclosure
Schedule; (iv) complied with all applicable laws, rules, and regulations
relating to the withholding of Taxes and the payment thereof (including, without
limitation, withholding of Taxes under Sections 1441 and 1442 of the Code, or
similar provisions under any foreign laws), and timely and properly withheld
from individual employee wages and paid over to the proper governmental
authorities all amounts required to be so withheld and paid over under all
applicable laws. True and correct copies of any and all Returns filed by any Tax
Affiliate have been provided to Parent.
(b) There are no liens for Taxes upon any assets of the Company or of
any Tax Affiliate, except liens for Taxes not yet due. The Company is not a
party to any tax sharing agreement or other arrangement for the payment or
reimbursement of Taxes.
(c) No deficiency for any Taxes has been proposed, asserted or assessed
against the Company or the Tax Affiliates that has not been resolved and paid in
full. No waiver, extension or comparable consent given by the Company or the Tax
Affiliates regarding the application of the statute of limitations with respect
to any Taxes or Returns is outstanding, nor is any request for any such waiver
or consent pending. There has been no Tax audit or other administrative
proceeding or court proceeding with regard to any Taxes or Returns, nor is any
such Tax audit or other proceeding pending, nor has there been any notice to the
Company by any Taxing authority regarding any such Tax, audit or other
proceeding, or, to the knowledge of the Company, is any such Tax audit or other
proceeding threatened with regard to any Taxes or Returns. The Company does not
expect the assessment of any additional Taxes of the Company or the Tax
Affiliates and is not aware of any unresolved questions, claims or disputes
concerning the liability for Taxes of the Company or the Tax Affiliates which
would exceed the estimated reserves established on its books and records.
(d) Neither the Company nor any Tax Affiliate is a party to any
agreement, contract or arrangement that would result, separately or in the
aggregate, in the payment of any "excess parachute payments" within the meaning
of Section 280G of the Code and the consummation of the transactions
contemplated by this Agreement will not be a factor causing payments to be made
by the Company or any Tax Affiliate that are not deductible (in whole or in
part) under Section 280G of the Code.
(e) Except as set forth on the Disclosure Schedule, neither the Company
nor any Tax Affiliate has requested any extension of time within which to file
any Return, which Return has not since been filed.
(f) No property of the Company or any Tax Affiliate is property that
the Company or any Tax Affiliates is or will be required to treat as being owned
by another person under the provisions of Section 168(f)(8) of the Code (as in
effect prior to amendment by the Tax Reform Act of 1986) or is "tax-exempt use
property" within the meaning of Section 168 of the Code.
(g) Neither the Company nor any Tax Affiliate is required to include in
income any adjustment under Section 481(a) of the Code by reason of a voluntary
change in accounting method initiated by the Company or any Tax Affiliate as a
result of the Tax Reform Act of 1986 and neither the Company nor any Tax
Affiliate has knowledge that the Internal Revenue Service has proposed any such
adjustment or change in accounting method.
(h) All transactions that could give rise to an understatement of
federal income tax (within the meaning of Section 6661 of the Code as it applied
prior to repeal) or an underpayment of tax (within the meaning of Section 6662
of the Code) were reported in a manner for which there is substantial authority
or were adequately disclosed (or, with respect to Returns filed before the
Closing Date, will be reported in such a manner or adequately disclosed) on the
Returns required in accordance with Sections 6661(b)(2)(B) and 6662(d)(2)(B) of
the Code.
(i) Except as set forth on the Disclosure Schedule, neither the Company
nor any Tax Affiliate has engaged in any transaction that would result in a
deemed election under Section 338(e) of the Code, and neither the Company nor
any Tax Affiliate will engage in any such transaction within any applicable
"consistency period" (as such term is defined in Section 338 of the Code).
(j) Neither the Company nor any Tax Affiliate has filed any consent
under Section 341(f) of the Code.
(k) The Company and the Tax Affiliates have evidence of payment for all
taxes, charges, fees, levies, or other assessments of a foreign country paid or
accrued from the date of the formation of each of them, respectively.
(l) Neither the Company nor any Tax Affiliate, to the extent they are
"controlled foreign corporations" within the meaning of Section 957 of the Code,
have now or have had at any time in the past "subpart F income" within the
meaning of Section 952 of the Code.
(m) The Company and the Tax Affiliates are, and at all times have been,
corporations or associations taxable as corporations for United States income
tax purposes.
(n) Any "FSC" (within the meaning of Section 922 of the Code) has been
properly operated in accordance with the provisions of Sections 921-927 of the
Code.
(o) All deductions claimed or reported on all Returns of the Company
and any Tax Affiliate on account of royalties or similar fees payable with
respect to any intellectual property of the Company or any other party are
allowable in full, except where the failure to be so allowable will not result
in any Tax liability to the Company.
(p) The Disclosure Schedule sets forth (i) all issuances of capital
stock of the Company and the value received therefor, (ii) all issuances of
options, warrants or other rights to purchase capital stock of the Company and
the value received therefor, (iii) all issuances of securities exchangeable for
or convertible into capital stock of the Company and the value received therefor
and (iv) to the Company's knowledge, all transfers of the foregoing, in each
case since June 15, 1997.
(q) For purposes of this Agreement, the term "Taxes" means all taxes,
charges, fees, levies, or other assessments, including, without limitation, all
net income, gross income, gross receipts, sales, use, ad valorem, transfer,
franchise, profits, license, withholding, payroll, employment, social security,
unemployment, excise, estimated, severance, stamp, occupation, property, or
other taxes, customs duties, fees, assessments, or charges of any kind
whatsoever, including, without limitation, all interest and penalties thereon,
and additions to tax or additional amounts imposed by any taxing authority,
domestic or foreign, upon the Company or any Tax Affiliate.
3.16 CONTRACTS AND COMMITMENTS.
(a) The Disclosure Schedule lists the following agreements, whether
oral or written, to which the Company is a party, which are currently in effect,
and which relate to the operation of the business of the Company: (i) collective
bargaining agreement or contract with any labor union; (ii) bonus, pension,
profit sharing, retirement or other form of deferred compensation plan, other
than as described in the Disclosure Schedule; (iii) hospitalization insurance or
other welfare benefit plan or practice, whether formal or informal; (iv) stock
purchase or stock option plan; (v) contract for the employment of any officer,
individual employee or other person on a full-time or consulting basis making in
excess of $75,000 per year or relating to severance pay for any such person;
(vi) confidentiality agreement with employees and with consultants, vendors,
customers or other third parties (other than the Company's standard Secrecy
Agreements with its employees); (vii) contract, agreement or understanding
relating to the voting of the Company's capital stock or the election of
directors of the Company; (viii) agreement or indenture relating to the
borrowing of money or to mortgaging, pledging or otherwise placing a lien on any
of the assets of the Company; (ix) guaranty of any obligation for borrowed money
or otherwise; (x) lease or agreement under which it is lessee of, or holds or
operates any property, real or personal, owned by any other party for which the
annual rental exceeds $25,000; (xi) lease or agreement under which it is lessor
of, or permits any third party to hold or operate, any property, real or
personal, for which the annual rental exceeds $10,000; (xii) contract or group
of related contracts with the same party (other than any contract or group of
related contracts for the purchase or sale of products or services) continuing
over a period of more than six months from the date or dates thereof, not
terminable by it on 30 days' or less notice without penalty and involving more
than $25,000; (xiii) contract which prohibits the Company from freely engaging
in business anywhere in the world; (xiv) contract for the distribution of the
products of the Company (including any distributor, sales and original equipment
manufacturer contract); (xv) franchise agreement; (xvi) license agreement or
agreement providing for the payment or receipt of royalties or other
compensation by the Company in connection with the intellectual property rights
listed in the Disclosure Schedule (other than shrink- wrap break-seal, click-on
or other similar licenses not executed by end-users); (xvii) contract or
commitment for capital expenditures in excess of $20,000, except any contract or
commitment for a single capital expenditure or commitment in the ordinary course
of business consistent with past practice not in excess of $50,000; (xviii)
agreement for the sale of any capital asset; (xix) contract with any affiliate
which in any way relates to the Company (other than for employment on customary
terms); or (xx) other agreement which is either material to the business of the
Company or was not entered into in the ordinary course of business involving
obligations to or from the Company in excess of $25,000 (other than agreements
required by Section 3.16(b) to be listed on the Disclosure Schedule).
(b) The Disclosure Schedule lists the following agreements, whether
oral or written, to which the Company is a party, which are currently in effect,
and which relate to the operation of the business of the Company: (i) contract
or group of related contracts with the same party for the purchase of products
or services by the Company under which the undelivered balance of such products
or services is in excess of $50,000; (ii) contract or group of related contracts
with the same party for the sale of products or services by the Company under
which the undelivered balance of such products or services (including, without
limitation, any free upgrades or ongoing services) has a sales price in excess
of $10,000; and (iii) sales agreement or other customer commitment (other than
the standard form of purchase order) which entitles any purchaser to a rebate or
right of set-off, to return any product of the Company after acceptance thereof
or to receive future services, upgrades or enhancements without full payment of
the Company's standard charges therefor, if the amount of such rebate, right of
set-off, product return or payment shortfall is in excess of $50,000.
(c) The Company has performed all material obligations required to be
performed through the date hereof by it in connection with the contracts or
commitments required to be disclosed in the Disclosure Schedule and is not in
receipt of any claim of default under any contract or commitment required to be
disclosed under such caption; the Company has no present intention of not
performing any material obligation pursuant to any contract or commitment
required to be disclosed under such caption; and the Company has no knowledge of
any breach or anticipated breach by any other party to any contract or
commitment required to be disclosed under such caption.
(d) Prior to the date of this Agreement, Parent has been supplied with
a true and correct copy of each written contract or commitment referred to in
the Disclosure Schedule, together with all amendments, waivers or other changes
thereto, subject in each case to applicable confidentiality provisions of which
Parent has been notified.
3.17 INTELLECTUAL PROPERTY RIGHTS.
(a) As used in this Agreement, the term "Intellectual Property Rights"
means patents, patent applications, trademarks, trademark applications, service
marks, trade names, corporate names, copyrights, mask works, trade secrets or
other intellectual property rights owned by, licensed to or otherwise controlled
by the Company or used in, developed for use in or necessary to the conduct of
the business of the Company as now conducted or relating to products, product
development tools or services presently under research and/or development in
their current state of development. The Disclosure Schedule describes all
patents, patent applications, trademarks, trademark applications, service marks,
trade names, corporate names, registered copyrights and mask works owned by,
licensed to (other than by means of shrink-wrap, break-seal, click-on or other
similar agreements not executed by end-users) or otherwise controlled by the
Company or used in, developed for use in or necessary to the conduct of the
business of the Company as now conducted or relating to products, product
development tools or services presently under research and/or development in
their current state of development.
The Company owns and possesses all right, title and interest,
or holds a valid license, in and to the rights set forth on the Disclosure
Schedule. The Disclosure Schedule describes all software products marketed or
that have been marketed by the Company within the past two years and identifies
the method of intellectual property protection utilized by the Company with
respect to such products. The Disclosure Schedule describes all Intellectual
Property Rights which have been licensed to third parties and those Intellectual
Property Rights which are licensed from third parties (in either case, other
than by means of shrink-wrap, break-seal, click-on or other similar agreements
not executed by end-users). Except as disclosed in the Disclosure Schedule, all
of the Intellectual Property Rights may be assumed by, and will become the
property of, the Surviving Corporation in the Merger, without the requirement
that any consent to assignment be obtained or any payment be made.
(b) All employees, contract workers, consultants and other agents of
the Company or any predecessor company have executed agreements sufficient to
vest in the Company ownership or the right to use the Intellectual Property
Rights on which they have performed services in the business of the Company as
currently conducted without the payment of royalties or penalties to such
individuals. None of the software products marketed or under research and/or
development by the Company or any predecessor company has entered the public
domain by disclosure of its source code or other documentation that would
disclose the source code, detailed design or internal functionality of the
software products. Except as set forth on the Disclosure Schedule, (i) the
Company has not received any notice of, nor are there any facts known to the
Company which indicate a likelihood of, any infringement or misappropriation by,
or conflict from, any third party with respect to the Intellectual Property
Rights (provided, that, for purposes of the representation and warranty in the
foregoing clause of this Section 3.17(b)(i) only, Intellectual Property Rights
shall not include rights relating to products, product development tools or
services which are under research and not yet marketed or under commercial
development); no claim by any third party contesting the validity of any
Intellectual Property Rights has been made, is currently outstanding or, to the
knowledge of the Company, is threatened in writing (or verbally to Terry Ross,
Jean- Luc Chatelain or Jeremy Rubin); (ii) the Company has not received any
notice of any infringement, misappropriation or violation of any intellectual
property rights of any third parties and, to its knowledge, the Company has not
infringed, misappropriated or otherwise violated any such intellectual property
rights; and (iii) to the knowledge of the Company, no infringement, illicit
copying, misappropriation or violation has occurred or will occur with respect
to products currently being sold by the Company or with respect to the products
currently under development (in their present state of development) or with
respect to the conduct of the business of the Company as now conducted. The
Company has not entered into any agreement restricting the Company from selling,
licensing or otherwise distributing any of its current products or products
under development to any class of customers, in any geographic area, during any
time period or in any segment of the market.
3.18 LITIGATION. There are no actions, suits, proceedings, orders or
investigations pending or, to the knowledge of the Company, threatened against
the Company, at law or in equity, or before or by any federal, state, municipal
or other governmental department, commission, board, bureau, agency or
instrumentality, domestic or foreign, nor, to the knowledge of the Company, is
there any basis therefor.
3.19 WARRANTIES; PRODUCTS.
(a) The Disclosure Schedule lists all claims outstanding, pending or,
to the knowledge of the Company, threatened in writing (or verbally to Terry
Ross, Jean-Luc Chatelain or Jeremy Rubin) for breach of any warranty relating to
any products sold by the Company prior to the date hereof. The description of
the product warranties and other material terms of sale of the Company set forth
under the caption referencing this Section 3.19 is correct and complete in all
material respects. The reserves for warranty claims on the Latest Balance Sheet
are consistent with the Company's prior practices and are fully adequate to
cover all warranty claims made or to be made against any products of the Company
sold prior to the date thereof.
(b) To the Company's knowledge, the Company's AutoRad 3.0 and Archive
Manager 2.0 products currently under development are expected to perform, when
such development is completed, substantially in accordance with the Company's
current technical specifications applicable to such products. The foregoing
representation and warranty (i) is contingent upon proper use of such products
in the applications for which they were intended as indicated in the Company's
current documentation for such products; (ii) applies only to reproducible
defects; (iii) does not apply to any third party hardware or software; (iv)
applies only to such products generally as a class and does not apply to any
particular unit of product; (v) assumes that such products have been updated
with all error corrections and other updates developed by the Company; and (vi)
does not apply to software defects, bugs, or non-operable features which do not
materially impair the operation of such product as a whole.
3.20 EMPLOYEES. (a) To the knowledge of the Company, no executive
employee of the Company and no group of the employees of the Company has any
plans to terminate his, her or their employment; (b) the Company has complied
with all laws relating to the employment of labor, including provisions thereof
relating to wages, hours, equal opportunity, collective bargaining and the
payment of social security and other taxes; (c) the Company has no labor
relations problem; (d) there are no workers' compensation claims pending against
the Company nor is the Company aware of any facts that would give rise to such a
claim; (e) to the knowledge of the Company, no employee of the Company is
subject to any secrecy or noncompetition agreement or any other agreement or
restriction of any kind that would impede in any way the ability of such
employee to carry out fully all activities of such employee in furtherance of
the business of the Company; and (f) no employee or former employee of the
Company, or any predecessor has any claim with respect to any Intellectual
Property Rights and which might have a material adverse effect on the Company's
business, financial conditions or results of operations. The Disclosure Schedule
lists, as of the date set forth in the Disclosure Schedule, each employee of the
Company. The Disclosure Schedule also states the position, title, remuneration
(including any scheduled salary or remuneration increases), date of employment
and accrued vacation pay of each such employee.
3.21 EMPLOYEE BENEFIT PLANS.
(a) Definitions. For the purposes of this Section 3.21, unless the
context clearly requires otherwise, the term "Plan" or "Plans" includes all
employee benefit plans as defined in Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended ("ERISA"), and all other benefit
arrangements (including, without limitation, any employment agreement or any
program, agreement, policy or commitment providing for insurance coverage of
employees, workers' compensation, disability benefits, supplemental unemployment
benefits, vacation benefits, retirement benefits, life, health, disability or
accidental benefits) applicable to the employees of the Company, to which the
Company contributes, or which the Company has committed to implement for its
employees prior to the date of this Agreement. Unless the context clearly
requires otherwise, "Plan" or "Plans" shall also include any similar program or
arrangement maintained by any organization affiliated by ownership with the
Company for which the Company is or could be completely or partially liable for
the funding or the administration either as a matter of law or by agreement.
(b) Except as disclosed on the Disclosure Schedule:
(i) Full Disclosure of All Plans. With respect to all
employees and former employees of the Company (and all dependents and
beneficiaries of such employees and former employees):
(A) The Company does not maintain or contribute to
any nonqualified deferred compensation or retirement plans,
contracts or arrangements;
(B) The Company does not maintain or contribute to
any qualified defined contribution plans (as defined in
Section 3(34) of ERISA or Section 414(i) of the Code);
(C) The Company does not maintain or contribute to
any qualified defined benefit plans (as defined in Section
3(35) of ERISA or Section 414(j) of the Code) ("Defined
Benefit Plans"); and
(D) The Company does not maintain or contribute to
any employee welfare benefit plans (as defined in Section 3(1)
of ERISA).
(ii) Funding. With respect to the Plans, (A) all required
contributions which are due have either been made or properly accrued
and (B) the Company is not liable for any "accumulated funding
deficiency" as that term is defined in Section 412 of the Code or any
penalty or excise tax in connection therewith.
(iii) Plan Documents. With respect to all Plans sponsored or
administered by the Company and with respect to any other Plan if
available to the Company, the Company has furnished Parent with true
and complete copies of (A) the most recent determination letter, if
any, received by the Company from the Internal Revenue Service
regarding each qualified Plan, (B) the Form 5500 and all Schedules and
accompanying financial statements, if any, for each Plan for which such
form is required to be filed for the three most recent fiscal Plan
years, (C) the most recently prepared actuarial valuation report, if
any, for each Plan, and (D) copies of the current Plan documents, trust
agreements, insurance contracts and all related contracts and documents
(including any material employee communications) with respect to each
Plan.
(iv) Defined Benefit Plans. Neither the Company nor any
affiliate of the Company maintains or has maintained any Defined
Benefit Plans for which the Company or Parent have or will have any
liability or, which if terminated, could result in any liability to the
Company or Parent under Title IV of ERISA. There are no unfunded vested
liabilities (determined using the assumptions used by the Plan for
funding and without regard to future salary increases) with respect to
Defined Benefit Plans sponsored by the Company. There have been no
reportable events under Section 4043 of ERISA (with respect to which
the 30-day notice requirement has not been waived by regulation) with
respect to any Defined Benefit Plan maintained by the Company. No
Defined Benefit Plan has been terminated that will result in a material
liability by the Company to the Pension Benefit Guaranty Corporation.
(v) Multiemployer Plans. The Company has no actual or
potential liabilities under Sections 4201 or 4205 of ERISA for any
complete or partial withdrawal from any multiemployer plan.
(vi) Fiduciary Breach; Claims. Neither the Company nor any of
its directors, officers, employees or other "fiduciaries" (as such term
is defined in Section 3(21) of ERISA) has committed any breach of
fiduciary duty imposed by ERISA or any other applicable law with
respect to the Plans which would subject the Company, directly or
indirectly, to any liability under ERISA or any applicable law. There
are no actions, suits or claims pending against the Company relating to
benefits other than routine, uncontested claims for benefits.
(vii) Prohibited Transaction. Neither the Company nor any
officer, director, employee, agent or fiduciary of any Plan has
incurred any liability for any civil penalty imposed by Section 4975 of
the Code or Section 502(i) of ERISA.
(viii) Material Compliance With Law. All Plans have been
consistently administered in accordance with their terms. To the extent
required either as a matter of law or to obtain the intended tax
treatment and tax benefits, all Plans comply with the requirements of
ERISA and the Code. All Tax information returns or reports and all
other required filings, disclosures and contributions have been made
with respect to all Plans. No condition exists that limits the right of
the Company to amend or terminate any such Plan (except as provided in
such Plans or limited under ERISA or the Code).
(ix) VEBA Funding. No Plan is funded in whole or in part
through a voluntary employees' beneficiary association exempt from tax
under Section 501(c)(9) of the Code. The limitations under Sections 419
and 419A of the Code have been computed, all unrelated business income
tax returns have been filed and appropriate adjustments have been made
on all other Tax returns.
(x) Retirement and COBRA Benefits. The Company has no actual
or potential liability under current law for benefits after separation
from employment other than (i) benefits under Plans described in
clauses (A), (B) or (C) of Section 3.18(b)(i), and (ii) health care
continuation benefits described in Section 4980B of the Code or Part G
of Subtitle B of Title I of ERISA or any comparable provisions under
the laws of any state.
(xi) Collective Bargaining. No Plan is maintained in whole or
in part pursuant to collective bargaining.
(xii) Parachute Payments. No Plan requires or would result,
separately or in the aggregate, in the payment of any "excess parachute
payments" within the meaning of Section 280G of the Code, and the
consummation of the transactions contemplated by this Agreement will
not be a factor in causing payments to be made by Patent or the Company
that are not deductible (in whole or in part) under Section 280G of the
Code.
3.22 INSURANCE. The Disclosure Schedule lists and briefly describes
each material insurance policy maintained by the Company with respect to the
properties, assets and operations of the Company and sets forth the date of
expiration of each such insurance policy. All of such insurance policies are in
full force and effect and are issued by insurers of recognized responsibility.
The Company is not in default with respect to its obligations under any of such
insurance policies.
3.23 AFFILIATE TRANSACTIONS. Other than pursuant to this Agreement, to
the knowledge of the Company, no officer, director or employee of the Company or
any member of the immediate family of any such officer, director or employee, or
any entity in which any of such persons owns any beneficial interest (other than
any publicly-held corporation whose stock is traded on a national securities
exchange or in the over-the-counter market and less than one percent of the
stock of which is beneficially owned by any of such persons) (collectively
"insiders"), has any agreement with the Company (other than normal employment
arrangements) or any interest in any property, real, personal or mixed, tangible
or intangible, used in or pertaining to the business of the Company (other than
ownership of capital stock of the Company). To the knowledge of the Company,
none of the insiders has any direct or indirect interest (other than beneficial
ownership of less than one percent of the stock of a publicly-held corporation
whose stock is traded on a national securities exchange or in the
over-the-counter market) in any competitor, supplier or customer of the Company
or in any person, firm or entity from whom or to whom the Company leases any
material property, or in any other person, firm or entity with whom the Company
transacts material business of any nature. For purposes of this Section 3.23,
the members of the immediate family of an officer, director or employee shall
consist of the spouse, parents, children, siblings, mothers- and fathers-in-law,
sons- and daughters-in-law, and brothers- and sisters-in-law of such officer,
director or employee. All agreements and transactions between the Company and
any insider identified in the Disclosure Schedule were made for bona fide
business purposes on terms no less favorable than could be obtained from an
unaffiliated third party.
3.24 CUSTOMERS AND SUPPLIERS. The Disclosure Schedule lists the 50
largest customers and the 50 largest suppliers of the Company for the
twelve-month period ended December 31, 1996, and sets forth opposite the name of
each such customer or supplier the approximate amount of net sales or purchases
by the Company attributable to such customer or supplier for such period. Since
the Balance Sheet Date, no customer or supplier listed on the Disclosure
Schedule has indicated in writing (or verbally to Terry Ross, Jean-Luc Chatelain
or Jeremy Rubin) that it will stop or materially decrease the rate of business
done with the Company.
3.25 OFFICERS AND DIRECTORS; BANK ACCOUNTS. The Disclosure Schedule
lists all officers and directors of the Company and all of the bank accounts of
the Company (designating each authorized signer).
3.26 COMPLIANCE WITH LAWS; PERMITS.
(a) The Company, its predecessors and their respective officers,
directors, agents and employees have complied in all material respects with all
applicable laws, regulations and other requirements, including, but not limited
to, federal, state, local and foreign laws, ordinances, rules, regulations and
other requirements pertaining to product labeling, consumer products safety,
equal employment opportunity, employee retirement, affirmative action and other
hiring practices, occupational safety and health, workers' compensation,
unemployment and building and zoning codes, which materially affect the business
of the Company or the Real Property and to which the Company or its predecessors
may be subject, and no claims have been filed against the Company alleging a
violation of any such laws, regulations or other requirements. The Company has
no knowledge of any action, pending or threatened, to change the zoning or
building ordinances or any other laws, rules, regulations or ordinances
affecting the Real Property. The Company is not relying on any exemption from or
deferral of any such applicable law, regulation or other requirement that, to
the knowledge of the Company, would not be available to the Surviving
Corporation after the Effective Time.
(b) The Company has, in full force and effect, all licenses, permits
and certificates, from federal, state, local and foreign authorities (including,
without limitation, federal and state agencies regulating occupational health
and safety) necessary to conduct its business as presently conducted and own and
operate its properties (other than Environmental Permits, as such term is
defined in Section 3.27(c) hereof) (collectively, the "Permits"). The Company
has conducted its business in compliance with all material terms and conditions
of the Permits.
(c) The Company has not made or agreed to make gifts of money, other
property or similar benefits (other than incidental gifts of articles of nominal
value) to any actual or potential customer, supplier, governmental employee or
any other person in a position to assist or hinder the Company in connection
with any actual or proposed transaction.
3.27 ENVIRONMENTAL MATTERS.
(a) As used in this Section 3.27, the following terms shall have the
following meanings:
(i) "Hazardous Materials" means any dangerous, toxic or
hazardous pollutant, contaminant, chemical, waste, material or
substance as defined in or governed by any federal, state or local law,
statute, code, ordinance, regulation, rule or other requirement
relating to such substance or otherwise relating to the environment or
human health or safety, including without limitation any waste,
material, substance, pollutant or contaminant that has been designated
by any governmental authority as capable of endangering or posing a
risk of injury to or an adverse effect on human health or safety,
property or the environment.
(ii) "Environmental Laws" means all applicable federal, state,
local and foreign laws, rules, regulations, codes, ordinances, orders,
decrees, directives, permits, licenses and judgments relating to
pollution, contamination or protection of the environment (including,
without limitation, all applicable federal, state, local and foreign
laws, rules, regulations, codes, ordinances, orders, decrees,
directives, permits, licenses and judgments relating to Hazardous
Materials in effect as of the date of this Agreement).
(iii) "Release" shall mean the spilling, leaking, disposing,
discharging, emitting, depositing, ejecting, leaching, escaping or any
other release or threatened release, however defined, whether
intentional or unintentional, of any Hazardous Material.
(b) The Company and the Company's activities at the Real Property are
in material compliance with all applicable Environmental Laws, and to the
Company's knowledge, the Real Property is in material compliance with all
applicable Environmental Laws to the extent such compliance is the obligation of
the Company.
(c) The Company has obtained, and maintained in full force and effect,
all environmental permits, licenses, certificates of compliance, approvals and
other authorizations necessary to conduct its business on the Real Property as
presently conducted (collectively, the "Environmental Permits"). A true and
correct copy of each such Environmental Permit shall be provided by the Company
to Parent at least fourteen (14) days prior to the Closing. The Company has
conducted its business in compliance with all terms and conditions of the
Environmental Permits. The Company has filed all reports and notifications
required to be filed under and pursuant to all applicable Environmental Laws.
(d) (i) No Hazardous Materials have been generated, treated, contained,
handled, located, used, manufactured, processed, buried, incinerated, deposited,
stored, or Released in violation of any Environmental Law on, under or about any
part of the Real Property by the Company or its agents during the period the
Company was in possession thereof, (ii) to the knowledge of the Company, the
Real Property and any improvements thereon, contain no asbestos, urea,
formaldehyde, radon at levels above natural background, polychlorinated
biphenyls (PCBs) or pesticides except to the extent that the Company has no
liability with respect to the foregoing, and (iii) to the knowledge of the
Company, no above-ground or underground storage tanks are located on, under or
about the Real Property except to the extent that the Company has no liability
with respect to the foregoing.
(e) The Company has not received any notice alleging in any manner that
any of them is, or might be potentially responsible for any Release of Hazardous
Materials, or any costs arising under or violation of Environmental Laws.
(f) To the knowledge of the Company, no expenditure by the Company will
be required in order for Parent, Merger Subsidiary or the Surviving Corporation
to comply with any Environmental Laws in effect at the time of the Closing in
connection with the operation or continued operation of the business of the
Company or the Real Property in a manner consistent with the current operation
thereof by the Company.
(g) To the knowledge of the Company, the Company and the Real Property
are not and have not been listed on the United States Environmental Protection
Agency National Priorities List of Hazardous Waste Sites, or any other list,
schedule, law, inventory or record of hazardous or solid waste sites maintained
by any federal, state or local agency except to the extent the Company has no
liability in connection with such listing of the Real Property.
(h) The Company has disclosed and delivered to Parent all environmental
reports and investigations which the Company has obtained or ordered with
respect to the business of the Company and the Real Property.
(i) To the knowledge of the Company, no part of the business of the
Company, or the Real Property has been used as a landfill, dump or other
disposal, storage, transfer, handling or treatment area for Hazardous Materials,
or as a gasoline service station or a facility for selling, dispensing, storing,
transferring, disposing or handling petroleum and/or petroleum products except
to the extent that the Company has no liability for such use of the Real
Property.
(j) To the knowledge of the Company, no lien has been attached or filed
against the Company or the Real Property in favor of any governmental or private
entity for (i) any liability or imposition of costs under or violation of any
applicable Environmental Law; or (ii) any Release of Hazardous Materials, except
to the extent the Company has no liability for such lien, liability, imposition
or Release with respect to the Real Property.
(k) The storage, transportation, handling, use or disposal, if any, by
the Company of Hazardous Materials on or under the Real Property and/or disposal
elsewhere by the Company, if any, of Hazardous Materials generated on or from
the Real Property is currently, and at all times has been, in compliance in all
materials respects with all applicable Environmental Laws. To the knowledge of
the Company, the Company has not transported or arranged for the transportation
of any Hazardous Materials or other material or substances to any location which
is: (i) listed on the National Priorities List; or (ii) listed for possible
inclusion on the National Priorities List, in CERCLA or on any similar state
list.
(l) For purposes of the representations and warranties provided in
Sections 3.27(d), (f), (g), (h), (i), (j) and (k) , the term "Real Property"
shall include all real property used or occupied by the Company currently or
previously used or occupied by the Company and its predecessors.
3.28 BROKERAGE. No third party shall be entitled to receive any
brokerage commissions, finder's fees, fees for financial advisory services or
similar compensation in connection with the transactions contemplated by this
Agreement based on any arrangement or agreement made by or on behalf of the
Company.
3.29 DISCLOSURE. Neither this Agreement nor any of the exhibits hereto
nor any of the documents delivered by or on behalf of the Company pursuant to
Article VII hereof, the Disclosure Schedule or any of the financial statements
referred to in Section 3.08 hereof contains any untrue statement of a material
fact regarding the Company or any of the other matters dealt with in this
Article III relating to the Company or the transactions contemplated by this
Agreement. This Agreement, the exhibits hereto, the documents delivered to
Parent by or on behalf of the Company pursuant to Article VII hereof, the
Disclosure Schedule and the financial statements referred to in Section 3.08
hereof do not omit any material fact necessary to make the statements contained
herein or therein, in light of the circumstances in which they were made, not
misleading, and there is no fact which has not been disclosed to Parent of which
the Company or any officer of the Company is aware which materially affects
adversely the assets, financial condition, relations with key management
employees or key OEM's, operating results or business condition of the Company.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER
SUBSIDIARY
Parent and Merger Subsidiary, jointly and severally, hereby represent
and warrant to the Company that:
4.01 INCORPORATION AND CORPORATE POWER. Each of Parent and Merger
Subsidiary is a corporation duly incorporated, validly existing and in good
standing under the laws of the State of Delaware, with the requisite corporate
power and authority to execute and deliver this Agreement and the agreements
identified in Article XI to which it is a party (the "Ancillary Agreements") and
perform its obligations hereunder and thereunder. The Merger Subsidiary has the
requisite corporate power and authority to execute and deliver the Certificate
of Merger and perform its obligations thereunder.
4.02 EXECUTION, DELIVERY; VALID AND BINDING AGREEMENT. The execution,
delivery and performance of this Agreement and the Ancillary Agreements by
Parent and Merger Subsidiary, and the Certificate of Merger by Merger
Subsidiary, and the consummation of the transactions contemplated hereby and
thereby have been duly and validly authorized by all requisite corporate action,
and no other corporate proceedings on their part are necessary to authorize the
execution, delivery or performance of this Agreement, the Certificate of Merger
or the Ancillary Agreements. This Agreement and the Ancillary Agreements have
been duly executed and delivered by Parent and Merger Subsidiary and constitute
the valid and binding obligation of Parent and Merger Subsidiary, enforceable in
accordance with their terms, and the Certificate of Merger, when executed and
delivered by Merger Subsidiary, will constitute the valid and binding obligation
of Merger Subsidiary, enforceable in accordance with its terms.
4.03 NO BREACH. The execution, delivery and performance of this
Agreement and the Ancillary Agreements by Parent and Merger Subsidiary, and the
Certificate of Merger by Merger Subsidiary, and the consummation by Parent and
Merger Subsidiary of the transactions contemplated hereby and thereby do not
conflict with or result in any breach of any of the provisions of, constitute a
default under, result in a violation of, result in the creation of a right of
termination or acceleration or any lien, security interest, charge or
encumbrance upon any assets of Parent or Merger Subsidiary, or require any
authorization, consent, approval, exemption or other action by or notice to any
court or other governmental body, under the provisions of the Certificate of
Incorporation or Bylaws of either Parent or Merger Subsidiary or any indenture,
mortgage, lease, loan agreement or other agreement or instrument by which either
Parent or Merger Subsidiary is bound or affected, or any law, statute, rule or
regulation or order, judgment or decree to which either Parent or Merger
Subsidiary is subject.
4.04 MERGER SUBSIDIARY. All of the outstanding capital stock of Merger
Subsidiary is owned by Parent free and clear of any lien, claim or encumbrance
or any agreement with respect thereto. Since the date of its incorporation,
Merger Subsidiary has not engaged in any activity of any nature except in
connection with or as contemplated by this Agreement, the Certificate of Merger
or the Ancillary Agreements.
4.05 GOVERNMENTAL AUTHORITIES; CONSENTS. Except for the applicable
requirements of the HSR Act, except for the filing of the Certificate of Merger
with the Secretary of State of the State of Delaware, and except for consents,
waivers, approvals, orders, authorizations, registrations, declarations and
filings as may be required under applicable state and federal securities laws
and the laws of any foreign country, (a) neither Parent or Merger Subsidiary is
required to submit any notice, report or other filing with any governmental
authority in connection with the execution or delivery by it of this Agreement,
the Certificate of Merger or the Key Management Agreements or the consummation
of the transactions contemplated hereby or thereby, and (b) no consent, approval
or authorization of any governmental or regulatory authority or any other party
or person is required to be obtained by either Parent or Merger Subsidiary in
connection with its execution, delivery and performance of this Agreement, the
Certificate of Merger or the Ancillary Agreements or the transactions
contemplated hereby or thereby.
4.06 BROKERAGE. Except for fees and compensation to Goldman Sachs & Co.
(which shall be paid in full by Parent), no third party shall be entitled to
receive any brokerage commissions, finder's fees, fees for financial advisory
services or similar compensation in connection with the transactions
contemplated by this Agreement based on any arrangement or agreement made by or
on behalf of Parent or Merger Subsidiary.
ARTICLE V
COVENANTS OF THE COMPANY
5.01 CONDUCT OF THE BUSINESS. The Company shall observe each term set
forth in this Section 5.01 and agrees that, from the date hereof until the
Effective Time, unless otherwise consented to by Parent or Merger Subsidiary in
writing, except for Permitted Transactions (as defined in Section 5.01(i)):
(a) The business of the Company shall be conducted only in, and the
Company shall not take any action except in, the ordinary course of the
Company's business, on an arm's-length basis and in accordance in all material
respects with all applicable laws, rules and regulations and the Company's past
custom and practice;
(b) The Company shall not, directly or indirectly, do or permit to
occur any of the following: (i) issue or sell any additional shares of capital
stock, or any options, warrants, conversion privileges or rights of any kind to
acquire any shares of, any of its capital stock (except (A) the Picker Shares
and Warrants, (B) upon exercise of currently outstanding options and warrants
set forth in the Disclosure Schedule); and (C) the granting of options to
purchase not more than 60,000 shares of Company Common Stock (when added to the
number of shares of Company Common Stock subject to other options granted by the
Company since March 12, 1997) to employees below the level of Vice President in
accordance with the terms and conditions of the Cemax-Icon, Inc. 1996 Stock
Option Plan, which options shall have an exercise price of not less than fair
market value on the date of grant; (ii) sell, pledge, dispose of or encumber any
of its assets, except in the ordinary course of business; (iii) amend or propose
to amend its Certificate of Incorporation or Bylaws; (iv) split, combine or
reclassify any outstanding shares of capital stock, or declare, set aside or pay
any dividend or other distribution payable in cash, stock, property or otherwise
with respect to shares of Capital Stock; (v) redeem, purchase or acquire or
offer to acquire any shares of capital stock or other securities (except for the
purchase of the Restricted Common Stock as provided by Section 7.01(p) hereof);
(vi) acquire (by merger, exchange, consolidation, acquisition of stock or assets
or otherwise) any corporation, partnership, joint venture or other business
organization or division or material assets thereof; (vii) incur any
indebtedness for borrowed money or issue any debt securities except the
borrowing of working capital in the ordinary course of business and consistent
with past practice; (viii) accelerate or defer the payment of undisputed
accounts payable or other accrued expenses owned to trade creditors or other
third parties having business relationships with the Company; (ix) accelerate,
beyond the normal collection cycle, or defer collection of manufacturers'
rebates, promotional allowances and other accounts receivable; (x) enter into or
propose to enter into, or modify or propose to modify, any Lease or agreement or
arrangement to use or occupy real property or exercise or waive any option, or
consent to any modification, act or omission by any landlord requiring tenant's
consent under any Lease (except, with the prior consent of Parent (which shall
not be unreasonably withheld), office leases in Seattle and Atlanta as
previously discussed with Parent); (xi) enter into or propose to enter into or
modify or propose to modify any agreement, arrangement or understanding with
respect to any of the matters set forth in this Section 5.01(b) in any material
respect; (xii) purchase inventories or supplies for its business in a manner
outside the ordinary course of business, inconsistent in amount, nature or
composition with prior practice; (xiii) sell, lease, license or otherwise
dispose of any material assets or properties, other than in the ordinary course
of business; (xiv) accelerate or defer the construction or improvements at any
of the locations of its business; or (xv) accelerate or defer the purchase of
material fixtures, equipment, leasehold improvements, vehicles, other items of
machinery and equipment and other capital expenditures;
(c) The Company shall not, directly or indirectly, (i) enter into or
modify any employment, severance or similar agreements or arrangements with, or
grant any bonuses, salary increases, severance or termination pay to, any
officers or directors or consultants; or (ii) in the case of employees, officers
or consultants who earn in excess of $75,000 per year, take any action with
respect to the grant of any bonuses, salary increases, severance or termination
pay or with respect to any increase of benefits payable in effect on the date
hereof;
(d) Except as set forth on the Disclosure Schedule, the Company shall
not adopt or amend any bonus, profit sharing, compensation, stock option,
pension, retirement, deferred compensation, employment or other employee benefit
plan, trust, fund or group arrangement for the benefit or welfare of any
employees or any bonus, profit sharing, compensation, stock option, pension,
retirement, deferred compensation, employment or other employee benefit plan,
agreement, trust, fund or arrangements for the benefit or welfare of any
director;
(e) The Company shall not cancel or terminate its current insurance
policies or cause any of the coverage thereunder to lapse, unless simultaneously
with such termination, cancellation or lapse, replacement policies providing
coverage equal to or greater than the coverage under the canceled, terminated or
lapsed policies for substantially similar premiums are in full force and effect;
(f) The Company shall (i) use commercially reasonable efforts to
preserve intact its business organization and goodwill, keep available the
services of its officers and employees as a group and maintain satisfactory
relationships with suppliers, distributors, customers and others with which it
has business relationships; (ii) confer on a regular and frequent basis with
representatives of Parent to report operational matters and the general status
of ongoing operations; (iii) not intentionally take any action which would
render, or which reasonably may be expected to render, any representation or
warranty made by it in this Agreement untrue at the Closing; (iv) notify Parent
of any emergency or other change in the normal course of its business or in the
operation of its properties and of any governmental or third party complaints,
investigations or hearings (or communications indicating that the same may be
contemplated) if such emergency, change, complaint, investigation or hearing
would be material, individually or in the aggregate, to the business, operations
or financial condition of the Company or to the Company's, Parent's or Merger
Subsidiary's ability to consummate the transactions contemplated by this
Agreement; and (v) promptly notify Parent and Merger Subsidiary in writing if
the Company shall discover that any representation or warranty made by it in
this Agreement was when made, or has subsequently become, untrue in any material
respect;
(g) Except as set forth in the Disclosure Schedule, the Company shall
(i) file any Tax returns, elections or information statements with respect to
any liabilities for Taxes of the Company or other matters relating to Taxes of
the Company which pursuant to applicable law must be filed (after taking into
account any properly applicable extensions of the due date of such returns,
elections or information statements) prior to the Closing; provided, however,
that the Company shall not file any such Tax returns, or other returns,
elections, claims for refund or information statements with respect to any
liabilities for Taxes (other than federal, state or local sales, use,
withholding or employment tax returns or statements) for any Tax period, or
consent to any adjustment or otherwise compromise or settle any matters with
respect to Taxes, without prior consultation with and consent of Parent (which
consent shall not be unreasonably withheld); (ii) promptly upon filing provide
copies of any such Tax returns, elections or information statements to Parent
and Merger Subsidiary; (iii) make or rescind any such Tax elections or other
discretionary positions with respect to Taxes taken by or affecting the Company
only upon prior consultation with and consent of Parent (which consent shall not
be unreasonably withheld); (iv) not amend any Return; and (v) not increase the
rate or policy for any accrual or reserve for Taxes or otherwise accrue therefor
in a manner inconsistent with its practices for previous periods as reflected in
the Latest Financial Statements; and (vi) not change any of its methods of
reporting income or deductions for federal income Tax purposes from those
employed in the preparation of the federal income Tax returns for the taxable
year ended December 31, 1995;
(h) The Company shall not perform any act referenced by (or omit to
perform any act which omission is referenced by) the terms of Section 3.11; and
(i) For purposes of this Section 5.01, "Permitted Transactions" include
(i) the port to NT of the AccuRad product, (ii) the pursuit of the U.S.
government DIN-PACS contract, (iii) the issuance to Picker, Inc. of up to 85,000
shares of Company Common Stock, at a price of at least $12.00 per share, and
warrants to purchase up to 85,000 shares of Company Common Stock, with an
exercise price of at least $17.00 per share (collectively, the "Picker Shares
and Warrants"), in the event Picker, Inc. enters into an OEM agreement with
Cemax- Icon (assignable by operation of law without modification of terms) with
a first-year commitment of at least $2.5 million in purchases of the Company's
products and containing terms and conditions no less favorable than terms and
conditions previously discussed with Parent, and (iv) the execution of an OEM
agreement with Fuji containing terms and conditions no less favorable than terms
and conditions previously discussed with Parent; provided, that, the aggregate
expenditures incurred or expected to be incurred by the Company in connection
with the Permitted Transactions described in clauses (i) and (ii) of this
Section 5.01(i) shall not exceed $2,000,000.
5.02 ACCESS TO BOOKS AND RECORDS. Between the date hereof and the
Closing Date, the Company shall afford to Parent and authorized representatives
(the "Parent's Representatives") full access at all reasonable times and upon
reasonable notice to the offices, properties, books, records, officers,
employees and other items of the Company, and the work papers of Ernst & Young
LLP and Mohler, Nixon and Williams LLP, the Company's independent accountants,
relating to work done by Ernst & Young LLP and Mohler, Nixon and Williams LLP
and otherwise provide such assistance as is reasonably requested by Parent and
Merger Subsidiary in order that Parent and Merger Subsidiary may have a full
opportunity to make such investigation and evaluation as it shall reasonably
desire to make of the business and affairs of the Company. In addition, the
Company, and its officers and directors shall cooperate fully (including
providing introductions, where necessary) with Parent and Merger Subsidiary and
to enable Parent, with prior written notice to the Company, to contact such
third parties, including customers, prospective customers, specifying agencies,
vendors, or suppliers of the Company as Parent and Merger Subsidiary deems
reasonably necessary to complete its due diligence.
5.03 MEETING OF STOCKHOLDERS. The Company shall cause to be duly called
and held, not later than 30 days following the effective date of the
Registration Statement (as defined in Section 6.03), a meeting of its
stockholders and will direct that this Agreement be submitted to a vote at such
meeting. Parent will (a) cause proper notice of such meeting to be given to its
stockholders in compliance with the Delaware Act, other applicable laws and
regulations and the Company's Certificate of Incorporation and Bylaws; (b)
recommend by the affirmative vote of all members of its Board of Directors a
vote in favor of approval of this Agreement; and (c) use its best efforts to
solicit from its stockholders proxies in favor thereof.
5.04 REGULATORY FILINGS. The Company shall, as promptly as practicable
after the execution of this Agreement, make or cause to be made all filings and
submissions under the HSR Act and any other laws or regulations applicable to
the Company for the consummation of the transactions contemplated herein. The
Company will coordinate and cooperate with Parent and Merger Subsidiary in
exchanging such information, will not make any such filing without providing to
Parent and Merger Subsidiary a final copy thereof for their review and consent
at least two full business days in advance of the proposed filing and will
provide such reasonable assistance as Parent and Merger Subsidiary may request
in connection with all of the foregoing.
5.05 REGISTRATION STATEMENT. The Company will furnish, or cause to be
furnished, to Parent all the information concerning the Company and its
subsidiaries required for inclusion in the Registration Statement and the
Prospectus- Proxy Statement (as defined in Section 6.03) or any statement or
application made by Parent to any governmental body in connection with the
transactions contemplated by this Agreement. Any financial statement for any
fiscal year provided under this paragraph must include the audit opinion and the
consent of Ernest & Young LLP, as independent accounts to the Company, to use
such opinion in such Registration Statement. None of the information regarding
the Company supplied or to be supplied by the Company for inclusion in the
Registration Statement and any other documents to be filed with the SEC or any
regulatory authority in connection with the transactions contemplated hereby
will, at the respective times the Registration Statement, Prospectus-Proxy
Statement and other documents are filed with the SEC or any regulatory authority
and, in the case of the Registration Statement, when it becomes effective and,
with respect to the Prospectus-Proxy Statement, when mailed, and, in the case of
the Prospectus- Proxy Statement or any amendment thereof or supplement thereto,
at the time of the meeting of stockholders referred to in Section 5.03 hereof
and at the Effective Time, contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make
the statements contained therein, in light of the circumstances under which they
were made, not misleading. All documents which the Company is responsible for
filing with the SEC and any other regulatory authority in connection with the
Merger will comply as to form in all material respects with the provisions of
applicable law.
5.06 FINANCIAL STATEMENTS. The Company shall have prepared and
delivered to Parent all quarterly and monthly financial statements for any
periods ending after the date of the Latest Balance Sheet and at least 30 days
prior to the Closing Date.
5.07 CONDITIONS. The Company shall take all commercially reasonable
actions necessary or desirable to cause the conditions set forth in Section 7.01
to be satisfied on or prior to June 30, 1997, if possible, but not later than
August 31, 1997, and to consummate the transactions contemplated herein as soon
as reasonably possible after the satisfaction thereof. Without limiting the
generality of the foregoing, the Company shall obtain, prior to the Closing
Date, all consents or waivers to the transactions contemplated by this Agreement
that may be required under any of the agreements or commitments of the Company
that are material to the business of the Company.
5.08 NO NEGOTIATIONS. Except in connection with the issuance of the
Picker Shares and Warrants (which discussions, proposals, offers and issuances
shall be limited to the Picker Shares and Warrants), the Company shall not,
directly or indirectly, through any officer, director, stockholder, agent or
otherwise, solicit, initiate or encourage submission of any proposal or offer
from any person or entity (including any of its or their officers, stockholders
or employees) relating to any liquidation, dissolution, recapitalization,
merger, consolidation or acquisition or purchase of all or a material portion of
the assets of, or any equity interest in, the Company or other similar
transaction or business combination involving the Company, or participate in any
negotiations regarding, or furnish to any other person any information with
respect to, or otherwise cooperate in anyway with, or assist or participate in,
facilitate or encourage, any effort or attempt by any other person or entity to
do or seek any of the foregoing. The Company shall promptly notify Parent if any
such proposal or offer, or any inquiry from or contact with any person with
respect thereto, is made and shall promptly provide Parent with such information
regarding such proposal, offer, inquiry or contact as Parent may request.
5.09 SUBSTITUTE OPTIONS AND WARRANTS. At the time of the distribution
of the Prospectus-Proxy Statement, the Company will distribute the Prospectus-
Proxy Statement to each holder of an Outstanding Stock Option or Outstanding
Stock Warrant. The Prospectus-Proxy Statement will indicate that (a) each holder
of an Outstanding Stock Option or Outstanding Stock Warrant has the right to
exercise such Outstanding Stock Option or Outstanding Stock Warrant to the
extent exercisable at the Effective Time, and (b) if not exercised to the extent
of the full number of shares subject thereto prior to the Effective Time, each
Outstanding Stock Option or Outstanding Stock Warrant will be converted into a
Substitute Option or Substitute Warrant, as the case may be, in accordance with
Section 2.01.
ARTICLE VI
COVENANTS OF PARENT AND MERGER SUBSIDIARY
Parent and Merger Subsidiary covenant and agree with the Company as
follows:
6.01 REGULATORY FILINGS. Parent or Merger Subsidiary shall, as promptly
as practicable after the execution of the Agreement, make or cause to be made
all filings and submissions under the HSR Act and any other laws or regulations
applicable to Parent and Merger Subsidiary for the consummation of the
transactions contemplated herein. Parent and Merger Subsidiary will coordinate
and cooperate with the Company in exchanging such information, will not make any
such filing without providing to the Company a final copy thereof for its review
and consent at least two full business days in advance of the proposed filing
and will provide such reasonable assistance as the Company may request in
connection with all of the foregoing.
6.02 CONDITIONS. Parent or Merger Subsidiary shall take all
commercially reasonable actions necessary or desirable to cause the conditions
set forth in Section 7.02 to be satisfied on or prior to June 30, 1997, if
possible, but not later than August 31, 1997, and to consummate the transactions
contemplated herein as soon as reasonably possible after the satisfaction
thereof (but in any event within three business days after such date).
6.03 REGISTRATION STATEMENT. As promptly as practicable after the
execution of this Agreement, Parent will file with the SEC a registration
statement on Form S-4 under the Securities Act relating to the Contingent
Payment Rights and the shares of Parent Common Stock which may be delivered to
the Company's stockholders pursuant to the Contingent Payment Rights (the
"Registration Statement"), and any other applicable documents, which will
include a prospectus and proxy statement (as amended or supplemented by any
amendment or supplement filed by Parent, the "Prospectus-Proxy Statement"), and
will use its best efforts to cause the Registration Statement to become
effective. At the time the Registration Statement becomes effective, the
Registration Statement will comply in all material respects with the provisions
of the Securities Act and the published rules and regulations thereunder, and
will not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein not false or misleading, and at the time of mailing thereof to the
stockholders of the Company, at the time of the stockholders' meeting referred
to in Section 5.03 hereof and at the Effective Time, the Prospectus-Proxy
Statement will not contain any untrue statement of a material fact or omit to
state any material fact necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading; provided, however,
that none of the provisions of this subparagraph shall apply to statements in or
omissions from the Registration Statement or the Prospectus-Proxy Statement made
in reliance upon and in conformity with information furnished by the Company for
use in the Registration Statement or the Prospectus-Proxy Statement. Parent
shall bear the costs of SEC filing fees with respect to the Registration
Statement, the costs of printing the Prospectus-Proxy Statement, and the costs
of qualifying the shares of Parent Common Stock under state securities laws as
necessary.
6.04 STOCK EXCHANGE LISTINGS. Prior to issuance, Parent will file all
documents required to be filed to list the Parent Common Stock to be issued
pursuant to the Contingent Payment Rights on the New York Stock Exchange and use
its best efforts to effect said listings.
6.05 DUE AUTHORIZATION, ETC. OF STOCK ISSUED IN MERGER. Any shares of
Parent Common Stock issued by Parent to the Company Stockholders pursuant to the
Contingent Payment Rights will, upon such issuance and delivery in accordance
with the terms of the Contingent Payment Rights, be duly authorized, validly
issued, fully paid and nonassessable and free of any preemptive rights or other
rights to purchase securities of Parent and will be issued in full compliance
with applicable securities laws.
6.06 BLUE SKY APPROVALS. Parent will file all documents required to
obtain, prior to the Effective Time, all necessary approvals under state
securities laws, if any, required to carry out the transactions contemplated by
this Agreement, will pay all expenses incident thereto and will use its best
efforts to obtain such approvals.
6.07 SUBSTITUTE OPTIONS REGISTRATION STATEMENT. Parent shall take all
corporate action necessary to reserve for issuance a sufficient number of shares
of Parent Common Stock for delivery upon exercise of Substitute Options and
Substitute Warrants. As soon as practicable after the Effective Time, Parent
shall file a registration statement on Form S-8 (or any successor or other
appropriate forms) with respect to shares of Parent Common Stock subject to
Substitute Options, and shall use its best efforts to maintain effectiveness of
such registration statement for so long as the Substitute Options remain
outstanding.
6.08 OPERATION OF THE BUSINESS. Parent shall be solely responsible for
determining the appropriate technical, engineering, quality assurance and sales
and marketing resources necessary to achieve its Image Management Systems
business objectives after the Effective Time. Notwithstanding the foregoing,
Parent shall spend, on a consolidated basis, in connection with these objectives
at least $14,000,000 between July 1, 1997 and June 30, 1998, and at least
$20,000,000 between July 1, 1998 and June 30, 1999, including expenditures
related to sales representatives, sales management, advertising, promotions,
product service, product engineering, research and development, and quality
assurance.
6.09 EMPLOYEE BENEFIT PLANS. The employee benefit plans of the Company
identified on the attached Schedule 6.09 shall become the employee benefit plans
of the Surviving Corporation at the Effective Time, subject to the modifications
identified on the attached Schedule 6.09. Notwithstanding the foregoing, (a) the
Surviving Corporation and the Parent shall have the right to modify, amend, or
terminate the employee benefit plans of the Surviving Corporation from time to
time, and (b) nothing in this Section 6.09, whether express or implied, shall
confer upon any employee of the Company or the Surviving Corporation, or any
other person, any rights or remedies, including, without limitation, (i) any
right to employment or recall, (ii) any right to continued employment for any
specified period, or (iii) any right to claim any particular compensation,
benefit or aggregation of benefits, of any kind or nature whatsoever, or any
right to receive any severance pay or benefits as a result of this Section 6.09.
ARTICLE VII
CONDITIONS TO CLOSING
7.01 CONDITIONS TO PARENT'S AND MERGER SUBSIDIARY'S OBLIGATIONS. The
obligation of Parent and Merger Subsidiary to consummate the transactions
contemplated by this Agreement is subject to the satisfaction of the following
conditions at or before the Effective Time:
(a) The representations and warranties set forth in Article III hereof
shall be true and correct in all material respects at and as of the Effective
Time as though then made and as though the Effective Time had been substituted
for the date of this Agreement throughout such representations and warranties
(without taking into account any disclosures by the Company of discoveries,
events or occurrences arising on or after the date hereof);
(b) The Company shall have performed in all material respects all of
the covenants and agreements required to be performed and complied with by it
under this Agreement prior to the Effective Time;
(c) The Company shall have obtained, or caused to be obtained, each
consent (including, without limitation, any consent to assignment of any
Intellectual Property Right) and approval necessary in order that the
transactions contemplated herein not constitute a breach or violation of, or
result in a right of termination or acceleration of, or creation of any
encumbrance on any of the Company's assets pursuant to the provisions of, any
agreement, arrangement or undertaking of or affecting the Company or any
license, franchise or permit of or affecting the Company which could be
reasonably expected to result in a material adverse change in the assets,
financial condition, relations with key management employees or key OEM's,
operating results or business condition of the Company;
(d) This Agreement, the Certificate of Merger and the Merger shall have
been duly and validly authorized by the Company's Board of Directors and this
Agreement shall have been duly and validly approved by the stockholders of the
Company, and the Company shall have delivered to Parent evidence, in form
satisfactory to Parent's counsel, of such authorization and approval, and the
Certificate of Merger shall have been duly executed by the Company;
(e) The applicable waiting periods under the HSR Act shall have expired
or been terminated, and all other material governmental filings, authorizations
and approvals that are required for the consummation of the transactions
contemplated by this Agreement or the Certificate of Merger will have been duly
made and obtained;
(f) There shall not be threatened, instituted or pending any action or
proceeding, before any court or governmental authority or agency, domestic or
foreign, (i) challenging or seeking to make illegal, or to delay or otherwise
directly or indirectly restrain or prohibit, the consummation of the
transactions contemplated hereby or seeking to obtain material damages in
connection with such transactions, (ii) seeking to prohibit direct or indirect
ownership or operation by Parent or Merger Subsidiary of all or a material
portion of the business or assets of the Company, or to cause Parent or Merger
Subsidiary or any of their subsidiaries or the Company to dispose of or to hold
separately all or a material portion of the business or assets of Parent or
Merger Subsidiary and their subsidiaries or of the Company, as a result of the
transactions contemplated hereby, (iii) seeking to require direct or indirect
transfer or sale by Parent or Merger Subsidiary of any of the shares of Company
Common Stock, (iv) seeking to invalidate or render unenforceable any material
provision of this Agreement or the Certificate of Merger or any of the other
agreements attached as exhibits hereto (collectively, the "Related Agreements"),
or (v) otherwise relating to and materially adversely affecting the transactions
contemplated hereby;
(g) There shall not be any action taken, or any statute, rule,
regulation, judgment, order or injunction enacted, entered, enforced,
promulgated, issued or deemed applicable to the transactions contemplated hereby
by any federal, state or foreign court, government or governmental authority or
agency, which would reasonably be expected to result, directly or indirectly, in
any of the consequences referred to in Section 7.01(f) hereof;
(h) Parent or Merger Subsidiary shall not have discovered any fact
existing as of the date of this Agreement which has not been disclosed to Parent
and Merger Subsidiary as of the date of this Agreement regarding the Company
which, individually or in the aggregate with other such facts, would result in a
material adverse change in the assets, properties, financial condition,
operating results or business condition of the Company;
(i) There shall have been no damage, destruction or loss of or to any
property or properties owned or used by the Company, whether or not covered by
insurance, which, in the aggregate, has, or would be reasonably likely to have,
a material adverse effect on the Company;
(j) Parent shall have received from counsel for the Company a written
opinion, dated the date of the Effective Time, addressed to Parent, in form and
substance substantially as set forth in Exhibit 7.01(j);
(k) Not more than seven percent (7%) of the outstanding shares of
Company Common Stock shall be qualified to be Dissenting Shares as of the
Effective Time;
(l) The Registration Statement (as amended or supplemented) shall have
become effective under the Securities Act and shall not be subject to any stop
order, and no action, suit, proceeding or investigation by the SEC to suspend
the effectiveness of the Registration Statement shall have been initiated and be
continuing, or have been threatened or be unresolved. Parent shall have received
all state securities law authorizations necessary to carry out the transactions
contemplated by this Agreement;
(m) Parent shall have received from Ernst & Young LLP, acting in their
capacity as independent public accountants to the Company, a "comfort" letter,
dated as of the effective date of the Registration Statement and updated through
the Effective Time, in form and substance satisfactory to Parent and reasonably
customary in scope and substance for letters delivered by independent public
accountants in connection with registration statements similar to the
Registration Statement and transactions such as those contemplated by this
Agreement;
(n) Prior to the Effective Time, the Company shall have delivered to
Parent all of the following:
(i) certificates of the identity of appropriate officers of
the Company or other persons satisfactory to Parent dated as of the
date of the Effective Time, stating that the conditions precedent set
forth in subsections (a) and (b) above have been satisfied;
(ii) copies of the third party and governmental consents and
approvals and of the authorizations referred to in subsections (c), (d)
and (e) above;
(iii) the minute books, stock transfer records, corporate seal
and other materials related to the corporate administration of the
Company;
(iv) resignations (effective as of the Effective Time) from
such of the Company's officers and directors as Parent shall have
requested prior to the Effective Time;
(v) a copy of the Certificate of Incorporation of the Company,
certified by the Secretary of State of the State of Delaware, and
Certificates of Good Standing from the Secretaries of States of the
States of Delaware and California evidencing the good standing of the
Company in such states;
(vi) a copy of each of (X) the text of the resolutions adopted
by the board of directors of the Company authorizing the execution,
delivery and performance of this Agreement and the Certificate of
Merger and the consummation of all of the transactions contemplated by
this Agreement and the Certificate of Merger and (Y) the bylaws of the
Company; along with certificates executed on behalf of the Company by
its corporate secretary certifying to Parent that such copies are true,
correct and complete copies of such resolutions and bylaws,
respectively, and that such resolutions and bylaws were duly adopted
and have not been amended or rescinded;
(vii) incumbency certificates executed on behalf of the
Company by its corporate secretary certifying the signature and office
of each officer executing this Agreement and the Certificate of Merger
and the Related Agreements executed by the Company;
(viii) an executed copy of each of the Related Agreements; and
(ix) such other certificates, documents and instruments as
Parent reasonably requests related to the transactions contemplated
hereby.
(o) The Company's employees shall have entered into Parent's form of
Employee Agreement (relating to confidentiality, inventions and competition)
attached hereto as Exhibit 7.01(o).
(p) Each of the Company's employees identified on the attached Schedule
7.01(p) shall have agreed (i) to repay to the Company, within five business days
after payment to such employee of the 1997 Cash Consideration to which such
employee is entitled as a stockholder of the Company hereunder, all interest and
principal outstanding under the promissory note set forth next to such
employee's name on the attached Schedule 7.01(p), or (ii) to permit the Company
to deduct the amount of such interest and principal from the payment of 1997
Cash Consideration to such employee. The Company shall have completed the
repurchase from each such employee of the number of shares of Restricted Common
Stock set forth next to such employee's name on, and for the price set forth on,
the attached Schedule 7.01(p).
7.02 CONDITIONS TO THE COMPANY'S AND THE STOCKHOLDERS' OBLIGATIONS. The
obligations of the Company to consummate the transactions contemplated by this
Agreement are subject to the satisfaction of the following conditions at or
before the Effective Time:
(a) The representations and warranties set forth in Article IV hereof
will be true and correct in all material respects at and as of the Effective
Time as though then made and as though the Effective Time had been substituted
for the date of this Agreement throughout such representations and warranties;
(b) Parent and Merger Subsidiary shall have performed in all material
respects all the covenants and agreements required to be performed by them under
this Agreement and the Certificate of Merger prior to the Effective Time, and
Merger Subsidiary shall have executed the Certificate of Merger;
(c) The applicable waiting periods under the HSR Act shall have expired
or been terminated and all other material governmental filings, authorizations
and approvals that are required for the consummation of the transactions
contemplated hereby will have been duly made and obtained;
(d) There shall not be threatened, instituted or pending any action or
proceeding, before any court or governmental authority or agency, domestic or
foreign, (i) challenging or seeking to make illegal, or to delay or otherwise
directly or indirectly restrain or prohibit, the consummation of the
transactions contemplated by this Agreement or the Certificate of Merger or
seeking to obtain material damages in connection with such transactions, (ii)
seeking to invalidate or render unenforceable any material provision of this
Agreement, the Certificate of Merger or any of the Related Agreements, or (iii)
otherwise relating to and materially adversely affecting the transactions
contemplated hereby or thereby;
(e) There shall not be any action taken, or any statute, rule,
regulation, judgment, order or injunction, enacted, entered, enforced,
promulgated, issued or deemed applicable to the transactions contemplated by
this Agreement or the Certificate of Merger by any federal, state or foreign
court, government or governmental authority or agency, which would reasonably be
expected to result, directly or indirectly, in any of the consequences referred
to in Section 7.02(d) hereof;
(f) The Registration Statement (as amended or supplemented) shall have
become effective under the Securities Act and shall not be subject to any order,
and no action, suit, proceeding or investigation by the SEC to suspend the
effectiveness of the Registration Statement shall have been initiated and be
continuing, or have been threatened and be unresolved. Parent shall have
received all state securities law or state securities laws authorizations and
the consent or approval of any exchange on which shares of Parent Common Stock
are traded, in each case to the extent necessary to carry out the transactions
contemplated by this Agreement,; and
(g) The Company shall have received from counsel for Parent a written
opinion, dated the date of the Effective Time, addressed to the Company, in form
and substance as set forth in Exhibit 7.02(g).
(h) Prior to the Effective Time, each of Parent and Merger Subsidiary
shall have delivered to the Company all of the following:
(i) certificates of the appropriate officers of Parent and
Merger Subsidiary dated as of the date of the Effective Time, stating
that the conditions precedent set forth in subsections (a) and (b)
above have been satisfied;
(ii) a copy of the Certificate of Incorporation of each of the
Parent and the Merger Subsidiary, certified by the Secretary of State
of the State of Delaware, and certificates of Good Standing from the
Secretary of State of the State of Delaware evidencing the good
standing of each of Parent and the Merger Subsidiary in the State of
Delaware.
(iii) a copy of each of (X) the text of the resolutions
adopted by the board of directors of each of Parent and Merger
Subsidiary authorizing the execution, delivery and performance of this
Agreement and the Certificate of Merger and the consummation of all of
the transactions contemplated by this Agreement and the Certificate of
Merger and (Y) the bylaws of Parent and Merger Subsidiary; along with
certificates executed on behalf of Parent and Merger Subsidiary by
their corporate secretaries certifying to the Company that such copies
are true, correct and complete copies of such resolutions and bylaws,
respectively, and that such resolutions and bylaws were duly adopted
and have not been amended or rescinded;
(iv) incumbency certificates executed on behalf of Parent and
Merger Subsidiary by their corporate secretaries certifying the
signature and office of each officer executing this Agreement and the
Certificate of Merger and the Related Agreements executed by Parent and
Merger Subsidiary;
(v) an executed copy of each of the Related Agreements; and
(vi) such other certificates, documents and instruments as the
Company reasonably requests related to the transactions contemplated
hereby.
(i) The Company shall have received from Parent evidence of transfer to
the Transfer Agent of cash in the amount of the aggregate 1997 Cash
Consideration, along with an executed letter of instruction to pay such funds to
the Company Stockholders.
ARTICLE VIII
TERMINATION
8.01 TERMINATION. This Agreement may be terminated at any time prior to
the Effective Time:
(a) by the mutual consent of Parent, Merger Subsidiary and the Company;
(b) by either Parent or Merger Subsidiary, on the one hand, or the
Company, on the other, if there has been a material misrepresentation, breach of
warranty or breach of covenant on the part of the other in the representations,
warranties and covenants set forth in this Agreement; provided, that, in the
event of a curable breach, the non-breaching party may terminate this Agreement
only after the breaching party has had a reasonable time, not to exceed 30 days,
to cure such breach after written notice of breach from the non-breaching party;
(c) by either Parent or Merger Subsidiary, on the one hand, or the
Company, on the other, if there shall be a final nonappealable order of a
federal or state court in effect preventing consummation of the Merger, or there
shall be any action taken, or any statute, rule, regulation or order enacted,
promulgated or issued or deemed applicable to the Merger by any governmental
authority or agency, foreign or domestic, which would make the consummation of
the Merger illegal;
(d) by either Parent or Merger Subsidiary, on the one hand, or the
Company, on the other, if there shall be any action taken, or any statute, rule,
regulation or order enacted, promulgated or issued or deemed applicable to the
Merger by any governmental authority of agency, which would (i) prohibit the
Company's or Parent's ownership or operation of all or a portion of the
Company's business, or (ii) compel Parent or the Company to dispose of or hold
separate all or a portion of the business or assets of the Company or Parent as
a result of the Merger;
(e) by Parent if more than seven percent (7%) of the outstanding shares
of Company Common Stock shall be qualified to be Dissenting Shares after the
first meeting of the Company's stockholders to approve this Agreement and the
Merger;
(f) by either Parent or Merger Subsidiary, on the one hand, or the
Company, on the other, if the transactions contemplated by this Agreement or the
Certificate of Merger have not been consummated on or before August 31, 1997;
provided that, neither will be entitled to terminate this Agreement pursuant to
this Section 8.01(f) if such party's willful breach of this Agreement has
prevented the consummation of the transactions contemplated by this Agreement or
the Certificate of Merger; or
(g) by Parent or Merger Subsidiary if, after the date hereof, there
shall have been a material adverse change in the assets, properties, financial
condition, operating results or business condition of the Company which shall
continue to constitute such a material adverse change on or after July 31, 1997.
8.02 EFFECT OF TERMINATION. In the event of termination of this
Agreement by either Parent or Merger Subsidiary, on the one hand, or the
Company, on the other, as provided in Section 8.01, all provisions of this
Agreement shall terminate, except Sections 8.03 (Termination Fees), Sections
12.01 (press releases and announcements), 12.02 (expenses), 12.09 (governing
law) and 12.10 (confidentiality) hereof shall survive indefinitely.
8.03 TERMINATION FEES.
(a) In the event that this Agreement terminates as a result of:
(i) The failure of a party to proceed with the Merger even
though all of the conditions of such party's obligations to consummate
the transactions contemplated by this Agreement have been satisfied; or
(ii) A material misrepresentation, breach of warranty or
breach of covenant on the part of a party in the representations,
warranties and covenants set forth in this Agreement, where such
misrepresentation or breach results or arises from the intentional,
willful or grossly negligent acts or omissions of such party, from
information or circumstances known by such party as of the date of this
Agreement, or from information or circumstances not known by such party
as of the date of this Agreement as a result of the intentional or
willful disregard or the gross negligence of such party.
then the breaching party shall promptly reimburse the non-breaching party for
out- of-pocket fees and expenses (in an amount not to exceed One Million Dollars
($1,000,000)) incurred by the non-breaching party in connection with the
transactions contemplated by this Agreement (which reimbursable fees and
expenses shall not include salaries paid to employees of Parent or the Company
and payments to financial advisors other than for out-of-pocket fees and
expenses of such advisors) (collectively, "Reimbursable Fees and Expenses").
In the event of such termination of this Agreement by Parent, the
Company may, at its option, make such payment by delivering to Parent that
number of shares of Company Common Stock equal to the Reimbursable Fees and
Expenses divided by Ten Dollars ($10.00) (subject to appropriate adjustment to
reflect stock splits, stock dividends, reorganizations, consolidations and
similar changes to the Company's capital stock hereafter effected).
(b) In the event that:
(i) Parent terminates this Agreement as a result of a material
misrepresentation, material breach of warranty or material breach of
covenant on the part of the Company in the representations, warranties
and covenants set forth in this Agreement (whether pursuant to Section
8.03(a) or otherwise), and
(ii) The Company engages in, becomes subject to, or enters
into an agreement or understanding with respect to, a Control
Transaction (as defined below) with a party other than Parent prior to
December 31, 1997,
then the Company shall promptly pay to Parent Three Million Dollars ($3,000,000)
(in addition to any amounts previously paid or required to be paid pursuant to
Section 8.03(a)).
For the purposes of this Agreement, a "Control Transaction" means (i)
any acquisition of effective control of the Company, whether by merger, purchase
of all or substantially all of the assets of the Company, purchase of a majority
of the equity of the Company or otherwise, or (ii) any issuance by the Company,
in a single or series of transactions, of shares of capital stock, or rights to
purchase shares of capital stock, representing equal to or greater than twenty
percent (20%) of the outstanding capital stock of the Company. Notwithstanding
the foregoing, a Control Transaction shall not include the issuance by the
Company of more than twenty percent (20%) of the outstanding capital stock of
the Company (A) pursuant to an initial public offering of the Company's equity
securities under Section 5 of the Securities Act, or (B) pursuant to a pro rata
or substantially pro rata offering of the Company's securities to the Company's
current stockholders entitled to participate in such offering pursuant to
applicable securities laws, provided, that, in either case, after such offering,
(1) none of the Company's current stockholders is the
beneficial owner of more than forty percent (40%) of the outstanding
capital stock of the Company (computed as if all securities
beneficially owned by such stockholder which are convertible into
capital stock of the Company had been converted), and
(2) none of Parent's competitors previously disclosed to the
Company is the beneficial owner of more than forty percent (40%) of the
outstanding capital stock of the Company (computed as if all securities
beneficially owned by such competitor which are convertible into
capital stock of the Company have been converted).
(c) The termination fees under this Section 8.03 shall be cumulative
and in addition to any other right, power or remedy available to the parties,
whether conferred hereunder, under the Option Agreement or now or hereafter
available at law or in equity or by statute or otherwise.
ARTICLE IX
THE STOCKHOLDERS' REPRESENTATIVE
9.01 APPOINTMENT. As used in this Agreement, the "Stockholders'
Representatives" shall mean Michael O'Donnell and David Titus or any person
appointed as a successor Stockholders' Representative pursuant to Section 9.02
hereof.
9.02 ELECTION AND REPLACEMENT. During the period ending upon the date
when all obligations under this Agreement have been discharged (including all
indemnification obligations pursuant to Section 10.02 hereof), the Company's
stockholders who, immediately prior to the Effective Time, held Company Common
Stock representing a majority of the aggregate number of shares of Company
Common Stock outstanding immediately prior to the Effective Time (a "Majority"),
may, from time to time upon written notice to the Stockholders' Representatives
and Parent, remove any of the Stockholders' Representatives or appoint one or
more new Stockholders' Representatives to fill any vacancy created by the death,
incapacitation, resignation or removal of one or more Stockholders'
Representatives. Furthermore, if a Stockholders' Representative dies, becomes
incapacitated, resigns or is removed by a Majority, the Majority shall appoint a
successor Stockholders' Representative to fill the vacancy so created. If the
Majority is required to appoint, but has-not appointed, a successor
Stockholders' Representative within 30 business days from a request by Parent to
appoint a successor Stockholders' Representative, Parent shall have the right to
appoint a Stockholders' Representative to fill any vacancy so created, and shall
advise all those who were holders of Company Common Stock immediately prior to
the Effective Time of such appointment by written notice. A copy of any
appointment by the Majority of any successor Stockholders' Representative shall
be provided to Parent promptly after it shall have been effected.
9.03 AUTHORITY. The Stockholders' Representatives shall be authorized
to take action by majority vote and to make and deliver any certificate, notice,
consent or instrument required or permitted to be made or delivered under this
Agreement or under the documents referred to in this Agreement (including,
without limitation, any such actions with respect to the Contingent Payment
Rights) (an "Instrument") which the Stockholders' Representatives determine in
their discretion to be necessary, appropriate or desirable, and, in connection
therewith, to hire or retain, at the sole expense of the Company's stockholders,
such counsel, investment bankers, accountants, representatives and other
professional advisors as they determine in their sole and absolute discretion to
be necessary, advisable or appropriate in order to carry out and perform their
rights and obligations hereunder. Any party receiving an Instrument from the
Stockholders' Representative shall have the right to rely in good faith upon
such certification, and to act in accordance with the Instrument without
independent investigation.
9.04 NO LIABILITY OF PARENT. Parent (and the Surviving Corporation)
shall have no liability to any stockholder of the Company or otherwise arising
out of the acts or omissions of the Stockholders' Representatives or any
disputes among the stockholders of the Company or among the Stockholders'
Representatives. Parent shall have no direct liability to the stockholders of
the Company under this Agreement or the other agreements referred to herein for
any action taken through agreement with the Stockholders' Representatives and
may rely entirely on its dealings with, and notices to and from, the
Stockholders' Representatives with respect to any obligations it might have
under this Agreement, any agreement referred to herein or otherwise to the
stockholders of the Company. Without limiting the foregoing, delivery to the
Stockholders' Representatives of cash or certificates for shares of Parent
Common Stock with respect to the Contingent Payment Rights shall extinguish any
obligations of Parent to the Company Stockholders with respect to such
Contingent Payment Rights, and Parent shall have no liability for subsequent
misdelivery to any Company Stockholder or any other act or omission of the
Stockholders' Representatives with respect to such cash or certificates.
ARTICLE X
SURVIVAL AND OFFSET
10.01 SURVIVAL OF REPRESENTATIONS AND WARRANTIES. Notwithstanding any
investigation made by or on behalf of any of the parties hereto or the results
of any such investigation and notwithstanding the participation of such party in
the Closing, the representations and warranties contained in this Agreement
shall survive the Closing until 30 days after the Determination Date for the
Second Earn- Out Year as defined under the Contingent Payment Rights (the
"Offset Period"), and shall have no further force or effect thereafter.
10.02 RIGHT OF OFFSET.
(a) Subject to Section 10.02(f) hereof, Parent shall have a right to
offset (the "Offset Right"), from time to time, its "Losses" (as hereinafter
defined) against payments to be made by Parent relating to the Contingent
Payment Rights, in accordance with the terms of this Section 10.02. Parent shall
be entitled to exercise its Offset Right, from time to time, against payments to
be made by Parent relating to the Contingent Payment Rights, with respect to any
loss, liability, deficiency, damage, expense or cost (including reasonable legal
expenses), whether or not actually incurred or paid during the Offset Period and
after taking into effect the Tax effects of such items and any use of the Offset
Right hereunder (collectively, the "Losses"), which Parent, the Surviving
Corporation or (but only in connection with any Losses incurred by, or Claims
against, Parent or the Surviving Corporation) any of their respective
affiliates, officers, directors, employees or agents (the " Protected Parties")
may suffer, sustain or become subject to, as a result of:
(i) Any misrepresentation in any of the representations and
warranties of the Company contained (1) in this Agreement or (2) in any
of the exhibits, schedules, certificates and other documents delivered
or to be delivered by or on behalf of the Company pursuant to this
Agreement or otherwise referenced or incorporated in this Agreement
(collectively, the "Related Documents");
(ii) Any breach of, or failure to perform, any agreement or
covenant of the Company contained in this Agreement or any of the
Related Documents;
(iii) Any "Claim" (as defined in Section 10.04(c)) or
threatened Claim against the Protected Parties arising out of actions
or inactions of the Company with respect to the Company's business or
the Real Property prior to the Effective Time.
(b) Parent may exercise its Offset Right, from time to time, in
accordance with the procedures set forth in paragraphs (c) and (d) of this
Section 10.02, against any payment or payments due or to become due under the
Contingent Payment Rights. Each time, if any, that Parent exercises its Offset
Right against payments due or to become due under the Contingent Payment Rights,
Parent shall promptly deliver to Stockholders' Representatives a schedule signed
by an officer of Parent reflecting the revised payments due or to become due
under the Contingent Payment Rights after giving effect to such exercise of its
Offset Right. In the event Parent exercises its Offset Right, such offset shall
be applied first, to the payment to be made in 1998 under the Contingent Payment
Rights, and second, to the payment being made in 1999 under the Contingent
Payment Rights.
(c) In the event any of the Protected Parties becomes involved in any
legal, governmental or administrative proceeding which may result in Losses
subject to Parent's Offset Right hereunder, or if any such proceeding is
threatened or asserted (any such third party action or proceeding being referred
to herein as a "Claim"), Parent shall promptly notify the Stockholders'
Representatives in writing of the nature of any such Claim and Parent's estimate
of the Losses arising therefrom.
(i) The Stockholders Representatives shall be entitled to
contest and defend such Claim; provided, that the Stockholders
Representatives have a reasonable basis for concluding such defense may
be successful and diligently contests and defends such Claim. Notice of
the intention so to contest and defend shall be given by the
Stockholders' Representatives to Parent within 20 days after Parent
provides notice of such Claim (but, in all events, at least five
business days prior to the date that an answer to such Claim is due to
be filed). Such contest and defense shall be conducted by reputable
attorneys employed by Stockholders' Representatives. Parent shall be
entitled at any time, at its own cost and expense (which expense shall
not constitute a Loss unless Seller is not adequately representing or,
because of a conflict of interest, may not adequately represent, any
interests of the Protected Parties, and only to the extent that such
expenses are reasonable), to participate in such contest and defense
and to be represented by attorneys of its own choosing. If Parent
elects to participate in such defense, Parent shall cooperate with
Stockholders' Representatives in the conduct of such defense. Neither
Parent nor Stockholders' Representatives may concede, settle or
compromise any Claim without the consent of the other, which consent
shall not be unreasonably withheld; provided, that Stockholders'
Representatives may, without the consent of Parent, settle any Claim
which is solely for money damages if Stockholders' Representatives
acknowledge that such Claim gives rise to a Loss that is subject to
Parent's Offset Right hereunder and if the entire amount of the
settlement amount may be recovered by Parent by means of Parent's
Offset Rights hereunder.
(ii) Notwithstanding the foregoing, if: (X) a Claim seeks
equitable relief against any of the Protected Parties, (Y) the subject
matter of a Claim relates to the ongoing business of Parent (other than
as it relates to the Surviving Corporation), which Claim, if decided
against a Protected Party, would materially adversely affect the
ongoing business or reputation of Parent (other than as it relates to
the Surviving Corporation), or (Z) the estimated Losses of the
Protected Parties related to the Claim exceed the amount Parent may
recover using its Offset Right hereunder, then, in each such case,
Parent alone may (but shall not be required to) contest, defend and
settle such Claim in the first instance and, if Parent does not
contest, defend or settle such Claim, Stockholders Representatives
shall have the right to contest and defend (but not settle) such Claim;
provided, however, that no such settlement shall be made without the
consent of the Stockholders Representatives (which consent shall not
be unreasonably withheld, delayed or denied) unless in connection with
such settlement, Parent and the Surviving Corporation shall waive all
Offset Rights and any other indemnification claims related to such
Claim.
(d) In the event Parent (on behalf of itself or any Protected Party)
should have a claim giving rise to an Offset Right that does not involve a
Claim, Parent shall deliver a notice (the "Offset Notice") of such claim with
reasonable promptness to Stockholders' Representatives. The Offset Notice shall
include a good faith estimate of Parent's Losses relating to such claim and
sufficient detail with regard to the nature of the facts underlying such Claim
to enable Stockholders' Representatives to analyze such Claim. If the
Stockholders' Representatives notify Parent that the Stockholders'
Representatives do not dispute the claim described in the Offset Notice, or if
the Stockholders' Representatives fail to notify Parent within 30 days after
delivery of the Offset Notice of any such dispute with respect to such claim,
the Losses in the amount specified in the Offset Notice will be conclusively
deemed Losses and Parent may exercise its Offset Right with respect to such
amount in accordance with the Offset Notice. If the Stockholders'
Representatives have timely disputed such claim, representatives of Parent and
Stockholders' Representatives will proceed in good faith to negotiate a
resolution of such dispute, and if not resolved through the negotiations of such
representatives within 60 days after the date of the Offset Notice of such
claim, such dispute shall be resolved fully and finally in the jurisdiction of
the principal office of Parent by an arbitration governed by the Center for
Public Resources Rules for Non-Administered Arbitration of Business Disputes,
provided that a sole arbitrator shall be employed. The arbitration shall be
governed by the state equivalent of the Federal Arbitration Act, 9 U.S.C. ss.
1-16, and judgment upon the award rendered by the arbitrator may be entered by
any court having jurisdiction thereof. The parties shall have 10 days from the
end of the discussion among the Stockholders' Representatives and Parent to
agree upon a mutually acceptable person to act as arbitrator. The arbitrator
shall be a neutral person (i.e., a person not affiliated with either of the
parties). If no arbitrator has been selected within such time, the Stockholders'
Representatives and Parent shall jointly request the Center for Public Resources
or another mutually agreed upon organization to supply within 10 business days
of such request a list of potential arbitrators with qualifications as specified
by the parties in the joint request. Within five days of receipt of the list,
the Stockholders' Representatives and Parent shall independently rank the
proposed candidates, shall simultaneously exchange rankings, and shall be deemed
to have selected as the arbitrator the individual receiving the highest combined
ranking who is available to serve. If there is a tie, then the tie shall be
broken by putting the names on slips of paper, mixing them up and having one
party draw one slip of paper. If either the Stockholders' Representatives or
Parent shall not cooperate in the selection of the arbitrator, the other may
solely select the arbitrator utilizing the procedures set forth in this Section
10.02. The costs of arbitration shall be apportioned between the Stockholders'
Representatives and Parent as determined by the arbitrator in such manner as the
arbitrator deems reasonable taking into account the circumstances of the case,
the conduct of the parties during the proceeding, and the result of the
arbitration. Any arbitration proceeding shall be concluded in a maximum of one
(1) year from the date of the Offset Notice. All negotiations pursuant to this
Section 10.02 shall be treated as compromise and settlement negotiations for
purposes of Rule 408 of the Federal Rules of Evidence and comparable state Rules
of Evidence. All negotiation and arbitration proceedings under this Section
10.02 shall be treated as confidential information in accordance with the
provisions of the Confidentiality Agreement. Any arbitrator shall be bound by an
agreement containing confidentiality provisions at least as restrictive as those
contained in the Confidentiality Agreement. Nothing herein shall preclude (i)
Parent from seeking equitable relief to prevent any immediate, irreparable harm
to its interest, including multiple breaches of this Agreement or the Related
Documents, or (ii) the Stockholders' Representatives from commencing litigation
to enforce payment of the Contingent Payment Rights not subject to Offset as
provided herein. Otherwise, these procedures are exclusive and shall be fully
exhausted prior to the initiation of any litigation. Either party may seek
specific enforcement of any arbitrator's decision under this Article IX. The
other party's only defense to such a request for specific enforcement shall be
fraud by or on the arbitrator.
(e) In the event of a Claim under Section 10.02(c) or a dispute
relating to the Offset Notice under Section 10.02(d), and if such Claim or
Offset Notice would, if determined to be valid, result in the an offset against
amounts due under the Contingent Payment Rights, Parent may exercise its Offset
Right to the extent of the estimated Losses of the Protected Parties until the
resolution of such Claim or dispute; provided, that prior to the time of such
resolution, if payment of the Contingent Payment Right against which Parent is
seeking to enforce its Offset Right would otherwise be due and payable, Parent
shall instead pay the amount of such Offset Right into an escrow account with a
third-party escrow agent mutually acceptable to the Parent and the Stockholders'
Representatives pursuant to an escrow agreement. Such funds shall be held in
such escrow until the time of resolution of such Claim (even if such Claim or
dispute is not resolved until after the end of the Offset Period) and thereafter
returned to the Parent to the extent that such Offset Right is allowed and
otherwise paid to the Stockholderss Representative, the Company Stockholders or
a paying agent under the Contingent Payment Rights, as may be appropriate. The
portion of any Contingent Payment Rights,payments suspended pursuant to the
terms of this Section 10.02(e) which are not subject to the exercise of the
Offset Right in dispute and which, by their terms, have become due, shall be
delivered to the Stockholders s Representative, the Company Stockholders or a
paying agent under the Contingent Payment Rights, as may be appropriate.
(f) Notwithstanding anything contained in this Agreement to the
contrary, the right of Parent to exercise its Offset Right hereunder shall be
subject to the following limitations:
(i) Parent shall not be entitled to exercise its Offset Right
with respect to any Losses, until the aggregate amount of all Losses
hereunder exceeds Two Hundred Fifty Thousand Dollars ($250,000);
provided that, once the aggregate amount of all Losses hereunder
exceeds Two Hundred Fifty Thousand Dollars ($250,000), Parent shall be
entitled to exercise its Offset Right with respect to all Losses,
including, without limitation, the initial Two Hundred Fifty Thousand
Dollars ($250,000) in Losses hereunder.
(ii) Parent shall not be entitled to exercise its Offset Right
with respect to any Losses unless Parent delivers to Stockholders'
Representatives an Offset Notice under Section 10.02(d) or notice of a
Claim under Section 10.02(c):
(A) prior to the end of the Offset Period with
respect to Losses as a result of any misrepresentation in any
of the representations and warranties of the Company contained
in Section 3.07 (Capital Stock), Section 3.15 (Tax Matters),
Section 3.17 (Intellectual Property Rights), Section 3.20
(Employees), Section 3.21 (Employee Benefit Plans), or Section
3.27 (Environmental Matters).
(B) prior to the one-year anniversary of the
Effective Time with respect to all Losses not described in
Section 10.02(f)(ii)(A).
(iii) Parent shall not be entitled to exercise its Offset
Right with respect to any Losses to the extent that such Losses result
from or arise out of the gross negligence or willful misconduct of any
Protected Party.
(iv) Parent shall be entitled to exercise its Offset Right
only for Losses in an aggregate amount not exceeding $9,650,979.
(v) The Offset Right shall be Parent's sole and exclusive
remedy with respect to any Losses that any Protected Party may suffer,
sustain or become subject to pursuant to the terms of this Agreement,
and Parent agrees that it shall not, and hereby waives all rights to,
institute or maintain any suit, proceeding or action against the
Company's stockholders or Stockholders' Representatives or utilize or
exercise any other legal or equitable remedy for the purpose of
recovering damages or other relief with respect to any Losses
(including, without limitation, an action seeking to recover any
portion of the purchase price previously paid to the Company's
stockholders) except for suits, proceedings or actions necessary to
enforce or implement the Offset Right; provided that, (i) nothing
herein shall prevent a party from bringing an action based upon
allegations of fraud or other intentional misconduct with respect to
another party hereto in connection with this Agreement, and (ii)
nothing herein shall limit in any manner any other legal rights or
remedies which any Protected Party which is a party to an agreement
identified under Article XI has against another party to such agreement
in accordance with the terms and conditions provided therein.
ARTICLE XI
ANCILLARY AGREEMENTS
11.01 OPTION AGREEMENT. Simultaneous with the execution and delivery of
this Agreement, Parent, Merger Subsidiary and the Company will enter into an
option agreement identical in form to Exhibit 11.01 (the "Option Agreement").
11.02 STOCKHOLDER AGREEMENTS. Simultaneous with the execution and
delivery of this Agreement, Parent, Merger Subsidiary, the Company and each
stockholder of the Company identified on Schedule 11.02 will enter into a
stockholder agreement identical in form to Exhibit 11.02 (the "Stockholder
Agreement").
11.03 AFFILIATE AGREEMENTS. Simultaneous with the execution and
delivery of this Agreement, Parent and each stockholder of the Company
identified on Schedule 11.03 will enter into an affiliate agreement identical in
form to Exhibit 11.03 (the "Affiliate Agreement").
11.04 KEY MANAGEMENT AGREEMENTS. Simultaneous with the execution and
delivery of this Agreement, the Company, Parent and each employee identified on
Schedule 11.04 will enter into a Key Management Agreement in the form of Exhibit
11.04 (the "Key Management Agreements").
11.05 NONCOMPETITION AGREEMENTS. Simultaneous with the execution and
delivery of this Agreement, the Company, Parent and each stockholder of the
Company identified on Schedule 11.04 will enter into a noncompetition agreement
identical in form to Exhibit 11.05 (the "Noncompetition Agreements").
ARTICLE XII
MISCELLANEOUS
12.01 PRESS RELEASES AND ANNOUNCEMENTS. Prior to the Effective Time, no
party hereto shall issue any press release (or make any other public
announcement) related to this Agreement or the transactions contemplated hereby
or make any announcement to the employees, customers or suppliers of the Company
without prior written approval of the other party hereto, except that Parent may
issue any such release (or other announcement) as it determines, in its sole
discretion, as may be necessary to comply with the requirements of this
Agreement or applicable law or by obligations pursuant to any listing agreement
with any national securities exchange. If Parent determines any such press
release or public announcement is so required, Parent shall use reasonable
efforts to consult in good faith with the Company (but shall not be required to
obtain the Company's consent) prior to issuing such press release or making such
announcement.
12.02 EXPENSES. Except as otherwise expressly provided for herein, the
Company, the Stockholders' Representatives, Parent and Merger Subsidiary will
each pay all of their own expenses (including attorneys' and accountants' fees)
in connection with the negotiation of this Agreement, the performance of their
respective obligations under this Agreement and the Certificate of Merger and
the consummation of the transactions contemplated hereby and thereby (whether
consummated or not). The attorney's fees of Wilson Sonsini Goodrich & Rosati,
legal counsel to the Company, shall be paid in full at the Closing.
12.03 AMENDMENT AND WAIVER. This Agreement may not be amended or waived
except in a writing executed by the party against which such amendment or waiver
is sought to be enforced; provided, however, that after the approval of this
Agreement by the stockholders of the Company, no amendment may be made which
reduces the Merger Consideration or which effects any changes which would
materially adversely affect the stockholders of the Company without the further
approval of the stockholders of the Company. No course of dealing between or
among any persons having any interest in this Agreement will be deemed effective
to modify or amend any part of this Agreement or any rights or obligations of
any person under or by reason of this Agreement.
12.04 NOTICES. All notices, demands and other communications to be
given or delivered under or by reason of the provisions of this Agreement will
be in writing and will be deemed to have been given when personally delivered or
three days after being mailed, if mailed by first class mail, return receipt
requested, or when receipt is acknowledged, if sent by facsimile, telecopy or
other electronic transmission device. Notices, demands and communications to
Parent, Merger Subsidiary, the Company and the Stockholders' Representatives
will, unless another address is specified in writing, be sent to the address
indicated below:
Notices to Parent or Merger Subsidiary: with a copy to:
Imation Corp. Dorsey & Whitney LLP
Legal Affairs 220 South Sixth Street
Imation Corp. Minneapolis, MN 55402
One Imation Place Attention: Gary L. Tygesson
Oakdale, MN 55128-3414 Telecopy: (612) 340-8753
Attn: Susan Laine
Imation Corp.
One Imation Place
Oakdale, MN 55128-3414
Attn: Brad T. Sauer
Notices to the Company: with a copy to:
Cemax-Icon, Inc. Wilson, Sonsini, Goodrich &
47281 Mission Falls Court Rosati, P.C.
Fremont, California 94539 650 Page Mill Road
Attn: Terry Ross Palo Alto, California 94304-1050
Attn: Michael J. O'Donnell
Telecopy: (415) 496-4092
Notices to Stockholders' Representatives with a copy to:
Wilson, Sonsini, Goodrich & Rosati, P.C. David Titus
650 Page Mill Road Windward Ventures
Palo Alto, California 94304-1050 221 Ocean Drive
Attn: Michael J. O'Donnell Coronado, California 92118
Telecopy: (415) 496-4092
12.05 ASSIGNMENT. This Agreement and all of the provisions hereof will
be binding upon and inure to the benefit of the parties hereto and their
respective successors and permitted assigns, except that neither this Agreement
nor any of the rights, interests or obligations hereunder may be assigned by any
party hereto without the prior written consent of the other parties hereto.
12.06 SEVERABILITY. Whenever possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or
invalid under applicable law, such provision will be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of
such provision or the remaining provisions of this Agreement.
12.07 COMPLETE AGREEMENT. This Agreement, the Certificate of Merger and
the Related Agreements and other exhibits hereto, the Disclosure Schedule and
the other documents referred to herein contain the complete agreement between
the parties and supersede any prior understandings, agreements or
representations by or between the parties, written or oral, which may have
related to the subject matter hereof in any way; provided, that the
Confidentiality Agreement, dated October 4, 1996, as amended November 14, 1996,
between Parent and the Company (the "Confidentiality Agreement") shall remain in
force and effect without modification thereof.
12.08 COUNTERPARTS. This Agreement may be execute in one or more
counterparts, any one of which need not contain the signatures of more than one
party, but all such counterparts taken together will constitute one and the same
instrument. Any such counterpart may be delivered by facsimile. Any party
delivering a counterpart by facsimile shall deliver an original copy within 48
hours, provided that the failure to so deliver an original shall not effect the
enforceability of this agreement against such party.
12.09 GOVERNING LAW. The internal law, without regard for conflicts of
laws principles, of the State of Delaware will govern all questions concerning
the construction, validity and interpretation of this Agreement and the
performance of the obligations imposed by this Agreement.
12.10 KNOWLEDGE. With respect to the knowledge of the Company, such
term shall mean the actual knowledge of the Company after reasonable inquiry and
review of the representations and warranties of the Company set forth in this
Agreement and the Disclosure Schedule.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.
IMATION CORP.
By /s/ C.T. Pinder
---------------------------
Its Vice President
---------------------------
CI ACQUISITION CORP.
By /s/ C.T. Pinder
---------------------------
Its President
---------------------------
CEMAX-ICON, INC.
By /s/ Terry Ross
---------------------------
Its President and C.E.O.
---------------------------
EXHIBIT B
SECTION 262 OF THE GENERAL
CORPORATION LAW OF THE STATE OF DELAWARE
SS. 262 APPRAISAL RIGHTS. (a) Any stockholder of a corporation of this
State who holds shares of stock on the date of the making of a demand pursuant
to subsection (d) of this section with respect to such shares, who continuously
holds such shares through the effective date of the merger or consolidation, who
has otherwise complied with subsection (d) of this section and who has neither
voted in favor of the merger or consolidation nor consented thereto in writing
pursuant to ss. 228 of this title shall be entitled to an appraisal by the Court
of Chancery of the fair value of the stockholder's shares of stock under the
circumstances described in subsections (b) and (c) of this section. As used in
this section, the word "stockholder" means a holder of record of stock in a
stock corporation and also a member of record of a nonstock corporation; the
words "stock" and "share" mean and include what is ordinarily meant by those
words and also membership or membership interest of a member of a nonstock
corporation; and the words "depository receipt" mean a receipt or other
instrument issued by a depository representing an interest in one or more
shares, or fractions thereof, solely of stock of a corporation, which stock is
deposited with the depository.
(b) Appraisal rights shall be available for the shares of any class or
series of stock of a constituent corporation in a merger or consolidation to be
effected pursuant to ss.251 (other than a merger effected pursuant to ss.251(g)
of this title), ss.252, ss.254, ss.257, ss.258, ss.263 or ss.264 of this title:
(1) Provided, however, that no appraisal rights under this section
shall be available for the shares of any class or series of stock, which stock,
or depository receipts in respect thereof, at the record date fixed to determine
the stockholders entitled to receive notice of and to vote at the meeting of
stockholders to act upon the agreement of merger or consolidation, were either
(i) listed on a national securities exchange or designated as a national market
system security on an interdealer quotation system by the National Association
of Securities Dealers, Inc. or (ii) held of record by more than 2,000 holders;
and further provided that no appraisal rights shall be available for any shares
of stock of the constituent corporation surviving a merger if the merger did not
require for its approval the vote of the stockholders of the surviving
corporation as provided in subsection (f) of ss.251 of this title.
(2) Notwithstanding paragraph (1) of this subsection, appraisal rights
under this section shall be available for the shares of any class or series of
stock of a constituent corporation if the holders thereof are required by the
terms of an agreement of merger or consolidation pursuant to ss.ss.251, 252,
254, 257, 258, 263 and 264 of this title to accept for such stock anything
except:
a. Shares of stock of the corporation surviving or resulting from such
merger or consolidation, or depository receipts in respect thereof;
b. Shares of stock of any other corporation, or depository receipts in
respect thereof, which shares of stock or depository receipts at the effective
date of the merger or consolidation will be either listed on a national
securities exchange or designated as a national market system security on an
interdealer quotation system by the National Association of Securities Dealers,
Inc. or held of record by more than 2,000 holders;
c. Cash in lieu of fractional shares or fractional depository receipts
described in the foregoing subparagraphs a. and b. of this paragraph; or
d. Any combination of the shares of stock, depository receipts and cash
in lieu of fractional shares or fractional depository receipts described in the
foregoing subparagraphs a., b. and c. of this paragraph.
(3) In the event all of the stock of a subsidiary Delaware corporation
party to a merger effected underss.253 of this title is not owned by the parent
corporation immediately prior to the merger, appraisal rights shall be available
for the shares of the subsidiary Delaware corporation.
(c) Any corporation may provide in its certificate of incorporation
that appraisal rights under this section shall be available for the shares of
any class or series of its stock as a result of an amendment to its certificate
of incorporation, any merger or consolidation in which the corporation is a
constituent corporation or the sale of all or substantially all of the assets of
the corporation. If the certificate of incorporation contains such a provision,
the procedures of this section, including those set forth in subsections (d) and
(e) of this section, shall apply as nearly as is practicable.
(d) Appraisal rights shall be perfected as follows:
(1) If a proposed merger or consolidation for which appraisal rights
are provided under this section is to be submitted for approval at a meeting of
stockholders, the corporation, not less than 20 days prior to the meeting, shall
notify each of its stockholders who was such on the record date for such meeting
with respect to shares for which appraisal rights are available pursuant to
subsections (b) or (c) hereof that appraisal rights are available for any or all
of the shares of the constituent corporations, and shall include in such notice
a copy of this section. Each stockholder electing to demand the appraisal of his
shares shall deliver to the corporation, before the taking of the vote on the
merger or consolidation, a written demand for appraisal of his shares. Such
demand will be sufficient if it reasonably informs the corporation of the
identity of the stockholder and that the stockholder intends thereby to demand
the appraisal of his shares. A proxy or vote against the merger or consolidation
shall not constitute such a demand. A stockholder electing to take such action
must do so by a separate written demand as herein provided. Within 10 days after
the effective date of such merger or consolidation, the surviving or resulting
corporation shall notify each stockholder of each constituent corporation who
has complied with this subsection and has not voted in favor of or consented to
the merger or consolidation of the date that the merger or consolidation has
become effective; or
(2) If the merger or consolidation was approved pursuant to ss.228 or
ss.253 of this title, each constituent corporation, either before the effective
date of the merger or consolidation or within ten days thereafter, shall notify
each of the holders of any class or series of stock of such constituent
corporation who are entitled to appraisal rights of the approval of the merger
or consolidation and that appraisal rights are available for any or all shares
of such class or series of stock of such constituent corporation, and shall
include in such notice a copy of this section; provided that, if the notice is
given on or after the effective date of the merger or consolidation, such notice
shall be given by the surviving or resulting corporation to all such holders of
any class or series of stock of a constituent corporation that are entitled to
appraisal rights. Such notice may, and, if given on or after the effective date
of the merger or consolidation, shall, also notify such stockholders of the
effective date of the merger or consolidation. Any stockholder entitled to
appraisal rights may, within 20 days after the date of mailing of such notice,
demand in writing from the surviving or resulting corporation the appraisal of
such holder's shares. Such demand will be sufficient if it reasonably informs
the corporation of the identity of the stockholder and that the stockholder
intends thereby to demand the appraisal of such holder's shares. If such notice
did not notify stockholders of the effective date of the merger or
consolidation, either (i) each such constituent corporation shall send a second
notice before the effective date of the merger or consolidation notifying each
of the holders of any class or series of stock of such constituent corporation
that are entitled to appraisal rights of the effective date of the merger or
consolidation or (ii) the surviving or resulting corporation shall send such a
second notice to all such holders on or within 10 days after such effective
date; provided, however, that if such second notice is sent more than 20 days
following the sending of the first notice, such second notice need only be sent
to each stockholder who is entitled to appraisal rights and who has demanded
appraisal of such holder's shares in accordance with this subsection. An
affidavit of the secretary or assistant secretary or of the transfer agent of
the corporation that is required to give either notice that such notice has been
given shall, in the absence of fraud, be prima facie evidence of the facts
stated therein. For purposes of determining the stockholders entitled to receive
either notice, each constituent corporation may fix, in advance, a record date
that shall be not more than 10 days prior to the date the notice is given;
provided, that if the notice is given on or after the effective date of the
merger or consolidation, the record date shall be such effective date. If no
record date is fixed and the notice is given prior to the effective date, the
record date shall be the close of business on the day next preceding the day on
which the notice is given.
(e) Within 120 days after the effective date of the merger or
consolidation, the surviving or resulting corporation or any stockholder who has
complied with subsections (a) and (d) hereof and who is otherwise entitled to
appraisal rights, may file a petition in the Court of Chancery demanding a
determination of the value of the stock of all such stockholders.
Notwithstanding the foregoing, at any time within 60 days after the effective
date of the merger or consolidation, any stockholder shall have the right to
withdraw his demand for appraisal and to accept the terms offered upon the
merger or consolidation. Within 120 days after the effective date of the merger
or consolidation, any stockholder who has complied with the requirements of
subsections (a) and (d) hereof, upon written request, shall be entitled to
receive from the corporation surviving the merger or resulting from the
consolidation a statement setting forth the aggregate number of shares not voted
in favor of the merger or consolidation and with respect to which demands for
appraisal have been received and the aggregate number of holders of such shares.
Such written statement shall be mailed to the stockholder within 10 days after
his written request for such a statement is received by the surviving or
resulting corporation or within 10 days after expiration of the period for
delivery of demands for appraisal under subsection (d) hereof, whichever is
later.
(f) Upon the filing of any such petition by a stockholder, service of a
copy thereof shall be made upon the surviving or resulting corporation, which
shall within 20 days after such service file in the office of the Register in
Chancery in which the petition was filed a duly verified list containing the
names and addresses of all stockholders who have demanded payment for their
shares and with whom agreements as to the value of their shares have not been
reached by the surviving or resulting corporation. If the petition shall be
filed by the surviving or resulting corporation, the petition shall be
accompanied by such a duly verified list. The Register in Chancery, if so
ordered by the Court, shall give notice of the time and place fixed for the
hearing of such petition by registered or certified mail to the surviving or
resulting corporation and to the stockholders shown on the list at the addresses
therein stated. Such notice shall also be given by 1 or more publications at
least 1 week before the day of the hearing, in a newspaper of general
circulation published in the City of Wilmington, Delaware or such publication as
the Court deems advisable. The forms of the notices by mail and by publication
shall be approved by the Court, and the costs thereof shall be borne by the
surviving or resulting corporation.
(g) At the hearing on such petition, the Court shall determine the
stockholders who have complied with this section and who have become entitled to
appraisal rights. The Court may require the stockholders who have demanded an
appraisal for their shares and who hold stock represented by certificates to
submit their certificates of stock to the Register in Chancery for notation
thereon of the pendency of the appraisal proceedings; and if any stockholder
fails to comply with such direction, the Court may dismiss the proceedings as to
such stockholder.
(h) After determining the stockholders entitled to an appraisal, the
Court shall appraise the shares, determining their fair value exclusive of any
element of value arising from the accomplishment or expectation of the merger or
consolidation, together with a fair rate of interest, if any, to be paid upon
the amount determined to be the fair value. In determining such fair value, the
Court shall take into account all relevant factors. In determining the fair rate
of interest, the Court may consider all relevant factors, including the rate of
interest which the surviving or resulting corporation would have had to pay to
borrow money during the pendency of the proceeding. Upon application by the
surviving or resulting corporation or by any stockholder entitled to participate
in the appraisal proceeding, the Court may, in its discretion, permit discovery
or other pretrial proceedings and may proceed to trial upon the appraisal prior
to the final determination of the stockholder entitled to an appraisal. Any
stockholder whose name appears on the list filed by the surviving or resulting
corporation pursuant to subsection (f) of this section and who has submitted his
certificates of stock to the Register in Chancery, if such is required, may
participate fully in all proceedings until it is finally determined that he is
not entitled to appraisal rights under this section.
(i) The Court shall direct the payment of the fair value of the shares,
together with interest, if any, by the surviving or resulting corporation to the
stockholders entitled thereto. Interest may be simple or compound, as the Court
may direct. Payment shall be so made to each such stockholder, in the case of
holders of uncertificated stock forthwith, and the case of holders of shares
represented by certificates upon the surrender to the corporation of the
certificates representing such stock. The Court's decree may be enforced as
other decrees in the Court of Chancery may be enforced, whether such surviving
or resulting corporation be a corporation of this State or of any state.
(j) The costs of the proceeding may be determined by the Court and
taxed upon the parties as the Court deems equitable in the circumstances. Upon
application of a stockholder, the Court may order all or a portion of the
expenses incurred by any stockholder in connection with the appraisal
proceeding, including, without limitation, reasonable attorney's fees and the
fees and expenses of experts, to be charged pro rata against the value of all
the shares entitled to an appraisal.
(k) From and after the effective date of the merger or consolidation,
no stockholder who has demanded his appraisal rights as provided in subsection
(d) of this section shall be entitled to vote such stock for any purpose or to
receive payment of dividends or other distributions on the stock (except
dividends or other distributions payable to stockholders of record at a date
which is prior to the effective date of the merger or consolidation); provided,
however, that if no petition for an appraisal shall be filed within the time
provided in subsection (e) of this section, or if such stockholder shall deliver
to the surviving or resulting corporation a written withdrawal of his demand for
an appraisal and an acceptance of the merger or consolidation, either within 60
days after the effective date of the merger or consolidation as provided in
subsection (e) of this section or thereafter with the written approval of the
corporation, then the right of such stockholder to an appraisal shall cease.
Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery
shall be dismissed as to any stockholder without the approval of the Court, and
such approval may be conditioned upon such terms as the Court deems just.
(l) The shares of the surviving or resulting corporation to which the
shares of such objecting stockholders would have been converted had they
assented to the merger or consolidation shall have the status of authorized and
unissued shares of the surviving or resulting corporation.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 20. INDEMNIFICATION OF OFFICERS AND DIRECTORS.
Section 145 of the General Corporation Law of the State of Delaware
(the "DGCL") provides, in summary, that the directors and officers of the
registrant may, under certain circumstances, be indemnified by the registrant
against all expenses incurred by or imposed upon them as a result of actions,
suits or proceedings brought against them as such directors and officers, or as
directors or officers of any other organization at the request of the
registrant, if they act in good faith and in a manner they reasonably believe to
be in or not opposed to the best interests of the registrant, and with respect
to any criminal action or proceeding, have no reasonable cause to believe their
conduct was unlawful, except that no indemnification shall be made against
expenses in respect of any claim, issue or matters to which they shall have been
adjudged to be liable to the registrant unless and only to the extent that the
court in which such action or suit was brought shall determine upon application
that, despite the adjudication of liability but in view of all the circumstances
of the case, they are fairly and reasonably entitled to indemnity for such
expenses which such court shall deem proper. Section 145 of the DGCL also
provides that directors and officers of the registrant are entitled to such
indemnification by the registrant to the extent that such persons are successful
on the merits or otherwise in defending any such action, suit or proceeding.
Article Fourteenth of Imation's Restated Certificate of Incorporation
provides that the liability of a director to Imation or its stockholders for
monetary damages for a breach of fiduciary duty as a director shall be
eliminated to the fullest extent permitted under the DGCL, as amended from time
to time.
The Bylaws of Imation provided that the officers and directors of
Imation shall be indemnified to the full extent authorized or permitted by the
DGCL, as amended from time to time. Expenses incurred by officers and directors
in defending actions, suits, or proceedings may be paid by Imation in advance of
any final disposition if such officer or director agrees to repay such amounts
if it is ultimately determined that he or she is not entitled to be indemnified
under Delaware law.
Imation has entered into individual Indemnity Agreements with each of
its directors pursuant to which Imation has agreed to indemnify each of its
directors for expenses and damages in connection with claims against each
director in connection with the director's service to Imation to the full extent
authorized or permitted by the DGCL, as amended from time to time.
Imation maintains a standard policy of officers' and directors'
liability insurance.
ITEM 21. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
(a) Exhibits
2 Agreement and Plan of Merger, dated as of May 13,
1997 by and among Cemax-Icon, Merger Subsidiary and
Imation, as amended (included as Exhibit A to the
Proxy Statement/Prospectus that forms a part of this
Registration Statement on Form S-4 (certain exhibits
and schedules omitted--the Registrant agrees to
furnish a copy of any exhibit or schedule to the
Commission upon request)).
3.1 Restated Certificate of Incorporation of Imation
(incorporated by reference to Exhibit 3.1 to
Amendment No. 3 to Imation's Registration Statement
on Form 10/A dated June 12, 1996, File No. 1-14310).
3.2 Amended and Restated Bylaws of Imation (incorporated
by reference to Exhibit 3.2 to Amendment No. 3 to
Imation's Registration Statement on Form 10/A dated
June 12, 1996, File No. 1-14310).
4.1 Rights Agreement, dated as of June 18, 1996 between
Imation and Norwest Bank Minnesota, N.A., as Rights
Agent (incorporated by reference to Exhibit 4.1 to
Amendment No. 3 to Imation's Registration Statement
on Form 10/A, dated June 12, 1996, File No. 1-14310).
4.2 Form of Certificate of Designations, Preferences and
Rights of Series A Junior Participating Preferred
Stock of Imation (incorporated by reference to
Exhibit 4.2 to Amendment No. 3 to Imation's
Registration Statement on Form 10/A, dated June 12,
1996, File No. 1-14310).
5 Opinion of Dorsey & Whitney LLP regarding validity of
securities.
10.1 Option Agreement, dated as of May 13, 1997 by and
among Cemax- Icon, Merger Subsidiary and Imation.
10.2 Form of Stockholder Agreements, dated as of May 13,
1997 by and among Cemax-Icon, Merger Subsidiary,
Imation and certain stockholders of Cemax-Icon.
10.3 Form of Affiliate Agreements, dated as of May 13,
1997 by and among Imation and certain stockholders of
Cemax-Icon.
10.4 Form of Key Management Agreements, dated as of May
13, 1997 by and among Cemax-Icon and certain
employees of Cemax-Icon.
10.5 Form of Noncompetition Agreements, dated as of May
13, 1997 by and among Cemax-Icon and certain
stockholders of Cemax-Icon.
15 Awareness Letter from Coopers & Lybrand L.L.P.
regarding unaudited interim financial statements.
21 Subsidiaries of Imation (incorporated by reference to
Exhibit 21 of Imation's Form 10-K for the year ended
December 31, 1996).
23.1 Consent of Coopers & Lybrand L.L.P. with respect to
financial statements of Imation.
23.2 Consent of Ernst & Young LLP with respect to
financial statements of Cemax-Icon.
23.3 Consent of Dorsey & Whitney LLP (included on Exhibit
5).
24 Power of Attorney.
99.1 Form of Proxy Card for the Special Meeting.
- --------------------------------
(b) Financial Statement Schedules
Not applicable.
ITEM 22. UNDERTAKINGS. The undersigned Registrant hereby undertakes:
(a)(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration
statement (or the most recent post- effective
amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the
information set forth in the registration statement.
Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the
total dollar value of securities offered would not
exceed that which was registered) and any deviation
from the low or high end of the estimated maximum
offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the
maximum aggregate offering price set forth in the
"Calculation of Registration Fee" table in the
effective Registration Statement.
(iii) To include any material information with respect to
the plan of distribution not previously disclosed in
the registration statement or any material change to
such information in the registration statement;
(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.
(b) Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the
Registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.
(c) To respond to requests for information that is incorporated by
reference into the Prospectus pursuant to Items 4, 10(b), 11 or 13 of this Form,
within one business day of receipt of such request, and to send the incorporated
documents by first class mail or other equally prompt means. This includes
information contained in documents filed subsequent to the effective date of the
Registration Statement through the date of responding to the request.
(d) To supply by means of a post-effective amendment all information
concerning a transaction, and the company being acquired involved therein, that
was not the subject of and included in the Registration Statement when it became
effective.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Oakdale,
State of Minnesota, on June 6, 1997.
IMATION CORP.
By /s/William T. Monahan
William T. Monahan
Chief Executive Officer,
President and Director
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities indicated on June 6, 1997.
NAME TITLE
By /s/ William T. Monahan Chief Executive Officer, President,
----------------------- Chairman and Director
William T. Monahan (principal executive officer)
By /s/ Jill D. Burchill Chief Financial Officer
----------------------- (principal financial officer)
Jill D. Burchill
By /s/ James R. Stewart Corporate Controller
----------------------- (principal accounting officer)
James R. Stewart
By * Director
-----------------------
Lawrence E. Eaton
By * Director
-----------------------
Linda W. Hart
By * Director
-----------------------
William W. George
By * Director
-----------------------
Ronald T. LeMay
By * Director
-----------------------
Marvin L. Mann
By * Director
-----------------------
Mark A. Pulido
By * Director
-----------------------
Daryl J. White
*By /s/ Carolyn A. Bates
-----------------------
Carolyn A. Bates
As Attorney-In-Fact
EXHIBIT INDEX
Exhibit
Number Description
2 Agreement and Plan of Merger, dated as of May 13, 1997 by and
among Cemax- Icon, Merger Subsidiary and Imation, as amended
(included as Exhibit A to the Proxy Statement/Prospectus that
forms a part of this Registration Statement on Form S-4
(certain exhibits and schedules omitted--the Registrant agrees
to furnish a copy of any exhibit or schedule to the Commission
upon request)).
3.1 Restated Certificate of Incorporation of Imation (incorporated
by reference to Exhibit 3.1 to Amendment No. 3 to Imation's
Registration Statement on Form 10/A dated June 12, 1996, File
No. 1-14310).
3.2 Amended and Restated Bylaws of Imation (incorporated by
reference to Exhibit 3.2 to Amendment No. 3 to Imation's
Registration Statement on Form 10/A dated June 12, 1996, File
No. 1-14310).
4.1 Rights Agreement, dated as of June 18, 1996 between Imation
and Norwest Bank Minnesota, N.A., as Rights Agent
(incorporated by reference to Exhibit 4.1 to Amendment No. 3
to Imation's Registration Statement on Form 10/A, dated June
12, 1996, File No. 1-14310).
4.2 Form of Certificate of Designations, Preferences and Rights of
Series A Junior Participating Preferred Stock of Imation
(incorporated by reference to Exhibit 4.2 to Amendment No. 3
to Imation's Registration Statement on Form 10/A, dated June
12, 1996, File No. 1-14310).
5 Opinion of Dorsey & Whitney LLP regarding validity of
securities.
10.1 Option Agreement, dated as of May 13, 1997 by and among
Cemax-Icon, Merger Subsidiary and Imation.
10.2 Form of Stockholder Agreements, dated as of May 13, 1997 by
and among Cemax-Icon, Merger Subsidiary, Imation and certain
stockholders of Cemax- Icon.
10.3 Form of Affiliate Agreements, dated as of May 13, 1997 by and
among Imation and certain stockholders of Cemax-Icon.
10.4 Form of Key Management Agreements, dated as of May 13, 1997 by
and among Cemax-Icon and certain employees of Cemax-Icon.
10.5 Form of Noncompetition Agreements, dated as of May 13, 1997 by
and among Cemax-Icon and certain stockholders of Cemax-Icon.
15 Awareness Letter from Coopers & Lybrand L.L.P. regarding
unaudited interim financial statements.
21 Subsidiaries of Imation (incorporated by reference to Exhibit
21 of Imation's Form 10-K for the year ended December 31,
1996).
23.1 Consent of Coopers & Lybrand L.L.P. with respect to financial
statements of Imation.
23.2 Consent of Ernst & Young LLP with respect to financial
statements of Cemax- Icon.
23.3 Consent of Dorsey & Whitney LLP (included on Exhibit 5).
24 Power of Attorney.
99.1 Form of Proxy Card for the Special Meeting.
EXHIBIT 5
[Dorsey & Whitney LLP Letterhead]
Imation Corp.
1 Imation Place
Oakdale, Minnesota 55128
Re: Registration Statement on Form S-4
Ladies and Gentlemen:
We have acted as counsel to Imation Corp., a Delaware corporation
(the "Company"), in connection with a Registration Statement on Form S-4 (the
"Registration Statement") relating to the issuance by the Company of up to
8,000,000 contingent payment rights (the "Contingent Payment Rights") in
connection with the acquisition by the Company of all of the issued and
outstanding capital stock of Cemax-Icon, Inc., a Delaware corporation
("Cemax-Icon") pursuant to that certain Agreement and Plan of Merger, dated as
of May 13, 1997 (the "Merger Agreement"), among the Company, CI Acquisition
Corp., a Delaware corporation and wholly owned subsidiary of the Company, and
Cemax-Icon. The Registration Statement also relates to shares of the Company's
common stock, $0.01 par value (the "Common Stock") which may be issued upon the
exercise of the Contingent Payment Rights.
We have examined such documents and have reviewed such questions of
law as we have considered necessary and appropriate for the purposes of our
opinions set forth below.
In rendering our opinions set forth below, we have assumed the
authenticity of all documents submitted to us as originals, the genuineness of
all signatures and the conformity to authentic originals of all documents
submitted to us as copies. We have also assumed the legal capacity for all
purposes relevant hereto of all natural persons and, with respect to all parties
to agreements or instruments relevant hereto other than the Company, that such
parties had the requisite power and authority (corporate or otherwise) to
execute, deliver and perform such agreements or instruments, that such
agreements or instruments have been duly authorized by all requisite action
(corporate or otherwise), executed and delivered by such parties and that such
agreements or instruments are the valid, binding and enforceable obligations of
such parties. As to questions of fact material to our opinions, we have relied
upon certificates of officers of the Company and of public officials. We have
also assumed that the Contingent Payment Rights and the Common Stock will be
issued as described in the Registration Statement.
Based on the foregoing, we are of the opinion that:
1. The Contingent Payment Rights have been duly authorized by all
requisite corporate action and, when issued and delivered as specified in the
Merger Agreement and the Registration Statement, will constitute valid and
binding obligations of the Company, enforceable in accordance with their terms.
2. The shares of Common Stock have been duly authorized by all
requisite corporate action and, when issued and delivered as specified in the
Contingent Payment Rights and the Registration Statement, will be validly
issued, fully paid and nonassessable.
The opinions set forth above are subject to the following
qualifications and exceptions:
(a) Our opinions are subject to the effect of any applicable
bankruptcy, insolvency, reorganization, moratorium or other similar law of
general application affecting creditors' rights.
(b) Our opinions are subject to the effect of general principles of
equity, including (without limitation) concepts of materiality,
reasonableness, good faith and fair dealing, and other similar doctrines
affecting the enforceability of agreements generally (regardless of
whether considered in a proceeding in equity or at law).
(c) Minnesota Statutes ss. 290.371, Subd. 4, provides that any
corporation required to file a Notice of Business Activities Report does
not have a cause of action upon which it may bring suit under Minnesota
law unless the corporation has filed a Notice of Business Activities
Report and provides that the use of the courts of the State of Minnesota
for all contracts executed and all causes of action that arose before the
end of any period for which a corporation failed to file a required report
is precluded. Insofar as our opinion may relate to the valid, binding and
enforceable character of any agreement under Minnesota law or in a
Minnesota court, we have assumed that any party seeking to enforce such
agreement has at all times been, and will continue at all times to be,
exempt from the requirement of filing a Notice of Business Activities
Report or, if not exempt, has duly filed, and will continue to duly file,
all Notice of Business Activities Reports.
Our opinions expressed above are limited to the laws of the State of
Minnesota, the General Corporation Law of the State of Delaware and the federal
laws of the United States of America.
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the reference to our firm under the caption "Legal
Matters" in the Proxy Statement/Prospectus constituting part of the Registration
Statement.
Dated: June 6, 1997
Very truly yours,
/s/ Dorsey & Whtiney LLP
EXHIBIT 10.1
OPTION AGREEMENT
This Option Agreement (this "Agreement") is made as of May 13, 1997, by
and among Cemax-Icon, Inc., a Delaware Corporation (the "Company"), and Imation
Corp., a Delaware corporation ("Imation").
RECITALS
WHEREAS, concurrently with the execution and delivery of this
Agreement, Company, Imation and CI Acquisition Corp., a Delaware corporation and
wholly owned subsidiary of Imation ("Merger Subsidiary"), have agreed that
Merger Subsidiary shall be merged (the "Merger") with and into the Company, in
accordance with that certain Agreement and Plan of Merger among the Company,
Imation and Merger Subsidiary dated as of the date hereof (the "Merger
Agreement"), pursuant to which the Company will be the surviving corporation and
a wholly owned subsidiary of Imation (the "Surviving Corporation"); and
WHEREAS, Imation and the Company have conditioned the execution of the
Merger Agreement on the execution of this Agreement.
NOW, THEREFORE, in consideration of the foregoing, the respective
undertakings of the parties set forth below, and other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, the
parties hereby agree as follows:
1. DEFINITIONS. Capitalized terms not expressly defined in this
Agreement shall have the meanings ascribed to them in the Merger Agreement.
2. GRANT OF OPTION. As an inducement to Imation to execute and deliver
the Merger Agreement, and to proceed with the Merger under the terms and
conditions set forth in the Merger Agreement, the Company hereby irrevocably
grants to Imation an option (the "Option") to purchase up to 1,075,917 shares of
the Company's common stock, par value $0.01 per share ("Common Stock"), at a
price equal to $11.96 per share of Common Stock.
3. EXERCISE OF OPTION. The Option may be exercised by Imation, in whole
or in part, at any time and from time to time, on or before December 31, 1997.
In the event that Imation desires to exercise the Option, Imation shall give a
written notice to the Company specifying the number of shares of Common Stock it
will purchase and a place and date (which date shall not be later than 10
business days after the date such notice is mailed, provided, however, that if
any domestic law or regulation will not permit such purchase to be consummated
during such 10-day period, the date of the closing of such purchase shall be
within five days following the cessation of such restriction) for the closing of
the purchase.
4. PAYMENT AND DELIVERY OF CERTIFICATES. At any closing hereunder, (a)
Imation will pay the aggregate purchase price for the shares of Common Stock to
be purchased by wire transfer of immediately available funds to an account
designated by the Company, and (b) the Company will deliver to Imation a
certificate or certificates representing the shares purchased.
5. REPRESENTATIONS AND WARRANTIES OF IMATION. Imation hereby represents
and warrants to the Company as follows:
(a) The execution, delivery and performance of this Agreement
by Imation has been duly authorized by all necessary corporate action on the
part of Imation; and this Agreement has been duly executed and delivered by
Imation and constitutes a valid and binding obligation of Imation enforceable in
accordance with its terms; and
(b) The purchase of any shares of Common Stock from the
Company pursuant to this Agreement will be for the account of Imation for
investment and not with a view to the sale and distribution thereof within the
meaning of the Securities Act; and any sale, transfer or other disposition of
the shares of Common Stock purchased hereunder will be made in compliance with
all applicable provisions of the Securities Act and the rules and regulations
thereunder.
6. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby
represents and warrants to Imation as follows:
(a) The Company has the requisite corporate power and
authority to enter into this Agreement and carry out its obligations hereunder;
the execution, delivery and performance of this Agreement by the Company has
been duly authorized by the Board of Directors of the Company and no other
corporate proceedings on the part of the Company are necessary to authorize the
execution, delivery and performance of this Agreement; this Agreement has been
duly executed and delivered by the Company and constitutes a valid and binding
obligation of the Company enforceable in accordance with its terms;
(b) Upon purchase by Imation hereunder, the shares of Common
Stock subject to this Option will be duly authorized, validly issued, fully paid
and nonassessable;
(c) Upon delivery of any shares of Common Stock purchased by
Imation hereunder, Imation will receive good title to such shares, free and
clear of any pledge, lien, security interest, charge, claim or encumbrance of
any kind;
(d) The execution, delivery and performance of this Agreement
by the Company do not and will not conflict with or result in any breach of any
of the provisions of, constitute a default under, result in a violation of,
result in the creation of a right of termination or acceleration or any lien,
security interest, charge or encumbrance upon any assets of the Company, or
require any authorization, consent, approval, exemption or other action by or
notice to any court or other governmental body, under the provisions of the
Certificate of Incorporation or Bylaws of the Company or any indenture,
mortgage, lease, loan agreement or other agreement or instrument by which the
Company is bound or affected, or any law, statute, rule or regulation or order,
judgment or decree to which the Company is subject; and
(e) The Company is not required to submit any notice, report
or other filing with any governmental authority in connection with the execution
or delivery by it of this Agreement or the consummation of the transactions
contemplated hereby except for filings required pursuant to applicable state
securities laws (which filings shall be made by the Company promptly in the
event Imation exercises its option hereunder). No consent, approval or
authorization of any governmental or regulatory authority or any other party or
person is required to be obtained by the Company in connection with its
execution, delivery and performance of this Agreement or the transactions
contemplated hereby.
(f) The Company currently has 5,379,587 shares of Common Stock
issued and outstanding.
7. EFFECT OF TERMINATION OF THE MERGER AGREEMENT. The termination of
the Merger Agreement and the payment of any termination fees by the Company
under the Merger Agreement shall in no way affect the validity of or
enforceability of this Agreement; provided, that, the Option may not be
exercised and this Agreement shall terminate and be of no further force or
effect in the event the Company terminates the Merger Agreement pursuant to
Section 8.01(b) thereof.
8. REGISTRATION RIGHTS. Imation shall be entitled to the registration
rights set forth on the attached Exhibit A with respect to any shares of Common
Stock purchased hereunder.
9. MISCELLANEOUS.
(a) Severability. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, void or unenforceable, then the remainder of the terms, provisions,
covenants and restrictions of this Agreement shall remain in full force and
effect and shall in no way be affected, impaired or invalidated.
(b) Binding Effect and Assignment. This Agreement and all of
the provisions hereof shall be binding upon and inure to the benefit of the
parties hereto and their respective successors, affiliates and assigns.
(c) Amendments and Modification. This Agreement may not be
modified, amended, altered or supplemented except upon the execution and
delivery of a written agreement executed by the party against whom enforcement
of such change is sought.
(c) Specific Performance; Injunctive Relief. The parties
hereto acknowledge that Imation will be irreparably harmed and that there will
be no adequate remedy at law for a violation of any of the covenants or
agreement of the Company set forth herein. Therefore, it is agreed that, in
addition to any other remedies that may be available to Imation upon any such
violation, Imation shall have the right to enforce such covenants and agreements
by specific performance, injunctive relief or by any other means available to
Imation at law or in equity, in any event without the necessity of posting bond
or proving actual damages.
(d) Notices. All notices, demands and other communications to
be given or delivered under or by reason of the provisions of this Agreement
will be in writing and will be deemed to have been given when personally
delivered or three days after being mailed, if mailed by first class mail,
return receipt requested, or when receipt is acknowledged, if sent by facsimile,
telecopy or other electronic transmission device. Notices, demands and
communications to Imation and the Company will, unless another address is
specified in writing, be sent to the address indicated below:
Notices to Imation: with a copy to:
Imation Corp. Dorsey & Whitney LLP
Legal Affairs 220 South Sixth Street
Imation Corp. Minneapolis, MN 55402
One Imation Place Attention: Gary L. Tygesson
Oakdale, MN 55128-3414 Telecopy: (612) 340-8753
Attn:
Imation Corp.
One Imation Place
Oakdale, MN 55128-3414
Attn:
Notices to the Company: with a copy to:
Cemax-Icon, Inc. Wilson, Sonsini, Goodrich &
47281 Mission Falls Court Rosati, P.C.
Fremont, California 94539 650 Page Mill Road
Attn: Terry Ross Palo Alto, California 94304-1050
Attn: Michael O'Donnell
(e) Governing Law. This Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware.
(f) Entire Agreement. This Agreement contains the entire
understanding of the parties in respect of the subject matter hereof, and
supersedes all prior negotiations and understandings between the parties with
respect to such subject matter.
(g) Counterparts. This Agreement may be executed in several
counterparts, each of which shall be an original, but all of which together
shall constitute one and the same agreement.
(h) Effect of Headings. The section headings herein are for
convenience only and shall not affect the construction or interpretation of this
Agreement.
(i) Effective Time. This Agreement and the Proxy delivered in
connection herewith shall become effective only upon execution of the Merger
Agreement by each of the Company, Imation and Merger Subsidiary.
IN WITNESS WHEREOF, the parties have executed and delivered this
Agreement as of the date first above written.
IMATION CORP.
By /s/ C.T. Pinder
-----------------------------
Its Vice President
------------------------
CEMAX-ICON, INC.
By /s/ Terry Ross
-----------------------------
Its President and C.E.O.
------------------------
EXHIBIT 10.2
FORM OF STOCKHOLDER AGREEMENT
This Stockholder Agreement (the "Agreement") dated as of April 1997, is
made and entered into by and among Imation Corp., a Delaware corporation
("Imation"), and the undersigned stockholder (the "Stockholder") of Cemax-Icon,
Inc., a Delaware corporation (the "Company").
RECITALS
WHEREAS, concurrently with delivery of this Agreement, Imation, the
Company and CI Acquisition Corp., a Delaware corporation and a wholly owned
subsidiary of Imation ("Sub"), are entering into an Agreement and Plan of Merger
(the "Merger Agreement") which provides for the merger (the "Merger") of Sub
with and into the Company. Pursuant to the Merger, shares of capital stock of
the Company will be converted into the right to receive cash and other
consideration on the basis described in the Merger Agreement. Capitalized terms
used but not defined herein shall have the respective meanings ascribed to them
in the Merger Agreement.
WHEREAS, the Stockholder is the record holder and beneficial owner (as
defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the
"Exchange Act")) of the number of shares of the outstanding capital stock of the
Company as is indicated on the signature page of this Agreement (the "Shares").
WHEREAS, as a material inducement to Imation to enter into the Merger
Agreement, the Stockholder is willing to enter into and be bound by this
Agreement pursuant to which the Stockholder agrees (a) not to transfer or
otherwise dispose of any of the Shares, or any other shares of capital stock of
the Company acquired hereafter and prior to the Expiration Date (as defined in
Section 1.1 below), and (b) to vote the Shares and any other such shares of
capital stock of the Company held by the Stockholder so as to facilitate
consummation of the Merger.
NOW, THEREFORE, in consideration of the foregoing and the respective
representations and covenants set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, and
intending to be legally bound hereby, the parties hereby agree as follows:
1. Agreement to Retain Shares.
1.1 Transfer and Encumbrance. The Stockholder agrees not to
transfer (except as may be specifically required by court order), sell,
exchange, pledge or otherwise dispose of or encumber any of the Shares or any
New Shares (as defined in Section 1.2 below), grant any proxies (except the
proxy referred to in Section 2(b)) with respect to the Shares or any New
Shares), or make any offer or agreement relating thereto, at any time prior to
the Expiration Date. As used herein, the term "Expiration Date" shall mean the
earlier to occur of (a) such date and time as the Merger shall become effective
in accordance with the terms and provisions of the Merger Agreement, and (b)
such date and time as the Merger Agreement shall be terminated pursuant to
Article VIII thereof.
1.2 Additional Purchases. The Stockholder agrees that any
shares of capital stock of the Company that such Stockholder purchases or with
respect to which such Stockholder otherwise acquires beneficial ownership after
the execution of this Agreement and prior to the Expiration Date ("New Shares")
shall be subject to the terms and conditions of this Agreement to the same
extent as if they constituted Shares.
2. Agreement to Vote Shares and Irrevocable Proxy.
(a) At every meeting of the stockholders of the Company called
with respect to any of the following, and at every adjournment thereof, and on
every action or approval by written consent of the stockholders of the Company
with respect to any of the following, the Stockholder agrees to vote the Shares
and any New Shares: (i) in favor of approval of the Merger Agreement and the
Merger and any matter that could reasonably be expected to facilitate the
Merger; and (ii) against approval of any proposal made in opposition to or
competition with consummation of the Merger and against any merger,
consolidation, sale of assets, reorganization or recapitalization, with any
party other than Imation, Sub and their affiliates and against any liquidation
or winding up of the Company (each of the foregoing is hereinafter referred to
as an "Opposing Proposal"). The Stockholder agrees not to take any actions
contrary to such Stockholder's obligations under this Agreement.
(b) In furtherance of Section 2(a), the Stockholder hereby
irrevocably appoints, during the term of this Agreement, Imation as proxy to
vote the Shares and any New Shares which the Stockholder is entitled to vote,
for and in the name, place and stead of such Stockholder (the "Proxy"), at any
annual, special or other meeting of the holders of capital stock of the Company
and at any adjournments thereof or pursuant to any consent in lieu of a meeting
or otherwise.
(c) The Proxy is granted in consideration of the execution and
delivery of the Merger Agreement by Imation. The Stockholder agrees that the
Proxy is coupled with an interest sufficient in law to support an irrevocable
proxy.
(d) The Proxy shall revoke all prior proxies given by the
Stockholder with respect to any Shares or New Shares.
3. Nonsolicitation. During the term of this Agreement, the Stockholder
shall not, directly or indirectly, solicit, initiate or encourage submission of
any proposal or offer from any person, group or entity relating to any
acquisition of the assets, business or capital stock of the Company, or other
similar transaction or business combination involving the business of the
Company; shall not participate in any negotiations or discussions regarding or
furnish to any other person any information with respect to, or otherwise
cooperate in any way with, or assist or participate in, facilitate or encourage
any effort or attempt by any other person or entity to do or seek such
acquisition or other transaction; and shall inform Imation of any such inquiry.
Without limiting the generality of the foregoing, the Stockholder will not, and
will not permit any person or entity under Stockholder's control to, (a) solicit
proxies or become a "participant" in a "solicitation" (as such terms are defined
in Regulation 14A under the Exchange Act) with respect to an Opposing Proposal
or otherwise encourage or assist any party in taking or planning any action that
would compete with, restrain or otherwise serve to interfere with or inhibit the
timely consummation of the Merger in accordance with the terms of the Merger
Agreement; (b) initiate a stockholders' vote or action by consent of the Company
stockholders with respect to an Opposing Proposal; or (c) become a member of a
"group" (as such term is used in Section 13(d) of the Exchange Act) with respect
to any voting securities of the Company with respect to an Opposing Proposal.
Imation agrees that the foregoing shall not prohibit the Company from issuing
the Picker Shares and Warrants.
4. Representations and Warranties of the Stockholders. The Stockholder
hereby represents and warrants to Imation as follows:
4.1 Ownership of Shares. The Stockholder (a) is the beneficial
owner of the number of Shares set forth on the signature page of this Agreement,
which at the date hereof and at all times up until the Expiration Date will be
free and clear of any liens, claims, options, charges or other encumbrances; and
(b) does not beneficially own any shares of capital stock of the Company other
than such Shares (excluding shares as to which Stockholder currently disclaims
beneficial ownership in accordance with applicable law).
4.2 Authority; Enforceability. The Stockholder has the legal
right and power, and all authorization and approval required by law, to enter
into this Agreement and to grant the Proxy. This Agreement, including the Proxy,
has each been duly authorized, executed and delivered by or on behalf of the
Stockholder and constitutes a valid and binding obligation of the Stockholder
enforceable in accordance with its respective terms.
4.3 No Conflict. The execution and delivery by the Stockholder
of, and the performance by the Stockholder of its obligations under, this
Agreement will not contravene any provision of applicable law, or the
certificate of incorporation or bylaws, partnership agreement, limited liability
company agreement, trust agreement or other charter documents of the
Stockholder, any agreement or other instrument binding upon the Stockholder, or
any judgment, order or decree of any governmental body, agency or court having
jurisdiction over the Stockholder, and no consent, approval, authorization or
order of, or qualification with, any governmental body or agency is required for
the performance by the Stockholder of its obligations under this Agreement,
except (i) such consents, approvals, orders, authorizations, registrations,
declarations and filings as may be required under applicable state and federal
securities laws, (ii) filings under the HSR Act, and (iii) such other consents,
authorizations, filings, approvals and registrations which if not obtained or
made would not have a material adverse effect on the ability of the Stockholder
to consummate the transactions contemplated by this Agreement and the Merger
Agreement.
5. Additional Documents. The Stockholder hereby covenants and agrees to
execute and deliver any additional documents necessary or desirable, in the
reasonable opinion of Imation, to carry out the intent of this Agreement.
6. Consent and Waiver. The Stockholder hereby gives any consents or
waivers that are reasonably required for the consummation of the Merger under
the terms of any agreements to which the Stockholder is a party or pursuant to
any rights the Stockholder may have.
7. Termination. This Agreement and the Proxy delivered in connection
herewith shall terminate and shall have no further force or effect as of the
Expiration Date.
8. Miscellaneous.
8.1 Severability. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, void or unenforceable, then the remainder of the terms, provisions,
covenants and restrictions of this Agreement shall remain in full force and
effect and shall in no way be affected, impaired or invalidated.
8.2 Binding Effect and Assignment. This Agreement and all of
the provisions hereof shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and permitted assigns, but,
except as otherwise specifically provided herein, neither this Agreement nor any
of the rights, interests or obligations of any Stockholder may be assigned by
the Stockholder without the prior written consent of Imation.
8.3 Amendments and Modification. This Agreement may not be
modified, amended, altered or supplemented except upon the execution and
delivery of a written agreement executed by the party against whom enforcement
is sought.
8.4 Specific Performance; Injunctive Relief. The parties
hereto acknowledge that Imation will be irreparably harmed and that there will
be no adequate remedy at law for a violation of any of the covenants or
agreement of any Stockholder set forth herein. Therefore, it is agreed that, in
addition to any other remedies that may be available to Imation upon any such
violation, Imation shall have the right to enforce such covenants and agreements
by specific performance, injunctive relief or by any other means available to
Imation at law or in equity, in any event without the necessity of posting bond
or proving actual damages.
8.5 Notices. All notices, demands and other communications to
be given or delivered under or by reason of the provisions of this Agreement
will be in writing and will be deemed to have been given when personally
delivered or three days after being mailed, if mailed by first class mail,
return receipt requested, or when receipt is acknowledged, if sent by facsimile,
telecopy or other electronic transmission device. Notices, demands and
communications to Imation and the Stockholders will, unless another address is
specified in writing, be sent to the address indicated below:
Notices to Imation or Sub: with a copy to:
Imation Corp. Dorsey & Whitney LLP
Legal Affairs 220 South Sixth Street
Imation Corp. Minneapolis, MN 55402
One Imation Place Attention: Gary L. Tygesson
Oakdale, MN 55128-3414 Telecopy: (612) 340-8753
Attn:
Imation Corp.
One Imation Place
Oakdale, MN 55128-3414
Attn:
Notices to the Stockholders:
To the address set forth on the signature page
8.6 Governing Law. This Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware.
8.7 Entire Agreement. This Agreement contains the entire
understanding of the parties in respect of the subject matter hereof, and
supersedes all prior negotiations and understandings between the parties with
respect to such subject matter.
8.8 Counterparts. This Agreement may be executed in several
counterparts, each of which shall be an original, but all of which together
shall constitute one and the same agreement.
8.9 Effect of Headings. The section headings herein are for
convenience only and shall not affect the construction or interpretation of this
Agreement.
8.10 Effective Time. This Agreement and the Proxy delivered in
connection herewith shall become effective only upon execution of the Merger
Agreement by each of the Company, Imation and Sub.
IN WITNESS WHEREOF, the parties have caused this Stockholders Agreement
to be duly executed on the date and year first above written.
IMATION CORP.
By _______________________________
Its _________________________
STOCKHOLDER:
__________________________________
Name:
Shares:___________________________
Address: _________________________
__________________________________
__________________________________
EXHIBIT 10.3
IMATION CORP.
FORM OF AFFILIATE AGREEMENT
MAY __, 1997
Imation Corp.
One Imation Place
Oakdale, MN 55128-3414
Gentlemen:
Pursuant to the terms of the Agreement and Plan of Merger dated as of
April __, 1997 (the "Agreement") among Imation Corp., a Delaware corporation
("Parent"), CI Acquisition Corp., a Delaware corporation and wholly owned
subsidiary of Parent ("Sub"), and Cemax-Icon, Inc., a Delaware corporation (the
"Company"), Parent will acquire the Company through the merger of the Sub with
and into Company (the "Merger"). Subject to the terms and conditions of the
Agreement, at the Effective Time (as defined in the Agreement), (a) outstanding
shares of the common stock of the Company (the "Company Common Stock") will be
converted into the right to receive cash and Contingent Payment Rights (as
defined in the Merger Agreement) on the basis described in the Agreement, and
(b) options and warrants to purchase Company Common Stock will be converted into
options and warrants to purchase shares of common stock of Parent ("Parent
Common Stock"). Pursuant to an irrevocable election to be made by the
undersigned as of or after the Effective Time, the Contingent Payment Rights may
be paid by Parent, in whole or in part, in Parent Common Stock.
The undersigned has been advised that as of the date hereof the
undersigned may be deemed to be an "affiliate" of the Company, as the term
"affiliate" is used in paragraphs (c) and (d) of Rule 145 of the Rules and
Regulations (the "Rules and Regulations") of the Securities and Exchange
Commission (the "Commission") under the Securities Act of 1933, as amended (the
"Act").
The undersigned understands that the representations, warranties and
covenants set forth herein will be relied upon by Parent and the Company.
The undersigned represents and warrants to and agrees with Parent that:
1. The undersigned has full power to execute and deliver this Affiliate
Agreement and to make the representations and warranties herein and to perform
its obligations hereunder.
2. The undersigned has carefully read this Affiliate Agreement and the
Agreement and discussed its requirements and other applicable limitations upon
its ability to sell, transfer or otherwise dispose of Parent Common Stock to the
extent the undersigned felt necessary, with its counsel or counsel for the
Company.
3. The undersigned shall not make any sale, transfer or other
disposition of Parent Common Stock in violation of the Act or the Rules and
Regulations.
4. The undersigned has been advised that, since, at the time the Merger
is to be submitted for a vote of the shareholders of the Company, the
undersigned may be deemed to be an affiliate of the Company, the undersigned may
not sell, transfer or otherwise dispose of Parent Common Stock issued to the
undersigned in the Merger unless such sale, transfer or other disposition is
made in conformity with the requirements of Rule 145 promulgated by the
Commission under the Act.
5. Except as provided in the Agreement, Parent is under no obligation
to register the sale, transfer or other disposition of Parent Common Stock by
the undersigned or on its behalf under the Act or to take any other action
necessary in order to make compliance with an exemption from such registration
available.
6. Stop transfer instructions will be given to Parent's transfer agents
with respect to the Parent Common Stock and will be placed on the certificates
for the Parent Common Stock issued to the undersigned, or any substitutions
therefor, a legend stating in substance:
"The shares represented by this certificate were issued in a
transaction to which Rule 145 promulgated under the Securities Act of
1933 applies. The shares represented by this certificate may only be
transferred in accordance with the terms of an Affiliate Agreement
dated April __, 1997 between the registered holder hereof and Parent, a
copy of which agreement is on file at the principal offices of Parent."
7. The legend set forth above shall be removed by delivery of
substitute certificates without such legend if the undersigned shall have
delivered to Parent a copy of an opinion of counsel in form and substance
reasonably satisfactory to Parent, to the effect that such legend is not
required for purposes of the Act.
8. The undersigned is the beneficial owner of all the shares of Company
Common Stock and options to purchase Company Common Stock as is indicated below
on this Affiliate Agreement (the "Company Securities"). Except for the Company
Securities, the undersigned does not beneficially own any shares of Company
Common Stock or any other equity securities of the Company or any options,
warrants or other rights to acquire any equity securities of the Company.
Number of shares of Company Common Stock beneficially owned by the
undersigned:
Common Stock __________
Number of shares of Company Common Stock subject to options or warrants
beneficially owned by the undersigned:
Common Stock __________
Very truly yours,
______________________________________________
(print name of shareholder above)
By:___________________________________________
Title:________________________________________
Accepted this ___ day of May, 1997, by
IMATION CORP.
By:____________________________
Name:__________________________
Title:_________________________
EXHIBIT 10.4
FORM OF KEY MANAGEMENT AGREEMENT
THIS AGREEMENT is entered into on the day of _____, 1997, but
effective at the Effective Time (as set forth below), by and between , an
individual resident of the State of ("Executive"), and Cemax-Icon, Inc., a
Delaware corporation (the "Company").
WHEREAS, Executive has heretofore been employed as an executive
officer of the Company; and
WHEREAS, Company, Imation Corp., a Delaware corporation ("Imation"),
and CI Acquisition Corp., a Delaware corporation and wholly owned subsidiary of
Imation ("Merger Subsidiary"), have agreed that Merger Subsidiary shall be
merged (the "Merger") with and into the Company, in accordance with the terms
and conditions of that certain Agreement and Plan of Merger among the Company,
Imation and Merger Subsidiary dated as of the date hereof (the "Merger
Agreement"), pursuant to which the Company will be the surviving corporation and
a wholly owned subsidiary of Imation;
WHEREAS, Imation has conditioned the execution of the Merger
Agreement on the execution of this Agreement; and
WHEREAS, the Company, as the surviving corporation in the Merger,
desires to retain the services of Executive subsequent to such Merger, and
Executive desires to be employed by the Company, on the terms and subject to the
conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the foregoing, the respective
undertakings of the Company and Executive set forth below, and other good and
valuable consideration, the receipt and adequacy of which are hereby
acknowledged, and as an inducement to Imation to complete the Merger pursuant to
the terms and conditions of the Merger Agreement, the Company and Executive
agree as follows:
1. Employment. The Company hereby agrees to employ Executive, and
Executive accepts such employment and agrees to perform services for the
Company, for the period after the Effective Time (as defined in the Merger
Agreement) and upon the other terms and conditions set forth in this Agreement.
2. Term.
2.01 Initial Term. Unless terminated at an earlier date in
accordance with Section 6 of this Agreement, the term of Executive's employment
hereunder shall commence at the Effective Time of the Merger and shall extend
for a period of months after the Effective Time (the "Initial Term"). The term
of this Agreement may be extended thereafter only by mutual agreement of the
Company and Executive.
2.02 Extension or Expiration of Initial Term. No later than six
months prior to the expiration of the Initial Term, the Company and Executive
will discuss the possible continued employment of Executive by the Company
beyond the Initial Term.
(a) In the event the Company provides written notice of
its intention not to continue the employment of Executive prior to
or on the expiration date of the Initial Term (other than for any of
the reasons set forth in Section 6.02(a), (b) or (c)), the
termination of Executive's employment shall be considered a
termination by the Company without "cause" pursuant to Section
6.01(d), AS OF THE DATE THE COMPANY PROVIDES THE WRITTEN NOTICE OF
ITS INTENTION NOT TO CONTINUE THE EMPLOYMENT OF EXECUTIVE, for the
purposes of Sections 4.05 (Substitute Option) and 6.06 (Wage
Continuation).
(b) In the event that the Company does not provide
written notice of its intention not to continue the employment of
Executive prior to expiration of the Initial Term and the Company
terminates its employment of Executive (other than for any of the
reasons set forth in Section 6.02(a), (b) or (c)) within the first
six months after the expiration of the Initial Term, the termination
of Executive's employment shall be considered a termination by the
Company without "cause" pursuant to Section 6.01(d), AS OF THE DATE
OF TERMINATION OF EMPLOYMENT, for the purposes of Sections 4.05
(Substitute Option) and 6.06 (Wage Continuation).
3. Position and Duties.
3.01 Service with Company; Relocation. During the term of this
Agreement, Executive agrees that Executive shall perform such reasonable
employment duties as the Board of Directors of the Company shall assign to him
substantially consistent with such Executive's duties and responsibilities
immediately prior to the Effective Time. Following the Effective Time, the
Executive shall initially have reporting responsibilities substantially
consistent with Executive's reporting responsibilities immediately prior to the
Effective Time.
In the event that employment of Executive is terminated by the
Company or Executive because the Company requires Executive to move his personal
residence from the State of California at any time prior to the expiration of
the Initial Term, such termination shall be considered a termination by the
Company without "cause" pursuant to Section 6.01(d), AS OF THE DATE OF
TERMINATION OF EMPLOYMENT, for the purposes of Sections 4.05 (Substitute Option)
and 6.06 (Wage Continuation).
3.02 Performance of Duties. Executive agrees to serve the Company
faithfully and to the best of his ability and to devote his full business time,
attention and efforts to the business and affairs of the Company during the term
of this Agreement. Executive represents to the Company that he is under no
contractual commitments inconsistent with his obligations set forth in this
Agreement, and that during the term of this Agreement, he will not render or
perform services for any other corporation, firm, entity or person which are
inconsistent with the provisions of this Agreement.
4. Compensation.
4.01 Base Salary. As base compensation for all services to be
rendered by Executive under this Agreement during the first year of the term of
this Agreement, the Company shall pay to Executive a base salary of $____, which
salary shall be paid on a twice-monthly basis in accordance with the Company's
normal payroll procedures and policies. The salary payable to Executive during
each subsequent year during the term of this Agreement shall be established by
the Company's Board of Directors following an annual performance review, but in
no event shall the salary for any subsequent year be less than the salary in
effect for the prior year.
4.02 Incentive Compensation. In addition to the base salary
described in Section 4.01, Executive shall be entitled to continued
participation in the Cemax-Icon incentive pay plan (the "Incentive Plan"),
subject to the following modifications:
(a) For the initial six months of this Agreement, the
payment and targets for incentive compensation shall be
based on the Cemax- Icon Baseline Sales Plan and the
amount of the payment shall be calculated as set forth
on the attached Exhibit A;
(b) During the succeeding six months of this Agreement,
quarterly payments and targets for incentive
compensation shall be based on the Imation Low Synergy
Sales Plan and the amounts of the payment shall be
calculated as set forth on the attached Exhibit A; and
(c) During the remaining months of this Agreement, quarterly
payments and targets shall be based on the Imation Low
Synergy Sales and Profits Plan and the amounts of the
payment shall be calculated as set forth on the attached
Exhibit A.
4.03 Participation in Benefit Plans. During the term of this
Agreement, Executive shall be entitled to receive such medical and
hospitalization insurance and other fringe benefits as are being provided to the
Company's other Executive level employees from time to time to the extent that
Executive's age, position or other factors qualify him for such fringe benefits.
4.04 Expenses. The Company will pay or reimburse Executive for all
reasonable and necessary out-of-pocket expenses incurred by him in the
performance of his duties under this Agreement, subject to the presentment of
appropriate vouchers in accordance with the Company's normal policies for
expense verification.
4.05 Substitute Options. At the Effective Time, an option to
purchase shares of the Company's common stock held by the Executive ("Current
Option") will be converted into options to purchase shares of Imation's common
stock ("Substitute Option") pursuant to Section 2.02 of the Merger Agreement.
Notwithstanding anything in the Merger Agreement or the terms of the Current
Option to the contrary, however, the Substitute Option will:
(a) Become fully vested and exercisable for a period of two
years after termination of employment (but in no event
after expiration of the term of the Substitute Option)
upon termination of employment pursuant to Section
6.01(a);
(b) Become fully vested and exercisable for the remaining
term of the Substitute Option upon termination of
employment pursuant to Section 6.01(b);
(c) Upon termination of employment for the reasons set forth
in Section 6.01(c) or Section 6.01(e) (whether such
termination is before or after the term of this
Agreement), (i) be forfeited and terminate immediately
as to the portion of such Substitute Option not vested
as of the date of termination, and (ii) be exercisable
for a period of five (5) business days after termination
of employment (but in no event after expiration of the
term of the Substitute Option) as to the portion of such
Substitute Option vested as of the date of termination;
or
(d) Become fully vested and exercisable for a period of 45
days after termination of employment (but in no event
after expiration of the term of the Substitute Option)
upon termination of employment pursuant to Section
6.01(d) or upon termination of employment after the term
of this Agreement other than for the reasons set forth
in Section 6.01(c) or Section 6.01(e).
5. Employee Agreement. As a material inducement to the Company to
enter into this Agreement and to perform its obligations hereunder, and as a
material inducement to Imation to enter into the Merger Agreement and to perform
its obligations thereunder, Executive is entering into the Employee Agreement
with the Company in the form attached hereto as Exhibit B (the "Employee
Agreement"), which Employee Agreement shall become effective as of the Effective
Time and shall survive the termination of this Agreement in accordance with its
terms.
6. Termination.
6.01 Grounds for Termination. This Agreement shall terminate prior
to the expiration of the initial term set forth in Section 2 or any extension
thereof in the event that at any time during such initial term or any extension
thereof:
(a) Executive dies, or
(b) Executive becomes disabled (as defined below), so that
he cannot perform the essential functions of his
position with or without reasonable accommodation, or
(c) The Board of Directors of the Company elects to
terminate this Agreement for "cause" and notifies
Executive in writing of such election, or
(d) The Board of Directors of the Company elects to
terminate this Agreement without "cause" and notifies
Executive in writing of such election, or
(e) Executive elects to terminate this Agreement.
If this Agreement is terminated pursuant to subsection (a), (b) or
(c) of this Section 6.01, such termination shall be effective immediately. If
this Agreement is terminated pursuant to subsection (d) or (e) of this Section
6.01, such termination shall be effective thirty (30) days after delivery of the
notice of termination.
6.02 "Cause" Defined.
(a) Executive has breached any provision of the Employee
Agreement in any material respect and has failed to
"cure" such breach within thirty (30) days after receipt
of written notice of default from the Company, or
(b) Executive has engaged in willful and material
misconduct, including willful and material failure to
perform Executive's duties as an officer or employee of
the Company and has failed to "cure" such default within
thirty (30) days after receipt of written notice of
default from the Company, or
(c) Executive has committed fraud, misappropriation or
embezzlement in connection with the Company's business,
or
(d) Executive has been convicted or has pleaded nolo
contendere to felony criminal misconduct, or
(e) Executive's use of narcotics, liquor or an illicit drug
has or has had a detrimental effect on the performance
of his employment responsibilities, as determined by the
Company's Board of Directors.
In the event that the Company terminates Executive's employment for
"cause" pursuant to Section 6.01(c) and Executive objects in writing to the
Board's determination that there was proper "cause" for such termination within
twenty (20) days after Executive is notified of such termination, the matter
shall be resolved by arbitration in accordance with the provisions of Section
7.01. If Executive fails to object to any such determination of "cause" in
writing within such twenty (20) day period, he shall be deemed to have waived
his right to object to that determination. If such arbitration determines that
there was not proper "cause" for termination, such termination shall be deemed
to be a termination pursuant to Section 6.01(d), Executive's sole remedy shall
be to receive the wage continuation benefits contemplated by Section 6.06, and
the Substitute Option and New Option shall be treated as if the Company
terminated this Agreement pursuant to Section 6.01(d) as of the date of
determination by arbitration that there was not proper "cause."
6.03 Effect of Termination Notwithstanding any termination of this
Agreement, Executive, in consideration of his employment hereunder to the date
of such termination, shall remain bound by the provisions of this Agreement
which specifically relate to periods, activities or obligations upon or
subsequent to the termination of Executive's employment.
6.04 "Disability" Defined. As used in this Agreement, the term
"disabled" means any mental or physical condition which renders Executive unable
to perform the essential functions of his position, with or without reasonable
accommodation, for a period of more than ninety (90) days.
6.05 Surrender of Records and Property. Upon termination of his
employment with the Company, Executive shall deliver promptly to the Company all
records, manuals, books, blank forms, documents, letters, memoranda, notes,
notebooks, reports, data, tables, calculations or copies thereof, which are the
property of the Company or which relate in any way to the business, products,
practices or techniques of the Company, and all other property, trade secrets,
source code, confidential information, hardware, software, product development
and service tools, source code and other intellectual property of the Company,
including, but not limited to, all documents which in whole or in part contain
any trade secrets, source code or confidential information of the Company, which
in any of these cases are in his possession or under his control.
6.06 Wage Continuation. If Executive's employment by the Company is
terminated by the Company pursuant to Section 6.01(b) or 6.01(d), the Company
shall, through the later of (a) the date this Agreement would otherwise have
expired pursuant to Section 2, or (b) six months from the date of termination of
employment, but in no event later than six months after the expiration of the
Initial Term of this Agreement,
(i) continue to pay to Executive his base salary (less any
payments received by Executive from any disability
income insurance policy provided to him by the Company
or other unemployment insurance benefits); and
(ii) continue to provide health insurance, life insurance and
long- term disability insurance benefits to Executive at
a level consistent with the level of such benefits as of
the date of termination of employment.
If this Agreement is terminated pursuant to Section 6.01(a), 6.01(c) or 6.01(e),
Executive's right to base salary and health insurance, life insurance and
long-term disability insurance benefits shall immediately terminate, except as
may otherwise be required by applicable law.
If Executive's employment by the Company is terminated by the
Company pursuant to Section 6.01(b) or 6.01(d), Executive shall also be entitled
to receive any incentive compensation that would have been payable to him, when
and if such payment accrues and is payable under the Incentive Plan through the
later of (a) the date this Agreement would otherwise have expired pursuant to
Section 2, or (b) six months from the date of termination of employment, but in
no event later than six months after the expiration of the Initial Term of this
Agreement. No such compensation will be payable to Executive with respect to any
fiscal year in which the Company does not meet the performance objectives set
forth in the Incentive Plan.
Any payment pursuant to this Section 6.06 shall be conditioned upon the
delivery by Executive to the Company of a full release by Executive of any and
all claims Executive may have against the Company that in any way relate to his
employment by the Company.
No severance or other consideration from any incentive compensation
plan (including, without limitation, the Incentive Plan) shall be payable to
Executive for a termination pursuant to Section 6.01(a), 6.01(c) or 6.01(e),
except to the extent Executive is entitled to such severance or other
consideration as of the date of such termination of employment.
7. Settlement of Disputes.
7.01 Arbitration. Except as provided in Section 7.02, any and all
claims or controversies arising between Executive and the Company (or any of its
affiliated companies) related to Executive's employment with the Company or
termination thereof, including claims for breach of contract, tort, employment
discrimination (including unlawful harassment), and any violation of any state
or federal law shall be resolved by arbitration in accordance with the
applicable labor arbitration rules of the American Arbitration Association.
However, claims under applicable workers compensation law and the National Labor
Relations Act shall not be subject to arbitration. The arbitrator shall be
selected from a panel provided by the Judicial Arbitration and Mediation
Service. The arbitration shall be conducted in the State of California.
Executive and the Company shall equally share the fees and costs of the
arbitrator and shall pay their own respective costs and attorneys fees, if any.
However, if any party prevails on a statutory claim that affords the prevailing
party attorneys fees, then the arbitrator may award reasonable attorneys fees
and costs to the prevailing party. EXECUTIVE UNDERSTANDS AND AGREES THAT THIS
AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF EXECUTIVE'S RIGHT TO TRIAL BY
JURY OF ANY MATTERS SUBJECT TO ARBITRATION UNDER THIS AGREEMENT.
The decision of the arbitrator(s) shall be final and binding upon
both parties. Judgment of the award rendered by the arbitrator(s) may be entered
in any court having jurisdiction thereof. In the event of submission of any
dispute to arbitration, each party shall, not later than thirty (30) days prior
to the date set for hearing, provide to the other party and to the arbitrator(s)
a copy of all exhibits upon which the party intends to rely at the hearing and a
list of all persons each party intends to call at the hearing.
7.02 Resolution of Certain Claims - Injunctive Relief. Section 7.01
shall have no application to claims by the Company asserting a violation of
Section 6.05 or seeking to enforce, by injunction or otherwise, the terms of
Section 6.05. Such claims may be maintained by the Company in a lawsuit subject
to the terms of Section 7.03. Executive agrees that, in addition to, but not to
the exclusion of any other available remedy, the Company shall have the right to
enforce the provisions of Section 6.05 by applying for and obtaining temporary
and permanent restraining orders or injunctions from a court of competent
jurisdiction without the necessity of filing a bond therefor, and the Company
shall be entitled to recover from the Executive its reasonable attorneys' fees
and costs in enforcing the provisions of Section 6.05.
7.03 Venue. Any action at law, suit in equity, or judicial
proceeding arising directly, indirectly, or otherwise in connection with, out
of, related to or from this Agreement or any provision hereof, shall be
litigated only in the courts of the state of Minnesota. Executive waives any
right the Executive may have to transfer or change the venue of any litigation
brought against Executive by the Company.
7.04 Severability. To the extent any provision of this Agreement
shall be invalid or unenforceable, it shall be considered deleted herefrom and
the remainder of such provision and of this Agreement shall be unaffected and
shall continue in full force and effect. In furtherance and not in limitation of
the foregoing, should the duration or geographical extent of, or business
activities covered by, any provision of this Agreement be in excess of that
which is valid and enforceable under applicable law, then such provision shall
be construed to cover only that duration, extent or activities which may validly
and enforceably be covered. Executive acknowledges the uncertainty of the law in
this respect and expressly stipulates that this Agreement be given the
construction which renders its provisions valid and enforceable to the maximum
extent (not exceeding its express terms) possible under applicable law.
8. Miscellaneous.
8.01 Governing Law. This Agreement is made under and shall be
governed by and construed in accordance with the laws of the State of Minnesota.
8.02 Prior Agreements. This Agreement contains the entire agreement
of the parties relating to the employment of Executive by the Company and the
ancillary matters discussed herein and supersedes all prior agreements and
understandings with respect to such matters, and the parties hereto have made no
agreements, representations or warranties relating to such employment or
ancillary matters which are not set forth herein.
8.03 Withholding Taxes. The Company may withhold from any benefits
payable under this Agreement all federal, state, city or other taxes as shall be
required pursuant to any law or governmental regulation or ruling or any other
amount owed to the Company.
8.04 Amendments. No amendment or modification of this Agreement
shall be deemed effective unless made in writing and signed by both the
Executive and the Company.
8.05 No Waiver. No term or condition of this Agreement shall be
deemed to have been waived, nor shall there be any estoppel to enforce any
provisions of this Agreement, except by a statement in writing signed by the
party against whom enforcement of the waiver or estoppel is sought. Any written
waiver shall not be deemed a continuing waiver unless specifically stated, shall
operate only as to the specific term or condition waived and shall not
constitute a waiver of such term or condition for the future or as to any act
other than that specifically waived.
8.06 Assignment. This Agreement constitutes a personal service
agreement on the part of Executive and his duties hereunder may not be assigned
or delegated to any other person without the prior written consent of the
Company. The Company may, without the consent of Executive, assign its rights
and obligations under this Agreement to Imation or to any corporation, firm or
other business entity with or into which the Company may merge or consolidate,
or to which the Company may sell or transfer all or substantially all of its
assets, or of which 50% or more of the equity investment and of the voting
control is owned, directly or indirectly, by, or is under common ownership with,
the Company.
8.07 Counterparts. This Agreement may be simultaneously executed in
any number of counterparts, and such counterparts executed and delivered, each
as an original, shall constitute but one and the same instrument.
8.08 Parties. No provision of this Agreement shall be binding on,
create any presumption of employment by, or provide any entitlement to any
benefits from Imation.
8.09 Captions and Headings. The captions and paragraph headings used
in this Agreement are for convenience of reference only, and shall not affect
the construction or interpretation of this Agreement or any of the provisions
hereof.
8.10 Notices. All notices, consents, waivers, and other
communications under this Agreement must be in writing and will be deemed to
have been duly given when (a) delivered by hand (with written confirmation of
receipt), (b) sent by facsimile (with written confirmation of receipt), provided
that a copy is mailed by registered mail, return receipt requested, or (c) when
received by the addressee, if sent by a nationally recognized overnight delivery
service (receipt requested), in each case to the appropriate addresses and/or
facsimile numbers set forth below (or to such other addresses and/or facsimile
numbers as a party may designate by notice to the other parties):
Notices to Executive: to the most recent address on record with the
Company.
Notices to the Company: with a copy to:
Imation Corp. Dorsey & Whitney LLP
Legal Affairs 220 South Sixth Street
One Imation Place Minneapolis, MN 55402
Oakdale, MN 55128-3414 Attention: Gary L. Tygesson
Attn: Susan Laine Telecopy: (612) 340-8753
Imation Corp.
One Imation Place
Oakdale, MN 55128-3414
Attn: Brad T. Sauer
IN WITNESS WHEREOF, Executive and the Company have executed
this Agreement as of the date set forth in the first paragraph.
CEMAX-ICON, INC.
By
---------------------------------
Its
------------------------------
------------------------------------
["Executive"]
EXHIBIT A
Incentive Compensation
Time Period Award Amount Modification of Award Amount
First 6 months: $
Section 4.02(a) -------------------- 100% of Award Amount based on
achievement of Cemax-Icon
Baseline Sales Plan. 100% of
target pays 100% of Award
Amount. Below target pays zero.
Above target pays up to 130% of
Award Amount on a directly
proportional basis (e.g. if 110%
of target achieved, 110% of
Award Amount paid).
Next 6 months: $
Section 4.02(b) ------------------ 100% of Award Amount based on
achievement of Imation Low
Synergy Sales Plan. Below 75% of
target pays zero. 75% of target
pays 50% of Award Amount, 100%
of target pays 100% of Award
Amount, and between 75% and 100%
pays an Award Amount that scales
linearly from 50% to 100% of the
Award Amount. Above target pays
up to 130% of Award Amount on a
directly proportional basis
(e.g. if 110% of target
achieved, 110% of Award Amount
paid).
Remaining months $
of Initial Term: -------------------- 50% of Award Amount based on
Section 4.02 achievement of Imation Low Sales
Plan and 50% on Imation Low
Synergy Profits Plan. Each of
these to pay as follows: 100% of
target pays 100% of allocated
Award Amount. Below 75% of
target pays zero. 75% of target
pays 50% of allocated Award
Amount, 100% of target pays 100%
of allocated Award Amount, and
between 75% and 100% pays an
Award Amount that scales
linearly from 50% to 100% of the
allocated Award Amount. Above
target pays up to 130% of Award
Amount on a directly
proportional basis (e.g. if 110%
of target achieved, 110% of
allocated Award Amount paid).
EXHIBIT 10.5
FORM OF NONCOMPETITION AGREEMENT
This Noncompetition Agreement (this "Agreement") is made as of , 1997,
by and among Cemax-Icon, Inc., a Delaware Corporation (the "Company"), Imation
Corp., a Delaware corporation ("Imation"), and _______, an individual resident
of the State of_______ ("Stockholder").
RECITALS
WHEREAS, Stockholder is the beneficial and record owner of shares of
the Company's capital stock and/or options to purchase shares of the Company's
capital stock;
WHEREAS, concurrently with the execution and delivery of this
Agreement, Company, Imation and CI Acquisition Corp., a Delaware corporation and
wholly owned subsidiary of Imation ("Merger Subsidiary"), have agreed that
Merger Subsidiary shall be merged (the "Merger") with and into the Company, in
accordance with that certain Agreement and Plan of Merger among the Company,
Imation and Merger Subsidiary dated as of the date hereof (the "Merger
Agreement"), pursuant to which the Company will be the surviving corporation and
a wholly owned subsidiary of Imation as the "Surviving Corporation"; and
WHEREAS, Imation and the Company have conditioned the execution of the
Merger Agreement on the execution of this Agreement.
NOW, THEREFORE, in consideration of the foregoing, the respective
undertakings of the parties set forth below, and other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, and as
an inducement to Imation to complete the Merger pursuant to the terms and
conditions of the Merger Agreement, the parties hereby agree as follows:
1. DEFINITIONS. Capitalized terms not expressly defined in this
Agreement shall have the meanings ascribed to them in the Merger Agreement.
2. EFFECTIVENESS AND TERMINATION OF AGREEMENT. This Agreement shall be
effective and binding against the parties only on and after the Effective Time
and shall immediately terminate in the event of termination of the Merger
Agreement prior to the Effective Time.
3. ACKNOWLEDGMENTS BY STOCKHOLDER. Stockholder acknowledges that:
(a) Stockholder has occupied a position of trust and confidence with
the Company prior to the date hereof and has become familiar with the following,
any and all of which constitute confidential information of the Company
(collectively the "Confidential Information"):
(i) Any and all trade secrets concerning the business and
affairs of the Company, product specifications, data, know-how,
formulae, compositions, processes, designs, sketches, photographs,
graphs, drawings, samples, inventions and ideas, past, current and
planned research and development, current and planned manufacturing and
distribution methods and processes, customer lists, current and
anticipated customer requirements, price lists, market studies,
business plans, computer software and programs (including object code
and source code), computer software and database technologies, systems,
structures and architectures and related processes, formulae,
compositions, improvements, devices, know-how, inventions, discoveries,
concepts, ideas, designs, methods and information of the Company and
any other information, however documented, of the Company that is a
trade secret;
(ii) Any and all information concerning the business and
affairs of the Company (which includes historical financial statements,
financial projections and budgets, historical and projected sales,
capital spending budgets and plans, the names and backgrounds of key
personnel, personnel training and techniques and materials, and
customer lists and distribution techniques), however documented; and
(iii) Any and all notes, analysis, compilations, studies,
summaries, and other material prepared by or for the Company containing
or based, in whole or in part, on any information included in the
foregoing;
provided, that Confidential Information shall not include any information which
is lawfully disclosed to Stockholder by a third party after the date of
termination of Stockholder's employment by the Imation Companies (as defined in
Section 5(a)).
(b) The business of the Company and Imation is international in scope;
(c) The products and services of the Company and Imation are marketed
throughout the world;
(d) The Company and Imation compete with other businesses that are or
could be located in any part of the world;
(e) Imation and the Company have required that Stockholder make the
covenants set forth in Sections 4 and 5 of this Agreement as a condition to the
Merger and any payments from the Company to the Stockholder under the Merger
Agreement.
(f) The provisions of Sections 4 and 5 of this Agreement are reasonable
and necessary to protect and preserve the Surviving Corporation's and Imation's
business; and
(g) The Surviving Corporation and Imation would be irreparably damaged
if Stockholder were to breach the covenants set forth in Sections 4 and 5 of
this Agreement.
4. CONFIDENTIAL INFORMATION. Stockholder acknowledges and agrees that
all Confidential Information known or obtained by Stockholder, whether before or
after the date hereof, is the property of the Company, and will be the property
of Imation and the Surviving Corporation after the Effective Time. Therefore,
Stockholder agrees that Stockholder will not, at any time, disclose to any
unauthorized persons or use for his own account or for the benefit of any third
party any Confidential Information, whether Stockholder has such information in
Stockholder's memory or embodied in writing or other physical form, without
Imation's prior written consent, unless and to the extent that the Confidential
Information is or becomes generally known to and available for use by the public
other than as a result of Stockholder's fault or the fault of any other person
bound by a duty of confidentiality to Imation or the Surviving Corporation.
Stockholder agrees to deliver to Imation at any other time Imation may request,
all documents, memoranda, notes, plans, records, reports, and other
documentation, models, components, devices, or computer software, whether
embodied in a disk or in other form (and all copies of all of the foregoing),
relating to the businesses, operations, or affairs of the Company and any other
Confidential Information that Stockholder may then possess or have under
Stockholder's control.
5. NONCOMPETITION. As an inducement to Imation and the Company to enter
into the Merger Agreement and as additional consideration for the Merger
Consideration to be paid to Stockholder under the Merger Agreement, Stockholder
agrees that:
(a) For a period of____ years after the Effective Time (the "Restricted
Period"), except as an employee or agent of Imation, the Surviving Corporation
or any of their affiliated companies (collectively, the "Imation Companies"):
(i) Stockholder will not, directly or indirectly, engage or
invest in, own, manage, operate, finance, control, or participate in
the ownership, management, operation, financing, or control of, be
employed by, lend Stockholder's name or any similar name to, lend
Stockholder's credit to, or render services or advice to, any business
whose products or activities compete in whole or in part with the
products or activities of the Company as in existence or proposed to be
developed or acquired by the Company on the date of this Agreement and
conducted by any of the Imation Companies after the Effective Time;
provided, however, that Stockholder may purchase or otherwise acquire
up to (but not more than) one percent of any class of securities of any
enterprise (but without otherwise participating in the activities of
such enterprise) if such securities are listed on any national or
regional securities exchange or have been registered under Section
12(g) of the Securities Exchange Act of 1934. Stockholder agrees that
this covenant is reasonable with respect to its duration, geographical
area and scope.
(ii) Stockholder will not, directly or indirectly, either for
himself or any other person, (A) induce or attempt to induce any
employee of any of the Imation Companies to leave the employ of such
Imation Company, (B) in any way interfere with the relationship between
an Imation Company and any employee of such Imation Company, (C)
without the prior written consent of Imation employ, or otherwise
engage as an employee, independent contractor or otherwise, any person
who has been an employee of the Company or an Imation Company during
the six months preceding such employment, or (D) induce or attempt to
induce any customer, supplier, licensee, or business relation of an
Imation Company to cease doing business with such Imation Company, or
in any way interfere with the relationship between any customer,
supplier, licensee or business relation of an Imation Company.
(iii) Stockholder will not, directly or indirectly, either for
himself or any other person, solicit the business of any person known
to Stockholder to be a customer of an Imation Company, whether or not
Stockholder had personal contact with such person, with respect to
products or activities which compete in whole or in part with the
products or activities of the Company as in existence or proposed to be
developed or acquired by the Company on the date of this Agreement and
conducted by any of the Imation Companies after the Effective Time.
(b) In the event of a breach by Stockholder of any covenant set forth
in Subsection 5(a) of this Agreement, the term of such covenant will be extended
by the period of the duration of such breach;
(c) Stockholder will not, at any time during or after Restricted
Period, disparage an Imation Company or any of its stockholders, directors,
officers, employees or agents, and the Imation Companies will not disparage
Stockholder at any time during or after the Restricted Period (except, in either
case, for disclosures required under applicable law); and
(d) Stockholder will, during the Restricted Period, within 10 days
after accepting any employment, advise Imation of the identity of any employer
of Stockholder. Imation may serve notice upon each such employer that
Stockholder is bound by this Agreement and furnish each such employer with a
copy of this Agreement or relevant portions thereof.
6. REMEDIES. If Stockholder breaches the covenants set forth in
Sections 4 or 5 of this Agreement, Imation will be entitled to the following
remedies:
(a) Damages to which Imation is legally entitled from Stockholder;
(b) To offset against any and all amounts owing to Stockholder under
the Merger Agreement, including any payments under the Contingent Payment
Rights, or under the Employment Agreement dated of even date herewith, any and
all amounts which Imation is entitled to under Section 6(a) of this Agreement,
provided that any such amounts withheld are delivered to a third party pursuant
to an escrow agreement that provides that the escrow agent shall distribute any
such funds to the party to whom they are due and owing after determination of
the validity of the claim under Section 6(a);
(c) In addition to its right to damages and any other rights it may
have, to obtain injunctive or other equitable relief to restrain any breach or
threatened breach or otherwise to specifically enforce the provisions of
Sections 4 and 5 of this Agreement without the necessity of posting bond or
providing actual damages, it is agreed that money damages alone would be
inadequate to compensate Imation and would be an inadequate remedy for such
breach; and
(d) The rights and remedies of the parties to this Agreement are
cumulative and not alternative.
7. SUCCESSORS AND ASSIGNS. This Agreement will be binding upon Imation,
the Company and Stockholder and will inure to the benefit of Imation and the
Company and their affiliates, successors and assigns and Stockholder and
Stockholder's assigns, heirs and legal representatives. Notwithstanding the
foregoing, Stockholder shall have no rights to assign Stockholder's obligations
hereunder, and any attempted assignment of such obligations shall be null and
void.
8. WAIVER. The rights and remedies of the parties to this Agreement are
cumulative and not alternative. Neither the failure nor any delay by any party
in exercising any right, power or privilege under this Agreement will operate as
a waiver of such right, power or privilege, and no single or partial exercise of
any such right, power, or privilege will preclude any other or further exercise
of such right, power or privilege or the exercise of any other right, power or
privilege. To the maximum extent permitted by applicable law, (a) no claim or
right arising out of this Agreement can be discharged by one party, in whole or
in part, by a waiver or renunciation of the claim or right unless in writing
signed by the other party; (b) no waiver that may be given by a party will be
applicable except in the specific instance for which it is given; and (c) no
notice to or demand on one party will be deemed to be a waiver of any obligation
of such party or of the right of the party giving such notice or demand to take
further action without notice or demand as provided in this Agreement.
9. GOVERNING LAW. This Agreement will be governed by the laws of the
State of Minnesota without regard to conflicts of laws principles.
10. SEVERABILITY. Whenever possible each provision and term of this
Agreement will be interpreted in a manner to be effective and valid, but if any
provision or term of this Agreement is held to be prohibited by or invalid, then
such provision or term will be ineffective only to the extent of such
prohibition or invalidity, without invalidating or affecting in any manner
whatsoever the remainder of such provision or term or the remaining provisions
or terms of this Agreement. If any of the covenants set forth in Section 4 of
this Agreement are held to be unreasonable, arbitrary, or against public policy,
such covenants will be considered divisible with respect to scope, time, and
geographic area, and in such lesser scope, time and geographic area, will be
effective, binding and enforceable against Stockholder.
11. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which will be deemed to be an original copy of this
Agreement and all of which, when taken together, will be deemed to constitute
one and the same agreement.
12. SECTION HEADINGS, CONSTRUCTION. The headings of Sections in this
Agreement are provided for convenience only and will not affect its construction
or interpretation. All references to "Section" or "Sections" refer to the
corresponding Section or Sections of this Agreement unless otherwise specified.
All words used in this Agreement will be construed to be of such gender or
number as the circumstances require. Unless otherwise expressly provided, the
word "including" does not limit the preceding words or terms.
13. NOTICES. All notices, consents, waivers, and other communications
under this Agreement must be in writing and will be deemed to have been duly
given when (a) delivered by hand (with written confirmation of receipt), (b)
sent by facsimile (with written confirmation of receipt), provided that a copy
is mailed by registered mail, return receipt requested, or (c) when received by
the addressee, if sent by a nationally recognized overnight delivery service
(receipt requested), in each case to the appropriate addresses and/or facsimile
numbers set forth below (or to such other addresses and/or facsimile numbers as
a party may designate by notice to the other parties):
Notices to Stockholder: to the address of Stockholder on the signature
page of this Agreement.
Notices to Imation: with a copy to:
Imation Corp. Dorsey & Whitney LLP
Legal Affairs 220 South Sixth Street
One Imation Place Minneapolis, MN 55402
Oakdale, MN 55128-3414 Attention: Gary L. Tygesson
Attn: Susan Laine Telecopy: (612) 340-8753
Imation Corp.
One Imation Place
Oakdale, MN 55128-3414
Attn: Brad T. Sauer
14. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties with respect to the subject matter of this Agreement and
supersede all prior written and oral agreements and understandings between the
Company, Imation and Stockholder with respect to the subject matter of this
Agreement. This Agreement may not be amended except by a written agreement
executed by the party to be charged with the amendment.
15. EMPLOYEE AGREEMENT. Notwithstanding Section 14 of this Agreement,
Stockholder and Imation agree that the Employee Agreement, dated as of the date
hereof, by and between Stockholder and Imation, addresses certain matters set
forth herein in Stockholder's capacity as an employee of the Company and
Imation. In the event of any inconsistencies between the Employee Agreement and
this Agreement, this Agreement shall govern. In addition, during the Restricted
Period, the Company shall have no obligation to make payments to me under
paragraph F.a of the Employee Agreement in order to enforce any of Stockholder's
obligations under this Agreement during the Restricted Period. This Agreement
shall not in any way modify the obligations of the Surviving Corporation
(including payment obligations of the Surviving Corporation) under the Key
Management Agreement, dated as of the date hereof, by and between Stockholder
and the Surviving Corporation.
IN WITNESS WHEREOF, the parties have executed and delivered this
Agreement as of the date first above written.
IMATION CORP.
By _______________________________________
Its ___________________________________
CEMAX-ICON, INC.
By _______________________________________
Its ___________________________________
STOCKHOLDER:
__________________________________________
Name
[Address]
Exhibit 15
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington D.C. 20549
Re: Imation Corp.
Registration on Form S-4
We are aware that our report dated April 30, 1997, on our reviews of
the interim consolidated information of Imation Corp. (the Company) for the
three month periods ended March 31, 1997 and 1996, and included in the Company's
quarterly report on Form 10-Q for the quarter ended March 31, 1997, is included
in this Registration Statement. Pursuant to Rule 436(c) under the Securities Act
of 1933, this report should not be considered a part of the Registration
Statement prepared or certified by us within the meaning of Sections 7 and 11 of
that Act.
/s/ COOPERS & LYBRAND L.L.P.
COOPERS & LYBRAND L.L.P.
Minneapolis, Minnesota
June 9, 1997
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the inclusion in this Registration Statement of Imation
Corp. on Form S-4 of our report dated February 14, 1997, on our audits of the
consolidated financial statements of Imation Corp. and subsidiaries as of
December 31, 1996 and 1995, and for each of the three years in the period ended
December 31, 1996. We also consent to the references to our firm under the
caption "Experts."
/s/ COOPERS & LYBRAND L.L.P.
COOPERS & LYBRAND L.L.P.
Minneapolis, Minnesota
June 9, 1997
Exhibit 23.2
CONSENT OF INDEPENDENT AUDITORS
We consent to the reference to our firm under the caption "Experts" and
to the use of our report dated March 12, 1997, with respect to the financial
statements of Cemax-Icon included in the Registration Statement (Form S-4) and
related Prospectus of Imation Corporation for the registration of contingent
payment rights and common stock.
/s/ ERNST & YOUNG LLP
Palo Alto, California
June 6, 1997
EXHIBIT 24
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints William T. Monahan, Jill D.
Burchill and Carolyn A. Bates, and each of them, his or her true and lawful
attorneys-in-fact and agents, each acting alone, with full power of substitution
and re-substitution, for him or her and in his or her name, place and stead, in
any and all capacities, to sign a Registration Statement on Form S-4 of Imation
Corp., and any and all amendments thereto, including post-effective amendments,
and to file the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys-in-fact and agents, each acting alone, full power and authority
to do and perform to all intents and purposes as he or she might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, each acting alone, or the substitutes for such attorneys-in-fact and
agents, may lawfully do or cause to be done by virtue hereof.
Name Title Date
Chairman, President, Chief May 13, 1997
/s/ William T. Monahan Executive Officer and Director
- --------------------------- (principal executive officer)
William T. Monahan
/s/ Jill D. Burchill Chief Financial Officer May 13, 1997
- --------------------------- (principal financial officer)
Jill D. Burchill
/s/ James R. Stewart Corporate Controller May 13, 1997
- --------------------------- (principal accounting officer)
James R. Stewart
/s/ Lawrence E. Eaton Director May 13, 1997
- ---------------------------
Lawrence E. Eaton
/s/ Linda W. Hart Director May 13, 1997
- ---------------------------
Linda W. Hart
/s/ William W. George Director May 13, 1997
- ---------------------------
William W. George
/s/ Ronald T. LeMay Director May 13, 1997
- ---------------------------
Ronald T. LeMay
/s/ Marvin L. Mann Director May 13, 1997
- ---------------------------
Marvin L. Mann
/s/ Mark A. Pulido Director May 13, 1997
- ---------------------------
Mark A. Pulido
/s/ Daryl J. White Director May 13, 1997
- ---------------------------
Daryl J. White
EXHIBIT 99.1
CEMAX-ICON, INC.
PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
Terry Ross, Jeremy B. Rubin, M.D. and Gregory C. Patti, or any of them,
are hereby appointed attorneys and proxies of the undersigned, each with the
power of substitution, to attend, vote and act for the undersigned at the
special meeting of shareholders of Cemax-Icon, Inc. (the "Company") to be held
on June __, 1997, at _____________, _____________, _____________, _____________,
and at any postponement or adjournment thereof, in connection therewith to vote
and present all of the shares of Common Stock ("Cemax-Icon Common Stock") of the
Company which the undersigned would be entitled to vote as follows:
1. To consider and to vote upon a proposal to approve and adopt an
Agreement and Plan of Merger (as it may be amended, supplemented or
modified from time to time, the "Merger Agreement"), dated as of May
13, 1997, among Cemax-Icon, Imation Corp. ("Imation") and CI
Acquisition Corp., a direct, wholly owned subsidiary of Imation
("Merger Subsidiary"), pursuant to which, among other things, Merger
Subsidiary will be merged with and into Cemax-Icon (the "Merger") and
Cemax-Icon shall be the surviving corporation (the "Surviving
Corporation") and to approve the appointment of Michael O'Donnell and
David Titus to act as the representatives of the stockholders of
Cemax-Icon (the "Stockholders' Representatives") in connection with the
Merger and to withhold up to $200,000 from the initial payments to
stockholders in a separate fund for reimbursement of the Stockholders'
Representatives' out-of-pocket expenses in acting on behalf of the
stockholders of Cemax-Icon in connection with the Merger. If the Merger
Agreement is approved and adopted and the Merger becomes effective, (a)
each outstanding share of common stock, $0.001 par value, of Cemax-Icon
(the "Cemax-Icon Common Stock") (other than shares of Cemax-Icon Common
Stock with respect to which dissenters' rights have been properly
exercised) will be converted into and become a right to receive (i) a
cash payment of $5.25, without interest thereon, and (ii) one right (a
"Contingent Payment Right") to receive contingent payments of up to
$8.50 over a two-year period in cash or shares of Imation Common Stock,
based on the gross revenues of the Surviving Corporation following the
Merger, net of any amount to which Imation is entitled pursuant to the
offset provisions of the Merger Agreement, and (b) each share of Series
A Preferred Stock, par value $0.001, of Cemax-Icon will be canceled and
extinguished, and no payment will be made therefor.
FOR [ ] AGAINST [ ] ABSTAIN [ ]
2. To transact such other business as may properly come before the meeting
or any adjournment or postponement thereof.
IF THIS PROXY IS DULY EXECUTED AND RETURNED, THIS PROXY WILL BE VOTED,
AND WILL BE VOTED IN ACCORDANCE WITH THE INSTRUCTIONS SPECIFIED ABOVE. IF NO
INSTRUCTION IS SPECIFIED, THE PROXY WILL BE VOTED FOR ITEM 1.
The undersigned hereby revokes any other proxy or proxies heretofore
given to vote or act with respect to such Common Stock and hereby ratifies and
confirms all action that said attorneys and proxies, their substitutes, or any
of them, may have lawfully taken by virtue thereof.
Dated: June ____, 1997 ___________________________________
___________________________________
Signature(s) of Shareholder
This proxy should be signed exactly as your name appears thereon. Joint
owners should both sign. If signed by an attorney, executor, guardian or in some
other capacity or as officer of a corporation, please add title as such.
PLEASE COMPLETE, DATE AND SIGN THIS PROXY
AND RETURN IT IN THE ENCLOSED ENVELOPE.
